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Abstract 
This Thesis begins by discussing the application of controlled drug delivery to the 
intravaginal delivery of hormones to control the oestrous cycle of farmed animals, 
with particular emphasis on the delivery of progestagens to cattle and sheep. The 
introduction highlights the recent advances made by animal physiologists in their 
knowledge of the oestrous cycle in cattle and sheep and how these advances have 
impacted upon the manner in which currently available intravaginal controlled 
release products are used. In addition it discusses the advances pharmaceutical 
scientists have made in response to the new knowledge. 
The CIDR@1900 Cattle insert is a commercially available silicone based intravaginal 
delivery system containing the natural steroid progesterone for fertility regulation in 
cattle. It was designed in 1987 to be inserted for 12 days. Advances made in 
oestrous cycle understanding by animal scientists have resulted in this product being 
inserted for much shorter treatment periods of 7 days. Rathbone et al. recently 
optimised the CIDR@1900 Cattle insert for seven day insertion periods. The 
outcome of these scientists work was a manufactured prototype which, when 
compared to the CIDR@1900 Cattle insert, contained a reduced initial drug load and a 
much lower residual drug load after use. For commercial production the prototype 
insert needed to be scaled up. This process required detailed pharmaceutical 
characterisation, invitro release assessment, invivo bioequivalency and chemical and 
physical stability studies to be performed on the scaled up product (CIDR@1380 
Cattle insert) to ensure the success of the scale up process. This characterisation 
process forms Chapters Two and Three of this Thesis. 
Knowledge of the mechanism of release of a drug from a pharmaceutical product 
provides the formulation scientist with the necessary insight to optimise, further 
develop or recognise the potential and limitations of a product. Chapter Four 
explores the mechanism of release of progesterone from the silicone based CIDR® 
Cattle insert both invitro and invivo. Cumulative release data from both invitro and 
invivo studies were fitted against conventional mathematical models to determine the 
mechanism of release of progesterone from the CIDR@ Cattle insert. In addition, an 
ii 
experimental method was developed to assess the validity of the models. The 
method involved taking thin consecutive horizontal slices from the surface of CIDR® 
Cattle inserts after various periods of release. Cumulative release of progesterone, 
both invitro and invivo, was linear when plotted against the square root of time, 
suggesting that release from the CIDR® Cattle insert occurred in accordance with the 
square root of time mechanism. However, experimental evidence from the 
horizontal slicing technique only supported the curve fitting evidence for invitro 
release. When the insert was investigated invivo, the slicing method indicated that a 
novel release mechanism was in operation which was better described by a zero 
order process. 
Chapters Five and Six of this Thesis direct their focus to oestrus control in sheep. 
Chapter Five utilises information gained from both Rathbone et al. and the work 
performed in this Thesis on the CIDR® Cattle insert to characterise and optimise the 
commercially available sheep equivalent of the CIDR ® 1900 Cattle insert (known as 
the CIDR® Sheep and Goat insert). The Chapter successfully characterises the 
CIDR® Sheep and Goat insert, defines the parameters of, and tests, an optimised 
version of this sheep product. 
The final Chapter of this Thesis investigates the use of poly-(s-caprolactone) as a 
platform for the intravaginal delivery of progesterone to control oestrus in sheep. 
Silicone has certain limitations as a drug delivery platform, and with animal 
physiologists recent advances in knowledge, pharmaceutical scientists will need 
more versatile delivery platforms to develop intravaginal drug delivery systems 
which fulfil the future demands of the animal scientists. 
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Chapter One - Controlled Release Intravaginal Veterinary Drug 
Delivery Systems 
1.1 Introduction 
This Thesis is concerned with the development and optimisation of intravaginal 
veterinary drug delivery systems in farmed animals. The vagina of animals has been 
the focus of much research since the beginning of the Centuryl, 2, and, since the mid 
1960's, has been commercially exploited as a portal for the systemic delivery of 
drugs to farmed animals3• Since that time researchers have focused their efforts on 
using the vagina to deliver honnones to control the oestrous cycle of cattle, sheep 
and, to a lesser extent deer and goats. Today, the delivery of hormones to control the 
oestrous cycle of these animals remains the only application of this route for drug 
delivery. Indeed, all currently available intravaginal controlled release drug delivery 
systems contain either progesterone or synthetic progestagens for this purpose. 
The development and optimisation of intravaginal veterinary drug delivery systems 
in farmed animals requires an in depth know ledge of both pharmaceutical science 
and the natural oestrous cycle of the animal in question. The former is required to 
rationally develop and optimise the product to ensure the quality, safety and efficacy 
of the final product. The latter is required to define the type of drugs which need to 
be delivered and the durations over which they must be administered. 
In recent times animal physiologists and endocrinologists have expanded their 
knowledge on the oestrous cycle of cattle and sheep3. New information on how to 
control the oestrous cycle while maintaining normal fertility has come to light. This 
new information has impacted on the specifications which products used to control 
the oestrous cycle must meet (e.g., the delivery period for progesterone has 
decreased from 12-15 days to 7-10 days to prevent the formation of stale follicles). 
In addition the new knowledge has highlighted the need for coadministration of other 
pharmacologic compounds such as oestradiol (for follicular turnover) and 
prostaglandins (to regress corpus lutea). Animal physiologists and endocrinologists 
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have introduced fertility programmes which involve the continuous delivery of 
progesterone from controlled release products coupled with inj ections of oestradiol 
and prostaglandin (at appropriate times in the treatment programme) to ensure 
precise synchrony coupled with normal fertility. 
On the pharmaceutical side, several conceptual and commercially available 
intravaginal veterinary drug delivery systems have been reported in the literature4, 5 
and several attempts have been made to optimise existing products4, 6. Only a limited 
number of polymers have been utilised as platforms for intravaginal drug delivery in 
farmed animals. 
All the above mentioned aspects of intravaginal veterinary drug delivery will be 
discussed in this Introduction, and the holes in the literature which provided the 
opportunity for the research performed in this Thesis will be highlighted. 
1.2 Fertility Control in Farmed Animals 
1.2.1 Introduction 
As already mentioned, substantial advances have been made in our understanding of 
the physiology and endocrinology of the oestrous cycles of livestock. Developments 
in controlled release drug delivery products have contributed substantially to this 
progress. The relationship between product availability and scientific advance is 
symbiotic. The availability of controlled release products has allowed animal 
scientists to control and study follicular development and ovulation in great depth, 
while the understanding gained from this research has allowed pharmaceutical 
scientists to optimise delivery systems which have been in existence for over 30 
years. The recent advances in the area of animal physiology and endocrinology of 
the oestrous cycles of livestock and the impact of these advances on the application 
of drug delivery to oestrus control in these species has recently been reviewed by 
Rathbone et al. 3, 4, 5. 
Control of the oestrous cycles of farmed animals is desirable for several reasons5• 
These include the synchronisation of oestrus in order to use artificial insemination to 
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spread desirable genes quickly, synchronisation of donor and recipient animals for 
embryo transfer, the breeding of synchronised animals as early in the season as 
possible and the breeding of synchronised animals out of season. These 
synchronisation practices can result in increased efficiency in production of meat and 
dairy produce. In addition, oestrous cycle control can contribute to maximisation of 
the number of offspring a fertile animal may produce within its lifespan. Finally, if 
all breeding activities can be carried out over a short time period, there are also 
advantages to the farmer with respect to time management. 
The development of theories on how to manipulate the oestrous cycle of farmed 
animals requires a detailed understanding of the biochemistry involved during a 
naturally occurring cycle. Once the endogenous hormones which control the 
oestrous cycle have been identified, together with their pharmacokinetic behaviour 
and phannacological interactions, then drug delivery systems for use in treatment 
programmes to control the cycle can be rationally developed. 
1.2.2 Cattle 
1.2.2.1 The Oestrous Cycle of Cattle 
A complete bovine oestrous cycle occurs over a period of 18-24 days3, 5. The 
pituitary gland in the brain produces follicle stimulating hormone (FSH) which 
promotes the growth of cohorts of four to ten follicles on the ovaries over a period of 
12-36 hours (Figure 1.2.l). Follicles require luteinising hormone (LH), which is 
released in pulses by the pituitary gland. In mono-ovulating species such as cattle, 
only one of these follicles is selected to become large and dominant. This process is 
not well understood but could involve competition for available LH. Follicles also 
secrete inhibin, which has a negative effect on FSH secretion, to restrict the growth 
of other follicles7 (Figure 1.2.l). If the follicles do not receive sufficient LH then 
follicular atresia occurs. The dominant follicle is then replaced by a new follicular 
wave, with waves occurring constantly every 8-10 days. The oestrous cycle is 
coordinated such that a second or third follicular wave is occurring before one 
follicle survives to become dominant and ovulatory. 
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The bovine oestrous cycle has been divided into two stages, each with two sub-
stages. The follicular phase has a duration of 3-7 days and comprises pro-oestrus 
and oestrus while the luteal phase completes the rest of the 18-24 day cycle and 
comprises metoestrus and dioestrus. 
Pro-oestrus is a period of 2-6 days while a dominant ovulatory follicle is maturing8• 
The dominant follicle produces oestradiol. When the oestradiol level is high enough, 
the oestrus phase begins with behavioral oestrus where cows will stand to be 
mounted by herdmates9• Oestradiol also stimulates the formation of oxytocin 
receptors in the uterus. 
Oestrus lasts for 8-30 hours3, 10 before the high level of oestradiol combined with a 
low level of progesterone in the system initiates a surge in LH level to >30 ng/mLS, 
at which time, ovulation occurs. Ovulation is referred to as day 0 of the oestrous 
cycle and marks the beginning of the luteal phase. 
Days 0-5 of the luteal phase are defined as metoestms3,5. In the 3-4 days following 
ovulation a corpus luteum (eL) fonus from the remnant theca and granulosa of the 
ovulatory follicle. The CL comprises small luteal cells which produce progesterone 
and large luteal cells which secrete oxytocin and develop prostaglandin F 2(1. (PGF) 
receptors (Figure 1.2.1). At day 4, progesterone levels are typically around 1 ng/mL. 
The fully formed CL produces increasing quantities of progesterone until, by day 8-
9, plasma levels reach around 4-10 ng/mL. Progesterone suppresses LH production 
and so, during the luteal phase, developing follicles will not receive sufficient LH to 
ovulate. 
The remaining days of the cycle (days 6-18) are termed di-oestrus5• During di-
oestrus, oxytocin produced by the large luteal cells acts upon the uterine 
endometrium to stimulate POF synthesis. At around day 16-17, the CL is destroyed 
in a process called luteolysis which involves release of POF from the uterus (Figure 
1.2.1). The trigger for POF release involves oxytocin and oestradiol. It can be 
prevented by interferon factors produced by a developing embryo (Figure 1.2.1). 
During luteolysis, there is a precipitous decline in progesterone level and in oxytocin 
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level. Luteolysis marks the end of the luteal phase and the beginning of the follicular 
phase. 
Anterior Pituitary 
-ve 
Figure 1.2.1 - Conceptual diagram of a cow and the interactions which control follicular 
development, ovulation, luteolysis and pregnancy responses (GnRH = gonadotrophin releasing 
hormone, LH = luteinising hormone, FSH = follicle stimulating hormone, CL = corpus luteum, 
P4 = progesterone, E2 = oestradiol, PGF = prostaglandin F2o" IFNtau = interferon-Tau) 
(personal communication, Chris Burke, Dairying Research Corporation) 
1.2.2.2 Control of Oestrus in Cattle 
Concepts for controlling the oestrous cycle have involved follicle wave regulation by 
either lengthening or shortening the luteal phase or by synchronised luteolysis. The 
challenges in controlling the oestrous cycle are to achieve a good level of 
synchronisation without compromising fertility. 
1.2.2.3 Single Drug Therapy for Oestrus Control in Cattle 
Early hormonal treatments for bovine oestrus control involved the injection of low 
doses of progesterone for up to three weeks to lengthen the luteal phase. These 
treatments produced a high degree of synchrony but poor ferti lity 1 1, 12 as did higher 
doses of progesterone per vaginum13, 14, Administration of orally active progestagens 
such as melengestrol acetate in feed resulted in reduced fertility unless progesterone 
was administered acutely about five days before termination of the feeding 
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treatment. The large progesterone dose was shown to induce atresia in persistently 
dominant follicles which form in the ovaries during prolonged periods of low 
circulating progesterone levels, particularly after spontaneous luteolysis of the CL 
has occurred 15. Concentrations of progesterone sufficient to suppress the pro-oestrus 
pattern of pulsatile LH release must be maintained if persistent follicles and low 
fertility are to be avoided. 
The inter-oestrus period can be shortened by surgical procedures on the CL, thus 
terminating the luteal phase and initiating pro-oestrus. However, it has long been 
known that synthetic prostaglandins will lyse the CL without causing any of the 
tissue damage associated with surgical procedures. POF was identified as the natural 
luteolytic hormone first in sheepl6 and then in cattle 17. A POF injection is only 
effective during the luteal phase and as such, a single administration results in 50 to 
70% of animals displaying oestrus within the next six days. If two POF injections 
are given within ten to fourteen days of each other then, at the second injection, all 
animals should be in their luteal phase. The resulting synchrony is good in heifers 
(80% in oestrus from 48 to 80 h after the second injection) but less precise in 
COWS I8,19. This double paF injection synchrony method may result in reduced 
fertility20. Attempts have also been made to control oestrus with oestradiol and 
gonadotrophin releasing hormone (OnRH). Their effects were variable and not 
successfully adopted into treatment programs21 . 
1.2.2.4 Combination Drug Therapy for Oestrus Control in Cattle 
Initial combination therapies used progesterone and oestradiol benzoate (ODB/2 or 
oestradiol valerate (ODV)23. Progesterone should prevent the ovulatory LH surge, 
while oestradiol compounds were intended to induce premature luteolysis. Using 
oestradiol in combination with progesterone allowed treatment durations of 10 days 
with subcutaneous progesterone23, or 12 days with intravaginal progesterone 14, 22. 
These treatments yielded acceptable fertility in heifers but lowered fertility in 
lactating cows. Availability of synthetic PGF allowed prostaglandins to be used to 
achieve luteolysis instead of oestradiol. Smith et a1. 24 showed that an 8 day 
progesterone treatment terminated with PGF administration could provide suitable 
synchrony to allow timed insemination post-treatment with acceptable fertility. 
Variations on this progesterone/PGF treatment will not always eliminate persistent 
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follicles and lowered fertility is associated with such follicles 14• In an effort to 
control follicle development patterns, a combination of GnRH and PGP was tested. 
Growing and mature follicles were luteinised or ovulated due to LH release 
following a GnRH injection25 • An injection of PGF 7 or 8 days later6,27 facilitated 
onset of oestrus but with poor synchrony as new wave emergence occurs 4 to 7 days 
after the GnRH administration26 • 
Combining follicular phase and luteal phase regulation appears to provide the most 
successful oestrus regulation to date. Adams28 and Bo et a1.29 showed that injected 
oestradiol produced a degree of synchrony in ovarian follicle development, with a 
new wave forming about four days post injection. Progesterone treatment periods of 
six to eight days have been shown to minimise the incidence of persistent follicles in 
heifers30, 31. These principles were combined by Day et al.32 along with the use of 
PGP as a luteolytic agent. Oestradiol was injected at the beginning of the treatment 
with progesterone being administered per vaginum for seven days. A luteolytic dose 
of PGF was administered at removal of the progesterone delivery system and then 
oestradiol was injected 48 hours after insert removal. In this treatment regime, 
synchronous follicular development, luteolysis and follicular maturation are 
combined to achieve synchronised oestrus and a fertile ovulation. 
1.2.2.5 Impacts of Current Understanding on Formulation Scientists 
Current understanding of oestrus control suggests that synchronisation of cattle with 
normal fertility rates is best achieved by a 7 day delivery of progesterone and 
coadministration of shorter acting injectable drugs which control follicular turnover 
(e.g., oestradiol or GnRH) or induce CL regression (e.g., prostaglandin)3. The 
success of such programmes is evident in that combined treatments regimes are now 
used in preference to the traditionally used single treatments which involved the 
prolonged release of progesterone. Such combination programmes have become 
commonplace in modem farming practice in both Australia and New Zealand. 
These new fertility programmes have impacted on drug delivery scientists working 
on delivery systems used in veterinary fertility regulation. Silicone intravaginal 
progesterone delivery systems such as CIDR@1900 Cattle inserts were originally 
developed with high initial drug loads to provide acceptable blood plasma 
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progesterone levels over 12 day treatments. The new programmes require that the 
inserts need only be used for shorter 7 day treatment programmes. As a result the 
intravaginal progesterone delivery systems exhibit a high residual progesterone 
content after use. This is not only wasteful in terms of drug utilisation and economy 
of manufacture but may also raise environmental issues. Rathbone et al. have 
recently addressed this problem and optimised the CIDR@1900 Cattle insert6 
(contains 1.9 g progesterone) to contain a lower initial progesterone load and to 
exhibit a lower residual load after a 7 day treatment while still maintaining blood 
plasma progesterone levels equivalent to the original CIDR@1900 Cattle insert. The 
resultant product is currently marketed under the name CIDR@1380 Cattle insert 
(contains 1.38 g progesterone). Rathbone et al. performed extensive research on a 
production made prototype of the CIDR@1380 Cattle insert to justify the steps taken 
to optimise the insert6 , however, no research has been performed on the large scale 
commercially manufactured CIDR®1380 Cattle insert and this has provided the 
opportunity for some of the research performed in this Thesis. 
The coadministration of oestradiol benzoate (ODB) and POF during these fertility 
programmes has, to date, been achieved by subcutaneous or intramuscular injection. 
However, in the field of veterinary drug delivery for farmed animals where costs 
must be minimised to make oestrus control economic to the farmer, the need for 
coadministration of these agents with the continuous delivery of progesterone 
presents an opportunity to the drug delivery scientist. The opportunity is to develop 
a single delivery system which is capable of delivering progesterone continuously, 
and ODB and PGF as pulsed doses at appropriate times in the treatment. This has 
been attempted by PLADE Holdings NZ Ltd who have developed an electronic 
delivery system called the Smartt l Intelligent Breeding Device (IBD). There appears 
to have been little pharmaceutical or biological characterisation of this delivery 
system. Although a thorough investigation of this product, or the development of a 
similar product, represents an opportunity for research, this is not pursued in this 
Thesis. However, it is important to highlight the development of this delivery 
system since it is a direct outcome of current understanding, and perhaps the future 
of drug delivery for oestrus control in cattle will involve such a technology. 
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1.2.3 Sheep 
1.2.3.1 The Oestrous Cycle of Sheep 
Reproduction in sheep is generally seasonal, with oestrous cycles of New Zealand 
sheep breeds commencing in late summer and continuing until the following spring 
if pregnancy does not occur33. These ewes are expected, therefore, to be anoestrus 
during late spring and early summer. 
Photoperiod has been established as the environmental cue for annual reproduction 
to begin. Melatonin is secreted by the pineal gland in response to darkness34. 
Daytime plasma levels are around 25 pg/mL while in the hours of darkness this may 
rise to between 150 and 300 pg/mL. The changing length of exposure to melatonin 
as seasons change trigger the sheep's reproductive system. Controlling the 
photoperiod of a sheep's environment in an appropriated sequence can advance the 
onset of the breeding season35 . 
During the breeding season, the ewe has oestrous cycles lasting 16-17 days. Oestrus 
itself tends to last 24-36 hours36 and it is generally believed that ovulation occurs at 
the end of oestrus and is timed to a surge of LH. GnRH is recognized as important to 
the generation of the pre-ovulatory LH surge37-39. 
Follicular dynamics are less understood in sheep than in cattle. The ovaries of young 
ewes contain between 40,000 and 300,000 primordial follicles4o,41 which are thought 
to emerge in an ordered sequence but at an unknown rate. It is estimated that 
development from the resting to pre-ovulatory stage takes about 6 months42 • A ewe's 
ovary may contain several hundred follicles at anyone time, of which 10-40 are 
visible43 . Souza et a1.44 have reported that follicular growth and ovarian steroid 
secretions occur in waves with two synchronous stages but with a decline in steroid 
secretion preceding any change in follicular diameter. Other researchers have also 
observed distinct follicular waves, with up to 5 or 6 occurring between ovulations45 . 
1.2.3.2 Control of Oestrus in Sheep 
Control of the oestrous cycle in sheep is desirable for the same reasons as it is 
desirable in cattle: for more rapid genetic advancement of the flock through artificial 
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insemination and for other advanced breeding activities such as synchronisation of 
superovulating ewes and embryo recipient ewes for embryo transplantation. 
As for cattle, efforts to manipulate oestrus in sheep have focused mainly on delivery 
of progestagens, as the physiology is essentially the same. A variety of delivery 
systems have been used for this purpose with some degree of synchrony being 
attained in flocks after removal of the progestagen releasing device4, 5. 
1.2.3.3 Impacts of Current Understanding on Formulation Scientists 
The CIDR® Sheep and Goat insert is a silicone rubber based intravaginal 
progesterone delivery system which has been impacted by the current understanding 
of the sheep oestrous cycle and the need for its use in embryo transfer programmes. 
The CIDR® Sheep and Goat insert was initially developed to deliver progesterone 
over a 14 day period for the synchronisation of oestrus in New Zealand and 
Australian sheep breeds. In recent embryo transfer programmes, blood plasma 
progesterone levels higher than those produced by single CIDR ® Sheep and Goat 
inserts are required. Indeed, in the case of the CIDR® Sheep and Goat insert, its 
usefulness in these embryo transfer programmes has needed either the replacement 
of the CIDR® Sheep and Goat insert with a fresh insert on day 8 of a 14 day 
treatment or the simultaneous insertion of two CIDR® Sheep and Goat inserts for the 
entire 14 day period46-48 • 
The use of the CIDR ® Sheep and Goat inserts in this manner has provided the 
opportunity for some of the research performed in this Thesis. The obvious response 
to the new applications of the CIDR® Sheep and Goat insert is the development of a 
single insert which exhibits elevated blood plasma progesterone profile which 
mimics those seen in the embryo transfer programmes (i.e., two CIDR® Sheep and 
Goat inserts inserted simultaneously or singly with replacement of the first with the 
second at day eight of treatment). 
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1.3 Intravaginal Veterinary Drug Delivery in Farmed Animals 
1.3.1 Oestrus Control Products for use in Cattle 
Initial studies into methods for the controlled delivery of progesterone to cattle were 
carried out by Roche in the early 1970's and focused on silicone implants inserted 
into the dewlap of cattle49, 50. The work was reasonably successful but such a large 
implant was undesirable for commercialisation51 , This lead Roche to focus his 
efforts on intravaginal administration, trialling silicone rings and coils, all of which 
exhibited poor retention characteristics51 , About the same time Abbott Laboratories 
independently developed an intravaginal drug delivery system and reported their 
initial field results in 197552, Their progesterone releasing intravaginal device 
(PRID®) comprised progesterone in a silicone rubber matrix, moulded onto a 
stainless steel coil. In 1987 a second silicone/progesterone drug delivery system was 
commercialised called the CIDR®1900 Cattle insert [personal communication, Dean 
Epps, InterAg Operations Manager]. Interdispersed over this time was the 
development of several conceptual intravaginal drug delivery systems for the 
delivery of progestagens including sponges4 and rubber tubing devices4• 
1.3.1.1 PRJD@ 
With the collaboration between Abbott and Roche\ the PRID® became the first 
commercially available intravaginal progesterone delivery system for cattle in the 
mid 1970's and is still widely used today. 
Figure 1.3.1 - Diagram of the PRID® progesterone releasing intravaginal device 
The currently available PRID® (Figure 1.3.1) consists of a 3.5 x 28.5 x 0.1 em 
stainless steel sheet enclosed in a silicone rubber matrix (which contains either 1.55 
g uniformly dispersed micronised progesterone) and is coiled into a spiral of 
approximately 4 em diameter and 12 em length3, 4, 5, A hard gelatin capsule 
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containing 10 mg oestradiol benzoate is glued to the inner surface of the coil and a 
nylon cord is connected at one end to facilitate removal of the device post-treatment. 
The PRID® is inserted using a special applicator (Figure 1.3.2). 
Plan 
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Figure 1.3.2 - Diagram of the specialised PRID® applicator 
All reported PRID® retention rates are greater than 92% with an average retention 
rate in cows and heifers of approximately 95%4,5. 
Following insertion of a PRID®, plasma progesterone levels rise rapidly and then 
decline gradually over the next 14 days, falling within hours to basal levels after 
removal of the device. This profile has been reported by several authors53-7o• The 
reported values for plasma progesterone vary but it is generally agreed now that 
steady state progesterone levels are around 3-4 ng/mL. After an insertion of 
recommended duration, the PRID® still contains a large amount of residual 
progesterone. McPhee et al. investigated use of the PRlD® for up to 3 successive 
treatments58 • Two different sterilisation methods were used before reinsertion of the 
devices including gas sterilisation with ethylene oxide and heat sterilisation by 
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autoclaving. The plasma progesterone levels produced by gas sterilised PRID® were 
observed to drop dramatically for each successive insertion. For autoc1aved PRID®, 
a profile similar to that of a fresh PRID® was obtained on the first reinsertion but a 
drop in progesterone levels occurred with a second reinsertion. 
The invitro release of progesterone from PRID® has not been reported although 
Winkler et al. have done so for hand made progesterone/silicone sheet52. The release 
of progesterone followed a square root of time mechanism (i.e., release was constant 
with respect to the square root of time). 
Winkler et al. also determined invivo release rates by removing PRID® devices at 
days 2, 6, 9, 12,16 and peeling off the skin of the PRID® and determining the 
residual progesterone load. Different rates were observed for the outer and inner 
surfaces (outside 2.597 mg/cm2/day1l2, inner 2.359 mg/cm2/day1!2) but due to different 
lag times to steady state (outside 1.7 days, inner 4. 7 days) the release profile was 
zero-order overall (i.e., release was constant with respect to time). 
1.3.1.2 CIDR@1900 Cattle Insert 
The CIDR@1900 Cattle insert was developed in New Zealand for the intravaginal 
delivery of progesterone to cattle. 
o 
Figure 1.3.3 - Diagram of the CIDR@1900 Cattle insert 
The CIDR@1900 Cattle insert (Figure 1.3.3) is described as T-shaped (body with 
hinged wings) and comprises a supporting nylon spine enclosed in a silicone rubber 
matrix which contains 1.9 g unifonnly dispersed micronised progesterone3, 4, 5. The 
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10% w/w progesterone in silicone matrix is injection moulded over the spine and 
cured at around 195°C. A groove in the H-cross-section body of the insert allows 
placement of a gelatin capsule for delivery of oestradiol benzoate. A tail fitted to the 
end of the insert facilitates its removal at the end of treatment. 
The CIDR®1900 Cattle insert is inserted using the special applicator (Figure 1.3.4) 
with its hinged wings folded forward together. 
Barrel 
33.5 em 
Plunger 
8.5 em 
o 
12.2 em 
Hand grip 
9.5 em 
Figure 1.3.4 - Diagram of the specialised CIDR@1900 Cattle insert applicator 
When released in the vagina, the hinged wings provide retention by exerting gentle 
pressure against the vaginal walls as they flex back towards their original T -shape 
position. Retention rates from 92 to 99.5% have been reported for heifers and 
COWS71 -83 • 
Following insertion of a CIDR®1900 Cattle insert, there is an initial sharp rise in 
plasma progesterone level before it declines to around 3 ng/mL where it remains 
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relatively constant or slowly declines until removal, at which time the level falls 
rapidly to basal concentration3, 5. This typical profile has been reported by several 
authors53, 56, 84-95. Residual progesterone loading in a CIDR@1900 Cattle insert post-
treatment is also large. The residual amount has been shown to be dependent upon 
the initial loading and upon the treatment duration87, 92,96. After a 9 day insertion the 
CID R ® 1900 Cattle insert still contains about 1.1 g and around 0.85 g remains after 
15 days. When three CIDR@1900 Cattle insert were inserted simultaneously each 
insert contained the same residual loading as an insert inserted singly92. Due to the 
high residual in used CIDR@1900 Cattle insert, investigations into reuse of inserts 
have been carried out87, 90, 97-100. Van Cleeff et al. washed, disinfected, dried and 
reinserted CIDR@1900 Cattle insert which had previously been used for 9 days and 
showed that the resulting plasma progesterone levels were significantly lower than 
those obtained for fresh inserts87• 
The invitro release of progesterone from CIDR@1900 Cattle insert has been reported 
by Bunt et al. 101. The release experiment was performed in 1100 mL of 60% alcohol 
to maintain sink conditions and the data was plotted in accordance with the square 
root of time mechanism. The release rate was shown to increase with the addition of 
light liquid paraffin to the matrix and with an increase in the initial progesterone 
loading. The release rate was decreased by the addition of fillers such as calcium 
carbonate to the matrix and by increasing the Shore hardness of the matrix 102. All 
reported observations are consistent with the square root of time mechanism. 
No invivo release profile for CIDR@1900 Cattle insert has been reported in the 
literature. 
1.3.1.3 INVAS 
The intravaginal application system3,4, 5,103,104 (INVAS) is a patented delivery system 
similar in design to the CIDR@1900 Cattle insert in its T-shaped design, but it is 
produced by a different manufacturing method. A polypropylene spine is used to 
give INV AS its form and provide retention in the vagina. Progesterone is 
incorporated with silicone by ball milling. A sheet of milled silicone/progesterone is 
placed in a split mould. The spine is placed on this bottom sheet before a top sheet is 
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positioned and the mould is closed. The sheets are then cured around the spine at 
temperatures between 70 and 120°C. The suggested advantage of curing below 
120°C is that this does not exceed the melting point of either the ~ (121°C) or the ex 
(130°C) crystal habit. 
Retention of the device is reported to be 'good' 103 with less instance of irritation than 
other (unspecified) devices. 
General characteristics of plasma progesterone profiles observed for INVAS are very 
similar to those observed for PruD® or CIDR®1900 Cattle insert, although steady 
state concentrations of approximately 1.5 ng/mL3 are a little lower than those 
achieved with PRID® or CIDR®1900 Cattle insert. 
Invitro release from INVAS is reported to follow a nearly zero-order rate 103 . 
Homykiewytsch obtained invitro data with INV AS devices in 5000 mL pH 7.4 
phosphate buffer, stirred with a blade stirrer, making it difficult to draw comparisons 
with the CrDR ® 1900 Cattle insert. The data also correlate well when plotted 
according to the square root of time model3, 
1.3.1.4 Rajamahendran Device 
Rajamehendran and co-workers developed an intravaginal device containing both 
progesterone and oestradiol-17~ for the control of oestrus in cattle3,4, 5, 105-107. 
Figure 1.3.5 - Diagram of the Rajamahendran Device 
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The device (Figure 1.3.5) is 'umbrella-shaped' and is manufactured from silicone 
rubber tubing (two 20 em lengths) with inside diameter 0.79 em and outside diameter 
1.27 cm4, 5. One end of each tube is sealed and 1 g of progesterone in diethyl ether 
solution is added to each. The open ends are sealed following evaporation of the 
solvent and an extra 1 mL of adhesive containing 10 mg oestradiol-17~ is coated 
onto each of the four tube ends. The two tubes are tied at their centres and curved 
into the 'umbrella' shape. Strings are secured to the free ends to facilitate removal of 
the device post-treatment. The device has a total surface area of around 160 cm2 
with about 40 cm2 initially releasing oestradiol-17~3. 
Retention of the Rajamehendran device is good with 21124 and 11111 heifers 
retaining the devices over 12 days in two studies105. Vaginal irritation was described 
as less than that observed for PRID®. 
Once again, plasma profiles observed follow those typically observed for the other 
silicone intravaginal progesterone delivery inserts although progesterone 
concentration appears to decline gradually over the entire period from day 2 to 12 
rather than achieving a plateau for several days. The presence of oestradiol-17~ was 
found not to influence the absorption of progesterone over a 3 day period105. 
1.3.1.5 SPONGES 
A number of authors have used sponges to deliver progesterone intravaginally in 
cattlelo8-111. Sponges are typically a polyurethane foam with a string tail to aid 
removal (Figure 1.3.6). 
Figure 1.3.6 - Diagram of a polyurethane sponge-type intravaginal insert 
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Devices of varying size and progesterone loading have been investigated. Sponges 
have also been impregnated with the more potent progestagens fluorogestone 
acetate 108, chlormadinone acetate I 12, megestrol acetate I 12, melengestrol acetate 112, 
northandrolonell3 and medroxy progesterone acetate 114-1 16. Sponges are typically 
cylindrical, 6-14 cm in diameter and 5-10 cm in length. Impregnation of a sponge 
with progestagen is typically achieved by applying the required amount of drug in an 
organic solvent. The solvent would then evaporate, leaving a fine dispersion of the 
drug within the sponge matrix. 
Sponges inserted either singly or numbering up to 12 simultaneously for small 
devices, exhibit variable retention characteristics in cattle with figures of between 50 
and 100% being reported. Factors affecting retention appear to be sponge diameter, 
length, density, animal age and vaginal sizel08, 110, 112,117-119. 
Plasma levels of methyl acetoxy progesterone arising from the insertion of 10 small 
(50 mg) sponges have been reportedl14. 
No invitro or invivo release rates have been reported for the sponges used in cattle. 
1.3.2 Oestrus Control Products for use in Sheep 
1.3.2.1 Sponges 
In 1964 and 1965 Robinson reported on the use of progestagen-containing 
intravaginal polyurethane sponges (Figure 1.3.6) for oestrus control in sheepl20, 121. 
Realising there was a market potential, the company GD Searle and Co. began 
manufacturing prototype 20 mg and 30 mg fluorogestone acetate sponges. Wishart 
trialed these devices in 2836 British ewesl22 and confinned Robinson's findings that 
such a device could be used for ewe synchrony. Vaginal retention rates of synthetic 
progestagen sponges are high, although their use is associated with a large volume of 
mucus dischargel21 and, particularly in maiden ewes, some adhesion to the vaginal 
mucosa 122 which results in difficulty of removal. Removal issues were largely 
resolved122 and a number of companies went into sponge manufacture. 
Commercially available products SYNCRO_MATEI22-144, Veramixl29, 145-147 
Repromap147-162 and Chronogese48, 149, 152, 159, 163-169 comprise fluorogestone acetate in 
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polyurethane sponge. Products including Veterdif-Cycle 50 mg126, 170-173, Spogosan 
50 mg 171 , 173, 17\ Repromap 40 mg147, 149, 160,162 and Veramix 60 mg175 comprise methyl 
acetoxy progesterone in polyurethane sponge. 
Plasma profiles for a single 40 mg fluorogestone acetate sponge were determined by 
Gaston-Parry et al. 141, 176. Invivo release was determined for 10, 30 and 90 mg 
sponges by Allison and Robinsonl77 • 
1.3.2.2 CIDR-S 
The CIDR-S was rabbit-eared in shape (Figure 1.3.7), contained 465 mg 
progesterone in a silicone matrix and was commercially available from 1983 to 1989. 
Several papers report the use of CIDR-S in sheepl63, 178-181. The CIDR-S was 
superseded by the CIDR® Sheep and Goat insert which is easier to insert and remove. 
Figure 1.3.7 - Diagram of the CIDR-S intravaginal insert for sheep 
1.3.2.3 CIDR@ Sheep and Goat Insert 
The CIDR® Sheep and Goat insert is a T-shaped insert containing 0.3 g (9% w/w) 
progesterone homogeneously dispersed throughout silicone for use in sheep and 
goats (Figure 1.3.8). 
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Figure 1.3.8 - Diagram of the CIDR® Sheep and Goat insert 
The CIDR® Sheep and Goat insert is approximately 5.4 cm long and 5.8 cm wide 
with a body diameter of around 9 mm. There is a good deal of literature on the 
performance of CIDR@ Sheep and Goat inserts in sheep46,47, 179, 182-190. Retention is 
excellent and ewes show no sign of discomfort when inserts are inserted. A typical 
progesterone profile191 is similar to that observed in cattle. Neither invitro nor invivo 
release data have been reported. 
1.3.2.4 C-Shaped Plasthyd Device 
Mandiki et al. 192 describe a C-shaped intravaginal insert containing progesterone in a 
'plasthyd' polymer device which, over a 12 day treatment period, produced steady 
state plasma progesterone levels of around 0.8-1.0 ng/mL. 
1.3.3 Summary 
This brief review has highlighted the conceptual and commercially available 
intravaginal veterinary drug delivery systems. A critical evaluation of these products 
suggests that there are only a few such delivery systems available, hence providing 
the opportunity for some of the research performed in this Thesis (i.e., the 
development of a new intravaginal veterinary drug delivery system). 
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1.4 Polymers as Platforms for Controlled Release Intravaginal 
Veterinary Drug Delivery 
From the above overvIew of the different technologies used to manufacture 
intravaginal veterinary drug delivery systems, a critical evaluation of those products 
reveals that the only two polymers which have been used as intravaginal drug 
delivery platforms are silicone and polyurethane. This provides a further opportunity 
for research to be performed in this Thesis (i.e. the use of a novel polymer, never 
before used as an drug delivery platform for intravaginal veterinary drug delivery). 
The following Section will discuss the properties of both the currently used 
polymers, namely, polyurethane and silicone and a biodegradable polymer, poly-(s-
caprolactone), which has recently been identified as potentially useful as an 
intravaginal drug delivery platform in farmed animals193, 194. 
1.4.1 Polyurethane 
Polyurethane has been used commercially as a platform for intravaginal drug 
delivery in the form of sponges3, 4, 5. 
1.4.1.1 History of Polyurethanes 
The polyurethanes have been exploited for the delivery of progestagens to control 
the oestrous cycle of sheep (see Section 1.3.2.l). The first urethane polymers were 
developed in the late thirties in the Leverlrusen laboratories of the German Bayer 
Groupl95. By varying monomers, a large number of polyurethanes were produced 
and application of these polymers started to flourish in the late forties. 
1.4.1.2 Synthesis of Polyurethanes 
Polyurethanes are formed by the reaction of a polyhydroxyl compound with an 
isocyanate by the polyaddition principle l95 . 
ROH + R'NCO ~ R'NH - COOR 
21 
CHAPTER ONE CONTROLLED RELEASE INTRA VAGINAL VETERINARY DRUG DELIVERY SYSTEMS 
1.4.1.3 Fabrication Methods Compatible with Polyurethanes 
Polyurethane foams are typically fabricated using foaming machines which pump 
metered amounts of two or more raw materials, mix them together and force the mix 
into a mould or cavity195. The mixture then expands, developing its open cell 
structure before it hardens and cures in the form of the mould. 
1.4.1.4 Properties and Applications of Polyurethanes 
As with all polymers, the properties of the polyurethanes are dependent upon the 
monomers used and the method by which they are processed. Polyurethane foams 
have an open structure which provides air and water permeability, although their 
affinity for water is lowl95 . Foams may be rigid or flexible. For example, 
polyurethanes synthesised from polyether based polyols have good acid and alkali 
resistance and are typically soft and elastic while those synthesised from polyester 
based polyols are resistant to oxidative degradation, are more rigid and have 
excellent strength properties195 . 
Elastic and thermally stable foams are suited to seating and bedding applications and 
are well used in furniture, automotive seating, carpet underlay and apparel 
paddings195. Both flexible and rigid foams are commonly used in packaging 
applications due to their excellent shock absorbing properties 195. Thermal and sound 
insulating properties of some polyurethanes have seen them used in the sandwich 
construction of refrigeration equipment, housing and industrial containment I 95 . The 
foam cell structure of polyurethanes also makes them ideal as air filters and as 
sponges in cleaning or painting applications l95. 
1.4.1.5 Limitations of Polyurethane as an Intravaginal Drug Delivery Platform 
As can be seen above polyurethanes have found application in many areas of 
everyday life. As a drug delivery platform for the intravaginal administration of 
progestagens to sheep and cattle it has found limitations. Firstly, the polymer comes 
preformed and exists as a porous open network. This has two limitations; (i) the 
drug must be incorporated into the polyurethane matrix after it has been formed into 
shape, thereby requiring an additional step in the manufacturing process, and (ii) the 
diameter of the pores is variable and the opportunity to control release using this 
variable does not exist. Secondly the properties of the preformed polymer change 
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following the addition of drugs into the porous network. The addition of 
progesterone to a prefonned sponge, for example, results in an increase in its density 
and flexibility resulting in a reduction in its retention rate in sheep5. Thirdly, the 
shape which can be made from polyurethane is limited to cubes and cylinders, which 
reduces the possibility of insert design. Fourthly, the method of drug incorporation 
is subject to variability leading to quality control issues. Depending upon the 
method of manufacture e.g., submersion in solvent, addition of solvent dropwise to 
the surface of the polyurethane, position solvent is added to the sponge, drying 
method (temperature, speed, etc.), the drug distribution within the sponge can vary 
and affect drug release profiles. Finally, polyurethane sponges tend to encourage a 
mucopurrelent discharge when inserted intravaginally which make them unpleasant 
to remove at the end of a treatment period. 
1.4.2 Silicone 
Silicone has been used commercially as a platfonn for intravaginal drug delivery in 
CIDR® and PRID® products3,4,5. 
1.4.2.1 History of Silicone 
Early work on the polysiloxanes (silicones) was done by Kipping and students at the 
tum of the century. In 1943, the first commercial silicones were manufactured for 
insulating sparkplugs in warplanes. By 1949, it was widely thought that silicones 
might be developed as materials for a variety of industrial uses. Then, in the 1950' s, 
investigations into medical applications for silicones began. By 1953, the first 
silicone specifically for medical application was produced196, 197. 
1.4.2.2 Synthesis of Silicones 
The synthesis of silicones can best be described by the following simplified 
Procedure197,198; 
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heat silica rock with carbon in an electric furnace 
SiOz +C~Si+COz 
treat the silicon with methyl chloride 
Si+CH3CI~SiCI(CH3)2 
treat the dimethyl dichlorosilane with water 
SiClz(CH)z + 2H20~Si(OH)2(CH3)Z + 2HCI 
the extremely unstable dimethyl dihydrosilane immediately condenses to a polymer 
CH3 CH3 
I I 
-Si-Q-Si-Q Si-Q-Si-Q-
I I 
CH3 x CH3 
silicone rubbers can be made heat curing with radical forming agents such as 
dichlorobenzoyl peroxide 
o 0 
11/0-0" II OCICIQ 
CI CI 
--.... - 2COz + 2 OCI 
CI 
the free radical extracts H . from a silicone methyl group and two methyl radicals combine to 
create a silicone crosslink 
CH3 
I 
CH3 
I 
2 -O-Si-O-
I 
HCH 
-O-Si-O-
I 
CHz 
I 
CH2 
I 
-O-Si-O-
1 
CH3 
Figure 1.4.1 - Synthesis of silicone polymers 
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1.4.2.3 Properties of Silicones 
The term silicone is extremely general and encompasses a huge variety of silicon 
based polymers. A wide variety of silicones can be manufactured by controlling the 
polymer chain length and any cross-linking to give silicone materials ranging from 
oils to rubbers. In addition, methyl groups can be substituted for other alkyl groups, 
giving the resulting polymer different properties. As the focus of this Thesis is 
polydimethylsiloxane rubber, the following discussion on properties of silicones 
shall refer largely to the silicone rubbers. 
1.4.2.3.1 Physical and Chemical Properties 196,197 
Fabrication: Silicone rubber is easily moulded into shape and the curing 
(vulcanisation) reaction can be accelerated by applying heat. Typical vulcanising 
agents include stannous octoate for room temperature cure and dichlorobenzoyl 
peroxide for heat cure. A variety of organic compounds can inhibit the curing of 
siliconesI99-201. Inhibitive compounds will contain one of the following functional 
groups: 
Acetylenic or vinylic (e.g. ethynyl oestradiol) 
Carboxylic (e.g. lauric acid) 
Basic amine (e.g. ephedrine, propranolol) 
Pyridine (e.g. nicotine) 
Sulphur (e.g. cimetidine) 
Mechanical properties: The cured polymer has high elongation to failure (100% or 
better). It also has Shore A hardness of around 40-60 or less and is thus not abrasive 
to biological tissues. Silicones can be strengthened by the addition of filler in their 
fabrication. The filler is commonly finely ground silica. 
Temperature resistance: Silicones are indifferent to temperatures, retaining their 
elasticity at low temperature (sub-zero) and retaining their strength at high 
temperatures. Silicones are thermally and oxidatively stable to 500°F (246°C) or 
higher. Also, they do not discolour with heat. This combination of properties allow 
silicones to be sterilized by autoclave for medical use. Silicone rubbers have 
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approximately twice the thermal conductivity of natural rubber, making them ideal 
for some electrical insulation applications. 
Chemical: Silicones have low solubility in organic solvents. Metals will not corrode 
in contact with silicone. When implanted in the body, silicone will not deteriorate 
with time, implying resistance to metabolism, oxidation and ozonization. Gases 
diffuse more readily through silicone than other polymeric materials. 
Table 1.4.1- Gas diffusion through silicone 197 
CO2 O2 N2 He 
Teflon 78 30 14 178 
Silastic 6310 1210 600 730 
millimetres/minute/atmosphere membranes - 0.001 inch thick at 25°C 
Surface properties: With the exception of specialized adhesives, nothing adheres to 
silicone. Tissues will not grow onto them. The viscosity of silicones is a function 
of chain length and cross-linking. Silicones differ from hydrocarbon oils due to the 
free rotation of the methyl groups around silicon. This free rotation leads to large 
interchain space and thus, low viscosity. This is why some low molecular weight 
silicones make excellent lubricants. Many silicones are strongly hydrophobic, 
making them useful as water repellent surface coatings. 
Electrical properties: Silicone is an excellent dielectric and may develop static 
charge on its surface. 
Table 1.4.2 - Electrical properties of Silastic® 372 medical grade elastomer 197 
Dielectric Constant 2.85 
Dissipation Factor 0.003 
Volume Resistivity 5 x 1014 Ohm-cm 
Electrical Strength 525 Volts/mL 
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1.4.2.3.2 Biocompatibility 
The monomeric precursors of silicones tend to be highly toxic. Tetraethyl-ortho-
silicate is acutely toxic202. Alkylchlorosilanes are highly corrosive203 (SiCI4 was used 
in warfare as an irritant gas). Ethoxysilanes cause lung and kidney damage203-205. 
However, polymeric silicones from fluids to higher weight solids are chemically 
inert, have exceedingly low oral toxicity203 and are well tolerated by tissues206 
provided toxic additives are left out of the manufacturing process. Silicone's 
chemical inertness also means that actives incorporated into the polymer will not be 
degraded by their matrix. 
Toxic substances are usually reactive chemicals, whereas polymers are normally 
unreactive. However, reactive chemicals may be used in making polymers and such 
chemicals are the usual cause of any observed toxicity from polymeric materials206. 
Toxic components within polymers may include: 
- Polymer precursors 
- Plasticisers 
- Sterilising chemicals (e.g. ethylene oxide207) 
- Solvents 
A variety of responses may be observed when materials are surgically implanted 
within the body. The foremost is surgical infection where external pathogens enter 
the surgical wound and cause an infection. If surgery is successfully sterile then the 
implant may cause an inflammatory response where the bodies natural defense of 
phagocytic attack occurs at the implant site. If the implant is degradable, the foreign 
material will be decomposed and adsorbed for excretion. When an implant causes 
no inflammation it is said to be biocompatible. In some cases, the body will grow 
into the implant which becomes part of the biological structure. More commonly (as 
is the case with silicone), a fibrous tissue will grow around and encapsulate the 
implanfo8-21I , sealing it off from the rest of the body. 
The definition of medical grade polymer is, therefore, a polymer which has been 
carefully manufactured to exclude any toxic components which may cause an 
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inflammatory reaction in biological tissues. Silicone, with its biocompatibility and 
other excellent properties, has found many applications in medicine197,212-214. 
1.4.2.4 Silicone as a Controlled Drug Delivery System 
Of the polymers used as matrices for drug delivery, silicone has played a prominent 
role. This is because silicone possesses a number of desirable characteristics. When 
selecting a polymer for use in drug delivery, the requirements are215 : 
• Suitable diffusivity and solubility of the drug in the polymer 
• Compatibility with the drug (drug must be stable in the matrix) 
• Compatibility of the polymer with the delivery environment (e.g. 
parenteral body cavity) 
• Stability in the delivery environment 
• Desirable mechanical properties 
• Ease of fabrication 
• Cost 
So, silicone is an excellent material based on all these criteria and all that remains is 
for drugs to be identified which have suitable release characteristics from the 
polymer for practical clinical application. 
1.4.2.5 Limitations of Silicone as an Intravaginal Drug Delivery Platform 
The curing (vulcanisation) of silicone rubbers generally requires high temperatures 
to achieve cure in an efficient time frame (i.e. CIDR@1900 Cattle inserts are moulded 
at 190°C and require approximately 50 seconds to cure at this temperature). Such a 
moulding temperature requires a high process energy input. Further to this, the high 
temperature of moulding limits the drug candidates which can be incorporated into 
silicone rubbers to those which are highly heat stable. 
The drug candidate list for incorporation into silicone intravaginal drug delivery 
systems is further limited by the hydrophobic nature of the polymer as only 
lipophilic drugs will permeate a hydrophobic matrix. Incorporation of pore-forming 
agents into polymeric delivery systems allows hydrophilic drugs to diffuse out of the 
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matrix via the pores that form, but loss of structural integrity tends to occur if pores 
are created within silicone rubbers. 
The elastic nature of silicone impels a requirement for some sort of supporting 
structure for intravaginal drug delivery systems to give them the rigidity needed to 
facilitate intravaginal retention (i.e. The CIDR®1900 Cattle insert comprises an inert 
nylon spine to support its silicone drug delivery matrix). This requirement for 
support adds an extra component to the manufacture of any silicone based 
intravaginal drug delivery system, and hence increases the cost of production. 
Finally, silicone rubbers are non-biodegradable and therefore, when disposed of by 
the common New Zealand method of 'land fill' (an excavated dumping ground in an 
isolated area which will eventually be covered over with earth), they will not 
decompose. 
1.4.3 Poly-( B-caprolactone): A Potential Polymer for Intravaginal Veterinary 
Controlled Drug Delivery 
The above account of the properties and suitability of polyurethane and silicone 
indicates that both these materials exhibit certain characteristics which make them 
ideal for use in the manufacture of intravaginal drug delivery systems. Indeed both 
these polymers have been successfully used in intravaginal veterinary drug delivery 
systems for over 30 years. However, as highlighted in the above accounts, both 
these polymers have limitations as intravaginal drug delivery systems which limit 
either the drug which can be incorporated into them, the clinical condition they may 
be used for, their aesthetic nature, pleasantness of use, etc. In light of these 
limitations, other polymers should be sought which have more ideal properties and 
exhibit greater flexibility with respect to their potential as intravaginal drug delivery 
systems. Although the use of new polymers has been and continues to be 
extensively studied by pharmaceutical scientists interested in controlled release, and 
many have been identified and are used within both the human and veterinary fields, 
until recently no attempts have been made to investigate or utilise newer polymers as 
platforms for intravaginal drug delivery. However, recently Bunt et al. have 
published the results of some preliminary work which suggested that poly-( B-
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caprolactone) may be usefully employed as a platform for the prolonged delivery of 
progesterone to cattle193 • This need for more flexible polymers and the reports by 
Bunt et al. have provided the opportunity for some of the research perfonned in this 
Thesis. In this respect investigations on the polymer poly-(e-caprolactone) are 
conducted and its potential as a platfonn for the delivery of progesterone to sheep is 
investigated. 
1.4.3.1 History of Poly-( 8-caprolactone) 
The ability to form polymers of e-caprolactone was first discovered in the early 
1930'8216• Poly-(e-caprolactone) was subsequently identified as a biodegradable 
polymer which aroused significant interest in its possible application to 
environmentally friendly packaging and for medical applications216. 
1.4.3.2 Synthesis of Poly-( 8-caproiactone) 
Poly-(e-caprolactone) is a linear aliphatic polyester. It is synthesised by ring 
opening polymerisation of epsilon-caprolactone. e-Caprolactone is synthesised by 
the oxidation of cyclohexanone with peracetic acid. The monomer can then be 
polymeri8ed by any of three mechanisms including anionic (Figure 1.5.1), cationic 
(Figure 1.5.2) and coordination (Figure 1.5.3)216, Each unique mechanism provides 
different degrees of control over molecular weight, end-group composition and 
structure of co-polymers. 
o 
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n 
Figure 1.4.2 - Anionic polymerisation of E-caprolactone to form poly-(a-caprolactone) 
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Figure 1.4.3· Cationic polymerisation of E-caprolactone to form poly-(a-caprolactone) 
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Figure 1.4.4 - Coordination polymerisation of E-caprolactone to form polY-(E-caprolactone) 
PolY-(E-caprolactone) can also be synthesised by the radical initiated polymerisation 
of 2-methylene-1, 3-dioxapane. 
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Figure 1.4.5 - Radical polymerisation of 2-methylene-l, 3-dioxapane to form poly-(e-
caprolactone) 
1.4.3.3 Fabrication Methods Compatible with Poly-( s-caprolactone)116 
Thin films «0.1 mm) of poly-(e-caprolactone) and poly-(e-caprolactone) 
copolymers can be prepared by casting from solution in one of the many available 
solvents. More substantial monoliths can be fabricated by various fonns of plastic 
moulding. For example, solid forms have been achieved by compression moulding 
at temperatures of 100-130°C. Tubing has been prepared by melt extrusion at around 
160°C. Fibres have been produced by melt spinning at 161 DC. Microcapsules may 
be prepared by fluidised bed air coating, mechanical or, more commonly, by solution 
methods involving emulsification of the polymer and drug in a two-phase solvent-
nonsolvent mixture in the presence of a surfactant. 
1.4.3.4 Properties of Poly-( a-caprolactone)216 
Poly-(s-caprolactone) is a semicrystalline polymer and melts in the range of 59-64°C 
and has a low glass transition temperature of -60DC. Crystallinity of the polymer 
increases with decreasing molecular weight. Poly-(s-caprolactone) of 100,000 
molecular weight has about 40% crystallinity, while poly-(c-caprolactone) of 5000 
molecular weight is around 80% crystalline. Crystallinity has a marked effect on 
both permeability and biodegradation of polymers. Increased crystallinity decreases 
solute solubility and increases the tortuosity of any diffusional pathways, both of 
which reduce permeability. Biodegradation is inhibited by increased crystallinity as 
the bulk crystalline phase is inaccessible to water. 
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Poly-( s-caprolactone) is soluble in a number of solvents including tetrahydrofuran, 
chloroform, methylene chloride, carbon tetrachloride, benzene, toluene, 
cyclohexanone, dihydropyran and 2-nitropropane. It is insoluble in alcohols, 
petroleum ether and diethyl ether. 
Permeability of poly-( s-caprolactone) to various drugs has been investigated (Table 
1.4.3). Perhaps surprisingly, permeability (J) of poly-(c-caprolactone) to the model 
steroid compound progesterone is of similar magnitude as that of silicone (Table 
1.4.4). This is because the permeability is the product of the saturation solubility 
(Cs) and the diffusion coefficient (D). 
Table 1.4.3 - Diffusion coefficients of various drugs in poly-(e-caprolactone)217 
Drug Diffusion coefficient (x 109 cm2/sec) 
Progesterone 3.6 
Testosterone 7.3 
Norgestrel 4.1 
Norethindrone 6.6 
Ethynyloestradiol 3.3 
Naltrexone 2.4 
Codeine 3.8 
Meperidine 2.5 
Methadone 1.9 
a-Acety Imethadol 2.6 
Table 1.4.4 - Comparison of permeability of silicone and poly-(e-caprolactone) to 
progesterone217 
C
s 
(g/cm3) D (cm2/sec) J (g/cm.sec) 
Silicone rubber 0.5xI0-3 4.5xl0-7 22x 10-11 
Poly-( s-caprolactone) 16.9 x 10-3 3.6 X 10-9 6.1 X 10-11 
Pitt et al.218 also studied factors which affect release rates from poly-( s-
caprolactone). Their work showed a linear relationship between initial drug load and 
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release rate and also an effect due to polymer film thickness. They identified 
fabrication methods of the films as the reason for this observed effect. One thickness 
was prepared by solvent casting while two others were prepared by compression 
moulding. The compression moulded films produced higher release rates. When 
compression moulded, the thinner film produced similar results to the two thicker 
films. Clearly, fabrication methods can affect polymer morphology and, 
subsequently, intrinsic diffusivity of the polymer. 
Poly-(t-caprolactone) is generally regarded as biocompatible and many commercial 
polycaprolactones have acquired FDA approval for medical uses. Toxicology has 
been studied extensively in rats, guinea pigs and monkeys with minimal tissue 
encapSUlating response being the worst observed effect of implanted poly-( 8-
caprolactone) over trials of 90 days to 2 full years216. The human contraceptive 
system Capronor has also been clinically tested in women216. 
1.4.3.5 Potential for Intravaginal Delivery 
Poly-( t-caprolactone) offers great potential as an intravaginal drug delivery platform. 
It has both good permeability to a variety of pharmaceutical agents and has physical 
properties which allow it to be fabricated into controlled drug delivery systems. It 
may be injection moulded into a variety of shapes, indeed injection moulding is a 
favoured technique for delivery system fabrication, as it does not require the use of 
solvents which would then have to be removed from the final product, as well as the 
occupational health and safety issues for the staff working with the solvents. These 
characteristics ofpoly-(t-caprolactone) coupled with the fact that InterAg specialises 
in injection moulding of veterinary intravaginal drug delivery products, has provided 
the opportunity for some of the research performed in this Thesis (i.e. the 
investigation of poly-( 8-caprolactone) as a platfonn for the intravaginal delivery of 
drugs). 
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1.5 Mechanisms of Release From Intravaginal Veterinary Drug 
Delivery Systems 
The invitro and invivo mechanism of release of progestagens from intravaginal 
veterinary drug delivery systems has been identified for both the PRID® and sponge 
delivery systems. The invitro drug release mechanism for the CIDR®1900 Cattle 
insert has also been reported. 
1.5.1 PRID@ 
The invitro release of progesterone from a commercially manufactured PRID® 
device has not been reported in the literature. However, in an effort to characterise 
the invitro release profile of PRID®, Winkler et a1.52 determined the invitro release 
from a hand manufactured progesterone/silicone sheee2• The release medium 
contained sheep serum to create sink conditions and the invitro release profile was 
estimated by detennining the amount of drug remaining in the sheet and calculating 
the amount released from knowledge of the initial drug content in the sheet. 
Although these progesterone containing sheets were not subj ect to the same 
manufacturing conditions as a PRID® device, it is likely that the results and 
conclusions drawn from this study would be applicable. The results suggested that 
the invitro release of progesterone was shown to occur via the square root of time 
mechanism (Equation 1.5.1) (Figure 1.5.1) 52, 
Equation 1.5.1 
where Q is the amount of drug released after time; t, per unit area of exposed area; A 
is the initial drug concentration; Cs is the solubility of the drug in the matrix; and D 
is the diffusion coefficient of the drug in the matrix material. 
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Figure 1.5.1 - PRID® invitro release 
The invivo release of progesterone from the PRID@ device was also investigated by 
Winkler et a1. 52 • Devices were inserted into the vagina of cattle and then removed 
after insertion periods of 2, 6, 9, 12 and 16 days. The silicone matrix on the inside 
and outside surfaces was peeled from the steel and analyzed for progesterone 
content. The progesterone released invivo was then determined by difference from 
the initial progesterone concentration of the device. The invivo release of 
progesterone from the inner and outer surfaces of the PRID® were observed to follow 
a square root of time mechanism, with similar rate constants for the inner and outer 
surfaces (outside rate = 2.597 mg/cm2/day~; inside rate = 2.359 mglcm2/dayY2), but 
with lag times to steady state (based on extrapolated intercepts) of 1.7 and 4.7 days 
respectively (Figure 1.5.2). 
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Figure 1.5.2 - Cumulative amount of progesterone released in vivo as a function of the square-
root-of-time for the inner (+) and outer (e) surface of the intravaginal PRID® device 
containing 7.8% initial progesterone concentration in an inert silicone matrix. Outside rate = 
2.597 and inside rate = 2.359 mg/cm2/dayV,. Based on extrapolated intercepts there are 1.7 and 
4.7 day lag times before reaching steady state for the outside and inside surfaces, respectively. 
Drawn from data given in reference 52. 
The difference between lag times was attributed to physical phenomena such as 
wetting at the polymer surface, establishment of steady state diffusion gradient and 
contact with the vaginal wall. The effect of the time lag difference between the two 
surfaces resulted in the PRlD® releasing progesterone in a pseudo zero-order fashion 
(Figure 1.5.3). 
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Figure 1.5.3 - PruD® total invivo release (zero-order) 
1.5.2 Sponge 
Chien reported an invitro system for studying the mechanism of release and 
intravaginal absorption of fluorogestone acetate from intravaginal sponges219 • The 
system determined the rate of fluorogestone acetate release from vaginal sponges 
and comprised donor and receptor cells which held up to 1 L of elution medium 
thermostatted to 38°C. A magnetic stirrer assembly thoroughly mixed the elution 
media from below. In the study an intravaginal sponge was inserted into the flange 
opening of the donor compartment and an impermeable barrier was sandwiched 
between the two compartments. The strirrers were turned on and 1000 mL of elution 
medium was poured into each of the compartments. At pre-selected time points 2 
mL samples were taken from both compartments. 
Chien's invitro release study suggested that release of fluorogestone acetate from 
polyurethane sponges containing 40 mg of drug dispersed inside the sponge matrix 
occurred by a matrix-diffusion controlled mechanism and was characterised by a 
linear relationship between cumulative amount released and the square root of time 
when sink conditions prevailed in the elution medium. Figure 1.5.4 shows the 
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results obtained when either 40%v/v or SO%v/v polyethylene glycol 400 were 
employed as the elution medium219 • 
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Figure 1.5.4 - Linear relationship between the cumulative amount of fluorogestone acetate (Q) 
and the square-root-of-time (tv,) released from a Chronogest sponge (manufactured from 800 
grade polyurethane sponge) containing 40 mg fluorogestone acetate under sink conditions into 
1000 mL release media comprising (.) 500/0 polyethylene glycol 400 (slope = 2.55 mg/hV,) and 
(a) 40% polyethylene glycol 400 (slope = 2.67 mg/hV,). Redrawn from reference 219. 
The invivo release of fluorogestone acetate from polyurethane sponges has been 
investigated by several authors 177, 220, 221. All these authors found that there was a 
non-linear relationships between the cumulative amount of drug released from 
polyurethane sponges and time (Figure 1.5.S). Allison and Robinson's results typify 
those seen by all of the above mentioned authors. These authors inserted 
flourogesterone acetate sponges containing 10, 30 and 90 mg into the vagina of 
different sheep for 2, 4, 6, 8, 10, 12 and 14 and 16 days. Analysis of residual drug 
content and knowledge of the initial drug load allowed them to determine the invivo 
release profile of fluorogestone acetate from the sponges. Their data indicated that 
the invivo release of fluorogestone acetate from polyurethane sponges occurred 
according to the square root of time release mechanism (Figure 1.5.6). 
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Figure 1.5.5 - Invivo drug release from polyurethane sponges containing 10 mg (e), 30 rug (II) 
and 90 mg (A) of fluorogestone acetate. Data from reference 177. 
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Figure 1.5.6 - Allison and Robinson's in vivo data plotted as a square root of time plot. Data 
from reference 177. 
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1.5.3 CIDR@1900 Cattle Insert 
The invitro release of progesterone from the CIDR@1900 Cattle insert has only 
recently been reported in the literature l01 • Release of progesterone from CIDR®1900 
Cattle insert into 1100 mL 60% alcohol/water mixture was shown to occur via a 
square root of time release mechanism (Figure 1.5.7). 
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Figure 1.5.7 - Invitro cumulative amount of progesterone release per unit area of CIDR®1900 
Cattle insert versus the square root of time101 
The invivo mechanism of release of progesterone from a CIDR@1900 Cattle insert 
has not been reported in the literature. This has provided the opportunity for some of 
the research performed in this Thesis. 
1.6 Recent Advances in Controlled Release Intravaginal Veterinary 
Drug Delivery 
Since the early 1990' s three significant advances have been made in the field of 
intravaginal veterinary drug delivery. Optimisation of the CIDR@1900 Cattle insert 
for the delivery of progesterone by Rathbone and co-workers, the optimisation of the 
sponge to deliver fluorogestone acetate by Chien and co-workers and the 
introduction of an electronically controlled drug delivery system which was capable 
of delivering progesterone, oestradiol and prostaglandin at different times and rates. 
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1.6.1 Optimisation of the CIDR@1900 Cattle Insert 
The CIDR@1900 Cattle insert has been described in Section 1.3.1.2. This insert has 
recently been optimised by Rathbone and co-workers6• The CIDR@1900 Cattle insert 
was originally developed for synchrony of oestrus and was designed for insertion 
periods of 12 days. The CIDR®1900 Cattle insert was originally designed to contain 
1.9 g (10%w/w) progesterone to assure 12 day effectiveness. In recent times our 
understanding of the physiology of cattle has increased (as described in Section 
1.2.2.5) and when progesterone is continuously administered and used in 
combination with other drugs progesterone only needs to be delivered for a 7 day 
period. The outcome of this is that the CIDR ® 1900 Cattle insert exhibits a high 
residual content of progesterone in spent devices which have been inserted for 
periods shorter than 12 days (e.g., 1.33 g of progesterone remains in the existing 
insert following removal after 7 days). The CIDR@1900 Cattle insert was therefore 
recently redeveloped so that it initially contained the minimum amount of 
progesterone for a 7 day treatment period, yet produced the same plasma 
progesterone profiles and which resulted in the minimum possible amount of 
progesterone left in the spent insert at the end of the 7 day insertion period. 
Initially in the optimisation process the CIDR@1900 Cattle insert was characterised 
by Rathbone et al. Part of this process identified that the CIDR@1900 Cattle insert 
had a variable skin thickness ranging from 1 to 5 rnm. Next variables which could 
potentially affect the amount of progesterone released from the intravaginal insert 
were investigated and included initial drug load and surface area. In addition, the 
extent of depletion of progesterone from the silicone rubber matrix was determined. 
It was found that lowering the initial drug load to below 10%w/w resulted in lower 
blood plasma progesterone levels in cows. However, increasing the initial drug load 
above 10%w/w did not produce elevated levels above those seen with a lO%w/w 
load6, 222. The surface area of the intravaginal inserts was found to affect the 
magnitude of blood plasma progesterone levels with increases in surface area 
producing increases in progesterone levels in a linear fashion6, 222. Analysis of spent 
inserts for progesterone depletion zones of the silicone rubber matrix revealed that 
42 
CHAPTER ONE CONTROLLED RELEASE INTRAVAGINAL VETERINARY DRUG DELIVERY SYSTEMS 
progesterone had only been released from the outer 1 mm of the silicone rubber 
matrix. 
As a result of these studies, Rathbone and co-workers determined that the 
optimisation criteria could not be met by simply reducing the initial percentage drug 
load of the silicone rubber matrix as this would result in lower blood plasma 
progesterone levels. Similarly, the insert could not be optimised by a reduction in 
physical size as a reduction in surface area would result in a reduction in plasma 
levels. However, as progesterone was only released from the outer millimetre of 
silicone rubber matrix, the CIDR@1900 Cattle insert could be successfully optimised 
by designing an insert to have the same 10%w/w initial drug loading and the same 
overall surface area but with an even skin thickness of 1 mm over the entire 
optimised insert. These design criteria resulted in the elimination of the deeper 
layers of skin which did not contribute to drug release. The optimised design called 
the CIDR@1380 Cattle insert contained a lower initial progesterone load (1.38 g 
compared to 1.9 g), produced the same clinical efficacy and contained only 700 mg 
of progesterone when it was removed after 7 days. 
1.6.2 Optimisation of the Sponge 
As early as 1967 it was known that sponges were wasteful in their delivery of 
progestagen223 • These authors showed that only 12-24% of progestagen released 
from a polyurethane sponge was absorbed from the vagina and that 98% of the 
absorbed drug was excreted in urine and faeces. 
In the late 1980' s, Kabadi and Chien set out to redesign the sponge in order to 
minimize the loading dose, overcome the declining (square root of time) intravaginal 
release profile and absorption profiles, as well as to improve systemic bioavailability 
and dose utilisation 144, 224. The pair developed two new intravaginal inserts, both 
employing polyurethane sponge as a mechanical support for retention (Figure 1.6.1). 
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Figure 1.6.1 - Diagram of Type 1 (top) and Type 2 (bottom) prototype sponges 
The Type 1 device comprised a progestagen/silicone monolith sandwiched between a 
rate-limiting non-drug loaded silicone membrane, however, this delivery system 
released insufficient drug to control the oestrous cycle of sheep. The authors 
predicted that a rate-limiting membrane thickness of 0.05 mm would have been 
required to achieve the desired release rate, but fabrication of such a thin coating was 
beyond their manufacturing capabilities. The Type 2 device simply comprised a 
progestagen/silicone monolith adhered to the outside of a sponge. The mechanism of 
release from such a design was shown to be dependent upon initial load. A 2% 
fluorogestone acetate load resulted in a zero-order release profile; a 0.2% load 
resulted in a square root of time release profile. The authors demonstrated that the 
invivo release could be modified by altering the surface area of silicone monolith225 
and used this information to optimise the surface area of their Type 2 silicone drug 
delivery system to produce a delivery system which was clinically efficacious. The 
resultant delivery system (18 cm2 (2% load), 20 mg fluorogestone acetate device) 
was evaluated in sheep and was found to exhibit comparable efficacy to the 
conventional polyurethane sponge containing 40 mg fluorogestone acetate. The 
resultant delivery system successfully reduced the loading dose, exhibited a zero-
order intravaginal release profile, as well as demonstrating improved dose utilisation. 
1.6.3 Electronically controlled drug delivery system 
The Intelligent Breeding Device (IBD) (Figure 1.6.2) is the most recent and 
technologically advanced controlled release drug delivery system to be developed for 
oestrus control. It was designed and marketed by PLADE Holdings Limited. It is 
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used for the control of the cattle oestrous cycle3, 4, 5. As discussed in Section 1.2.2.5, 
current fertility control programmes involve administration of a number of 
pharmacologically active compounds to ensure precise oestrus synchrony and 
ovulation coupled with high fertility rates. The continuous administration of 
progesterone to control the cycle, an initial dose of oestradiol at the beginning of 
treatment to induce follicular turnover and the administration of a prostaglandin one 
to two days before cessation of progesterone delivery are common treatment 
programs used in modem day animal breeding programs. The IBD was designed to 
contain the three drugs commonly used in fertility treatment programmes (oestradiol, 
prostaglandin and progesterone) and release these at different rates (oestradiol and 
prostaglandin-pulsed delivery; progesterone-continuous release) and times 
(oestradiol-l hour after insertion; prostaglandin 6 days after insertion; progesterone-
continuously for 1 0 days) following administration. 
The delivery system contains a circuit board which controls the timing of release of 
each of the incorporated drugs. The circuit board, along with drug reservoirs and 
batteries are enclosed in a plastic sheath which has a tail to aid removal and an eight 
pronged shaped retention mechanism. The IBD contains four drug reservoirs (one 
large reservoir at the base of the device which contains progesterone and three 
smaller reservoirs at the head of the device). The large progesterone reservoir was 
under pressure due to a loaded spring and plunger arrangement. The progesterone 
was prevented from being released from the reservoir by a closed orifice. However, 
a solenoid frequently opened the orifice at intervals to allow the progesterone 
solution to be released continuously throughout treatment. The smaller reservoirs 
were located at the head of the device and these were also under pressure by a spring 
and plunger arrangement. One of the smaller reservoirs contained a single dose of 
oestradiol and another contained a single dose of prostaglandin. A secured plastic 
cord held the plunger taught and was secured over a resistor. Release of the plunger 
occurred by melting the cord on activation of the resistor. The electronic circuitry 
controlled when these smaller reservoirs delivered their contents. Despite the 
complexity in design and manufacturing requirements, the IBD offers the advantage 
of minimising the requirements for stock handling and veterinary visits for farmers 
in synchrony treatments resulting in lower cost treatment programmes. 
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Figure 1.6.2 - External featores of the SMARTT I'M mo. 
1.7 Aims of Thesis 
A review of the current scientific literature has identified several areas where new 
work could be carried out to add to the knowledge base on intravaginal drug delivery 
for the control of oestrus in farmed livestock. 
Recent advances in our understanding of the control of oestrus in cattle have been 
discussed and have identified that use of progesterone in fertility programmes should 
be restricted to shorter treatment periods with the coadministration of other 
compounds to ensure precise synchrony and high fertility. This knowledge led 
Rathbone and co-workers to the optimise the CIDR<1i1900 Cattle insert to produce 
appropriate plasma progesterone levels while containing both lower initial and 
residual progesterone contents. This Thesis performs a thorough invitro and invivo 
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pharmaceutical characterisation of the resultant commercially available (CIDR@1380 
Cattle insert) as well as the original CIDR@1900 Cattle insert (Chapters Two and 
Three). In Chapter Four the invivo mechanism of release of CIDR®1900 Cattle 
inserts is investigated. In this Chapter a novel mechanism of release is identified and 
elucidated. 
In the Introduction to this Thesis, recent advances in fertility control applications in 
sheep were discussed. A need to optimise the current commercially available CIDR® 
Sheep and Goat insert to assure efficacy in more demanding applications was 
identified. The knowledge gained from the CIDR@1900 Cattle insert characterisation 
process was used to optimise the silicone CIDR ® Sheep and Goat insert technology 
for use in sheep (Chapter Five). 
Only two polymers have been utilised as platforms for the delivery of progestagens 
via the vagina of sheep (silicone and polyurethane). Although both these polymers 
have been successfully utilised in commercially available intravaginal veterinary 
drug delivery systems, they both have inherent limitations and disadvantages. In this 
Thesis poly-( s-caprolactone) was identified as an alternate material to these 
polymers which overcomes their limitations and disadvantages. Chapter Six 
discusses the development and optimisation of an intravaginal delivery system 
manufactured from poly-( s-caprolactone) for the control of oestrus in sheep. The 
results suggest that poly-( s-caprolactone) may be a suitable polymer for use as a 
platform for the intravaginal delivery of progesterone. 
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systems for the delivery of progesterone for control of the bovine 
oestrous cycle. I. Chemical, physical and biological characteristics 
of CIDR@1900 Cattle insert and CIDR@1380 Cattle insert. 
2.1 Introduction 
The introductory Chapter of this Thesis described some limitations of the 
commercially available CIDR@1900 Cattle insert intravaginal veterinary drug 
delivery system. These limitations were recognised by Rathbone and his co-workers 
who have recently reported on the optimisation of the CIDR®1900 Cattle insert6. 
Their work resulted in prototype inserts which exhibited a reduction in the initial 
progesterone content and reduced residual progesterone content compared to the 
CIDR®1900 Cattle insert. However, their prototype inserts delivered sufficient 
progesterone such that plasma profiles were equivalent to those exhibited by the 
CIDR®1900 Cattle insert. 
Optimisation of the CIDR®1900 Cattle insert was achieved following an extensive 
study which investigated those factors which affected the invitro and invivo release 
of progesterone from CIDR@1900 Cattle insert6• 102.222. Rathbone and his co-workers 
used this information to define the procedure which should be undertaken to 
optimise the CIDR®1900 Cattle insert. They then demonstrated the validity of their 
optimisation recommendations by manufacturing an intravaginal insert using a 
prototype mould. 
Recently, precision made commercial moulds have been manufactured to produce an 
intravaginal insert referred to as the CIDR®1380 Cattle insert. Rathbone and his co-
workers have not performed any pharmaceutical characterisation experiments on the 
CIDR@1380 Cattle insert. Hence, this chapter is concerned with the in-depth invitro 
and invivo pharmaceutical characterisation of the CIDR ®13 80 Cattle insert and 
covers both the initial I-up tooling (a stainless steel tool which allowed only 
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one insert to be injection moulded at a time) and 6-up tooling processes (a stainless 
steel tool which allowed six inserts to be injection moulded at a time) which were 
undertaken as the CIDR@1380 Cattle insert went through its production scale-up to 
final manufacture. A I-up tool was manufactured to assure the Company that the 
theories developed by Rathbone et al. which led to their prototype insert were valid 
with production made inserts. To assess the performance of the I-up CIDR@1380 
Cattle insert, its invitro and invivo characteristics were compared to the CIDR@1900 
Cattle insert. A six-up tool was manufactured to increase manufacturing capacity of 
the CIDR@1380 Cattle insert. To assess the performance of the 6-up CIDR®1380 
Cattle insert, its invitro and invivo characteristics were compared to the I-up 
CIDR®1380 Cattle insert. 
Invitro characterisation involved determination of initial drug load, surface area, skin 
thickness, skin weights, percentage drug load and invitro drug release profile. Invivo 
characterisation involved bioequivalence studies and determination of residual 
content in spent inserts. The reasons for choosing these characteristics for 
investigation are shown in Table 2.1.1. 
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Table 2.1.1 - Pharmaceutical characteristics investigated 
Characteristic Reason for Selection Reference 
Initial drug load Optimisation aim was to 6,222 
reduce drug load 
Skin weight Shot weight variation 6 
occurs in manufacturing 
which creates possible 
variation in drug load and 
is required to determine 
percentage drug load 
Percentage drug load Because of shot weight 6 
variation, percentage drug 
load is a more consistent 
variable. 
Rathbone et al. 
demonstrated that 
biological effect is more 
dependent on percentage 
drug load rather than total 
drug load 
Surface area Bunt et al. demonstrated 222 
that surface area is an 
important determinant of 
the magnitude of plasma 
profiles 
Skin thickness Rathbone et al. reported 6 
progesterone is only 
released from the first 1 
mm of silicone skin from 
an intravaginal insert 
Invitro drug release profile A rapid measure of the 101 
release characteristics of a 
controlled release product 
Bioequivalence A definitive measure of 6 
the comparative 
performance of the test 
insert with the original 
Residual content in spent Reduction in residual 6 
inserts content was a goal of the 
optimisation process 
Amount released In conjunction with the 6 
bioequivalence study this 
gives a measure of the 
comparative performance 
of the test insert with the 
original 
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2.2 Experimental Methods 
2.2.1 Ultra-Violet (UV) Spectrophotometric Assay for Progesterone in CIDR® 
Cattle Inserts Following Extraction from Silicone Skin or Released During an 
Invitro Drug Release Test 
2.2.1.1 Method 
Progesterone content In ethanolic solutions was determined by UV 
Spectrophotometry at 240 run (DU650i, Beckman, USA). This method was applied 
to detennine progesterone content of CIDR® cattle inserts after extraction of the 
progesterone from the silicone skin, or after its release during an invitro drug release 
test. 
2.2.1.2 Standard Preparation 
Standards were prepared by transferring 0.1000 g progesterone standard (USP 
micronised, Pharmacia & Upjohn , USA) into a 100 mL volumetric flask followed 
by the addition of 50 mL alcohol (SDA-3A, Mobil, New Zealand). The mixture 
was sonicated until the progesterone completely dissolved, made up to volume with 
alcohol (SDA-3A, Mobil, New Zealand) and mixed by inversion. 200 ~L, 500 iJ-L, 
1000 j.lL, 1500 ~L and 2000 ~L aliquots were then pipetted into 50 mL volumetric 
flasks, made up to volume with alcohol (SDA-3A, Mobil, New Zealand) and mixed 
by inversion. 
2.2.1.3 Sample Preparation (Extraction Procedure) 
CIDR® Cattle insert samples were prepared for progesterone content 
determination by a Soxhlet extraction procedure. Drug loaded silicone skin was 
removed from the nylon spine and weighed on a four figure analytical balance 
(BP110S, Sartorius, Germany). The skin was cut into 5-8 cm lengths using a 
scalpel and the lengths were placed into a Soxhlet apparatus, ensuring that all 
lengths sat below the siphon level. 350 mL ethanol (SDA-3A, Mobil, New 
Zealand) was added to the round bottom flask of the Soxhlet apparatus and then 
the flask, Soxhlet and water cooled condenser were assembled in a heating 
mantle (Electromantle ME, Electrothennal, Britain). Skins were extracted for at 
least 12 hours and allowed to cool before transferring (with rinsing) to a 500 mL 
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volumetric flask and making the volume up to the mark with ethanol (SDA-3A, 
Mobil, New Zealand). This solution was then diluted (0.5 mL to 100 mL) with 
alcohol (SDA-3A, Mobil, New Zealand) prior to analysis by UV 
Spectrophotometry at 240 nm. 
2.2.1.4 Sample Preparation (Invitro Drug Release Test) 
Samples collected during invitro drug release testing of CIDR® Cattle inserts were 
prepared for analysis by evaporating off the hydro-alcoholic release media in a 
drying oven (SERIES FIVE OVEN, Contherrn, UK) at 80°C over 24 hours and then 
reconstituting the samples in 5 mL ethanol (SDA-3A, Mobil, New Zealand). The 
reconstitution step involved addition of the 5 mL ethanol aliquot from a dispenser 
(dosipet 30 mL, Kartell) followed by 10 seconds vortexing, sonication for at least 5 
minutes (SONOREX SUPER RK 5l0H, Bandelin Electronic, Germany) and a 
further 10 seconds vortexing. A 0.5 mL aliquot of the reconstituted solution was 
then diluted by addition of 5 mL ethanol (SDA-3A, Mobil, New Zealand) before 
analysis by UV spectrophotometry at 240 run. The sample preparation by 
reconstitution method was validated by performing the procedure as written on 
replicate ImL aliquots of standard solutions at low (0.22 mg/mL) and high (1.10 
mg/mL) concentrations and analysing the reconstituted validation standards by the 
UV spectrophotometric method. 
2.2.1.5 Validation of the UV Spectrophotometric Assay 
The UV spectrophotometric assay was validated by assessment of its linearity and 
range, accuracy, precision, ruggedness, limit of quantitation and specificity226-228. 
2.2.1.5.1 Linearity and Range 
The linearity of an analytical method is defined as its ability to elicit test results that 
are directly proportional to the concentration of analyte in samples within a given 
range; the range being the interval between the upper and lower levels of analyte that 
have been demonstrated to be detennined with precision, accuracy, and linearity 
using the method as written. Linearity was determined by analysing two sets of 
calibration standards (4, 10, 20, 30 and 40 J.lg/mL) and perfonning linear regression 
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upon the results. The range was detennined by analysing validation standards at 4 
and 40 j.lg/mL and determining their concentrations against the linear regression. 
2.2.1.5.2 Accuracy 
Accuracy is defined as the nearness of a result to the true or accepted value. 
Accuracy was determined by analysing validation standards at 8, 15 and 35 .ug/mL, 
calculating their concentrations against the linear regression and assessing the 
deviation of the calculated results from their true concentrations. 
2.2.1.5.3 Precision 
Precision is defined as the agreement of repeat observations made under the same 
conditions. Precision occurs on different levels including repeatability (multiple 
absorbance readings of the same solution), and reproducibility (determination of 
multiple known samples). Repeatability was assessed by executing repeat 
absorbance readings of a single standard solution and determining the relative 
standard deviation of the results about their mean value. Reproducibili ty was 
determined in association with accuracy. The concentrations of replicate 8, 15 and 
35 J-tg/mL validation standards were calculated against the linear regression and the 
relative standard deviations of the results about their means were determined. 
2.2.1.5.4 Ruggedness 
Ruggedness is an element of precision and is defined as agreement in the 
determination of multiple known samples using the same method but under different 
conditions such as day of analysis and analyst carrying out the experiment. 
Ruggedness was detennined by replicate analyses of CIDR® inserts on multiple days 
and with multiple analysts. 
2.2.1.5.5 Limit of quantitation 
The limit of quantitation is defined as the lowest concentration of analyte in a sample 
that can be determined with acceptable precision and accuracy under the stated 
experimental conditions. The limit of quantitation was detennined by detennining 
the background response of the method from mUltiple blank determinations, 
followed by analysis of standards near the determined limit. 
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2.2.1. 5. 6 Specificity 
Specificity is defined as the ability of the method to resolve a substance from its 
impurities and any other substances such as degradation products or placebo 
ingredients of the product. Specificity of the UV spectrophotometric assay was 
assessed by analysis of progesterone standards in the presence of any unknown 
compounds extractable from the silicone CIDR® matrix. 
2.2.2 Invitro Drug Release Test 
2.2.2.1 Invitro Drug Release Test Method 
Release of progesterone from CIDR® Cattle inserts was assessed using a modified 
USP dissolution apparatus (Hanson SRlI8 Dissolution Test Station, Hanson 
Instruments, USA). Inserts were held in specially manufactured stirrer paddles 
(Figure 2.2.1) so that they could be centralised in the flasks (Figure 2.2.2) and 
rotated at 150 rpm. Lids were specially designed (Figure 2.2.3) to accommodate the 
specially designed stirrer paddles and the standard autosampler probes while 
minimising the evaporative loss of release media over the duration of each invitro 
drug release assessment test. The release media used comprised 1100 mL of 62.5% 
ethanol (SDA-3A, Mobil, New Zealand) and 37.50/0 double distilled water 
(AUTOSTILLTM Auto Four WS SYSTEM, Jencons Scientific Ltd., UK) maintained 
at 37°C. Release media composition was selected based on the requirement for 
maintenance of perfect sink conditions in the release media throughout the duration 
of the invitro drug release assessment test. The volume of 1100 mL was identified as 
a suitable volume which could be used to fully cover the CIDR® with the vortexing 
created by rotating the stirring system at 150 rpm. Sink conditions are maintained 
provided the concentration of drug in the release media does not exceed 10% of its 
saturation solubility in the release media. Solubility of progesterone in a1cohol:water 
media was determined by Rathbone et al. (personal communication) (Table 2.2.1). If 
all 1900 mg progesterone were released into 1100 mL release media of the selected 
composition then progesterone would be present at approximately 6% of its 
saturation concentration. Samples (1 mL) were collected automatically (Hanson SIP 
Control, Hanson Instruments, USA), evaporated to dryness and reconstituted prior to 
analysis by the UV spectrophotometric assay described in Section 2.2.1. Predefined 
sample collection times were 2 minutes, 2, 4, 8, 12, 24, 48, 72 and 96 hours. Since 
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the CIDR@1380 Cattle insert approached exhaustion of its load sooner than the 
CIDR@1900 Cattle insert, rate constants were calculated using data up to and 
including 48 hours for both inserts. Data to this time was linear as a function of the 
square root of time and allowed direct comparison of all inserts. 
Figure 2.2.1 - Front elevation (top left), side elevation (top right) and plan view of mounted 
existing CIDR®1900 Cattle insert in specially designed holder (bottom left). 
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Figure 2.2.2 - Front view of a mounted existing CIDR@1900 Cattle insert and position in flask. 
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Figure 2.2.3 - Lid design for release assessment apparatus. 
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Table 2.2.1 - Solubility of progesterone in various alcohol:water mixtures at 37°C (Rathbone et 
al., personal communication). 
Alcohol concentration 
(%w/w) 
100 
80 
60 
50 
40 
20 
o 
Solubility 
(mg/mL) 
101.29 
76.68 
25.00 
10.85 
3.86 
0.15 
0.01 
2.2.2.2 Validation of the Invitro Drug Release Test 
sem 
(N=3) 
4.13 
4.02 
2.38 
0.47 
0.06 
0.00 
0.00 
Validation of the accuracy of the invitro drug release test was not possible as there 
are no applicable external standards to measure the CIDR® Cattle inserts against. 
However, the invitro drug release test was validated for reproducibility, ruggedness 
and robustness to demonstrate that the technique was suitable for use. 
2.2.2.2.1 Reproducibility and Ruggedness 
Reproducibility is an element of precision (i.e., the agreement of repeat observations 
made under the same conditions) and is defined as the determination of multiple 
known samples. Ruggedness is an element of precision and is defined as agreement 
in the determination of multiple known samples using the same method but under 
different conditions such as day of analysis. 
Reproducibility of the invitro drug release test was determined by testing a number 
of I-up CIDR®1380 Cattle insert from the same production batch. Ruggedness was 
determined by subjecting further inserts from each of a second and third production 
batch to the invitro drug release test. 
2.2.2.2.2 Robustness 
Robustness is defined as the ability of the method to produce accurate, reproducible 
determinations in spite of deliberate deviations from the method as written. 
Robustness was assessed by inducing deviations from both method variables and 
sample variables. Several different parameters were assessed. The speed at which 
samples were rotated or stirred was examined by reprogramming the dissolution test 
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apparatus. The alcohol concentration of the release media was examined by mixing 
different ratios of ethanol (SDA-3A, Mobil, New Zealand) and double distilled 
water. The ionic strength of the release media was examined by the addition of 
appropriate quantities of sodium chloride to the release media (AnalaR®, BDH, New 
Zealand). The pH of the release media was examined by the dropwise addition of 
either concentrated hydrochloric acid (AnalaR®, BDH, New Zealand) or 2M sodium 
hydroxide (AnalaR®, BDH, New Zealand), measuring pH (GP353 ATC pH METER, 
EDT Instruments) after each addition until the desired pH was achieved. Finally, the 
initial drug load of CIDR@ inserts was examined using progesterone loaded I-up 
CIDR@I380 Cattle insert containing 2.5, 5, 7.5, 10, 15 and 25 %w/w. 
2.2.3 Manufacture of CIDR® inserts 
All CIDR® Cattle inserts were manufactured using InterAg's patented high 
temperature injection moulding process. Progesterone (USP micronised, Pharmacia 
& Upjohn , USA) was mixed at IO% w/w in both parts A and B silicone (Silastic® 
Q7-4840, Dow Coming, USA) in a dynamic epicentric mixer (InterAg, Hamilton, 
New Zealand) for a minimum of 2 hours. The mixture was then evacuated for a 
minimum of 2 hours at 60 kilopascals. Nylon (Ultramid A3K, BASF, Germany) 
spines were annealed in a water bath at 70°C for 7.5 hours. Spines were then placed 
in a tool cavity in an injection moulding machine (LIM-I00-35V, Sanjo Seiki Co., 
Ltd., Japan; Type PS40E5A, Nissei Plastic Industrial Co., Ltd., Japan; 320M-500-
210, Arburg GmbH & Co., Gennany) and drug loaded silicone parts A and B were 
simultaneously injected through a pre-mixing static mixer around the nylon spines 
and cured for approximately 50 seconds at around I90°C. 
2.2.4 Invitro Characterisation of CIDR® Cattle Inserts 
2.2.4.1 Location of Progesterone in CIDR@ Cattle Inserts 
The location of progesterone in CIDR® Cattle inserts after moulding was determined 
by separating the silicone skin from the nylon spine of CIDR®1900 Cattle inserts and 
performing a separate Soxhlet extraction on both the skin and spine. Drug content 
was determined by the UV assay described in Section 2.2.1. 
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2.2.4.2 CIDR@ Cattle Insert Skin Weight 
The weight of the progesterone containing silicone skin of CIDR® Cattle inserts was 
determined by first removing the skin from the nylon spine using a scalpel and then 
weighing the removed skin on a four figure analytical balance (BP 11 OS, Sartorius, 
Germany). 
2.2.4.3 Initial Drug Load 
The amount of drug in CIDR ® Cattle inserts was determined by Soxhlet extraction of 
the skin with ethanol (SDA-3A, Mobil, New Zealand) and analysis of the resulting 
extracts by UV Spectrophotometry (See 2.2.1). The amount of drug in CIDR® Cattle 
inserts was also determined as a percentage of the total weight of the injection 
moulded skin by dividing the amount of drug extracted from the skin by the initial 
skin weight and multiplying by one hundred. 
In cases where initial loads were not directly determined by Soxhlet extraction and 
UV spectrophometry due to insufficient supply of CIDR® Cattle inserts from the 
same manufacturing batch, initial load was estimated mathematically (defined 
below) from the mean residual determination, the total residual skin weight and the 
known percentage initial load. This applied to both the CIDR ® 1900 Cattle insert 
and CIDR®1380 Cattle insert, each manufactured to contain 10%w/w progesterone. 
R + r = I and .... 
R + Ws = 1/10% = Wr 
=> I - r = (I/ 0.1) - Ws 
=> (I / 0.1) - I = Ws - r 
=> (I - 0.1 I) / 0.1 = W s - r 
=> 91 = Ws - r 
=> I = (W s - r) / 9 
where 
I Initial progesterone load in CIDR® Cattle insert 
R Amount of progesterone released (g) 
r Residual progesterone in spent CIDR ® Cattle insert (g) 
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Ws = Weight of skin containing progesterone of spent CIDR® Cattle insert (g) 
W f Weight of skin containing progesterone of fresh CIDR ® Cattle insert (g) 
2.2.4.4 Surface Area 
The surface area of CIDR® Cattle inserts was determined by wrapping inserts in 
aluminium foil of known density per unit area (0.0034 g/cm2) and weighing 
(BPI lOS, Sartorius, Germany) the foil required to cover the insert. The surface area 
was calculated by dividing the foil weight by its density per square centimetre. 
2.2.4.5 Skin Thickness 
The skin thickness of CIDR ® Cattle inserts was measured at a series of pre-
determined positions (Figure 2.2.4) using an outside micrometer (Moore and Wright, 
Sheffield). 
3 
2 4 
5 6 
iio'l 
L.. ..... .J 
9 
7 8 
Figure 2.2.4 - CIDR® Cattle insert with pre-chosen positions depicted 
2.2.5 Invivo Characterisation of CIDR® Cattle inserts 
2.2.5.1 Plasma Progesterone Profiles 
Ethical approval was obtained from both the AgResearch, Ruakura Animal Ethics 
Committee and from the University of Waikato Animal Ethics Committee on the 
Welfare of Experimental Animals. All animal work was carried out with supervision 
from a veterinarian. 
The invivo plasma progesterone profiles were determined in the following manner. 
CIDR® Cattle inserts were inserted into the vagina of bilaterally ovariectomised 
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Friesian cows maintained by Dairying Research Corporation (DRC) using a standard 
CIDR ® Cattle insert applicator. Treatments were terminated by removing the insert 
from the vagina. Plasma samples were collected by trained AgResearch personnel 
from the coccygeal vein of the cows on predetermined days over the insertion period. 
For more intensive bleeding schedules, cows were cannulated in the jugular vein by 
a veterinarian. The cannulation procedure was accompanied by antibiotic treatment 
and cows were kept in stalls while cannulated. Plasma was separated by 
centrifugation and stored at -20°C for subsequent progesterone analysis. 
Concentrations of progesterone in plasma were determined by direct radio immuno 
assay by trained technicians at DRC laboratories using a commercial solid phase 1125 
label (Coat-a-count, DPC, USA). 
The liveweight and liver function of all ovariectomised cows was monitored to 
ensure no bias was introduced to the data. 
The experimental design of the invivo trials carried out in this chapter are shown in 
Tables 2.2.2 to 2.2.5. 
Table 2.2.2 -7 day bioequivalency trial comparing I-up CIDR@1380 Cattle insert to CIDR®1900 
Cattle insert 
Formulations Insertion Time Number of Crossover Trial 
Animals design 
A versus B (days) (N) (Yes or No) 
CIDR@1900 I-up 7 8 Yes 
Cattle insert CIDR@1380 
Cattle insert 
Table 2.2.3 - 10 day bioequivalency trial comparing I-up CIDR@1380 Cattle insert to 6-up 
CIDR@1380 Cattle insert 
Formulations Insertion Time Number of Crossover Trial 
Animals design 
A versus B (days) (N) (Yes or No) 
CIDR@1900 I-up 10 10 Yes 
Cattle insert CIDR@1380 
Cattle insert 
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Table 2.2.4 - 20 day bioequivalency trial comparing I-up CIDR@1380 Cattle insert to 
CIDR@1900 Cattle insert 
Formulations Insertion Time Number of Crossover Trial 
Animals design 
A versus B (days) (Nl (Yes or No) 
CIDR®I900 I-up 20 10 Yes 
Cattle insert CIDR@1380 
Cattle insert 
Table 2.2.5 - 10 day bioequivalency trial comparing I-up CIDR@1380 Cattle insert to 
CIDR@1900 Cattle insert 
Formulations Insertion Time Number of Crossover Trial 
Animals design 
A versus B (days) (N) (Yes or No) 
I-up 6-up 10 24 No 
CIDR®1380 CIDR@1380 
Cattle insert Cattle insert 
2.2.5.2 Pharmacokinetic Analysis of In vivo Plasma Profiles Following Insertion 
ojCIDR@ Cattle Inserts 
The Area Under the Curve (AUC) was determined from the blood plasma 
progesterone levels determined at given time points over the duration of treatment 
with intravaginal inserts for each individual cow treated. The AVC were determined 
by simple numeric estimation using the trapezoidal rule229 using the following 
equations: 
Ck +C j AUC. = xT,. 
I 2 Equation 2.2.1 
Equation 2.2.2 
where: 
AUC j is the area under the curve over the ith time interval (i.e., Area under curve 
between the fh sample time and the kth sample time). 
Ck is the plasma level (ng/mL) at the kth sample time. 
Cj is the plasma level at the fh sample time. 
T j is the numerical value of the ith time interval (days) (Le., Time at which the kth 
sample was taken minus time at which the /h sample was taken). 
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2.2.5.3 Residual Progesterone Content Remaining in CIDR@ Cattle Inserts 
Following Intravaginal Insertion 
The residual progesterone content remaining in CIDR ® Cattle inserts following 
intravaginal insertion was determined by Soxhlet extraction of the skin with ethanol 
(SDA-3A, Mobil, New Zealand) and analysis of the resulting extracts by UV 
Spectrophotometry at 240 run (Beckman DV650i, USA) (See Section 2.2.1). Prior to 
extraction, the silicone skin of each used CIDR ® Cattle insert was removed from its 
nylon spine, washed in cold water to remove any vaginal mucus deposits and dried 
with paper towels. 
2.2.5.4 Amount of Progesterone Released/rom CIDR@ Cattle Inserts 
The amount of progesterone released from CrDR ® Cattle inserts over a particular 
insertion period was determined by subtracting the experimentally determined 
residual progesterone load from the initial load in the eIDR ® Cattle inserts. 
2.2.6 Statistical Analysis 
The statistical significance of each and every comparison between Ave of different 
treatments, initial progesterone loads, residual progesterone loads and amounts of 
progesterone released during intravaginal insertion was determined by Oneway 
Unstacked ANOV A (MINIT AB 8.2 Statistical Software). 
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2.3 Results 
2.3.1 UV Assay Validation 
2.3.1.1 Linearity and Range 
Data for two sets of calibration standards are presented in Table 2.3.1. Combined 
regression analysis of the two curves is presented in Table 2.3.2. 
Table 2.3.1 - Analysis of Calibration Working Standards for validation of the UV assay 
Concentration (J,.Lg/mL) Standard A Absorbance Standard B Absorbance 
4 0.2174 0.2203 
10 0.5385 0.5421 
20 1.0800 1.0871 
30 1.6278 1.6262 
40 2.1590 2.1677 
Slope 0.0541 0.0541 
Intercept 0.0002 0.0029 
R2 1.0000 1.0000 
Table 2.3.2 - Combined Regression Analysis of both A and B Working Standards for validation 
of the UV assay 
Parameter Result S.E ± 95% C.L ±99% C.L 
B1 0.0538 0.000116 0.000259 0.000368 
BO 0.00726 0.00260 0.00581 0.00826 
Data acquired to confirm the range of the assay is presented in Table 2.3.3. 
Table 2.3.3 - Analysis of Range Validation Standards for validation of the UV assay 
QC Sample Absorbance Calculated concentration 
(Jlg/mL) 
4 J...lg/mL 0.2224 4.00 
4 J...lg/mL 0.2189 3.93 
40 ~g/mL 2.1393 39.63 
40 ~g/mL 2.1366 39.58 
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2.3.1.2 Accuracy 
Data for the method validation parameter of accuracy is presented in Table 2.3 .4. 
Table 2.3.4 - Analysis of Accuracy Validation Standards (8, 15 & 35 J.Lg/mL) for validation of 
the UV assay 
8 J.Lg/mL day 0 day 1 day 2 day 3 mean SD %RSD 0/0 deviation 
Rep. A 7.91 7.88 7.92 7.84 7.89 0.04 0.46 1.41 
Rep. B 7.81 8.01 7.98 7.89 7.92 0.09 1.14 0.97 
mean 7.86 7.95 7.95 7.87 7.91 0.05 0.62 1.19 
SD 0.07 0.09 0.04 0.04 0.02 
%RSD 0.90 1.16 0.53 0.45 0.31 
%Dev. 1.75 0.69 0.62 1.69 1.19 
15 J.Lg/mL day 0 day 1 day 2 day 3 mean SD %RSD % deviation 
Rep. A 14.83 14.71 14.91 14.90 14.84 0.09 0.62 1.08 
Rep. B 14.86 14.76 15.05 14.90 14.89 0.12 0.81 0.72 
mean 14.85 14.73 14.98 14.90 14.87 0.10 0.69 0.90 
SD 0.02 0.04 0.10 0.00 0.04 
%RSD 0.14 0.27 0.68 0.00 0.26 
0/0 Dev. 1.03 1.77 0.13 0.68 0.90 
35 J.Lg/mL day 0 day 1 day 2 day 3 mean SD %RSD 0/0 deviation 
Rep. A 34.76 34.73 35.02 34.64 34.79 0.16 0.47 0.61 
Rep.B 34.81 34.71 35.03 34.76 34.83 0.14 0.40 0.49 
mean 34.79 34.72 35.03 34.70 34.81 0.15 0.43 0.55 
SD 0.04 0.02 0.01 0.08 0.03 
%RSD 0.10 0.05 0.03 0.24 0.08 
0/0 Dev. 0.61 0.80 0.07 0.86 0.55 
2.3.1.3 Precision 
Reproducibility precision was determined in conjunction with the accuracy 
experiment and relative standard deviation data for this parameter is presented in 
Table 2.3.4. Repeatability precision data is presented in Table 2.3.5. 
Table 2.3.5 - Repeatability (Replicate Readings) for validation of the UV assay 
Sample Absorbance Calculated concentration 
(j..Lg/mL) 
20 j..Lg/mL 1.0835 20.00 
20 J.,tg/mL 1.0837 20.01 
20 J.,tg/mL 1.0839 20.01 
20 J.!g/mL 1.0835 20.00 
20 J.,tg/mL 1.0833 20.00 
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2.3.1.4 Ruggedness 
Data pertaining to the ruggedness of the UV spectrophotometric assay is presented in 
Tables 2.3.6 through 2.3.9. 
Table 2.3.6 - Ruggedness data for validation of the UV assay: I-up CIDR®1380 Cattle insert 
B t h 7246227 D I a c 
- ~y 
Sample Skin Weight Absorbance I Absorbance 2 Progesterone Progesterone 
(I-up (g) (g) (% w/w) 
CIDR®1380 
Cattle insert) 
1 13.4218 0.7792 0.7683 1.32 9.81 
2 13.2927 0.7753 0.7861 1.33 9.99 
3 13.4532 0.8013 0.8023 1.36 10.14 
4 13.3506 0.7947 0.7934 1.35 10.12 
5 13.4464 0.7814 0.7794 1.33 9.87 
Mean 1.34 9.98 
SEM 0.01 0.07 
Table 2.3.7 - Ruggedness data for validation of the UV assay: I-up CIDR®1380 Cattle insert 
B h 7246227 D 2 atc 
-
ay 
Sample Skin Weight Absorbance I Absorbance 2 Progesterone Progesterone 
(I-up (g) (g) (0/0 w/w) 
CIDR®1380 
Cattle insert) 
1 13.4392 0.8090 0.8108 1.35 10.01 
2 13.3861 0.8298 0.8209 1.37 10.24 
3 13.4228 0.7852 0.7815 1.30 9.70 
4 13.3131 0.8195 0.8156 1.36 10.20 
5 13.4316 0.8224 0.8260 1.37 10.19 
Mean 1.35 10.07 
SEM 0.01 0.10 
Table 2.3.8 - Ruggedness data for validation of the UV assay: I-up CIDR®1380 Cattle insert 
B h 7246227 D 3 atc - ay 
Sample Skin Weight Absorbance 1 Absorbance 2 Progesterone Progesterone 
(I-up (g) (g) (0/0 w/w) 
CIDR®1380 
Cattle insert) 
1 13.4662 0.8175 0.8196 1.32 9.82 
2 13.4348 0.8245 0.8207 1.33 9.89 
3 13.3475 0.7600 0.7546 1.22 9.16 
4 13.4027 0.8023 0.8040 1.30 9.68 
5 13.3921 0.8117 0.8128 1.31 9.80 
Mean 1.30 9.67 
SEM 0.02 0.13 
67 
CHAPTER Two CHARACTERISATION OF THE CIDR@1900 AND CIDR@1380 CATTLE INSERTS 
Table 2.3.9 - Ruggedness data for validation of the UV assay: I-up CIDR@1380 Cattle insert 
Batch 7246227 - Day 3 analyst two 
Sample Skin Weight Absorbance 1 Absorbance 2 Progesterone Progesterone 
(I-up (g) (g) (% w/w) 
CIDR@1380 
Cattle insert) 
1 13.4662 0.8328 0.8320 1.34 9.92 
2 13.4348 0.8375 0.8382 1.34 10.01 
3 13.3475 0.7734 0.7798 1.25 9.34 
4 13.4027 0.8169 0.8166 1.31 9.78 
5 13.3921 0.8200 0.8241 1.32 9.85 
Mean 1.31 9.78 
SEM 0.02 0.12 
2.3.1.5 Limit of Quantitation 
Data acquired for the determination of the limit of quantitation is presented in Table 
2.3.10. 
Table 2.3.10 - Limit of quantitation data obtained in the validation of the UV assay 
Sample Absorbance Calculated concentration 
(J..Lg/mL) 
blank 0.0154 0.15 
blank 0.0153 0.15 
blank 0.0152 0.15 
blank 0.0154 0.15 
blank 0.0153 0.15 
1 J..Lg/mL 0.0837 1.42 
0.1 J..Lg/mL 0.0377 0.57 
0.01 J..tg/mL 0.0258 0.34 
2.3.1.6 Specificity 
Data pertaining to the specificity of the UV spectrophotometric assay with respect to 
placebo components ofCIDR® inserts is presented in Table 2.3.11. 
Table 2.3.11 - Specificity data obtained to validate the UV assay 
Sample Absorbance Calculated concentration 
(J..Lg/mL) 
20 J.lg/mL in specially denatured 1.0953 20.22 
alcohol 
20 }.lg/mL in silicone extract (normal 1.0919 20.16 
dilution) 
Silicone extract (normal dilution) 0.0004 -0.13 
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2.3.1. 7 Soxhlet extraction Validation 
The efficiency of the Soxhlet extraction method is 99 ± 1 %, as determined from the 
data obtained in the ruggedness experiment where replicate CIDR@ Cattle inserts 
were extracted on four different occasions by two analysts (see Section 2.3.1.4). 
2.3.1.8 Invitro Drug Release Test Sample Reconstitution Validation 
Recovery data determined to validate the reconstitution of invitro drug release test 
samples is shown in Table 2.3.12. 
Table 2.3.12 - Absorbance and calculated progesterone recovery data for low and high level 
spikes analysed following reconstitution (N=5) 
Spike Level (mg) Absorbance Progesterone Recovered (g) 
(Mean±SEM) (Mean±SEM) 
0.22 0.216 ± 0.001 0.216 ± 0.001 
1.10 1.06 ± 0.01 1.09 ± 0.01 
2.3.2 Invitro Drug Release Test Validation 
2.3.2.1 Reproducibility and Ruggedness 
Release rate data acquired for I-up CIDR@1380 Cattle inserts from three 
manufacturing batches are presented in Table 2.3.13. 
Table 2.3.13 - Intra-batch and inter-batch release rates for I-up CIDR@1380 Cattle inserts 
Batch # N Release Rate Intercept 
(J.!gl cm 2/hr1l2) (Jlg/cm2) 
Mean SEM Mean SEM 
7317 15 1426 62 955 143 
7313 5 1142 34 1337 125 
7307 5 1455 74 303 152 
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2.3.2.2 Robustness 
Invitro drug release rate data for I-up CIDR®1380 Cattle inserts determined with 
variations to the standard method are presented in Table 2.3.14. 
Table 2.3.14 - Effect of system dependent variables upon release rates for I-up CIDR@1380 
Cattle insert (N=3) 
Parameter * Release Rate (J,!g/cm2/hr1l2) 
Mean ± SEM 
Rotation speed 50 rpm 1239 ± 13 
Rotation speed 100 rpm 1329 ± 23 
Rotation speed 150 rpm 1361 ± 15 
Release media 40% ethanol 1192 ± 53 
Release media 50% ethanol 1276 ± 94 
Release media 60% ethanol 1361 ± 15 
Release media 80% ethanol 1695 ± 97 
Release media ionic strength 0.00 1361 ± 15 
Release media ionic strength 0.15 1426 ± 21 
Release media ionic strength 0.30 1474 ± 86 
Release media ionic strength 0.50 1256 ± 84 
Release media pH 4 1343 ± 102 
Release media pH 6 1326 ± 92 
Release media pH 8 1391 ± 21 
*Only parameter listed was varied from the standard conditions. (N.B. Standard conditions are 
rotation speed = 150 rpm, 62.5% ethanol, ionic strength = 0, pH = 5-6) 
Invitro drug release rate data for I-up CIDR@1380 Cattle inserts with different initial 
drug loads are presented in Table 2.3.15. 
Table 2.3.15 - Effect of initial drug load upon release rates for 1-up CIDR@1380 Cattle insert 
under standard release assessment test conditions (N=2) 
Initial Drug Load (% w/w) Release Rate (J,!g/cm2/hr1l2) 
(Mean±SEMl 
2.5 321 ± 8 
5.0 826 ± 8 
7.5 1193 ± 61 
15.0 1838 ± 30 
20.0 2508 ± 108 
25.0 2855 ± 79 
These results are also shown in Figure 2.3.1. 
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Figure 2.3.1 - Effect of initial drug load as seen by the cumulative progesterone released per 
unit area per square root of time (0 = 2.5% load; X = 5% load; A = 7.5% load; = 100/0 load; 
* = 150/0 load; • = 20% load) 
2.3.3 Invitro Characterisation (CIDR@1900 Cattle insert) 
2.3.3.1 Location of Drug in CIDR@ Cattle Inserts 
The levels of progesterone detennined in both the silicone skin and in the nylon 
spine ofCIDR@1900 Cattle inserts are presented in Table 2.3.16. 
Table 2.3.16 - Levels of progesterone determined in both the silicone skin and nylon spine of 
CIDR® Cattle insert 
Location Progesterone content (g) 
(Mean ± SEM) 
Silicone Skin (N=30) 1.90 ± 0.01 
Nylon Spine (N=2) 0.011 ± 0.002 
2.3.3.2 Skin Weight and Initial Load 
Determinations of the skin weight and drug load of CIDR@1900 Cattle insert are 
presented in Table 2.3.17. 
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Table 2.3.17 - Skin Weight and Total Initial Drug Load of a CIDR®1900 Cattle insert (N=21) 
Parameter Result 
Mean±SEM 
Skin Weight (g) 19.97 ± 0.03 
Drug Weight (g) 1.90 ± 0.01 
Drug Load (%w/w) 9.51 ± 0.03 
2.3.3.3 Surface area 
The surface area of CIDR®1900 Cattle insert (N=3) was detennined to be 120 ± 1.6 
cm2• 
2.3.3.4 Skin thickness 
The skin thickness ofCIDR®1900 Cattle insert (N=5) ranged from 1 to 5 nun. 
2.3.3.5 Invitro Drug Release 
The invitro drug release rate for CIDR®1900 Cattle inserts (N=17) was 1302 ± 33 
J..lg/cm2/hr lf2 • A summary of the data is presented in Table 2.3.18. 
Table 2.3.18 - Cumulative amount of progesterone released per unit area at given time and the 
resulting release rate for CIDR®1900 Cattle inserts 
Cumulative amount of progesterone released per unit area at given time Rate 
(f.lg/cm2) (J.l.g/cm2 Ihrlll)* 
Replicate 0.03 2 4 8 12 24 48 72 96 
1 392 1774 2556 3761 4260 6453 9035 10619 11953 1294 
2 368 1805 2438 3442 4389 5934 8171 9607 10837 1165 
3 622 2000 2749 3921 4915 6740 9215 10910 12335 1298 
4 456 1847 2529 3576 4614 6248 8705 10363 11681 1238 
5 557 1854 2665 3868 4724 6864 9381 10999 12494 1342 
6 642 2103 2864 4043 5028 7041 9446 10993 12077 1333 
7 1187 1893 2613 3717 4621 6716 9584 11255 12647 1298 
8 1012 1647 2331 3360 4217 6183 8886 10464 11755 1219 
9 1108 1775 2473 3526 4393 6360 8846 10608 11837 1203 
10 1072 1719 2401 3418 4332 6134 8550 10308 11687 1162 
11 1118 1797 2479 3579 4518 6518 9219 10917 12414 1258 
12 1100 1693 2402 3432 4313 6128 8598 10435 11755 1167 
13 992 1994 2719 3835 4830 6867 9337 11065 12615 1287 
14 964 2570 3471 4709 5660 7636 10256 11932 13045 1393 
15 974 1825 2624 3736 4667 6697 9189 11155 12182 1272 
16 536 2321 3301 4794 5845 7693 10557 12478 13353 1495 
17 814 2530 3414 5186 6465 8779 12015 13583 15218 1702 
Mean 1302 
SEM 33 
*Calculated based on data up to 48 hours 
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2.3.4 Invitro Characterisation (I-up CIDR@1380 Cattle insert) 
2.3.4.1 Skin Weight and Initial Load 
Skin weight and initial drug load data for the I-up CIDR®1380 Cattle insert is 
presented in Table 2.3.19. 
Table 2.3.19 - Skin Weight and Drug Load of a I-up CIDR@1380 Cattle insert (N=15) 
Parameter Result 
(Mean ±SEM) 
Skin Weight (g) 13.87 ± 0.01 
Drug Weight (g) 1.38 ± 0.004 
Drug Load (%w/w) 9.93 ± 0.03 
2.3.4.2 Surface Area 
The surface area of the I-up CIDR@1380 Cattle insert (N=3) were determined to be 
123 ± 1.4 cm2• 
2.3.4.3 Skin Thickness 
The skin thickness of the I-up CIDR@1380 Cattle insert was determined (N=5) to be 
approximately 1 rnm over the entire insert except for an area on the wing tips which 
was deliberately made thicker for animal comfort. These areas were approximately 
1.6 mm thick. 
2.3.4.4 Invitro Drug Release 
The invitro drug release rate for the I-up CIDR@I380 Cattle insert was determined 
(N=30) to be 1320 ± 22 J..lg/cm2/hr1l2. The data is summarised in Table 2.3.20. 
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Table 2.3.20 - Cumulative amount of progesterone released per unit area at given time and the 
resulting release rate for I-up CIDR@I380 Cattle inserts 
Cumulative amount of progesterone released per unit area at given time Rate 
(~g/cm2) (~g/cm2 
Ihrl/2)* 
Replicate 0.03 2 4 8 12 24 48 72 96 
1 1189 3796 4902 6077 7196 8686 10351 11371 11695 1332 
2 430 1767 2514 3731 4713 6673 8981 10647 11100 1304 
3 599 2293 3054 4337 5245 7211 9498 11121 11516 1337 
4 660 2429 3268 4603 5730 7704 9810 10817 11169 1387 
5 787 2541 3401 4698 5799 7642 9740 10988 11809 1351 
6 345 1883 2858 4203 5253 7300 9698 12035 11871 1422 
7 804 2979 3850 5463 6393 8379 10336 11168 11419 1427 
8 515 1889 2657 3816 4754 6893 9103 11913 11093 1312 
9 1112 3446 3999 4926 6176 7476 9443 11242 10962 1205 
10 1428 4115 5012 6064 6989 8673 10039 11848 12045 1246 
11 577 2161 3101 4242 5191 7058 9240 9315 10127 1303 
12 692 2202 2989 4140 5059 6748 8888 11142 11669 1232 
13 1048 3153 3857 4979 5905 7553 9418 10995 11487 1230 
14 1254 3187 3853 5051 5757 7518 9340 10733 11423 1194 
15 1323 3824 4614 5570 6359 7798 9595 10788 11179 1176 
16 1267 3026 4840 6018 6672 9062 11187 10597 11275 1489 
17 802 2128 3114 3955 4877 6893 8931 10181 10667 1234 
18 429 1631 2315 3270 4081 5882 7767 11721 13307 1118 
19 684 1956 2716 3764 4631 6526 8515 11188 11246 1194 
20 507 1783 3093 4218 4922 6401 8170 11697 12207 1156 
21 1567 2830 3732 5073 6130 8100 10337 10907 11443 1351 
22 1474 2737 3504 4822 5849 7599 9654 10839 11009 1258 
23 1779 3298 4029 5328 6425 8010 10230 7772 8370 1277 
24 1856 3191 4058 5418 6724 8330 10086 10766 11120 1278 
25 1132 2290 3067 4348 5402 7584 9896 9242 10019 1359 
26 866 2995 4049 5663 6904 8749 10798 11537 11752 1497 
27 854 2454 3218 4733 5575 7277 9603 9331 10128 1315 
28 847 1626 4070 5750 6870 8694 11054 10956 11458 1600 
29 352 1303 2778 4340 5334 6918 10110 11789 11795 1485 
30 640 1887 2855 4480 5631 7964 10537 11868 12177 1539 
Mean 1320 
SEM 22 
*Calculated based on data up to 48 hours 
2.3.5 Invitro Characterisation (6-up CIDR®1380 Cattle insert) 
2.3.5.1 Skin Weight and Initial Load 
Skin weights and initial loads for three individual manufacturing batches of 6-up 
CIDR@1380 Cattle insert are presented in Table 2.3.21, by batch and by cavity 
position. 
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Table 2.3.21 - Skin weights and drug loads for three production batches of 6-up CIDR@1380 
Cattle insert with results presented by batch and by tool cavity position 
Parameter Skin Weight (g) Drug Load (g) Drug Load (%w/w) 
(Mean ± SEM) (Mean +SEM) (Mean +SEM) 
Batch 8065 (N=18) 13.92 ± 0.03 1.32 ± 0.003 9.49 ± 0.02 
Batch 8067 (N= 18) 13.95 ± 0.02 1.34 + 0.002 9.58 + 0.01 
Batch 8069 (N=18) 13.87 ± 0.02 1.32 ± 0.002 9.54 ± 0.01 
Cavity 1 (N=9) 13.87 ± 0.03 1.33 ± 0.006 9.56 ± 0.03 
Cavity 2 (N=9) 13.91 ± 0.02 1.33 ± 0.003 9.56 ± 0.02 
Cavity 3 (N=9) 13.83 ± 0.02 1.32 ± 0.003 9.55 ± 0.02 
Cavity 4 (N=9) 13.96 ± 0.02 1.33 ± 0.002 9.54 ± 0.02 
Cavity 5 (N=9) 14.02 ± 0.02 1.33 ± 0.004 9.49 ± 0.03 
Cavity 6 (N=9) 13.89 ± 0.04 1.32 ± 0.004 9.50 ± 0.02 
2.3.5.2 Surface Area 
The surface area of the 6-up CIDR@1380 Cattle insert were determined to be 123 ± 1 
cm2 (N = 30). Mean results for the three batches are presented in Table 2.3.22, by 
batch and by tool cavity position. 
Table 2.3.22 - Surface areas (cm2) for three production batches of 6-up CIDR@1380 Cattle insert 
with results presented by batch and by tool cavity position 
Parameter Surface Area (cm2) 
(Mean ± SEM) 
Batch 8065 (N=6) 120.7 ± 0.7 
Batch 8067 (N=6) 125.8 ± 1.0 
Batch 8069 (N= 18) 123.6 ± 0.7 
Cavity 1 (N=5) 126.6 ± 1.5 
Cavity 2 (N=5) 122.2 ± 1.3 
Cavity 3 (N=5) 121.8 ± 1.6 
Cavity 4 (N=5) 122.5 ± 0.9 
Cavity 5 (N=5) 122.7 ± 0.3 
Cavity 6 (N=5) 124.9 ± 1.4 
2.3.5.3 Skin Thickness 
The skin thickness of 6-up CIDR@1380 Cattle insert (N=30) was determined to be 
approximately 1 mm over the entire insert except for an area on the wing tips which 
was deliberately made thicker for animal comfort. These areas were approximately 
1.6 nun thick. 
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2.3.5.4 Invitro Drug Release 
The invitro release rate for the 6-up CIDR@1380 Cattle insert was detennined (N=30) 
to be 1236 ± 9 J.lg/cm2/hr1l2• The data is shown in Table 2.3.23 and summarised on 
an individual cavity position basis in Table 2.3.24. 
Table 2.3.23 - CumUlative amount of progesterone released per unit area at given time and the 
resulting release rate for 6-up CIDR®1380 Cattle inserts 
Cavity / Cumulative amount of progesterone released per unit area at 
Replicate Jiven time (~g/cm2) 
0.03 2 4 8 
111 371 1646 2325 3265 
2/1 323 1733 2427 3482 
3/1 311 1712 2401 3480 
411 293 1639 2313 3370 
5/1 270 1650 2358 3477 
6/1 292 1566 2240 3205 
112 424 1822 2584 3762 
2/2 430 1907 2742 3834 
3/2 418 2016 2914 4095 
4/2 369 1775 2561 3706 
5/2 358 1843 2726 3844 
6/2 389 1807 2598 3670 
1/3 331 1711 2386 3465 
2/3 304 1794 2508 3634 
3/3 311 1753 2490 3635 
4/3 302 1745 2456 3589 
5/3 311 1746 2448 3587 
6/3 343 1644 2287 3316 
1/4 441 1827 2559 3556 
2/4 427 1902 2630 3737 
3/4 426 1876 2608 3695 
4/4 392 1800 2531 3621 
5/4 382 1804 2520 3565 
6/4 369 1801 2517 3572 
1/5 373 1549 2275 3364 
2/5 330 1735 2450 3519 
3/5 310 1780 2552 3696 
4/5 298 1686 2430 3529 
5/5 287 1679 2432 3526 
6/5 339 1668 2402 3430 
Mean 
SEM 
*Calculated based on data up to 48 hours 
u>Lost sample 
12 24 
4026 5769 
4320 6229 
4333 6176 
4173 5976 
4267 6092 
3983 5683 
4686 6726 
4735 6761 
5094 7173 
4677 6742 
4822 6922 
4582 6503 
4296 6164 
4508 6409 
4540 6465 
4447 6270 
4509 6388 
4147 5915 
4338 6169 
4575 6480 
4559 6525 
4459 6315 
4378 6282 
4406 6308 
4161 5980 
4362 6356 
4577 6512 
4383 6287 
4418 6336 
4258 6095 
48 72 
7811 9609 
8332 9462 
8380 9628 
8081 9164 
8303 9315 
7885 9111 
8831 9797 
8926 9951 
9322 10296 
8805 9648 
9028 9952 
8702 9765 
8269 9450 
8650 9789 
8768 9984 
8392 9414 
8573 9668 
8184 9440 
8350 9534 
8596 9771 
8824 10063 
8475 9529 
8541 9789 
8535 9647 
8316 9540 
8656 '\l' 
8864 10129 
8460 10059 
8681 10006 
8426 9645 
Rate 
(J..lg/cm2/hrl/2)* 
1121 
1210 
1216 
1175 
1210 
1140 
1283 
1286 
1350 
1290 
1320 
1257 
1200 
1257 
1277 
1221 
1250 
1181 
1187 
1232 
1265 
1219 
1226 
1229 
1203 
1256 
1288 
1235 
1267 
1217 
1236 
9 
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Table 2.3.24 - Release rates for 6-up CIDR®1380 Cattle inserts from each of the individual 
cavity positions (N=5) 
Cavity Rate (J..Lg/cm2/hr1l2) 
(Mean ± SEM) 
1 1199 ± 26 
2 1248 ± 13 
3 1279 ± 22 
4 1228 ± 18 
5 1255 ± 19 
6 1205 ± 20 
2.3.6 Comparative Invivo Characterisation (CIDR®1900 Cattle insert versus 1-
up CIDR@1380 Cattle insert) 
2.3.6.1 Plasma Profiles 
Plasma progesterone data obtained from the 7 day bioequivalency trial comparing 1-
up CIDR®1380 Cattle insert to CIDR@1900 Cattle insert invivo trial are presented in 
Tables 2.3.25 through 2.3.27. Data which comprises the absorption profile for the 
two CIDR® fonnulations is presented in Table 2.3.25. Data which comprises the 
clearance profile following removal of the two CIDR@ fonnulations is presented in 
Table 2.3.26 and the daily data acquired for the two CIDR ® formulations over the 
course of the seven day insertion is presented in Table 2.3.27. 
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Table 2.3.25 - Absorption data for 7 day bioequivalency trial comparing I-up CIDR@1380 
Cattle insert to CIDR@I900 Cattle insert 
Formulation 0 10 20 30 45 1 h 2h 4h 6h 8h 
mins mins mins mins 
CIDR@1900 0.04 1.36 1.98 4.00 4.01 5.09 4.48 4.97 5.58 6.08 
Cattle insert 
0.10 4.62 6.08 5.87 6.42 7.45 5.77 4.72 5.01 5.33 
0.18 2.57 2.91 2.43 2.26 2.11 1.35 1.19 1.40 1.85 
0.03 2.99 5.06 6.44 6.82 6.88 6.15 5.64 5.63 5.88 
0.00 4.94 6.30 6.46 5.91 6.16 6.81 4.85 5.71 5.62 
0.03 3.15 3.70 4.31 4.66 4.78 5.23 4.25 7.25 4.65 
0.10 4.7 4.36 'fr 4.99 4.50 5.27 4.29 4.87 4.53 
0.00 4.56 2.79 4.90 4.84 5.08 4.94 4.82 4.21 4.85 
1-up 0.00 4.38 5.31 5.77 6.43 5.69 6.61 5.36 5.75 6.26 
CIDR@1380 
Cattle insert 
0.17 1.66 3.35 3.72 3.65 4.16 4.54 4.28 4.84 4.53 
0.09 3.47 4.45 4.39 4.70 4.72 4.90 3.76 4.19 4.22 
0.05 2.36 3.59 3.74 4.38 4.99 4.31 3.66 4.00 3.82 
0.00 3.62 3.16 2.60 3.10 3.39 3.85 3.78 3.70 3.87 
0.05 4.02 4.13 4.41 4.27 4.41 3.86 3.43 4.18 3.83 
0.41 2.93 5.38 6.14 5.21 4.41 3.99 4.09 4.18 4.53 
0.00 3.39 4.63 4.73 5.77 5.50 4.06 3.36 4.33 4.36 
\/'L08t sample 
Table 2.3.26 - Clearance data for 7 day bioequivalency trial comparing I-up CIDR@1380 Cattle 
insert to CIDR®1900 Cattle insert 
Time after 0 15 30 Ih 2h 4h 8h 24 h 
removal mins mins 
CIDR@1900 Cattle 3.21 2.37 1.73 0.99 0.63 0.39 0.17 0.21 
insert 
2.92 2.10 1.53 0.79 0.59 0.33 0.20 0.13 
3.28 2.51 1.66 0.80 0.60 0.26 0.23 0.08 
3.00 2.12 1.38 0.82 0.47 0.19 0.14 0.05 
2.93 1.85 1.35 0.78 0.59 0.41 0.37 0.22 
2.42 1.33 0.76 0.67 0.51 0.29 0.26 'fr 
2.25 1.39 0.86 0.77 0.36 0.27 0.11 0.09 
2.67 1.21 0.72 0.66 0.55 0.40 0.09 0.01 
I-up CIDR@1380 3.54 2.40 2.00 1.22 0.88 0.41 0.24 0.28 
Cattle insert 
2.67 1.91 1.47 0.91 0.67 0.35 0.22 0.28 
2.57 1.78 1.13 0.69 0.52 0.30 0.17 0.11 
2.50 1.74 1.00 0.53 0.27 1.82 0.16 0.07 
2.57 1.52 1.16 0.77 0.40 0.34 0.22 0.16 
1.98 1.04 0.55 0.52 0.31 0.37 0.27 0.10 
3.78 1.72 0.82 0.57 0.63 0.24 0.11 0.00 
2.70 1.54 0.94 0.66 0.34 0.20 0.16 0.00 
\/'L08t sample 
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Table 2.3.27 - Daily data for 7 day bioequivalency trial comparing I-up CIDR®1380 Cattle 
insert to CIDR®1900 Cattle insert 
Time after insertion 1 day 2 2.25 3 4 5 6 7 
(days) 
CIDR@1900 Cattle 5.04 3.49 3.94 2.82 2.84 3.48 2.77 3.21 
insert 
5.33 4.23 3.63 2.71 2.80 2.51 2.53 2.92 
4.98 3.74 3.78 2.66 2.69 3.14 3.35 3.28 
6.36 4.20 3.57 2.90 2.77 3.13 3.33 3.00 
6.03 6.10 3.82 3.98 4.00 3.52 3.49 2.93 
5.63 8.56 3.61 3.68 3.31 2.92 3.31 2.42 
3.42 4.34 3.42 3.59 3.60 3.03 3.10 2.25 
3.44 4.18 3.40 3.87 3.09 3.22 3.27 2.67 
I-up CIDR®1380 5.85 4.67 4.39 3.51 3.50 3.45 3.38 3.54 
Cattle insert 
4.85 4.03 3.59 2.76 2.82 2.51 2.24 2.67 
4.36 3.44 2.65 2.47 2.70 2.75 2.99 2.57 
3.44 3.44 2.27 3.22 3.56 3.43 2.84 2.50 
4.46 4.05 3.86 3.81 3.69 3.52 2.82 2.57 
4.46 3.43 4.03 3.19 2.59 2.78 1.97 1.98 
4.87 4.12 3.06 3.l8 3.39 2.69 2.55 3.78 
4.37 3.66 2.90 3.21 2.81 2.76 3.25 2.70 
Table 2.3.28 contains data obtained in the 10 day bioequivalency trial comparing 1-
up CIDR@1380 Cattle insert to CIDR@1900 Cattle insert. 
Table 2.3.28 - Data for 10 day bioequivalency trial comparing I-up CIDR®1380 Cattle insert to 
CIDR®1900 Cattle insert 
Time 0 0.25 1 2 3 4 5 6 7 8 9 10 10.3 
(days) 
1900 0.04 6.21 4.81 4.23 4.69 3.77 3.27 3.53 3.02 2.51 2.76 2.62 0.31 
0.06 5.77 4.13 2.77 3.92 2.51 3.30 2.80 2.69 2.25 2.34 2.41 0.20 
0.05 5.92 3.93 3.05 4.84 2.92 3.65 3.45 3.32 2.10 2.10 2.21 0.16 
0.04 4.69 4.16 2.70 3.20 2.77 3.50 3.85 3.69 1.93 1.81 1.76 0.06 
0.00 1.52 2.02 2.37 3.56 1.89 2.66 2.88 2.19 1.84 1.55 1.92 0.22 
0.00 6.03 4.42 3.93 2.89 2.30 2.57 2.87 2.16 1.91 1.97 1.81 0.27 
0.00 4.54 4.19 2.46 2.47 2.05 2.00 1.98 1.77 1.37 1.42 1.74 0.17 
0.00 4.10 3.67 3.59 3.32 2.62 2.88 2.95 2.62 2.41 2.57 2.70 0.27 
0.92 6.71 5.38 4.49 2.80 4.50 5.01 2.53 3.27 4.26 2.73 2.33 0.25 
0.00 5.07 2.99 3.00 1.91 2.22 4.68 1.47 1.51 1.74 1.65 1.34 0.24 
1380 0.09 5.26 3.69 2.85 3.81 3.47 3.49 3.00 3.62 2.33 2.41 2.12 0.30 
0.09 4.41 4.17 3.05 3.29 2.21 2.87 2.38 2.68 1.95 2.11 1.71 0.21 
0.00 3.99 3.90 4.11 6.89 2.64 3.42 2.99 2.60 1.95 1.93 1.94 0.56 
0.82 6.20 6.50 4.41 7.25 5.11 5.80 3.77 6.95 5.00 3.78 3.56 0.25 
0.03 3.81 3.75 3.23 3.10 2.88 2.21 2.59 4.11 2.24 2.05 2.03 0.04 
0.01 6.20 4.91 3.48 4.35 3.92 4.04 3.50 3.40 1.82 2.14 2.11 0.18 
0.04 5.04 5.65 3.82 3.29 3.12 3.16 2.48 2.19 2.75 1.76 2.55 0.23 
0.00 5.45 4.41 3.81 3.33 3.27 2.84 2.52 2.82 1.75 1.91 3.48 0.26 
0.00 6.16 4.69 4.02 7.81 2.40 1.93 3.31 2.63 2.06 1.83 2.13 0.38 
0.04 4.02 3.99 2.92 3.05 2.90 2.81 1.97 2.33 1.62 1.68 2.25 0.l7 
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Tables 2.3.29 and 2.3.30 contain data obtained in the 20 day bioequivalency trial 
comparing 1-up CIDR@1380 Cattle insert to CIDR@1900 Cattle insert. 
Table 2.3.29 - Data for 20 day bioequivalency trial comparing I-up CIDR@1380 Cattle insert to 
CIDR@1900 Cattle insert (days 0-10) 
Time 0 0.25 1 2 3 4 5 6 7 8 9 10 
(days) 
1900 0.03 5.20 4.39 3.17 3.44 2.41 2.74 2.70 2.67 2.08 1.85 1.88 
0.00 7.26 3.96 4.67 4.22 2.68 3.65 3.86 3.59 2.55 2.52 3.06 
0.07 2.89 3.16 3.37 4.65 2.96 3.47 3.28 2.86 1.90 1.88 2.10 
0.00 13.1 4.47 4.25 4.39 3.65 4.08 3.01 3.08 2.70 2.41 3.08 
0.00 6.33 3.85 4.32 3.40 3.23 3.22 3.87 2.68 2.47 1.99 2.21 
0.00 4.65 4.48 3.94 2.57 2.62 3.22 2.46 2.52 1.73 1.82 2.26 
0.04 3.98 3.33 2.69 2.55 2.58 1.94 2.73 2.37 1.61 2.00 2.29 
0.02 3.54 2.32 2.07 2.84 2.17 2.14 2.75 2.01 2.16 1.59 2.70 
0.03 4.46 3.64 3.52 2.82 2.46 2.53 2.42 2.17 1.65 1.80 1.93 
0.00 5.51 4.72 4.03 2.85 3.13 3.50 2.57 2.94 2.45 1.71 3.40 
1380 0.00 4.90 4.31 2.80 3.55 2.84 2.84 3.49 3.37 1.68 2.05 1.67 
0.03 5.68 4.82 3.59 4.00 2.75 2.32 3.03 2.54 1.57 1.36 1.57 
0.02 3.79 3.49 2.81 3.55 3.54 2.48 2.62 2.89 1.79 1.61 1.43 
0.05 5.19 3.15 4.45 4.16 2.02 2.50 2.37 2.03 1.60 1.72 2.57 
0.15 4.80 4.57 3.72 3.92 2.91 2.89 3.63 2.36 1.84 2.67 1.81 
0.02 4.31 3.83 4.52 3.23 2.78 4.18 2.64 2.12 2.41 1.57 2.37 
0.02 5.64 4.85 4.03 3.39 3.06 2.70 2.50 2.87 2.10 2.99 3.58 
0.12 3.79 4.47 3.65 4.06 3.17 2.52 1.69 2.30 1.44 1.81 1.13 
0.00 7.66 4.36 4.80 4.10 4.49 4.13 2.81 2.96 3.13 2.77 3.27 
0.02 4.17 3.73 2.35 1.84 3.12 2.69 2.15 2.48 2.70 2.20 1.91 
Table 2.3.30 - Data for 20 day bioequivalency trial comparing I-up CIDR@1380 Cattle insert to 
CIDR@1900 Cattle insert (days 11 - 20) 
Time 11 12 13 14 15 16 17 18 19 20 20.25 
(days) 
1900 1.86 2.10 2.44 1.78 1.67 1.72 1.37 1.07 1.06 1.17 0.12 
2.95 3.19 3.05 2.88 2.46 2.46 1.68 2.16 1.95 1.70 0.11 
1.73 1.81 1.97 1.23 1.54 1.64 1.64 1.80 1.24 1.06 0.10 
2.60 2.26 4.18 2.15 1.73 2.72 1.80 1.67 1.99 1.25 0.13 
1.75 4.67 3.57 1.22 1.42 2.30 2.15 3.01 2.02 1.25 0.13 
2.26 1.56 1.32 1.21 0.98 1.66 1.57 1.65 1.36 1.21 0.13 
2.68 1.34 1.50 1.09 1.39 1.17 1.60 '\I '\I '\I '0' 
2.69 2.14 1.08 1.40 1.62 1.32 2.04 2.80 2.11 1.34 0.28 
4.29 1.42 1.58 1.37 1.16 1.45 1.90 1.96 1.46 1.55 0.10 
2.84 1.68 1.37 1.30 1.49 1.23 2.13 1.57 1.47 1.86 0.13 
1380 2.14 2.96 2.57 2.50 1.60 1.21 0.92 0.83 0.73 0.65 0.38 
1.42 1.17 1.82 0.97 0.77 1.29 0.87 0.65 0.82 0.50 0.37 
2.01 1.67 1.98 1.21 1.27 1.39 0.78 0.86 1.20 0.58 0.12 
3.97 6.03 4.10 2.88 0.96 1.71 1.30 1.17 1.97 0.62 0.09 
1.57 2.14 1.94 1.62 1.57 1.42 1.18 1.92 0.87 0.77 0.09 
2.21 1.26 0.96 1.27 1.12 0.75 1.08 1.40 0.98 0.66 0.10 
3.21 1.68 1.54 1.24 1.70 2.07 1.56 '\I '\I 'it '0' 
1.71 1.67 1.03 0.89 1.17 0.72 1.05 0.92 0.73 0.64 0.08 
3.85 1.62 1.85 1.36 1.48 1.65 2.01 1.18 1.02 0.79 0.14 
3.34 1.47 2.06 1.61 1.28 1.91 1.40 1.47 1.07 1.29 0.12 
'\ILost sample 
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2.3.6.2 Pharmacokinetic analysis of In vivo Plasma Profiles of CIDR@ Cattle 
Inserts 
Areas under the Curve calculated for the invivo plasma profiles of CIDR ® 1900 
Cattle insert and I-up CIDR®1380 Cattle insert in the 7 day trial are presented in 
Table 2.3.31. The corresponding AUC data for the 10 day trial and the 20 day trial 
are presented in Tables 2.3.32 and 2.3.33, respectively. 
Table 2.3.31 - Area under the curve data for invivo plasma profIles of CIDR®1900 Cattle insert 
and I-up CIDR®1380 Cattle insert in a 7 day insertion (N=8) 
Formulation Area Under Curve (AUC) 
0-4 hours Day 7-8 Day 0-8 
(Avera~e ± SEM) JA verage ± SEM) (Average ± SEM) 
CIDR®1900 Cattle insert 0.77 ± 0.08 0.26 ± 0.03 26.17 ± 0.96 
CIDR®1380 Cattle insert 0.70 ± 0.04 0.27 ± 0.04 24.10 ± 0.90 
Table 2.3.32 - Area under the curve data for invivo plasma profiles of CIDR®1900 Cattle insert 
and I-up CIDR®1380 Cattle insert in a 10 day insertion (N=10) 
Formulation Area Under Curve (AVe) 
(Average ± SEM) 
CIDR@1900 Cattle insert 29.85 ± 1.78 
CID R@ 13 80 Cattle insert 33.39 ± 2.39 
Table 2.3.33 - Area under the curve data for invivo plasma profiles of CIDR®1900 Cattle insert 
and I-up CIDR@1380 Cattle insert in a 20 day insertion (N=10) 
Formulation Area Under Curve (AUC) 
Day 0-15 Day 15-20 
(Average ± SEM) (Average ± SEM) 
CIDR@1900 Cattle insert 40.56 ± 2.30 8.35 ± 0.70 
CIDR@1380 Cattle insert 39.79 ± 1.66 5.81 ± 0.38 
2.3.6.3 Residual Progesterone Load and Amount Released (CIDR@1900 Cattle 
insert versus l-up CIDR@1380 Cattle insert) 
Residual progesterone load and amount released data for CIDR®1900 Cattle insert 
used in the 7 day, 10 day and 20 day trials and CIDR®1380 Cattle insert used in the 7 
day, 10 day and 20 day trials are presented in Tables 2.3.34 and 2.3.35 respectively. 
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Table 2.3.34 - Residual progesterone load in spent CIDR@1900 Cattle insert and the calculated 
amount released in the 7, 10 and 20 day trials 
Trial Length (days) Residual (g) Amount Released (g) 
(Mean ±SEM} (Mean ±SEM) 
7 (N=8) 1.38 ± 0.01 0.61 + 0.01 
10 (N=10) 1.19±0.03 0.78 + 0.03 
20 (N=10) 0.79 ± 0.04 1.20 + 0.04 
Table 2.3.35 - Residual progesterone load in spent CIDR@1380 Cattle insert and the calculated 
amount released in the 7, 10 and 20 day trials 
Trial Length (days) Residual (g) Amount Released (g) 
(Mean ±SEM} (Mean ± SEM) 
7 (N=8) 0.72 ± 0.02 0.62 + 0.02 
10 (N=10) 0.48 ± 0.01 0.87 + 0.01 
20 (N=10) 0.20 ± 0.01 1.16±0.01 
2.3.7 Comparative Invivo Characterisation (I-up CIDR@1380 Cattle insert 
versus 6-up CIDR@1380 Cattle insert) 
2.3.7.1 Plasma Profiles 
Plasma progesterone data obtained from the 10 day bioequivalency trial comparing 
I-up CIDR@1380 Cattle insert to 6-up CIDR ®1380 Cattle insert are presented in 
Table 2.3.36. 
Table 2.3.36 - Absorption data for 10 day bioequivalency trial comparing I-up CIDR®1380 
Cattle insert to 6-up CIDR@1380 Cattle insert 
Plasma progesterone level (n~/mL) over days 0 to 10 
CIDR Cavity 0 1 2 3 4 5 6 7 8 9 10 
8927 1 0.23 3.89 3.15 2.39 3.16 2.55 2.02 2.63 2.03 2.66 2.40 
8931 1 0.14 3.08 3.42 4.29 2.61 2.35 1.98 2.71 2.72 2.31 2.56 
8934 1 0.24 2.74 2.52 3.94 2.30 2.33 1.78 2.26 1.73 1.53 1.52 
8927 2 0.51 4.89 5.09 4.61 4.49 3.48 2.31 3.06 3.27 2.22 2.44 
8931 2 0.20 3.14 2.78 4.16 3.13 2.43 2.37 2.75 2.20 2.52 2.80 
8934 2 0.13 3.52 3.33 2.65 3.15 3.71 2.61 2.97 2.66 2.07 2.75 
8927 3 0.17 2.65 2.03 1.70 1.89 1.67 1.46 1.84 1.72 1.68 2.59 
8934 3 0.14 3.08 4.00 4.37 3.15 3.16 3.06 2.86 2.09 3.16 3.48 
8927 4 0.27 3.16 3.96 2.47 5.00 1.98 1.44 1.95 1.92 1.71 2.18 
8931 4 0.15 4.85 3.66 4.49 3.54 2.88 2.51 3.43 2.42 2.55 3.10 
8934 4 0.25 3.24 2.41 3.66 1.86 2.72 1.65 1.62 2.05 1.85 2.09 
8927 5 0.18 3.29 2.09 2.55 2.67 2.79 1.68 2.73 1.98 2.72 3.04 
8934 5 0.16 4.06 5.18 if 3.85 2.87 2.44 2.77 2.30 2.45 2.58 
8931 6 0.48 3.17 3.70 4.47 3.54 2.55 2.08 2.62 1.82 2.00 1.80 
8934 6 0.45 2.68 2.57 2.90 3.17 2.17 2.11 1.12 1.08 1.98 1.67 
I-up - 0.68 2.37 2.72 2.87 2.35 2.37 1.27 1.48 1.42 2.52 2.29 
I-up - 0.37 2.65 3.06 2.75 2.92 3.00 2.69 2.00 1.94 2.01 2.15 
'frLost sample 
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2.3.7.2 Ph arm a cokin etic analysis of In vivo Plasma Profiles of CIDR@ Cattle 
Inserts 
Areas under the Curve calculated for the invivo plasma profiles of I-up CIDR@1380 
Cattle insert and 6-up CIDR@1380 Cattle insert in the 10 day trial comparing the 1-
up CIDR@1380 Cattle insert with the 6-up CIDR@1380 Cattle insert are presented in 
Table 2.3.37. 
Table 2.3.37 - Area under the curve data for invivo plasma profiles of I-up CIDR®1380 Cattle 
insert (N=4) and 6-up CIDR®1380 Cattle insert overall (N=16), by batch { batch 8927 (N=6), 
batch 8931 (N=4), batch 8934 (N=6)} and by cavity {cavity 1 (N=3), cavity 2 (N=3), cavity 3 
(N=2), cavity 4 (N=3), cavity 5 (N=2), cavity 6 (N=3)} in a 10 day insertion 
Formulation Area Under Curve (AVe) Day 0-10 
(Average ± SEM) 
I-up CIDR@1380 Cattle insert 26.50 ± 2.45 
6-up CIDR@1380 Cattle insert 26.56 ± 1.15 
6-up CIDR@1380 Cattle insert Batch 8927 26.82 ± 2.56 
6-up CIDR@1380 Cattle insert Batch 8931 28.20 ± 1.25 
6-up CIDR@1380 Cattle insert Batch 8934 25.20 ± 1.65 
6-up CIDR@1380 Cavity 1 24.87 ± 1.47 
6-up CIDR@1380 Cavity 2 29.98 ± 2.47 
6-uj) CIDR@1380 Cavity 3 24.38 ± 6.37 
6-up CIDR@1380 Cavity 4 26.33 ± 2.91 
6-up CIDR@1380 Cavity 5 25.69 ± 1.59 
6-up CIDR@1380 Cavity 6 27.07 ± 3.60 
2.3.7.3 Residuals 
Residual progesterone load and amount released data for I-up CIDR@1380 Cattle 
insert and 6-up CIDR@1380 Cattle insert used in the 10 day trial are presented in 
Table 2.3.37. 
Table 2.3.38 - Residual and amount released data for I-up CIDR®1380 Cattle insert (N=4) and 
6-up CIDR®1380 Cattle insert batch 8927 (N=6), batch 8931 (N=4), and batch 8934 (N=6) in a 
10 day insertion 
CIDR@ insert Residual (g) Amount Released (g) 
(Mean ± SEM) (Mean ±SEM) 
I-up CIDR@1380 0.68 ± 0.03 0.66 ± 0.03 
6-up CIDR@1380 batch 8927 0.72 ± 0.02 0.63 ± 0.02 
6-up CIDR@1380 batch 8931 0.76 ± 0.02 0.58 ± 0.02 
6-up CIDR@1380 batch 8934 0.68 ± 0.02 0.65 ± 0.02 
83 
CHAPTER Two CHARACTERISATION OF THE CIDR@1900 AND CIDR@1380 CATTLE INSERTS 
2.4 Discussion 
The aim of this chapter was to characterise the CIDR@1900 Cattle insert and its 
optimised counterpart, the CIDR@1380 Cattle insert, as it passed through the two 
stages of manufacturing scale-up (I-up CIDR®1380 Cattle insert and 6-up 
CIDR@1380 Cattle insert). Within this aim was the objective to experimentally 
determine evidence that the CIDR®1380 Cattle insert was bioequivalent to the 
original CIDR®1900 Cattle insert and released drug invitro at the same rate. A 
further objective of the characterisation was to document the physical differences 
between the CIDR@1900 Cattle insert and the CIDR@1380 Cattle insert. 
2.4.1 Validation of Experimental Methods 
2.4.1.1 Validation of the UV Spectrophotometric Assay for Progesterone in 
CIDR@ Inserts 
Guidelines posted on the world wide web by the United States Food and Drug 
Administration Centre for Veterinary Medicine226 recommend that an assay can be 
considered validated if the method exhibits a linearity of R2 >0.999, intercept ~ 0, an 
accuracy and specificity (% bias) of <4%, a precision (%RSD) of <2% and a 
ruggedness (%RSD) of <40/0. 
Using standards at 27, 67, 133, 200 and 267% of the target value, the developed 
method yielded linear regressions with R2 values of >0.999 and acceptably low 
intercept values (Table 2.3.1). The regression line produced accurate «2% deviation 
at low and <1 % deviation at high level) determinations of the concentrations of 
validation standards at the extremes of the calibration range. These results validated 
the method to be linear within the range of 4 to 40 ~g/mL (Table 2.3.3). The 
regression line also produced accurate «2% deviation at 8 Jlg/mL and <10/0 
deviation at 15 and 35 !J.g/mL) determinations of 8, 15 and 35 /-lg/mL standards, 
validating the accuracy of the method (Table 2.3.4). Results for 5 replicate analyses 
of the same standard using the developed method exhibited a 0.03% relative standard 
deviation from their mean result (Table 2.3.5). Intra and inter-day repeat 
determinations of 8, 15 and 35 Jlg/mL standards yielded mean results with relative 
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standard deviations <2% (Table 2.3.4) which validated the precision (repeatability 
and reproducibility) of the developed method. The method also proved to be 
rugged. Interday and interanalyst determinations of progesterone in I-up 
CIDR®1380 Cattle insert yielded results with relative standard deviations <3% 
(Tables 2.3.6 to 2.3.9). Progesterone standards were accurately quantitated in the 
presence of placebo ingredients from the silicone matrix of CIDR® inserts (Table 
2.3.11) thereby confirming that the developed method was specific. In addition, the 
limit of quantitation, although not absolutely necessary for a potency assay which is 
developed to measure relatively high levels of analyte, was determined to be 1 
j..lg/mL (Table 2.3.10) which is suitably sensitive for the intended studies. 
2.4.1.2 Validation of the Extraction Method of Progesterone/rom CIDR@ Inserts 
It is desirable that an extraction method should reproducibly recover as close to 
100% of the analyte to be measured as possible to enable accurate analyte 
determination. The developed method was shown to recover 99 ± 1 % of the 
progesterone in CIDR® inserts (Tables 2.3.6 to 2.3.9) thereby validating the 
suitability of the Soxhlet extraction method. 
2.4.1.3 Validation of the Reconstitution Method of Progesterone from Invitro 
Drug Release Test Samples 
As for an extraction method, the reconstitution of samples for analysis should 
provide close to 100% recovery of analyte to allow accurate analyte determination. 
Reconstituted samples were determined within 2% of their known values (Table 
2.3.12), validating the suitability of the reconstitution method. 
2.4.1.4 Validation of the Invitro Drug Release Test/or CIDR@ Inserts 
The effect of both system dependent and manufacturing variables on the release of 
progesterone from the I-up CIDR®1380 Cattle insert were investigated in order to 
validate the reproducibility and ruggedness of the release assessment test and enable 
the setting of limits to enable comparison of different inserts. 
To be considered validated, an invitro drug release test should be capable of 
reproducibly demonstrating the release characteristics of a controlled release drug 
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product yet rugged enough to do so consistently at different times. It should be 
robust enough to not be heavily influenced by system dependent variables but be 
sensitive enough to be capable of distinguishing between different products. 
Experiments conducted to validate the release assessment test used in this Thesis 
showed acceptable intra-day and inter-day reproducibility and ruggedness. 
Robustness experiments showed that the test could reproduce typical results 
independent of some system dependent variables. However, the results also showed 
that the test method was sensitive to differentiate between formulation variables such 
as drug load. 
To allow for the comparison of different products, based on the release rates 
determined in the validation procedure, specifications were set for the invitro release 
rate and intercept value of the square root of time release curve. The specifications 
were set, based upon the mean release rate and twice the standard deviation from the 
reproducibility and ruggedness experiment. The specification for the release rate 
was set at 1375 ± 463 J.lgi cm2 /hr0.5 • Specifications for the intercept value was set at 
900 ± 1143 J..lg/cm2• 
2.4.2 Invitro and Invivo Characterisation of the I-up CIDR®1380 Cattle Insert, 
6-up CIDR@1380 Cattle Insert and CIDR@1900 Cattle Insert 
2.4.2.1 Confirmation that Tools Produced Inserts Which Fulfilled Defined 
Criteria 
The design parameters for an optimised CIDR® insert for oestrus synchronisation in 
cattle were defined by Rathbone and co-workersc315 • These parameters were based 
on an insert with a surface area of 120 cm2 and an even 1 mm thick skin of silicone 
matrix impregnated with progesterone at an initial load of 10%w/w. Once defined 
InterAg's manufacturing team progressively applied those criteria to the design of 
several stainless steel tools which were capable of producing inserts which fulfilled 
the defined parameters. Initially a I-up tool (a stainless steel tool which allowed 
only one insert to be injection moulded at a time) was made to assure the Company 
that the theories developed by Rathbone et a1. were valid with production made 
inserts. Then a 6-up tool (a stainless steel tool which allowed six inserts to be 
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injection moulded at a time) was made. The 6-up tool was manufactured to increase 
manufacturing capacity, thus ensuring a commercially viable process. 
Initially the physical characteristics of each insert were compared to ensure that the 
design criteria had been met and to characterise the inserts. These included skin 
weight, surface area, initial drug load and skin thickness. In addition the invitro drug 
release characteristics of the product were determined. 
Preliminary experiments were performed to determine where the progesterone was 
located within the insert following its manufacture (i.e., within the skin, spine, or 
both). Although it had always been assumed with the CIDR@1900 Cattle insert that 
all the progesterone is located in the silicone skin, this had never been proved 
experimentally. Experimental results showed that the progesterone was located 
within the silicone skin after manufacture with insignificant quantities being 
determined within the nylon spine materiaL 
Table 2.4.1 shows the experimentally determined skin weight, initial drug load, 
surface area and skin thicknesses of the different inserts. 
Table 2.4.1 - Table - skin weight, initial load, surface area and skin thickness 
CIDR@1900 Cattle I-up CIDR@1380 6-up CIDR@1380 
insert Cattle insert Cattle insert 
Surface Area 120 123 123 
(cm2) 
Skin Weight (g) 19.97 13.87 13.91 
Initial Load (gl 1.90 1.38 1.34 
Initial Load 9.51 9.92 9.53 
i%w/w) 
Skin thickness 1 - 5 ~ 1.0 over entire ~ 1.0 over entire 
range (mm) insert* insert* 
*Except for wing tips which were dehberately made thicker for ammal comfort 
Examination of Table 2.4.1 indicate that both the I-up and 6-up tooling designs 
produced inserts in accord with the specified design criteria. Each exhibited a 
uniform skin thickness of 1 mm, had a surface area of 120 cm2 and contained a 
10%w/w initial load. 
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2.4.2.2 Invitro drug release profile of the CIDR@ Cattle inserts 
Table 2.4.1 indicated that both the I-up and 6-up tooled CIDR@1380 Cattle inserts 
exhibited a unifOlm skin thickness of 1 mm, had a surface area of 120 cm2 and 
contained a IO%w/w initial load. However, Table 2.4.1 also shows that the amount 
of progesterone in the I-up and 6-up tooled CIDR@1380 Cattle inserts is 
considerably lower compared to the CIDR@I900 Cattle insert. We therefore set out 
to assess the drug release properties of each of the inserts to determine how this 
reduction in initial drug load affected the release of drug from the inserts. The 
results are shown in Figure 2.4.1. 
Examination of Figure 2.4.1 reveals that the CIDR@I900 Cattle insert, I-up 
CIDR@1380 Cattle insert and 6-up CIDR®1380 Cattle insert all release progesterone 
at the same release rates in accord with the same mechanism of release, despite the 
reduction in the amount of progesterone in each insert. This can be explained when 
one examines the equations relating to the square root of time mechanism. When 
drug is released from a matrix containing an homogenous dispersion drug in excess 
of its solubility it will be released according to the following equation230• 
Equation 2.4.1 
where Q is the amount of drug released after time, t, per unit area of exposed area; A 
is the initial drug concentration (amount per unit volume); Cp is the solubility of the 
drug in the matrix; and Dp is the diffusion coefficient of the drug in the matrix 
material. 
This equation shows that the rate of release is dependent not upon the absolute 
amount of drug in the matrix, but its concentration. The reason why all three inserts 
give the same release rate, despite differences in initial amount of progesterone 
content, is because they contain that amount of progesterone in the same 
concentration (1 O%w/w). 
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2.4.2.3 Invivo Equivalency Determination and Characterisation 
Following confinuation that the physical characteristics of each insert met the design 
criteria and the invitro release characteristics were identical, the invivo performance 
of the inserts was compared. 
This was performed in several ways which reflected the progressive nature of the 
design and manufacture of the I-up and 6-up tools. Initially, a crossover 
bioequivalency trial over a 7 day treatment period (standard anoestrus cow 
synchrony programme) was carried out using 8 ovariectomised cows which 
compared the I-up CIDR®I380 Cattle insert with the CIDR®1900 Cattle insert. This 
trial included a rigorous sampling upon insertion and removal of the inserts to obtain 
detailed drug absorption and clearance data. Figure 2.4.2 shows the entire profile 
while Figure 2.4.3 and 2.4.4 show the detailed absorption and clearance portions of 
the profile, respectively. 
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Figure 2.4.2 - Entire blood plasma progesterone profile for CIDR@1900 Cattle insert versus 1-
up CIDR@1380 Cattle insert (0 = CIDR@1900 Cattle insert, • = CIDR@1380 Cattle insert, N = 
8, error bars = SEM) 
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Figure 2.4.3 - Blood plasma progesterone absorption profIle for the CIDR@1900 Cattle insert 
(0) and the I-up CIDR@1380 Cattle insert ( • ) (n = 8; error bars = SEM) 
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Figure 2.4.4 - Blood plasma progesterone clearance profile for the CIDR@1900 Cattle insert (0) 
and the I-up CIDR@1380 Cattle insert (.) (n = 8; error bars = SEM) 
Statistical analysis of the areas under the curve (AVC) (Table 2.3.30) for Figures 
2.4.2, 2.4.3 and 2.4.4 suggest that the CIDR@1380 Cattle insert and CIDR@1900 
Cattle insert were bioequivalent over a 7 day insertion in respect to both the 
absorption profile (AUCo_4hr; p=0.452), clearance profile (AUC7_8day; p=0.702) as well 
as the overall profile (AUCO_8day; p=0.137). 
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The second crossover bioequivalency trial again compared the 1-up CIDR®1380 
Cattle insert with the CIDR@1900 Cattle insert, but on this occasion it was carried 
out in 10 ovariectomised Friesian cows over a 10 day treatment period (which 
corresponded to a standard heifer synchrony programme). Results are shown in 
Figure 2.4.5. 
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Figure 2.4.5 - Blood plasma progesterone levels in ovariectomised cows produced by 
CIDR@1900 Cattle insert (0) and I-up CIDR@I380 Cattle insert ( • ) over a 10 day treatment 
crossover study (N=10; error bars = SEM) 
The profiles obtained can be seen to be overlapping throughout the ten day treatment 
period and statistical analysis of AUC's (Table 2.3.31) for the two CIDR® Cattle 
inserts over the ten days yielded p=O.2S1. Therefore, the CIDR@1900 Cattle insert 
and CIDR®1380 Cattle insert were shown to be bioequivalent over a ten day 
insertion period (Figure 2.4.5) as well as a 7 day period (Figure 2.4.2). 
A third crossover bioequivalency trial was conducted comparing the CIDR@1900 
Cattle insert and I-up CIDR@I380 Cattle insert in 10 ovariectomised Friesian cows 
over a 20 day treatment period to determine how long an insertion would be possible 
before the I-up CIDR@1380 Cattle insert would fail to maintain plasma progesterone 
levels equivalent to the CIDR@1900 Cattle insert. Results are presented in Figure 
2.4.6. 
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Figure 2.4.6 - Blood plasma progesterone levels in ovariectomised cows produced by 
CIDR®I900 Cattle insert (0) and I-up CIDR®I380 Cattle insert ( .) over a 20 day treatment 
crossover study (N=10; error bars = SEM) 
Statistical analysis of AVe values (Table 2.3.32) showed that there was no 
difference between the two inserts between days 0-15 (p=O.789), however, there was 
a significant difference between the inserts over days 15-20 (p<0.001) of the 
insertion period. This is a reflection of the lower amount of progesterone originally 
incorporated into the I-up CIDR®1380 Cattle insert. 
A final bioequivalency trial was performed when the 6-up tool had been 
manufactured. This trial compared the I-up CIDR®1380 Cattle insert with the 6-up 
CIDR@13 80 Cattle insert. The bioequivalency trial involved 24 ovariectomised 
Friesian cows comparing three production batches of 6-up CIDR@1380 Cattle insert 
with I-up CIDR®1380 Cattle insert was carried out over a 10 day treatment period. 
Six animals per cell were used to assess the variables. Figure 2.4.7 shows the mean 
profile of the three 6-up CIDR@1380 Cattle insert batches versus the I-up 
CIDR@1380 Cattle insert. 
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Figure 2.4.7 - Blood plasma progesterone profiles for 1-up CIDR@1380 Cattle insert (0; N = 4) 
versus 6-up CIDR@1380 Cattle insert (.; N = 16) (error bars = SEM) 
Figure 2.4.7 shows that the 6-up CIDR@1380 Cattle insert produced overlapping 
plasma progesterone profiles with those produced by the I-up CIDR@1380 Cattle 
insert. Statistical analysis of AVC data (Table 2.3.36) suggests that these inserts are 
indeed bioequivalent (p=0.8IO) over a ten day insertion period. 
Figure 2.4.8 shows the individual batch comparisons of the 6-up CIDR@1380 Cattle 
insert to the I-up CIDR®1380 Cattle insert. 
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Figure 2.4.8 - Blood plasma progesterone profiles for I-up CIDR@1380 Cattle insert (X, N = 4) 
and three batches of 6-up CIDR@1380 Cattle insert (0= batch 8927, N =6;. = batch 8931, N = 
4; .. = batch 8934, N = 6) 
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Figure 2.4.8 shows that each of the three separate production batches of 6-up 
CIDR@1380 Cattle insert produce overlapping plasma progesterone profiles with 
those produced by the I-up CIDR@1380 Cattle insert. Statistical analysis of AUe 
data (Table 2.3.36) suggests that these inserts are each bioequivalent (p=0.81 0) over 
a ten day insertion period to the I-up CIDR@I380 Cattle insert. 
A further analysis is shown in Figure 2.4.9 which shows the mean profile of each of 
the individual cavities which make up the 6-up CIDR®I380 Cattle insert batches 
compared to the I-up CIDR®1380 Cattle insert. 
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Figure 2.4.9 - Blood plasma progesterone profiles for I-up CIDR®1380 Cattle insert (X, N = 4) 
and 6-up CIDR@1380 Cattle insert from each of the six tool cavities (. = cavity I, N = 3; ... = 
cavity 2, N = 3; = cavity 3, N = 2; * = cavity 4, N = 3; 0== cavity 5, N = 2; I = cavity 6, N = 3) 
Figure 2.4.9 shows that each of the six individual cavities which make up the 6-up 
tool produce overlapping plasma progesterone profiles with those produced by the 1-
up CIDR@1380 Cattle insert. Statistical analysis of AVC data (Table 2.3.36) 
suggests that each cavity produces inserts which are each bioequivalent (p=0.892) 
over a ten day insertion period to the I-up CIDR@1380 Cattle insert. 
2.4.2.4 Residual Progesterone Content in Spent Inserts 
The residual content of progesterone in CIDR ® Cattle inserts inserted for various 
insertion periods is summarised in Table 2.4.2. 
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Table 2.4.2 - Initial and residual progesterone loads in CIDR® Cattle inserts inserted for various 
insertion periods and the calculated amount of progesterone released over that period 
Insert Insertion Initial amount Residual Amount 
period of progesterone progesterone released 
(day~) (g) (e:) (g) 
CID R@1900 Cattle insert 7 1.99 1.38 + 0.01 0.61 + 0.01 
CIDR@1900 Cattle insert 10 1.97 1.19 ± 0.03 0.78 + 0.03 
CIDR@1900 Cattle insert 20 1.99 0.79 + 0.04 1.20 + 0.04 
l-up CIDR@1380 Cattle insert 7 1.34 0.72 ± 0.02 0.62 + 0.02 
l-up CIDR@1380 Cattle insert 10 1.35 0.48 ± 0.01 0.87 + 0.01 
I-up CIDR@1380 Cattle insert 20 1.36 0.20 + 0.01 1.16+0.01 
I-up CIDR@1380 Cattle insert 10 1.34 0.68 + 0.03 0.66 + 0.03 
6-up CIDR@1380 Cattle insert 10 l.35 0.72 ± 0.02 0.63 ± 0.02 
Batch 8927 
6-up CIDR@1380 Cattle insert 10 1.34 0.76 ± 0.02 0.58 ± 0.02 
Batch 8931 
6-up CIDR@1380 Cattle insert 10 1.33 0.68 ± 0.02 0.65 ± 0.02 
Batch 8934 
Table 2.4.2 shows that the residual amount of progesterone remaining in a used 
CIDR@ Cattle insert is dependent upon the length of insertion and the type of insert 
used (CIDR@1900 Cattle insert versus I-up and 6-up CIDR@I380 Cattle insert). The 
CIDR@1900 Cattle insert contains the highest residual compared to either the I-up or 
6-up CIDR®I380 Cattle insert, whereas the I-up and 6-up CIDR@I380 Cattle inserts 
contain the same residual after a given insertion period in the same trial (p<0.1). 
2.4.2.5 Amount released 
Table 2.4.2 also shows the amount of progesterone released from each insert 
following insertion. Over seven days, the CIDR@1900 Cattle insert and I-up 
CIDR@1380 Cattle insert released the same amount of drug (p=0.6I4) which was 
approximately 0.6 g. Over 20 days these two inserts also released the same amount 
of drug (p=0.370), approximately 1.2 g. In contrast, the amounts of progesterone 
released for the CIDR@1900 Cattle insert and I-up CIDR@1380 Cattle insert over ten 
days was shown to be statistically different (p=O.024), however, this seems an 
unusual observation given the overlapping plasma progesterone profiles. 
Determination of the amount of progesterone released from I-up CID R@1380 Cattle 
insert and the three batches of 6-up CIDR@1380 Cattle insert during a ten day 
insertion showed that these inserts all released the same amount of progesterone 
(p>O.l). 
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2.5 Conclusions 
Table 2.5.1 highlights both the successful implementation by the manufacturing team 
of the recommendations of Rathbone et al. and the successful nature of these 
workers' optimisation process for the CID R ® 1900 Cattle insert. 
Table 2.5.1 - Comparison of the characteristics of the CIDR@1900 Cattle insert, I-up 
CIDR®1380 Cattle insert and 6-up CIDR@1380 Cattle insert. 
Parameter CIDR@1900 I-up CIDR@1380 6-up CIDR@1380 
Cattle insert Cattle insert Cattle insert 
initialloads(g} 1.90 1.38 1.34 
Amount released 7 0.61 0.62 not detennined 
days (g) 
Amount released 10 0.78 0.87a / 0.66b 0.58-0.65d 
days (g) 
Amount released 20 1.20 1.16 not detennined 
days (g) 
Skin thickness (mm) 1-5 ~ 1.0 over entire ~ 1.0 over entire 
insert* insert* 
Residual 7 days {g) 1.38 0.72 not detennined 
Residual 10 days {g} 1.19 OA8a / 0.68b 0.68-0.76d 
Residual 20 days (g) 0.79 0.20 not detennined 
Bioequivalencyc 7 26 24 not detennined 
days 
Bioequivalencyc 10 30 33a / 27b 25-28d 
days 
Bioequivalencyc 20 49 45 not determined 
days 
Invitro release rate 1302 1320 1236 
illg/cm2/hr 1/2) 
Surface area (cm2) 120 123 123 
a = result from 10 day trial #1; b = result from 10 day trial #2; c = quantified in terms of AVe 
(ng.day/mL); d = range of results between each of the 3 batches and or 6 cavity positions determined 
* = Except for wing tips which were deliberately made thicker for animal comfort 
I-up and 6-up tools were successfully designed and manufactured which resulted in 
the production of CIDR® inserts which exhibited a uniform skin thickness of 1 mm, 
contained a 10%w/w initial load and had a surface area of 120 cm2 (Table 2.5.1). 
The resultant CIDR@1380 Cattle inserts manufactured with these tools were shown to 
release progesterone invitro at the same rate as the CIDR@1900 Cattle insert and to 
release the same amount of progesterone over a given insertion period, resulting in 
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invivo bioequivalence to the CIDR®1900 Cattle insert up to a 15 day insertion period 
(Table 2.5.1). However, the redevelopment of a CIDR®1380 Cattle insert with a 
unifonn I mm skin thickness resulted in a reduction in the initial progesterone load 
(Table 2.5.1). Since the same percentage load was included in the CIDR®1380 
Cattle insert as the CIDR®1900 Cattle insert (Table 2.5.1) the release characteristics 
of the insert were equivalent and this was reflected in the two inserts exhibiting 
bioequivalence. In addition all inserts were shown to release the same amount of 
progesterone over a given insertion period (irrespective of initial load or skin 
thickness) (Table 2.5.1). Thus, because the CIDR®1380 Cattle insert contained a 
lower initial load (1.34 g) compared to the CIDR®1900 Cattle insert (1.90 g), the 
residual progesterone content of the CIDR® 1380 Cattle insert (0.7 g) was lower than 
that of the CIDR@1900 Cattle insert (1.32 g). 
The CIDR®1380 Cattle insert therefore exhibits a lower initial load, lower residual 
drug load and is bioequivalent to the CIDR@1900 Cattle insert (Table 2.5.1). In 
addition to these favourable attributes of the CIDR@1380 Cattle insert because of the 
elimination of wasted drug loaded silicone skin, it achieves a significant 
improvement in material utilisation over the CIDR®1900 Cattle insert. 
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systems for the delivery of progesterone for control of the bovine 
oestrous cycle. II. Physical and chemical stability characteristics of 
CIDR@1900Cattle insertsandl~up CIDR@1380 Cattle inserts. 
3.1 Introduction 
Stability testing is an integral component of any drug product profile. It provides 
experimental evidence for the length of time the chemical and physical 
characteristics of a drug product remain within acceptable limits of quality, safety 
and efficacy after its date of manufacture226 • 
Stability studies should be conducted in accord with a predefined stability 
programme. Essential components of a stability programme include a fully validated 
stability indicating chemical assay, well controlled temperature and humidity 
conditions, statements which specify pre-defined sample points, limits on 
temperature and humidity parameters and definitions of the quality characteristics of 
the product. In addition, for a controlled release product, the stability programme 
should include an assessment of the invitro drug release profile over the duration of 
the trial to demonstrate that the release characteristics of the drug do not change 
detrimentally upon storage231 • 
In a stability study, a product would be considered stable over a given period of time 
if the level of active contained within product stored for that time period remained 
greater than 90% of the stated label claim. A tentative shelf life for a product can be 
proposed on the basis of short term (6-12 months) data obtained for product stored 
under accelerated time (elevated temperature and humidity; 40°C, 75%RH) 
conditions. This tentative shelf life would then be confinned using real time 
(ambient temperature and humidity; 25°C, 60%RH) data generated over the time 
period corresponding to the proposed shelf life. 
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In this chapter the chemical and physical stability of the CIDR ® 1900 Cattle insert 
and I-up CIDR@1380 Cattle insert were detennined under real time and accelerated 
time conditions. The predefined parameters which describe the quality 
characteristics of the product are shown in Table 3.1.1. The selection of these 
product quality parameters was based on InterAg's previous experience with the 
product and were known to influence the quality, safety and efficacy of the product. 
Table 3.1.1 - Product variables assessed in the stability study testing programme 
Potential changes Potential chemical Rationale for Action in stability 
on storage and physical the selection of trial 
changes based on product 
previous variables 
experience included in the 
testing 
programme 
Chemical changes 
Loss of potency Decrease in potency Potential loss of Determination of 
profile with time efficacy degree of chemical 
change to establish 
storage conditions and 
determine shelf life 
Increase in Increase in Potential loss of Determination of 
degradation products degradation profile efficacy change in degradation 
with time profile 
Physical changes 
Colour Very slight and Loss of Visually assess colour 
gradual change from phannaceutical change and ensure 
white to a duller elegance change falls within 
white colour specified limits 
Surface progesterone Gradual appearance Loss of Determination of 
of progesterone on phannaceutical degree of change of 
the surface of the elegance initial burst effect in 
insert over the first the invitro drug 
three months release test and ensure 
change falls within 
specified limits 
Change in release Change in potency Potential loss of Determination of 
profiles profile with time efficacy degree of change of 
could result in release characteristics 
change in release and ensure change 
characteristics falls within 
prespecified limits 
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3.2 Methods 
3.2.1 Stability Trial 
3.2.1.1 Stability-Indicating and Potency HPLC Assay 
3.2.1.1.1 Method 
HPLC System: 
Reagents: 
Column: 
WatersTM LC Module I Plus, Degasys DG2410 
Double distilled water CAUTOSTILLTM Auto Four WS 
SYSTEM, Jencons Scientific Ltd.) and methanol 
(HiperSolvTM for HPLC, BDH, N.Z.) filtered and degassed, 
Progesterone CUSP micronised, Pharmacia & Upjohn, USA) 
Waters SymmetryTM CI8 3.9 x 150 mm, 5 micron HPLC 
Cartridge Column 
Guard Column: Waters SentryTM Guard Column 
Column Conditions: Mobile Phase: 70:30v/v Cmethanol:water) 
Mobile Phase Flow: 1 mL per minute 
Injection Volume: 20 /-tL 
AUFS: 1.000 
Progesterone Retention Time: 9.2 ± 0.4 minutes 
Detection Wavelength: 240 nm 
Integration: Peak Area 
3.2.1.1.2 Standard Preparation 
Standards were prepared by transferring 0.1000 g progesterone standard CUSP 
micronised, Phannacia &Upjohn, USA) into a 100 mL volumetric flask followed by 
the addition of 50 mL alcohol (SDA-3A, Mobil, New Zealand). The mixture was 
sonicated until the progesterone completely dissolved, made up to volume with 
alcohol (SDA-3A, Mobil, New Zealand) and mixed by inversion. 200 J..lL, 500 J..lL, 
1000 J..lL, 1500 /-lL and 2000 J..lL aliquots were then pipetted into 50 mL volumetric 
flasks, made up to volume with alcohol (SDA-3A, Mobil, New Zealand) and mixed 
by inversion. 
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3.2.1.1.3 Sample Preparation 
Drug loaded silicone skin was removed from the nylon spine and weighed on a four 
figure analytical balance (BPI IDS, Sartorius, Germany). The skin was cut into 5-8 
em lengths using a scalpel and the lengths were placed into a Soxhlet apparatus, 
ensuring that all lengths sat below the siphon level. 350 mL ethanol (SDA-3A, 
Mobil, New Zealand) was added to the round bottom flask of the Soxhlet apparatus 
and the flask, Soxhlet and condenser were assembled. Skins were extracted for 12 
hours and allowed to cool before transferring (with rinsing) to a 500 mL volumetric 
flask and making the volume up to the mark with ethanol (SDA-3A, Mobil, New 
Zealand). This solution was then diluted (0.5 mL to 100 mL) in ethanol (SDA-3A, 
Mobil, New Zealand) prior to analysis using the stability-indicating HPLC assay. 
3.2.1.2 Validation of the Stability-Indicating and Potency HPLC Assay 
The HPLC-UV assay was validated by assessment of its linearity and range, 
accuracy, precision, limit of quantitation, stability indicating nature, and 
ruggedness226-228 . 
3.2.1.2.1 Linearity and Range 
The linearity of an analytical method is defined as its ability to elicit test results that 
are directly proportional to the concentration of analyte in samples within a given 
range, the range being the interval between the upper and lower levels of analyte 
that have been demonstrated to be determined with precision, accuracy, and linearity 
using the method as written. Linearity was determined by analysing two sets of 
calibration standards (4, 10, 20, 30 and 40 J-Lg/mL) and performing linear regression 
upon the results. The range was determined by analysing validation standards at 4 
and 40 ~g/mL and determining their concentrations against the linear regression. 
3.2.1.2.2 Accuracy 
Accuracy is defined as the nearness of a result to the true or accepted value. 
Accuracy was determined by analysing validation standards at 8, 15 and 35 J-Lg/mL, 
calculating their concentrations against the linear regression and assessing the 
deviation of the calculated results from their true concentrations. 
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3.2.1.2.3 Precision 
Precision is defined as the agreement of repeat observations made under the same 
conditions. Precision occurs on different levels including repeatability (multiple 
injections of the same solution), reproducibility (determination of multiple known 
samples). Repeatability was assessed by executing repeat injections of a single 
standard solution and detennining the relative standard deviation of the results about 
their mean value. Reproducibility was detennined in association with accuracy. The 
concentrations of replicate 8, 15 and 35 J-tg/mL validation standards were calculated 
against the linear regression and the relative standard deviations of the results about 
their means were determined. 
3.2.1.2.4 Ruggedness 
Ruggedness is an element of precision and is defined as agreement in the 
determination of multiple known samples using the same method but under different 
conditions such as day of analysis and analyst carrying out the experiment. 
Ruggedness was determined by replicate analyses of CIDR® inserts on multiple days 
and with multiple analysts. 
3.2.1.2.5 Limit of quantitation 
The limit of quantitation is defined as the lowest concentration of analyte in a sample 
that can be determined with acceptable precision and accuracy under the stated 
experimental conditions. The limit of quantitation was determined by estimating the 
background response of the method from multiple blank injections, followed by 
analysis of standards near the determined limit. 
3.2.1.2.6 Specificity 
Specificity is defined as the ability of the method to resolve a substance from its 
impurities and any other substances such as degradation products or placebo 
ingredients of the product. Specificity of the stability-indicating assay was assessed 
by analysis of progesterone standards in the presence of analogous compounds 
(Figure 3.2.1) and any unknown compounds extractable from the silicone CIDR® 
matrix. 
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Figure 3.2.1 - Chemical structure of progesterone and some of its structurally related analogues 
3.2.2 Real and Accelerated Time Stability Study 
3.2.2.1 Manufacture of CIDR@1900 Cattle Inserts and 1-up CIDR@1380 Cattle 
Inserts 
All CrDR inserts were manufactured as described in Chapter Two (see Section 
2.2.3). 
3.2.2.2 Stability Trial Protocol 
3.2.2.2.1 Batch production and sample selection procedure 
Three production batches each of both CIDR@1900 Cattle inserts and I-up 
CIDR@1380 Cattle inserts were manufactured under large scale manufacturing 
conditions. As the inserts were manufactured they were placed into large 
polyethylene bags and labeled according to CIDR@ type and batch number. CIDR@ 
inserts were then selected at random from the large poly-bags and packed in lots of 
two in the closure system. Once packaged, bags of CIDR ® 1900 Cattle inserts and 1-
up CIDR@1380 Cattle inserts from each production batch were randomly selected, 
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allocated a sample time point, closure condition (open or closed bags) and storage 
condition (real or accelerated time) and then labeled accordingly. 
3.2.2.2.2 Closure 
The closure used in the studies was the same as that which is used for the packaging 
of retailed product. The packaging comprised opaque white resealable (Minigrip® 
zipseal) 60 J-lm polyethylene bags with tamper evident perforated closure strips. 
Inserts were stored in both open and closed (heat sealed) closures during the trial. 
3.2.2.2.3 Storage conditions 
Inserts were stored under conditions representing 'real time' (25°C/60%RH) and 
'accelerated time' (40°C/75%RH) storage conditions227 , Precise temperature control 
(±2°C) was achieved using thermoregulated incubators (Contherm, UK). Humidity 
was controlled to within ±5% of nominated values within the incubators by use of 
saturated salt solutions; 60% humidity at 25°C was achieved with the presence of a 
saturated solution of NaBr (GPRTM, BDH, New Zealand) while 75% humidity at 
40°C was achieved with the use of a saturated NaCl (GPRTM, BDH, New Zealand) 
solution232 • No natural or artificial lighting was present within the incubators. 
3.2.2.2.4 Sampling Plan 
The predefined sampling schedule for the CIDR@1900 Cattle insert and I-up 
CIDR@1380 Cattle insert stability trial is presented in Table 3.2.1. Ticks represent 
the time points at which samples stored under real time and accelerated time 
conditions, in open and in closed bags, were sampled for analysis. 
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Table 3.2.1- Sampling protocol for potency, invitro drug release and physical stability during 
the stability trial 
Potency Invitro release Physical stability 
assessment assessment 
Time CIDR@1900 I-up CIDR@I900 I-up CIDR@1900 I-up 
(months) CIDR@1380 CIDR<!ilI380 CIDR@1380 
0 .., ~ ~ IJ .., .., 
0.5 ~ 
1 ~ 
2 ~ 
2.5 ~ 
3 .., ~ IJ 
6 ~ ~ IJ .., ~ 
9 ~ ~ 
12 ~ ~ .., ~ .., ~ 
18 ~ ~ 
24 .., ~ .., ~ ~ ~ 
3.2.2.3 Assessment of Chemical Changes 
3.2.2.3.1 Potency Assay 
It was previously shown in Chapter Two, Section 2.3.3.1, that following manufacture 
of CIDR® inserts using InterAg's standard manufacturing technique and materials, 
drug was contained in the skin. To determine the potency of each sample, two 
samples were removed from their controlled storage conditions at each allocated 
time point and silicone skins were prepared for analysis by a Soxhlet extraction 
technique using ethanol (SDA-3A, Mobil, New Zealand) (see Chapter Two, Section 
2.2.1.3). They were then analysed to determine drug potency by a validated 
stability-indicating and potency HPLC assay (see Section 3.2.1). 
3.2.2.3.2 Degradation Products 
The presence of degradation products was determined by visually examining each of 
the HPLC chromatograms generated during the potency assay determinations for the 
presence of new peaks which were not originally apparent in time zero 
chromatograms. 
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3.2.2.4 Assessment of Physical Changes 
3.2.2.4.1 Physical Observations 
The colour of the inserts was subjectively assessed by visual examination of two 
inserts from each batch at each storage condition employed in the study. 
The amount of progesterone powder appearing on the surface with time was 
subjectively assessed by looking at the surface and subjectively estimating the extent 
of surface progesterone. 
3.2.2.4.2 Invitro Drug Release 
CIDR inserts removed from controlled storage conditions at each predefined time 
point were subjected to a validated invitro drug release test which was developed 
based upon the criteria described in the Drug Release monograph of the 23rd United 
States Pharmacopeia233 (see Chapter Two, Sections 2.2.2 and 2.3.2). 
3.2.2.5 Analysis of Stability Data 
3.2.2.5.1 Accelerated Time Data 
Accelerated time potency data was plotted as the average percent label claim of the 
duplicate samples from each production batch at each sample time point and least 
squares regression was performed on the data. A one sided lower 95% confidence 
interval about this regression line was used to estimate the time frame in which 
potency would decline to 90% of the label claim. The one-sided lower 950/0 
confidence interval about the regression line was calculated from the following 
equations234 • The least squares line (y = a + bx) constants 'a' and 'b' are given by: 
where 
b = the slope of the least squares line 
LXY is the sum of the cross-products of corresponding x and y values 
LX = the sum of all x (time) values 
LY = the sum of all y (potency) values 
Equation 3.2.1 
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N = the total number of data points (sets ofx,y data) 
2:(x2) = the sum of all squared x (time) values 
where 
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Equation 3.2.2 
a = the intercept of the least squares line with the y axis 
There will be a ~ confidence interval, z, about a predicted value y (i.e. Yi ± zJ where 
where: 
tN-2'~ = the tabulated student's t value with N - 2 degrees of freedom and ~ confidence 
Sxy = the square root of sx/ 
Equation 3.2.4 
where 
2:y2 is the sum of the squared y values 
3.2.2.5.2 Real Time Data 
Real time potency data was plotted as the average percent label claim of the 
duplicate samples from each production batch at each sample time point. The curve 
was then visually assessed to ascertain if values determined under real time 
conditions remained above the 90% label claim specification. 
3.2.3 Manufacturing Study 
The "manufacturing study" investigated manufacturing factors that affected the rate 
and extent of appearance of progesterone on the surface of the I-up CIDR®1380 
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Cattle insert. In this study, only the I-up CIDR®1380 Cattle insert was investigated 
as InterAg planned for the CIDR®1380 Cattle insert to supersede the CIDR®1900 
Cattle insert in the marketplace. The I-up CIDR ® 13 80 Cattle inserts investigated in 
this manufacturing study were not subjected to a stability trial, instead, the amount of 
progesterone appearing on the surface was quantified as a function of storage time at 
40°C/75%RH using a surface wash technique. 
3.2.3.1 Manufacture of I-up CIDR@1380 Cattle Inserts 
A range of I-up CIDR®1380 Cattle inserts were fabricated under different 
manufacturing conditions (Table 3.2.2) in order to assess the effect of moulding 
temperature, curing time and spine annealing time on the rate and extent to which 
progesterone appeared on the surface of the product. The I-up CIDR®1380 Cattle 
inserts were manufactured with the same equipment normally employed by InterAg 
to manufacture CIDR ® inserts, however, modified manufacturing conditions were 
impelled as described in Table 3.2.2. In all cases Dow Silastic® Q7-4840 silicone 
and Pharmacia & Upjohn USP micronised progesterone were used in the 
formulations. 
Table 3.2.2 - Variables in the fabrication of I-up CIDR®1380 Cattle inserts which were 
investigated in the manufacturing study 
Test Manufacturin~_ condition 
Mould Time in mould (s) Spine anneal time 
temperature ee) (bours) 
1 130 50 7.5 
2 130 110 7.5 
3 160 50 7.5 
4 190 35 7.5 
5 190 50 7.5 
6 190 65 7.5 
7 190 80 7.5 
8 210 50 7.5 
9 210 65 7.5 
10 190 50 0 
11 190 50 2.5 
12 190 50 4.5 
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3.2.3.2 Trial Protocol 
3.2.3.2.1 Batch Production and Sample Selection Procedure 
A single production batch of I-up CIDR@1380 Cattle inserts were manufactured, 
altering manufacturing variables (Table 3.2.2) as the production run progressed to 
produce the different inserts. As the inserts were manufactured they were placed 
into large polyethylene bags and labeled according to their manufacturing variation. 
CIDR@ inserts from each manufacturing variant were then selected at random from 
their large polyethylene bag and packed in lots of two in the closure system. Once 
packaged, bags of I-up CIDR@1380 Cattle inserts were randomly selected, allocated 
a sample time point and labeled accordingly. 
3.2.3.2.2 Closure 
Product closure was the same as that used in the Real and Accelerated Stability Trial 
(see Section 3.2.2.2.2). Product was stored in open bags. 
3.2.3.2.3 Storage Conditions 
Samples were stored under accelerated time conditions (40°C, 75% RH) using the 
equipment and chemicals described in Section 3.2.2.2.3. 
3.2.3.2.4 Sampling Plan 
Two inserts were sampled at tin1e points of 0, 3 and 12 months. 
3.2.3.3 Assessment of Surface Progesterone 
3.2.3.3.1 Determination o/Surface Progesterone 
In this part of the study attempts to quantify the amount of progesterone appearing 
on the surface were made (in the stability study this parameter was only subjectively 
assessed). Quantification of the amount of progesterone on the surface of the I-up 
CIDR@1380 Cattle insert was achieved by rinsing the skin of the CIDR@ insert with 
between 45 and 50 mL of ethanol (SDA-3A, Mobil, New Zealand). The ethanolic 
wash was collected in a 400 mL beaker, transferred to a 100 mL volumetric flask and 
made up to volume using ethanol. Progesterone content was then determined by UV 
Spectrophotometry using the assay described in Section 2.2.1. 
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3.2.3.3.2 Determination of Progesterone in Silicone Skin 
Following the skin rinsing, each skin was subjected to soxhlet extraction as described 
in Chapter Two, Section 2.2.1.3 to determine the remainder of its progesterone 
content by UV Spectrophotometry using the assay described in Chapter Two, 
Section 2.2.1. 
3.2.4 Potential Future Manufacturing Strategies 
In this part of the study, a stability study was used to determine the ability of two 
potential manufacturing strategies to decrease the appearance of progesterone on the 
surface of the I-up CIDR@1380 Cattle insert. These strategies included the use of a 
water-free (non-annealed) spine material and a silicone that allows manufacture of 
the CIDR ® insert at low curing telnperatures. 
3.2.4.1 Alternate Spine Material 
3.2.4.1.1 Manufacture of I-up CIDR@1380 Cattle Inserts 
I-up CIDR®1380 Cattle inserts were manufactured with InterAg's standard injection 
moulding technique using Dow Silastic® Q7 -4840 silicone and Pharmacia & Upjohn 
USP micronised progesterone (see Chapter Two, Section 2.2.3). However, in this 
part of the study, inserts were manufactured with a non-annealed polyester 
(Hoescht™ Riteflex® 677) spine. 
3.2.4.1.2 Trial Protocol 
3.2.4.1.2.1 Batch Production and Sample Selection Procedure 
A single production batch of I-up CIDR®1380 Cattle inserts was manufactured. As 
the inserts were manufactured they were placed into large polyethylene bags. CIDR® 
inserts were then selected at random from the large polyethylene bags and packed in 
lots of two in the closure system. Once packaged, bags of CIDR® inserts were 
labeled appropriately for storage. 
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3.2.4.1.2.2 Closure 
Product closure was the same as that used in the Real and Accelerated Stability 
Study (see Section 3.2.2.2.2). Product was stored in open bags. 
3.2.4.1.2.3 Storage Conditions 
Samples were stored under real time conditions (25°C, 60% RH) uSIng the 
equipment and chemicals described in Section 3.2.2.2.3. 
3.2.4.1.2.4 Sampling Plan 
No predefined sampling plan was specified and samples were removed from storage 
for analysis at convenient times. 
3.2.4.1.3 Assessment of Chemical Changes 
3.2.4.1.3.1 Potency Assay 
Drug content in the silicone skins of the I-up CIDR@1380 Cattle inserts which were 
manufactured with a polyester spine was determined by Soxhlet extraction of the 
silicone skins with ethanol (SDA-3A, Mobil, New Zealand) (see Section 3.2.1.2) 
followed by analysis by UV assay (see Chapter Two, Section 2.2.1). 
3.2.4.1.3.2 Determination of Progesterone in the Polyester Spine 
Drug content in the polyester spine was determined after the silicone skin had been 
removed from the polyester spine. After removal of the silicone skin, the spine was 
accurately weighed (BPII0S, Sartorius, Germany) and cut into 5-8 em lengths using 
an hacksaw. The lengths were placed into a Soxhlet apparatus, ensuring that all 
lengths sat below the siphon level. 350 mL ethanol (SDA-3A, Mobil, New Zealand) 
was added to the round bottom flask of the Soxhlet apparatus and the flask, Soxhlet 
and condenser were assembled. Spines were extracted for 12 hours and allowed to 
cool before transferring (with rinsing) to a 500 mL volumetric flask and making the 
volume up to the mark with ethanol (SDA-3A, Mobil, New Zealand). This solution 
was then diluted 1 to 15 and analysed by HPLC (see Section 3.2.1). 
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3.2.4.2 Low Temperature Cure Silicone 
3.2.4.2.1 Manufacture of I-up CIDR@1380 Cattle Inserts 
I-up CIDR®1380 Cattle inserts were manufactured using a low temperature curing, 
two part (A and B) silicone elastomer (Wacker Chemicals Elastosil® LR3004-40). 
Progesterone (USP micronised, Pharmacia & Upjohn, USA) was thoroughly mixed 
at 10% w/w into each of the silicone parts A and B, degassed and then the two parts 
inj ection moulded over an annealed nylon spine and cured at 130°C for 
approximately 35 seconds. 
3.2.4.2.2 Stability Trial Protocol 
3.2.4.2.2.1 Batch Production and Sample Selection Procedure 
A single production batch of I-up CIDR®1380 Cattle inserts was manufactured with 
Wacker Elastosil® LR3004-40 silicone instead of Dow Silastic® Q7-4840 silicone. 
As the inserts were manufactured they were placed into large polyethylene bags. 
CIDR ® inserts were then selected at random from the large polyethylene bags and 
packed in lots of two in the closure system. Once packaged, bags of CIDR® inserts 
were randomly selected, allocated a sample time point and storage condition (real or 
accelerated) and labeled accordingly. 
3.2.4.2.2.2 l7losure 
Product closure was the same as that used in the Real and Accelerated Stability Trial 
(see Section 3.2.2.2.2). Product was stored in open bags. 
3.2.4.2.2.3 Storage l7onditions 
Samples were stored under real time (25°C, 60% RH) and accelerated time 
conditions (40°C, 75% RH) using the equipment and chemicals described in 
3.2.2.2.3. 
3.2.4.2.2.4 Sampling Plan 
Sufficient samples were allocated to real time and accelerated time storage for 
predefined periods of 0, 3, 6, 9, 12, 18, 24 and 36 months. 
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3.2.4.2.3 Assessment of Chemical Changes 
3.2.4.2.3.1 Potency Assay 
Low temperature cure I-up CIDR@I380 Cattle inserts were prepared for analysis as 
described in Section 3.2.1.2 and their potency (drug content in skin) was determined 
as described in Chapter Two, Section 2.2.1 (UV Assay). 
3.2.4.2.4 Assessment of Physical Changes 
3.2.4.2.4.1 Invitro Drug Release 
Low temperature cure I-up CIDR@1380 Cattle inserts were subjected to the invitro 
drug release test as described in Chapter Two, Section 2.2.2). 
3.2.4.2.5 Invivo Performance 
A bioequivalency study was carried out to compare the low temperature cure silicone 
I-up CIDR@1380 Cattle insert with the conventional silicone CIDR@1900 Cattle 
insert over a 10 day insertion period. The study involved 12 ovariectomised Friesian 
cows (n = 6 per treatment). The study followed the invivo protocol as described in 
Chapter Two, Section 2.2.5 and plasma samples were collected prior to CIDR@ 
insertion, daily for the 10 days and finally, 6 hours following CIDR@ insert removal. 
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3.3 Results 
3.3.1 Stability-Indicating and Potency HPLC Assay Validation 
3.3.1.1 Linearity and Range 
Calibration curve data obtained on day one of the validation is presented in Table 
3.3.1. The combined regression analysis of this data is presented in Table 3.3 .2. 
Determinations of range validation standards are presented in Table 3.3.3. 
Table 3.3.1 - Peak areas and regression analysis of A and B calibration working standards in 
the stability-indicating and potency HPLC assay validation 
Concentration (J-Lg/mL) Standard A Peak Area Standard B Peak Area 
(UV*sec) (UV*sec) 
4 229212 231802 
10 578548 576392 
20 1145270 1171457 
30 1742761 1737551 
40 2326720 2327017 
Slope 58268 58170 
Intercept -7477 -1101 
r2 0.9999 1.0000 
Table 3.3.2 - Combined regression analysis of both A and B working standards in the stability-
indicating and potency HPLC assay validation 
Value Standard ±95% ± 990/0 
Error Confidence Confidence 
Limit Limit 
Bl 58201.558 141.409 315.342 448.266 
BO -3926.185 3170.424 7070.046 10050.245 
Table 3.3.3 - Peak areas and calculated concentrations of range validation standards in the 
stability-indicating and potency HPLC assay validation 
QC Sample Peak Area (UV*sec) Calculated 
Concentration (J..Lg/mL) 
4 J1E/mL 233900 4.09 
4 J..lg/mL 230280 4.02 
40 J.lg/mL 2337437 40.23 
40 J.lg/mL 2300335 39.59 
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3.3.1.2 Accuracy 
Detenninations of accuracy validation standards are presented in Table 3.3.4. 
Table 3.3.4 - Analysis of accuracy validation standards in the stability-indicating and potency 
HPLC assay validation 
8 j.lg/mL day 0 day 1 day 2 day 3 mean SD %RSD %deviation 
Rep. A 7.97 7.75 8.02 7.85 7.90 0.12 1.54 1.28 
Rep. B 7.99 7.8 7.93 7.93 7.91 0.08 1.01 1.09 
mean 7.98 7.78 7.98 7.89 7.91 0.10 1.21 1.19 
SD 0.01 0.04 0.06 0.06 0.01 
%RSD 0.18 0.45 0.80 0.72 0.13 
0/0 Dev. 0.25 2.81 0.31 1.38 1.19 
15 f.,Lg/mL day 0 Day 1 day 2 day 3 mean SD %RSD % deviation 
Rep. A 14.83 14.72 14.84 14.82 14.80 0.05 0.37 1.30 
Rep.B 15.00 14.75 14.96 14.81 14.88 0.12 0.80 0.79 
mean 14.92 14.74 14.90 14.82 14.84 0.08 0.56 1.05 
SD 0.12 0.02 0.08 0.00 0.05 
%RSD 0.81 0.12 0.56 0.03 0.36 
%Dev. 0.57 1.76 0.65 1.21 1.05 
35 f.,L~/mL day 0 day 1 day 2 day 3 mean SD %RSD 010 deviation 
Rep. A 34.83 34.65 34.99 34.63 34.78 0.17 0.49 0.64 
Rep. B 34.86 34.74 35.46 34.75 34.95 0.34 0.98 0.14 
mean 34.85 34.69 35.23 34.69 34.86 0.25 0.72 0.39 
SD 0.02 0.06 0.32 0.09 0.12 
O/oRSD 0.06 0.18 0.93 0.25 0.36 
%Dev. 0.44 0.88 0.64 0.88 0.39 
3.3.1.3 Precision 
Reproducibility precision data (%RSD) are presented in Table 3.3.4 along with 
accuracy data. Data on the injection repeatability precision are presented in Table 
3.3.5. 
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Table 3.3.5 - Determination of injection repeatability in the stability-indicating and potency 
HPLC assay validation 
Sample Absorbance Concentration 
15 J-lg/mL 857114 14.79 
15 J,!g/mL 857229 14.80 
15 J,!g/mL 857844 14.81 
15 J,!g/mL 856535 14.78 
15 J,.Lg/mL 855794 14.77 
15 J,.Lg/mL 859369 14.83 
3.3.1.4 Ruggedness 
Results for calibration curves derived on different days and by different analysts are 
presented in Table 3.3.6. Results obtained from the analysis of I-up CIDR@1380 
Cattle inserts on multiple days with multiple analysts are presented in Table 3.3.7 to 
Table 3.3.10. 
Table 3.3.6 - Calibration curve ruggedness data from the stability-indicating and potency 
HPLC assay validation 
Regression Correlation (R2) Slope (Bl) Intercept (BO) 
(UV.sec.mL.J..L~fl) (UV.sec) 
Analyst 1 Day 1 0.999 55784 -4852 
Analyst 1 Day 2 0.999 57093 -993 
Analyst 1 Day 3 0.999 57781 -3289 
Analyst 2 Day 3 0.999 58999 -13662 
Table 3.3.7 - Reproducibility data (I-up CIDR®1380 Batch 7246227 - Day 1) from the stability-
indicating and potency HPLC assay validation 
Sample Skin Weight Peak Area 1 Peak Area 2 Progesterone Progesterone 
(g) (UV*sec) (UV*sec) (g) % w/w 
1 13.4218 840373 826963 1.32 9.80 
2 13.2927 838075 846379 1.33 10.00 
3 13.4532 863742 966529 1.36 10.14 
4 13.3506 859681 858364 1.36 10.02 
5 13.4464 844145 846854 1.33 9.92 
Mean 1.34 10.00 
SEM 0.01 0.06 
%RSD 1.50 1.50 
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Table 3.3.8 - Reproducibility data (I-up CIDR@1380 Batch 7246227 - Day 2) from the stability-
indicating and potency HPLC assay validation 
Sample Skin Weight Peak Area 1 Peak Area 2 Progesterone Progesterone 
(g) (UV*sec) _(UV*sec) 19) 010 w/w 
1 13.4392 857928 856878 1.32 9.79 
2 13.3861 868648 884091 1.34 10.04 
3 13.4228 859985 826621 1.29 9.64 
4 13.3131 883781 868091 1.34 10.10 
5 13.4316 867452 881429 1.34 9.99 
Mean 1.33 9.91 
SEM 0.01 0.09 
%RSD 1.70 1.93 
Table 3.3.9 - Reproducibility data (I-up CIDR®I380 Batch 7246227 - Day 3) from the stability-
indicating and potency HPLC assay validation 
Sample Skin Weight Peak Area I Peak Area 2 Progesterone Progesterone 
(g) (UV*sec) (UV*sec) (g) 0/0 w/w 
1 13.4662 862838 864153 1.31 9.75 
2 13.4348 874595 865350 1.32 9.84 
3 13.3475 812535 808310 1.23 9.23 
4 13.4027 842169 850939 1.29 9.60 
5 13.3921 854666 857114 1.30 9.72 
Mean 1.29 9.63 
SEM 0.02 0.11 
%RSD 2.75 2.47 
Table 3.3.10 - Reproducibility data (I-up CIDR®1380 Batch 7246227 - analyst two) from the 
stability-indicating and potency HPLC assay validation 
Sample Skin Weight Peak Area I Peak Area 2 Progesterone Progesterone 
(g) (UV*sec) (UV*sec) (g) 0/0 w/w 
1 13.4662 895953 877396 1.34 9.92 
2 13.4348 886536 894320 1.34 9.98 
3 13.3475 815976 820556 1.23 9.24 
4 13.4027 861366 859335 1.30 9.67 
5 13.3921 865533 871212 1.31 9.77 
Mean 1.30 9.72 
SEM 0.02 0.13 
%RSD 3.29 2.99 
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3.3.1.5 Limit of quantitation 
Data acquired for determination of the limit of quantitation are presented in Table 
3.3.11. 
Table 3.3.11 - Limit of quantitation determination data from the stability-indicating and 
potency HPLC assay validation 
Sample Peak Area (UV*sec) Concentration wg/mL) 
blank 0 0.07 
blank 0 0.07 
blank 0 0.07 
blank 0 0.07 
blank 0 0.07 
1 Jlg/mL 56024 1.03 
0.1 J.lg/mL 5769 0.17 
0.01 ~g/mL 0 0.07 
3.3.1. 6 Specificity 
Determinations of progesterone standards in the presence of analogous compounds 
or placebo ingredients extracted from silicone are presented in Table 3.3.12. 
Table 3.3.12 - Specificity data from the stability-indicating and potency HPLC assay validation 
Sample Peak area (UV*sec) Concentration (Jlg/mL) 
20 Jlg/mL in specially 1156097 19.93 
denatured alcohol 
20 J..lg/mL in silicone 1175375 20.26 
extract (normal dilution) 
Blank silicone extract 0 0.07 
(nonnal dilution) 
20 J.lg/mL in analogue 1160259 20.00 
mixture 
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3.3.2 Stability Study 
3.3.2.1 Manufacture of CIDR@1900 Cattle Inserts and i-up CIDR@1380 Cattle 
Inserts 
Table 3.3.13 and 3.3.14 contain manufacturing details for CIDR®1900 Cattle inserts 
and I-up CIDR@1380 Cattle inserts, respectively, manufactured for the real and 
accelerated time stability study. 
Table 3.3.13 - Manufacturing details of CIDR@1900 Cattle inserts produced for the stability 
trial 
Batch Number Manufacturing Date 
7313 March 1997 
7317 March 1997 
7324 March 1997 
Table 3.3.14 - Manufacturing details of I-up CIDR@1380 produced for the stability trial 
Batch Number Manufacturing Date 
7307 March 1997 
7313 March 1997 
7317 March 1997 
3.3.2.2 Chemical changes 
3.3.2.2.1 Potency 
3.3.2.2.1.1 CIDR@1900 Cattle Inserts 
Results from the analysis by stability-indicating and potency HPLC assay of three 
production batches of CIDR@1900 Cattle inserts stored under real time and 
accelerated time conditions in open and closed bags are shown in Tables 3.3 .15 
through 3.3.26. 
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Table 3.3.15 - Potency data for CIDR®1900 batch 7313 stored under real time conditions 
(2soC/60%RH) in open bags determined using the stability-indicating and potency HPLC assay 
Time Absolute Potency (g) % label claim 
(monthsl 
Re~ 1 Rep 2 Rep 1 Rep 2 Mean 
0 1.87 1.91 98.21 100.52 99.36 
3 1.93 1.93 101.61 101.49 101.55 
6 1.84 1.86 96.94 97.85 97.40 
9 1.82 1.81 95.81 95.48 95.65 
12 1.76 1.83 92.52 96.19 94.36 
18 1.91 l.93 100.30 101.65 100.98 
Table 3.3.16 - Potency data for CIDR®1900 batch 7317 stored under real time conditions 
(25°C/60%RH) in open bags determined using the stability-indicating and potency HPLC assay 
Time Absolute Potency (g) % label claim 
(monthsl 
ReQl Rep 2 Rep 1 Rep 2 Mean 
0 1.91 1.96 100.64 103.01 101.83 
3 1.86 1.93 98.06 101.63 99.85 
6 1.93 1.90 101.72 99.87 100.80 
9 1.82 1.85 95.67 97.30 96.49 
12 1.82 1.80 95.67 94.83 95.25 
18 1.89 1.91 99.74 100.32 100.03 
Table 3.3.17 - Potency data for CIDR®1900 batch 7324 stored under real time conditions 
(25°C/60% RH) in open bags determined using the stability-indicating and potency HPLC assay 
Time Absolute Potency (g) 0/0 label claim 
(months) 
Rep 1 Rep 2 Rep 1 Rep 2 Mean 
0 1.93 1.92 101.84 101.19 101.51 
3 1.92 1.90 100.83 99.95 100.39 
6 1.86 1.87 98.06 98.35 98.21 
9 1.76 1.80 92.57 94.67 93.62 
12 1.79 1.80 94.05 94.67 94.36 
18 1.88 1.89 99.11 99.46 99.28 
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Table 3.3.18 - Potency data for CIDR®1900 batch 7313 stored under real time conditions 
(2soC/60% RH) in closed bags determined using the stability-indicating and potency HPLC 
assay 
Time Absolute Potency (g) % label claim 
(months) 
Rep 1 Rep 2 Rej! 1 Rep 2 Mean 
0 1.87 1.91 98.21 100.52 99.36 
3 1.93 1.92 101.36 101.09 101.23 
6 1.92 1.92 101.25 100.92 101.09 
9 1.83 1.82 96.34 95.83 96.09 
12 1.83 1.83 96.42 96.53 96.47 
18 1.92 1.89 101.21 99.70 100.46 
Table 3.3.19 - Potency data for CIDR®1900 batch 7317 stored under real time conditions 
(2soC/60 % RH) in closed bags determined using the stability-indicating and potency HPLC 
assay 
Time Absolute Potency (g) 010 label claim 
(months) 
Rep 1 Rep 2 Re~l ReI> 2 Mean 
0 1.91 1.96 100.64 103.01 101.83 
3 1.95 1.91 102.62 100.35 101.49 
6 1.83 1.88 96.12 99.05 97.59 
9 1.83 1.79 96.16 94.26 95.21 
12 1.80 1.85 94.92 97.49 96.20 
18 1.92 1.86 100.84 97.81 99.33 
Table 3.3.20 - Potency data for CIDR®1900 batch 7324 stored under real time conditions 
(2soC/60% RH) in closed bags determined using the stability-indicating and potency HPLC 
assay 
Time Absolute Potency (g) 010 label claim 
(months) 
Rep 1 Rep 2 Rep_l Rep 2 Mean 
0 1.93 1.92 101.84 101.19 101.51 
3 1.87 1.91 98.42 100.48 99.45 
6 1.83 1.90 96.40 99.98 98.19 
9 1.83 1.83 96.21 96.35 96.28 
12 1.75 1.79 91.95 94.00 92.97 
18 1.92 1.90 100.93 99.99 100.46 
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Table 3.3.21 - Potency data for CIDR<!il1900 batch 7313 stored under accelerated time conditions 
(40°CI75%RH) in open bags determined using the stability-indicating and potency HPLC assay 
Time Absolute Potency (g) 0/0 label claim 
(months) 
Rep 1 Rep 2 Rep 1 Rep 2 Mean 
0 1.87 1.91 98.21 100.52 99.36 
3 1.97 1.94 103.64 101.97 102.81 
6 1.82 1.81 95.88 95.44 95.66 
9 1.84 1.91 96.88 100.39 98.63 
12 1.87 1.86 98.44 97.64 98.04 
18 1.83 1.87 96.27 98.32 97.29 
Table 3.3.22 - Potency data for CIDR<!il1900 batch 7317 stored under accelerated time conditions 
(40°CI75% RH) in open bags determined using the stability-indicating and potency HPLC assay 
Time Absolute Potency (g) 0/0 label claim 
(months) 
ReQ 1 Rep 2 Rep 1 Rep 2 Mean 
0 1.91 1.96 100.64 103.01 101.83 
3 1.98 1.90 103.95 99.91 101.93 
6 1.80 1.82 94.62 95.82 95.22 
9 1.85 1.79 97.37 93.98 95.68 
12 1.84 1.85 96.94 97.18 97.06 
18 1.90 1.85 100.14 97.50 98.82 
Table 3.3.23 - Potency data for CIDR®1900 batch 7324 stored under accelerated time conditions 
(40°CI75%RH) in open bags determined using the stability-indicating and potency HPLC assay 
Time Absolute Potency (g) 0/0 label claim 
(months) 
Rep 1 Rep 2 Rep 1 Rep 2 Mean 
0 1.93 1.92 101.84 101.19 101.51 
3 1.91 1.90 100.56 99.82 100.19 
6 1.78 1.70 93.89 89.54 91.72 
9 1.80 1.82 94.92 95.77 95.34 
12 1.77 1.78 93.30 93.80 93.55 
18 1.85 1.89 97.15 99.51 98.33 
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Table 3.3.24 - Potency data for CIDR@1900 batch 7313 stored under accelerated time conditions 
(40°C/75% RH) in closed bags determined using the stability-indicating and potency HPLC 
assay 
Time Absolute Potency (g) % label claim 
(months) 
Rep 1 Rep 2 Rep 1 Rep 2 Mean 
0 1.87 1.91 98.21 100.52 99.36 
3 1.91 1.95 100.61 102.54 101.58 
6 1.79 1.79 93.95 94.39 94.17 
9 1.86 1.89 97.71 99.56 98.63 
12 1.84 1.90 97.01 99.86 98.43 
18 1.86 1.89 97.87 99.60 98.73 
Table 3.3.25 - Potency data for CIDR@1900 batch 7317 stored under accelerated time conditions 
(40°C/75%RH) in closed bags determined using the stability-indicating and potency HPLC 
assay 
Time Absolute Potency (g) 010 label claim 
(months) 
Rep 1 Rep 2 Rep 1 Rep 2 Mean 
0 1.91 1.96 100.64 103.01 101.83 
3 1.92 1.97 100.99 103.46 102.23 
6 1.79 1.87 93.98 98.28 96.13 
9 1.80 1.84 94.74 96.76 95.75 
12 1.82 1.89 95.92 99.26 97.59 
18 1.90 1.88 100.23 98.69 99.46 
Table 3.3.26 - Potency data for CIDR@1900 batch 7324 stored under accelerated time conditions 
(40°C/75% RH) in closed bags determined using the stability-indicating and potency HPLC 
assay 
Time Absolute Potency (g) 010 label claim 
(months) 
Rep 1 Rep 2 Rep 1 Rep 2 Mean 
0 1.93 1.92 101.84 101.19 101.51 
3 1.92 1.88 101.30 99.18 100.24 
6 1.84 1.78 96.72 93.60 95.16 
9 1.83 1.83 96.29 96.57 96.43 
12 1.80 1.82 94.88 95.93 95.41 
18 1.90 1.85 99.94 97.13 98.53 
3.3.2.2.1.2 l-up CIDR@1380 Cattle Inserts 
Results from the analysis by a stability-indicating and potency HPLC assay of three 
production batches of I-up CrDR ® 1380 Cattle inserts stored under real time and 
accelerated time conditions in open and closed bags are shown in Tables 3.3.27 
through 3.3.38. 
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Table 3.3.27 - Potency data for I-up CIDR®1380 batch 7307 stored under real time conditions 
(25°C/60%RH) in open bags determined using the stability-indicating and potency HPLC assay 
Time Absolute Potency (g) % label claim 
(months) 
Rep 1 Rep 2 Rep 1 Rep 2 Mean 
0 1.39 1.39 100.46 100.68 100.57 
0.5 1.38 1.39 100.01 100.77 100.39 
1 1.32 1.35 95.83 97.81 96.82 
2 1.32 1.38 95.91 100.04 97.98 
2.5 1.34 1.34 97.19 96.92 97.06 
3 1.40 1.39 101.12 100.55 100.84 
6 1.36 1.32 98.89 95.52 97.21 
9 1.32 1.36 95.41 98.52 96.96 
12 1.29 1.26 93.54 91.03 92.28 
18 1.26 1.30 91.24 94.28 92.76 
Table 3.3.28 - Potency data for I-up CIDR®I380 batch 7313 stored under real time conditions 
(25°C/60%RH) in open bags determined using the stability-indicating and potency HPLC assay 
Time Absolute Potency (g) % label claim 
(months) 
Rep 1 Rep 2 Rep 1 Rep 2 Mean 
0 1.36 1.42 98.23 102.72 100.47 
0.5 1.40 1.38 101.69 100.08 100.89 
1 1.39 1.35 100.53 98.08 99.31 
2 1.36 1.38 98.40 100.04 99.22 
2.5 1.37 1.33 99.53 96.17 97.85 
3 1.35 1.36 97.83 98.32 98.07 
6 1.31 1.34 95.23 97.01 96.12 
9 1.36 1.35 98.30 97.65 97.98 
12 1.27 1.29 92.04 93.16 92.60 
18 1.29 1.27 93.77 91.68 92.72 
Table 3.3.29 - Potency data for I-up CIDR®I380 batch 7317 stored under real time conditions 
(25°C/60%RH) in open bags determined using the stability-indicating and potency HPLC assay 
Time Absolute Potency (g) 0/0 label claim 
(months) 
Rep 1 Rep 2 Rep 1 Rep 2 Mean 
0 1.40 1.39 101.39 100.58 100.98 
0.5 1.37 1.36 98.95 98.34 98.64 
1 1.37 1.35 99.01 98.19 98.60 
2 1.37 1.36 99.47 98.73 99.10 
2.5 1.38 1.36 99.94 98.54 99.24 
3 1.38 1.39 99.84 100.61 100.22 
6 1.34 1.34 97.20 97.15 97.17 
9 1.37 1.39 99.14 100.66 99.90 
12 1.27 1.26 92.07 91.65 91.86 
18 1.28 1.25 93.09 90.69 91.89 
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Table 3.3.30 - Potency data for I-up CIDR@1380 batch 7307 stored under real time conditions 
(25°C/600/0RH) in closed bags determined using the stability-indicating and potency HPLC 
assay 
Time Absolute Potency (g) 0/0 label claim 
(months) 
Rep 1 Rep 2 R~1 Rep 2 Mean 
0 1.39 1.39 100.46 100.68 100.57 
0.5 1.38 1.39 99.67 101.07 100.37 
1 1.39 1.37 100.92 99.16 100.04 
2 1.35 1.35 97.97 97.69 97.83 
2.5 1.37 1.35 99.38 97.95 98.66 
3 1.39 1.38 100.48 99.99 100.24 
6 1.34 1.37 96.79 99.28 98.04 
9 1.32 1.34 95.65 96.93 96.29 
12 1.28 1.27 92.47 91.68 92.07 
18 1.28 1.27 92.65 91.70 92.18 
Table 3.3.31 - Potency data for I-up CIDR@1380 batch 7313 stored under real time conditions 
(25°C/600/0RH) in closed bags determined using the stability-indicating and potency HPLC 
assay 
Time Absolute Potency (g) 0/0 label claim 
(months) 
Rep 1 Rep 2 Rep 1 Rep 2 Mean 
0 1.36 1.42 98.23 102.72 100.47 
0.5 1.37 1.39 99.28 100.92 100.10 
1 1.36 1.37 98.80 99.44 99.12 
2 lAO 1.35 101.20 97.62 99.41 
2.5 1.38 1.37 99.87 98.99 99.43 
3 1.38 1.29 100.34 93.64 96.99 
6 1.33 1.36 96.49 98.24 97.36 
9 1.34 1.34 96.87 96.85 96.86 
12 1.29 1.29 93.80 93.16 93.48 
18 1.31 1.31 95.21 94.77 94.99 
Table 3.3.32 - Potency data for I-up CIDR@1380 batch 7317 stored under real time conditions 
(25°C/600/0RH) in closed bags determined using the stability-indicating and potency HPLC 
assay 
Time Absolute Potency (g) 0/0 label claim 
(months) 
Rep 1 Rep 2 Rep 1 Rep 2 Mean 
0 1.40 1.39 101.39 100.58 100.98 
0.5 1.38 1.40 100.16 101.33 100.75 
1 1.38 1.40 99.93 101.70 100.82 
2 1.41 1.39 102.48 100.96 101.72 
2.5 1.37 1.38 98.98 99.96 99.47 
3 1.38 1.39 99.80 100041 100.10 
6 1.30 1.34 94.34 97.05 95.70 
9 1.36 1.34 98.68 97.46 98.07 
12 1.28 1.29 92.90 93.53 93.21 
18 1.29 1.31 93.61 95.28 94.45 
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Table 3.3.33 - Potency data for I-up CIDR@I380 batch 7307 stored under accelerated time 
conditions (40°C/75% RH) in open bags determined using the stability-indicating and potency 
HPLC assay 
Time Absolute Potency (g) 0/0 label claim 
(months) 
Rep 1 Rep 2 R~p 1 Rep 2 Mean 
0 1.39 1.39 100.46 100.68 100.57 
0.5 1.36 1.39 98.59 100.42 99.51 
1 1.30 1.36 94.14 98.51 96.33 
2 1.36 1.34 98.40 96.94 97.67 
2.5 1.33 1.37 96.64 99.29 97.97 
3 1.26 1.29 91.27 93.46 92.37 
6 1.31 1.33 95.16 96.48 95.82 
9 1.27 1.24 92.26 89.98 91.12 
12 1.16 1.20 84.32 87.31 85.82 
18 1.26 1.30 91.42 93.89 92.65 
Table 3.3.34 - Potency data for I-up CIDR@I380 batch 7313 stored under accelerated time 
conditions (40°C/750/0RH) in open bags determined using the stability-indicating and potency 
HPLC assay 
Time Absolute Potency (g) 0/0 label claim 
(months) 
Rep 1 Rep 2 Re~1 Rep 2 Mean 
0 1.36 1.42 98.23 102.72 100.47 
0.5 1.37 1.35 99.53 97.70 98.62 
1 1.38 1.36 99.98 98.68 99.33 
2 1.37 1.36 99.17 98.20 98.69 
2.5 1.36 1.36 98.29 98.54 98.41 
3 1.37 1.36 99.27 98.25 98.76 
6 1.34 1.25 96.81 90.38 93.60 
9 1.29 1.31 93.21 94.90 94.05 
12 1.23 1.21 89.01 87.78 88.40 
18 1.25 1.34 90.70 97.18 93.94 
Table 3.3.35 - Potency data for I-up CIDR®1380 batch 7317 stored under accelerated time 
conditions (40°C/750/oRH) in open bags determined using the stability-indicating and potency 
HPLC assay 
Time Absolute Potency (g) 0/0 label claim 
(months) 
Rep 1 Rep 2 Rep 1 Rep 2 Mean 
0 1.40 1.39 101.39 100.58 100.98 
0.5 1.33 1.33 96.64 96.49 96.56 
1 1.32 1.33 95.39 96.09 95.74 
2 1.35 1.31 97.92 95.13 96.53 
2.5 1.31 1.27 95.22 91.82 93.52 
3 1.32 1.25 95.70 90.90 93.30 
6 1.27 1.36 92.33 98.56 95.44 
9 1.27 1.31 92.29 95.08 93.68 
12 1.16 1.22 84.09 88.57 86.33 
18 1.29 1.32 93.12 96.01 94.57 
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Table 3.3.36 - Potency data for I-up CIDR®1380 batch 7307 stored under accelerated time 
conditions (40°CI7S%RH) in closed bags determined using the stability-indicating and potency 
HPLC assay 
Time Absolute Potency (g) % label claim 
(months) 
Rep 1 Rep 2 Rep 1 Rep 2 Mean 
0 1.39 1.39 100.46 100.68 100.57 
0.5 1.31 1.37 94.99 98.95 96.97 
1 1.36 1.36 98.59 98.27 98.43 
2 1.35 1.32 97.57 95.96 96.76 
2.5 1.30 1.35 94.43 98.15 96.29 
3 1.31 1.34 95.15 97.18 96.17 
6 1.29 1.34 93.81 97.13 95.47 
9 1.29 1.32 93.69 95.59 94.64 
12 1.22 1.21 88.64 87.74 88.19 
18 1.31 1.29 94.66 93.58 94.12 
Table 3.3.37 - Potency data for I-up CIDR®1380 batch 7313 stored under accelerated time 
conditions (40°CI7S%RH) in closed bags determined using the stability-indicating and potency 
HPLC assay 
Time Absolute Potency (g) 0/0 label claim 
(months) 
Rep 1 Rep 2 Rep 1 Rep 2 Mean 
0 1.36 1.42 98.23 102.72 100.47 
0.5 1.37 1.36 99.04 98.56 98.80 
1 1.30 1.36 94.19 98.33 96.26 
2 1.35 1.39 97.59 100.88 99.24 
2.5 1.32 1.32 95.90 95.44 95.67 
3 1.34 1.32 97.38 95.35 96.36 
6 1.27 1.23 91.97 88.79 90.38 
9 1.31 1.31 94.73 94.71 94.72 
12 1.26 1.28 91.42 92.92 92.17 
18 1.31 1.29 94.67 93.42 94.05 
Table 3.3.38 - Potency data for I-up CIDR®1380 batch 7317 stored under accelerated time 
conditions (40°CI7S%RH) in closed bags determined using the stability-indicating and potency 
HPLC assay 
Time Absolute Potency (g) 0/0 label claim 
(months) 
Rep 1 Rep 2 Rep 1 Rep 2 Mean 
0 1.40 1.39 101.39 100.58 100.98 
0.5 1.40 1.40 101.15 101.76 101.46 
1 1.40 1.34 101.22 96.99 99.11 
2 1.33 1.35 96.61 98.16 97.39 
2.5 1.30 1.34 93.99 97.38 95.68 
3 1.32 1.32 95.45 95.88 95.66 
6 1.32 1.36 95.88 98.62 97.25 
9 1.28 1.31 93.10 94.74 93.92 
12 1.24 1.20 89.83 87.21 88.52 
18 1.26 1.33 91.45 96.10 93.78 
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3.3.2.2.2 Degradation Products 
3.3.2.2.2.1 CIDR@1900 Cattle Inserts 
No degradation products were observed on any of the HPLC chromatograms. 
3.3.2.2.2.2 1-up CIDR@1380 Cattle Inserts 
No degradation products were observed on any of the HPLC chromatograms. 
3.3.2.3 Physical Changes 
3.3.2.3.1 Physical Observations 
3.3.2.3.1.1 CIDR@1900 Cattle Inserts 
The three production batches ofCIDR®1900 Cattle inserts stored under real time and 
accelerated time conditions in open and closed bags were all the same in appearance. 
Typical observations of their physical characteristics are shown in Table 3.3.39. 
Table 3.3.39 - Physical observations for CIDR@1900, batches 7313, 7317 and 7324 stored under 
both real time conditions (25°C/60% RH) and accelerated time conditions (40°CI75%RH) in 
open and in closed bags 
Sample Time Sample Colour Surface 
(Months) Progesterone 
0 1 Off White Absent 
0 2 Off White Absent 
6 1 Off White Slight 
6 2 Off White Slight 
12 1 Off White Slight 
12 2 Off White Slight 
3.3.2.3.1.2 1-up CIDR@1380 Cattle Inserts 
The three production batches of I-up CIDR®1380 Cattle inserts stored under real 
time and accelerated time conditions in open and closed bags were all the same in 
appearance. Typical observations of their physical characteristics are shown in Table 
3.3.40. 
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Table 3.3.40 - Physical observations for I-up CIDR®1380, batches 7307,7313 and 7317, stored 
under both real time conditions (25°C/60%RH) and accelerated time conditions (40DC/75 % RH) 
in both open and closed bags 
Sample Time Sample Colour Surface 
(Months) Pro2esterone 
0 1 Off White Absent 
0 2 Off White Absent 
6 1 Off White Slight 
6 2 Off White Slight 
12 1 Off White Slight 
12 2 Off White Slight 
3.3.2.3.2 Invitro Drug Release 
3.3.2.3.2.1 CIDR@1900 Cattle Inserts 
Results from the invitro drug release testing of three production batches of 
CIDR ®1900 Cattle inserts stored under real time and accelerated time conditions in 
open and closed bags are shown in Tables 3.3.41 through 3.3.44. 
Table 3.3.41 - Invitro drug release test results for CIDR®1900 stored under real time conditions 
in open bags 
Batch Replicate Initial 12 Months 
Rate Intercept Rate Intercept 
(J..Lg/cm2/hro.5) (J..Lg/cm2) (Ug/ cm2 /hrO.5) (J..Lg/cm2) 
7313 Replicate 1 1231 173 1256 684 
7313 Replicate 2 1098 341 1211 724 
7313 Mean 1165 257 1234 704 
7317 Replicate 1 1240 425 1049 1141 
7317 Replicate 2 1187 282 1269 1116 
7317 Mean 1214 353 1159 1129 
7324 Replicate 1 1273 280 1371 1785 
7324 Replicate 2 1225 583 1129 1946 
7324 Mean 1249 431 1250 1865 
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Table 3.3.42- Invitro drug release test results for CIDR@1900 stored under real time conditions 
in closed bags 
Batch Replicate Initial 12 Months 
Rate Intercept Rate Intercept 
(J..l2/cm2/hro.s) (Jlglcm2) . (f..Lg/cm2!hro.s) (J.Lg/cm2) 
7313 Replicate 1 1231 173 1247 528 
7313 Replicate 2 1098 341 1113 826 
7313 Mean 1165 257 1180 677 
7317 Replicate 1 1240 425 1083 529 
7317 Replicate 2 1187 282 1299 1290 
7317 Mean 1214 353 1191 910 
7324 Replicate 1 1273 280 1053 708 
7324 Replicate 2 1225 583 1220 934 
7324 Mean 1249 431 1161 821 
Table 3.3.43 - Invitro drug release test results for CIDR@1900 stored under accelerated time 
conditions in open bags 
Batch Replicate Initial 12 Months 
Rate Intercept Rate Intercept 
(J..l2!cm2/hro.s) (J..l2/cm2) (J..lgi cm2!hro.s) (J..l2/cm2) 
7313 Replicate 1 1231 173 1263 433 
7313 Replicate 2 1098 341 1169 861 
7313 Mean 1165 257 1216 647 
7317 Replicate 1 1240 425 1077 1008 
7317 Replicate 2 1187 282 1158 1064 
7317 Mean 1214 353 1118 1036 
7324 Replicate 1 1273 280 1270 1440 
7324 Replicate 2 1225 583 1259 1380 
7324 Mean 1249 431 1264 1410 
Table 3.3.44 - Invitro drug release test results for CIDR@1900 stored under accelerated time 
conditions in closed bags 
Batch Replicate Initial 12 Months 
Rate Intercept Rate Intercept 
(J..l2/ cm2 Ihro.s) (/lg/cm2) (/lg/cm2!hro.s) (J.l2/cm2) 
7313 Replicate 1 1231 173 1328 497 
7313 Replicate 2 1098 341 1182 825 
7313 Mean 1165 257 1255 661 
7317 Replicate 1 1240 425 1107 583 
7317 Replicate 2 1187 282 1230 956 
7317 Mean 1214 353 1169 770 
7324 Replicate 1 1273 280 1269 1971 
7324 Replicate 2 1225 583 1209 825 
7324 Mean 1249 431 1239 1398 
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3.3.2.3.2.2 l-up CIDR@1380 Cattle Inserts 
Results from the invitro drug release testing of three production batches of I-up 
CIDR@1380 Cattle inserts stored under real time and accelerated time conditions in 
open and closed bags are shown in Tables 3.3.45 through 3.3.48. 
Table 3.3.45 - Invitro drug release test results for I-up CIDR®1380 stored under real time 
conditions in open bags 
Batch Replicate Initial 3 Month 6 Month 12 Month 
Rate Intercept Rate Intercept Rate Intercept Rate Intercept 
(J,l~/crnl/hro.s) (J,l~/crnl) (J,l~/crn2/hro.s) (J,lwcm2) (J,l~/crn2/hro.s) (J,lg/cml) (J,lg/cm2/hro.S) (gg/cml) 
7307 1 1586 1402 1661 1057 1343 336 1211 443 
7307 2 1345 -9 1292 446 1275 268 1297 447 
7307 Mean 1465 697 1476 751 1309 302 1254 445 
7313 1 1410 318 1613 2678 1364 1301 1373 1754 
7313 2 1512 341 1162 72 1405 67 1374 1495 
7313 Mean 1461 329 1388 1375 1385 684 1373 1624 
7317 1 1474 513 1250 301 1429 1668 1328 1274 
7317 2 1503 -62 1291 307 1470 1094 1456 1515 
7317 Mean 1489 225 1271 304 1449 1381 1392 1394 
Table 3.3.46 - Invitro drug release test results for I-up CIDR®1380 stored under real time 
conditions in closed bags 
Batch Replicate Initial 3 Month 6 Month 12 Month 
Rate Intercept Rate Intercept Rate Intercept Rate Intercept 
(J,lg/cm1/hro.s) ().1g/crnl) (J,l~/cml/hro.S) (J..Lg/cml) I (J.lg/cm1/hro.S) (J.lg/cml) (J.lg/cm2/hro.S) (J.lg/crn2) 
7307 1 1586 1402 1619 658 1619 2234 1399 879 
7307 2 1345 -9 1361 67 1500 1518 1374 1156 
7307 Mean 1465 697 1490 363 1560 1876 1387 1017 
7313 1 1410 318 1334 1237 1360 1511 1300 1904 
7313 2 1512 341 1499 1687 1332 1052 1235 1625 
7313 Mean 1461 329 1417 1462 1346 1281 1268 1765 
7317 1 1474 513 1434 614 1467 727 1265 1528 
7317 2 1503 -62 1312 468 1524 1147 1163 846 
7317 Mean 1489 225 1373 541 1495 937 1214 1187 
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Table 3.3.47 - Invitro drug release test results for I-up CIDR®1380 stored under accelerated 
time conditions in open bags 
Batch Replicate Initial 3 Month 6 Month 12 Month 
Rate Intercept Rate Intercept Rate Intercept Rate Intercept 
(1lg!cm2/hro.5) (flg/cm2) (flglcm2/hro.s) (!J.g!cm2) (!J.g/cm2Jhro.5) (!J.g/cm2) (!J.g/cm1/hro.5) (!J.g/cm1) 
7307 1 1586 1402 1450 351 1386 804 1470 1603 
7307 2 1345 -9 1292 400 1257 383 1238 544 
7307 Mean 1465 697 1371 376 1322 594 1354 1074 
7313 1 1410 318 1258 315 1252 925 1330 1427 
7313 2 1512 341 1372 588 1327 1077 1239 982 
7313 Mean 1461 329 1315 451 1290 1001 1285 1205 
7317 1 1474 513 1396 1412 1392 1485 1341 887 
7317 2 1503 -62 1459 484 1398 816 1330 1176 
7317 Mean 1489 225 1428 948 1395 1151 1336 1031 
Table 3.3.48 - Invitro drug release test results for I-up CIDR®1380 stored under accelerated 
time conditions in closed bags 
Batch Replicate Initial 3 Month 6 Month 12 Month 
Rate Intercept Rate Intercept Rate Intercept Rate Intercept 
(llg/cm2/hro.5) (llwcm2) (J.lg/cm2/hro.5) (f..lWcm1) (J.lg/cm1/hrO.5) (f..lg/cm1) I (J.l.g/cm1/hro.5) (J.l.g/cm2) 
7307 1 1586 1402 1388 303 1467 1164 1594 1348 
7307 2 1345 -9 1301 433 1446 640 1323 710 
7307 Mean 1465 697 1345 368 1456 902 1458 1029 
7313 1 1410 318 1367 1048 1471 1401 1274 1816 
7313 2 1512 341 1315 1197 1435 1267 1233 1629 
7313 Mean 1461 329 1341 1123 1453 1334 1254 1723 
7317 1 1474 513 1337 1622 1410 1004 1275 1186 
7317 2 1503 -62 1480 4066 1463 905 1235 1377 
7317 Mean 1489 225 1409 2844 1437 954 1255 1281 
3.3.3 Manufacturing Study 
3.3.3.1 Manufacture of 1-up CIDR@1380 Cattle Inserts 
Table 3.3.49 contains manufacturing details for 1-up CIDR@1380 Cattle inserts 
fabricated for use in the manufacturing study. 
Table 3.3.49 - Manufacturing details for I-up CIDR®1380 fabricated for use in the 
manufacturing study 
Batch Number Date of Manufacture 
7D22 December 1997 
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3.3.3.2 Surface Progesterone 
Tables 3.3.50 and 3.3.51 contain surface progesterone data determined in the 
manufacturing study. 
Table 3.3.50 - Amount of progesterone determined on the surface of i-up CIDR@1380 
manufactured at different temperatures and cure times 
Time Replicate Amount of surface progesterone (mg) 
(Months) 
130 opt 130 + 160 opt 190 - 190 opt 190 + 190+ 210 opt 
60s 15s 15s 30s 
0 1 26 37 18 22 29 28 69 70 
0 2 44 23 21 23 35 30 104 81 
0 mean 35 30 19 23 32 29 86 76 
3 1 50 110 138 145 233 196 306 348 
3 2 44 135 192 244 362 192 315 247 
3 mean 47 123 165 195 297 194 311 297 
12 1 79 126 178 213 185 270 188 
12 2 46 124 148 219 207 250 190 
12 mean 62 125 163 219 213 196 260 189 
Table 3.3.51 - Amount of progesterone determined on the surface of I-up CIDR@1380 
manufactured with spines annealed for different lengths of time 
Time Replicate Amount of surface progesterone (mg) 
(Months) 
no anneal 2.5h anneal 4.5h anneal 7.5h anneal 
0 1 40 35 40 29 
0 2 37 41 39 35 
0 mean 39 38 39 32 
3 1 79 221 309 233 
3 2 104 145 290 
3 mean 91 183 299 233 
12 1 182 179 308 213 
12 2 124 170 331 
12 mean 153 175 319 213 
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3.3.3.3 Progesterone in Silicone Skin 
Tables 3.3.52 and 3.3.53 contain skin progesterone data determined in the 
manufacturing study. 
Table 3.3.52 - Amount of progesterone determined in the skin of I-up CIDR®1380 
manufactured at different temperatures and cure times 
Time 
(Months) 
0 
0 
0 
3 
3 
3 
12 
12 
12 
Time 
Replicate Observed skin progesterone for each variant (mg) 
130 opt 130 + 160 opt 190 - 190 opt 190 + 190 + 
60s 15s ISs 30s 
1 1351 1341 1359 1358 1350 1351 1310 
2 1333 1355 1358 1357 1344 1348 1277 
mean 1342 1348 1359 1357 1347 1350 1293 
1 1329 1260 1231 1216 1110 1163 1038 
2 1334 1236 1169 1107 977 1163 1034 
mean 1332 1248 1200 1161 1043 1163 1036 
1 1300 1246 1187 1046 1141 1180 1068 
2 1332 1248 1220 1121 1199 1154 1093 
mean 1316 1247 1203 1083 1170 1167 1081 
Table 3.3.53 - Amount of progesterone determined in the skin of I-up CIDR®1380 
manufactured with spines annealed for different lengths of time 
Replicate Amount of skin progesterone (mg) 
210 opt 
1310 
1297 
1303 
991 
1105 
1048 
1173 
1173 
1173 
(Months) 
no anneal 2.Sh anneal 4.5h anneal 7.5h anneal 
a 1 1339 1344 1340 1350 
0 2 1341 1337 1341 1344 
0 mean 1340 1341 1341 1347 
3 1 1290 1137 1036 1110 
3 2 1263 1220 1056 977 
3 mean 1277 1179 1046 1043 
12 1 1176 1184 1042 1141 
12 2 1238 1190 1020 1199 
12 mean 1207 1187 1031 1170 
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3.3.4 Potential Future Manufacturing Strategies 
3.3.4.1 Alternate Spine Material 
3.3.4.1.1 Manufacture of i-up CIDR@1380 Cattle Inserts (polyester spines) 
Table 3.3.54 contains manufacturing details for I-up CIDR@1380 Cattle inserts 
manufactured for the study. 
Table 3.3.54 - Manufacturing details for 1-up CIDR®1380 moulded for the alternate spine 
material study 
Batch Number Date of Manufacture 
7313 March 1997 
3.3.4.1.2 Chemical Changes 
3.3.4.1.2.1 Potency 
Results from potency assay of the silicone skin of the I-up CIDR@1380 Cattle inserts 
manufactured using polyester spines are shown in Table 3.3.55. 
Table 3.3.55 - Amount of progesterone determined in the skins of 1-up CIDR®1380 
manufactured with polyester spines as a function of time 
Time (Days) Skin Progesterone Content (mg) 
Replicate 1 Replicate 2 Replicate 3 Mean 
0 1359 1321 1302 1327 
1 1319 1319 1320 1319 
2 1330 1313 1258 1300 
4 1327 1342 1309 1326 
10 1274 1371 1260 1302 
14 1289 1280 1332 1300 
18 1286 1336 1288 1303 
24 1361 1271 1363 1332 
31 1307 1320 1310 1312 
74 1334 1330 1229 1298 
128 1383 1352 1362 1366 
257 1344 1356 1382 1361 
376 1350 1331 1327 1336 
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3.3.4.1.2.2 Progesterone in the Polyester Spine 
Results from the assessment of progesterone in the polyester spine of I-up 
CIDR®1380 Cattle inserts manufactured with polyester spines are shown in Table 
3.3.56. 
Table 3.3.56 - Amount of progesterone determined in the polyester spine as a function of time 
Time (Days) Polyester Spine Progesterone Content (mg) 
Replicate 1 Replicate 2 Replicate 3 Mean 
0 58 58 63 60 
1 63 60 62 62 
2 58 60 54 57 
4 59 60 50 56 
10 53 55 57 55 
14 53 53 51 52 
18 49 52 61 54 
24 52 50 54 52 
31 53 48 52 51 
74 47 46 49 48 
128 56 53 54 55 
257 48 43 44 45 
376 44 46 46 45 
3.3.4.2 Low Temperature Cure Silicone 
3.3.4.2.1 Manufacture of I-up CIDR@I380 Cattle Inserts (low temperature cure 
silicone) 
Table 3.3.57 contains manufacturing details for I-up CIDR®1380 Cattle inserts 
manufactured for this study. 
Table 3.3.57 - Manufacturing details for l-up CIDR@1380 moulded for the low temperature 
cure silicone study 
Batch Number Date of Manufacture 
8902 September 1998 
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3.3.4.2.2 Chemical Changes 
3.3.4.2.2.1 Potency 
Results from potency assay of the low temperature cure silicone I-up CIDR®1380 
Cattle inserts stored under real and accelerated conditions are shown in Tables 3.3.58 
and 3.3.59. Note that only twelve months data was available at the time of writing 
this thesis. 
Table 3.3.58 - Results from the potency assay of low temperature cure I-up CIDR®1380 stored 
under real time conditions (25°C/60% RH) in open bags 
Time Absolute load (g) 0/0 Label claim 
(months) 
Replicate Replicate Replicate Replicate Replicate Replicate Mean 
1 2 3 1 2 3 
0 1.42 1.41 1.42 102.73 102.03 102.69 102.49 
3 lAO 1.38 1.41 101.72 99.97 102.07 101.25 
6 1.42 1.44 102.97 104.04 103.51 
9 lAO 1.42 100.05 101.29 100.67 
12 lAO 1.38 99.67 98.79 99.23 
Table 3.3.59 - Results from the potency assay of low temperature cure I-up CIDR®1380 stored 
under accelerated time conditions (40°C/75%RH) in open bags 
Time Absolute load (g) 0/0 Label claim 
(months) 
Replicate Replicate Replicate Replicate Replicate Replicate Mean 
1 2 3 1 2 3 
0 1.42 1.41 1.42 102.73 102.03 102.69 102.49 
3 1.42 1.38 1.39 103.00 99.91 100.56 101.16 
6 1041 1.39 102.23 100.94 101.59 
9 1.36 1.42 97.27 101.31 99.29 
12 1.39 1.42 99.52 101.43 100048 
3.3.4.2.3 Physical Changes 
3.3.4.2.3.1 Invitro Drug Release 
Tables 3.3.60 and 3.3.61 contain invitro drug release data determined for I-up 
CIDR@1380 Cattle inserts manufactured using low temperature cure silicone. Note 
that only six months data was available at the time of writing this thesis. 
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Table 3.3.60 - Invitro drug release test results for low temperature cure I-up CIDR@1380 stored 
under real time storage conditions in open bags 
Replicate Initial 3 Months 6 Months 
Rate Intercept Rate Intercept Rate Intercept 
( I-lg/cm2/hr0.5) (J.!g/cm2) (/J.g/cm2/hr0.51 (J.!g/cm2) (~g/cm21hr0.5) (J.!g/cm2) 
1 1085 24 942 216 1083 236 
2 1011 19 999 56 1096 254 
Mean 1048 21 971 136 1089 245 
Table 3.3.61 - Invitro drug release test results for low temperature cure I-up CIDR@I380 stored 
under accelerated time storage conditions 
Replicate Initial 3 Months 6 Months 
Rate Intercept Rate Intercept Rate Intercept 
(J.!g/cm2/hr0.5) (J.!g/cm2) (J..Lgl cm2/hr0.51 (J..Lg/cm2) (J.!g/cm2 Jhr0.5) (J.Lg/cm2) 
1 1085 24 976 46 1041 491 
2 1011 19 1198 40 1254 172 
Mean 1048 21 1087 43 1148 332 
3.3.4.2.4 Invivo performance 
Table 3.3.62 contains plasma progesterone data determined in the invivo trial 
comparing the performance of the low temperature cure silicone I-up CIDR@1380 
Cattle insert with the CIDR®1900 Cattle insert. 
Table 3.3.62 - Plasma progesterone levels in ovariectomised cows following insertion of 
CIDR@1900 (Dow silicone) and low temperature cure I-up CIDR@1380 (Wacker silicone) 
CIDR Plasma progesterone level on given day (ng/mL) 
type 
0 1 2 3 4 5 6 7 8 9 10 
Dow 0.00 3.33 3.27 4.03 4.37 2.76 3.26 2.64 3.09 2.70 2.15 
Dow 0.00 3.75 3.56 4.27 4.53 4.61 3.40 3.49 3.76 2.43 3.38 
Dow 0.00 3.22 2.43 2.69 2.77 3.74 2.38 2.51 2.43 2.06 1.99 
Dow 0.00 4.12 3.51 3.38 3.06 3.05 2.44 2.10 2.51 2.25 1.70 
Dow 0.00 2.89 2.81 3.30 2.61 3.06 2.18 2.50 2.34 2.38 2.35 
Dow 0.00 2.86 2.98 3.32 2.74 2.92 2.97 2.41 1.75 2.86 2.27 
Wacker 0.00 4.62 4.56 4.02 3.55 2.88 3.27 2.76 3.35 2.35 2.42 
Wacker 0.00 3.67 3.34 3.36 3.24 3.65 2.50 2.68 2.23 2.08 2.95 
Wacker 0.00 3.55 2.84 3.56 3.59 2.74 2.59 2.30 3.21 2.07 1.90 
Wacker 0.00 3.58 3.24 3.83 3.47 2.93 2.90 1.94 2.36 2.86 2.23 
Wacker 0.04 4.44 5.21 3.42 3.01 3.13 2.77 2.45 2.84 2.21 2.18 
Wacker 0.00 4.47 4.09 3.28 3.08 3.28 3.25 2.45 1.89 2.89 2.14 
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3.4 Discussion 
3.4.1 Validation of Stability-indicating HPLC Assay 
3.4.1.1 Linearity and range 
A calibration curve should be linear and proportional, therefore validation 
specifications for acceptable linearity are based upon both the correlation coefficient 
and the intercept of the regression line226 • Correlation coefficients should be >0.999 
and intercept values should be close enough to zero to allow an acceptable limit of 
quantitation226 • In terms of the range, for the method to be considered validated, 
standards at the high and low levels which define the method range should be 
determined with a bias of <40/0226 • Using standards at 27, 67, 133, 200 and 267% of 
the typical target value, the developed method yielded linear regressions with y2 
values of >0.999 and acceptably low intercept values (Table 3.3.1). The combined 
regression analysis line (Table 3.3.2) produced accurate (2.25% deviation at low 
level and 0.58% deviation at high level) determinations of the concentrations of the 
validation standards at the extremities of the calibration range. These results 
validated the range of the developed method to be 4 to 40 /-lg/mL (Table 3.3.3). 
3.4.1.2 Accuracy 
An accurate method is defined as one which allows the determination of analyte at 
between 96 and 104% of its true value226 • Determinations of 8, 15 and 35 J-lg/rnL 
validation standards using the developed method yielded results for each standard 
which exhibited <3% deviation from its known concentration. These results 
validated the accuracy of the developed method. 
3.4.1.3 Precision 
A precise method should be repeatable and reproducible with relative standard 
deviations about the mean result of <2%226. Results for 5 replicate analyses of the 
same standard using the developed method exhibited a 0.15% relative standard 
deviation from their mean result (Table 3.3.5). Intra and inter-day repeat 
determinations of 8, 15 and 35 J-lg/mL standards yielded mean results with relative 
standard deviations <2% (Table 3.3.4). These results validated the precision 
(repeatability and reproducibility) of the developed method. 
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3.4.1.4 Ruggedness 
A rugged method should allow determination of results for the same product on any 
day and by any analyst with a relative standard deviation about the mean result of 
<4%226. Calibration curves derived on different days and by different analysts using 
the developed method were linear and proportional (Table 3.3.8). Interday and 
interanalyst potency determinations of I-up CIDR@1380 Cattle inserts yielded results 
with observed relative standard deviations of <30/0. These results confirmed that the 
developed method was rugged. 
3.4.1.5 Limit of quantitation 
The limit of quantitation of a stability-indicating method should be sufficiently low 
to determine significant quantities of degradation or impurity compounds should 
they occur in the analyte. Limit of quantitation was determined to be 1 ~g/mL 
(Table 3.3.6) which is suitably sensitive for the intended study. 
3.4.1.6 Specificity 
A stability-indicating method should allow quantitation of the target compound 
without interference from any degradation, impurity or placebo components of the 
analyte. Absence of interference is confirmed by the accurate «2% bias) 
determination of a standard in the presence of possible interferences226. Results 
indicated that progesterone standards could be quantitated with <2% bias in the 
presence of analogous compounds or placebo ingredients of the silicone matrix 
(Table 3.3.7). In addition, analysis of blank silicone extracts showed no interfering 
peaks. These results confirm that the developed method is stability-indicating and 
specific. 
3.4.2 Prediction of Shelf Life 
A veterinary product will typically be considered stable over a given period of 
time if its drug content does not deviate ±10% from its labeled potency226,234. 
The prediction of the shelf life of a veterinary product can be estimated from data 
generated under accelerated (40°C, 75% RH) conditions using a one-sided lower 
95% confidence intervaf34, The potency data is plotted against time and 
subjected to linear regression. The one-sided lower 95% confidence interval is 
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then applied to this regression line. The time at which the one-sided lower 95% 
confidence interval line crosses the 90% of labeled potency line is multiplied by 
two to give the predicted shelf life235 • 
This approach assumes that the degradation process occurs in accordance with 
zero order kinetics. In our studies, degradation of the progesterone may follow 
kinetics of a more complex nature. However, in our case, the validity of using an 
alternate degradation kinetics equation as a predictor for the product shelf life 
would be difficult to justify given the limited number of data points and the 
limited amount of degradation that has occurred over the period of investigation. 
Potency data for three batches each of CIDR@1900 Cattle inserts and I-up 
CIDR@1380 Cattle inserts stored under accelerated conditions in closed bags ("in use 
conditions") are shown in Figure 3.4.1. Each profile has been subj ected to linear 
regression and a one-sided lower 95% confidence interval has been applied to the 
regression line. The predicted shelf-life expiration times for each batch have been 
calculated from the intercept of the one-sided lower 95% confidence interval line 
with the 90% of labeled potency line. These are shown in Table 3.4.1. 
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Figure 3.4.1 - Effect of time on the potency of CIDR@1900 Cattle inserts and 1-up CIDR®1380 
Cattle inserts (expressed as 010 label claim) stored under accelerated time conditions 
(40°CI75%RH) in closed bags 
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Table 3.4.1- One sided lower 950/0 confidence interval data for CIDR®1900 Cattle inserts and 
I-up CIDR@1380 Cattle inserts stored under accelerated conditions (40°C/75 % RH) in closed 
bags 
CIDR@ Formulation Batch Calculated Predicted Average 
Number Intercept Time Expiry Time Predicted 
(months) (months) Expiry Time 
(months) 
CIDR®1900 Cattle 7313 27.0 54.0 
CIDR ® 1900 Cattle 7317 22.6 45.2 47.4 
CIDR®1900 Cattle 7324 21.5 43.0 
I-up CIDR@1380 Cattle 7307 14.8 29.6 
I-up CIDR@1380 Cattle 7313 15.5 31.0 29.6 
I-up CIDR@1380 Cattle 7317 14.1 28.2 
Examination of Table 3.4.1. shows that the CIDR@1900 Cattle insert exhibits a 
significantly longer predicted shelf life (48 months) than the I-up CIDR@I380 Cattle 
insert (30 months) (p = 0.007). However, both these products exhibit acceptable 
shelf life values (personal communication, James Anderson, Marketing Manager). 
However, chemical stability is not the only factor to consider when estimating a shelf 
life for a controlled release veterinary product. The drug release characteristics must 
also be considered226 , and be shown not to change upon storage. Tables 3.4.2 and 
3.4.3 contain pooled data from the invitro drug release testing of CIDR@I900 Cattle 
inserts and I-up CIDR@1380 Cattle inserts. 
Table 3.4.2 - Pooled invitro drug release test data for CIDR@1900 stored under accelerated 
conditions (40°CI75% RH) in closed bags 
Time Average Rate SEM Average SEM 
(Months) (~g/ cm2/hro.s) Intercept 
(Jlg/cm2) 
0 1209.1 24 347.2 57 
12 1221.0 30 942.8 216 
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Table 3.4.3 - Pooled in vitro drug release test data for l-up CIDR®1380 stored under accelerated 
conditions (40°C/75%,RH) in closed bags 
Time Average Rate SEM Average SEM 
(Months) (J.lgi cm2 Ihro.5) Intercept 
(J..l2/cm2) 
0 1472 34 417 217 
3 1365 27 1445 561 
6 1449 9 1063 112 
12 1322 56 1344 156 
Inspection of pooled invitro drug release test data for CIDR®1900 Cattle inserts 
(Table 3.4.2) and for I-up CIDR@1380 Cattle inserts (Table 3.4.3) reveals that the 
release rates for both formulations remained constant over the testing period. The 
intercept values for the I-up CIDR®1380 Cattle inserts displayed a larger increase 
above their initial values than those for the CIDR ® 1900 Cattle inserts as the stability 
trial progressed, but intercept values for both formulations remained within 
specifications (see Chapter Two, Section 2.4.1.4). Therefore the invitro drug release 
test data supports the shelf life predictions drawn from the chemical stability data. 
Another factor which can influence the shelf life of a veterinary product is its 
physical stability. The term 'physical stability' encompasses a variety of parameters 
which should be visually assessed during a stability trial to ensure product integrity. 
Physical stability parameters may not affect either the potency or release 
characteristics of the product, but may be detrimental to the products aesthetic 
quality and hence marketability. Subjective observations made on the CIDR®1900 
Cattle insert and I-up CIDR@1380 Cattle insert during the stability trial (see Section 
3.3.2.3.1) showed a slight appearance of powder on the surface of the inserts with 
time. These observations are the likely cause for the increase in intercept values 
observed in the invitro drug release test. Matrix type controlled release veterinary 
drug delivery systems are typically associated with a 'burst effect'. This is where the 
drug particles in the very outermost layer of the delivery matrix are exposed to the 
environment and therefore, are available for immediate release when they come in 
contact with a release media. This results in a high initial value in an invitro drug 
release test. In our study, the typical initial value determined at the first time point (t 
= 2 minutes) for a freshly made CIDR@ (Le. one which was subjected to a release 
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assessment test within a few days of fabrication) was approximately 400 Ilg/cm2 (see 
Table 3.3.41). Upon storage higher initial values were observed in the invitro drug 
release test. This observation was due to the migration of progesterone to the surface 
of the CIDR® inserts; these increased values being the result of the traditional 
inherent burst effect plus the migrated progesterone. However, migration of 
progesterone does not have a detrimental effect on the quality, safety or efficacy of 
the product since the burst effect value falls within specifications for the invitro drug 
release test. Therefore, the study demonstrates that the product is physically stable 
over the time course of the investigation supporting the shelf life predictions drawn 
from the chemical stability data. 
3.4.3 Confirmation of Shelf Life 
Accelerated storage conditions are employed so that tentative expiration times can be 
proposed to regulatory bodies based on limited data e.g., 6-12 months data. This 
expedites the drug registration process, allowing companies to submit registration 
documents before the actual shelf life of the product has been established (e.g. 3 
years). Following submission the proposed expiration time is verified using real 
time stability data obtained over the entire period of the proposed shelf life. In this 
study the accelerated time stability data predicted a product shelf life of greater than 
2 years. Figure 3.4.2 presents the real time stability data generated to date for the 
CIDR®1900 Cattle insert and I-up CIDR®1380 Cattle insert. 
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Figure 3.4.2 - Effect of time on the potency of CIDR®1900 Cattle inserts and 1-up CIDR®1380 
Cattle inserts (expressed as % label claim) stored under real time conditions (25°C/60 % RH) in 
closed bags 
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Examination of Figure 3.4.2 reveals that all data points up to the 18 month time point 
lie above the 90% label claim limit for veterinary pharmaceutical product stability. 
The real time data generated to date therefore supports the shelf life predictions 
drawn from the accelerated stability study. 
Tables 3.4.4 and 3.4.5 show the pooled invitro drug release test data for the CIDR® 
inserts stored under real time conditions in closed bags. 
Table 3.4.4 - Pooled invitro drug release data for CIDR®1900 Cattle inserts stored under real 
time conditions (25°C/60 % RH) in closed bags 
Time Average Rate SEM Average SEM 
(Months) (f.!g/cm2/hro.5) Intercept 
(J..lg/cm2) 
0 1209 25 347 58 
12 1169 41 803 118 
Table 3.4.5 - Pooled invitro drug release test data for 1-up CIDR®1380 Cattle inserts stored 
under real time conditions (25°C/60%RH) in closed bags 
Time Average Rate SEM Average SEM 
(Months) (f.!gl cm2 Ihro.5) Intercept 
(J..Lg/cm2) 
0 1472 34 417 217 
3 1426 48 789 237 
6 1467 44 1365 212 
12 1289 36 1323 175 
Inspection of Table 3.4.4 and Table 3.4.5 reveals that the release rates for both 
formulations remained constant across the observed time frame. The intercept 
values for the I-up CIDR®1380 Cattle insert exhibited a larger increase above their 
initial values than those for the CIDR ®1900 Cattle insert as the stability trial 
progressed, however, intercept values for both formulations remained below the 
predetermined specifications set for the burst effect. Overall, the chemical, physical 
and invitro drug release test data observed during the real time study supported the 
shelf life predictions drawn from the accelerated stability trial. 
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3.4.4 Observations on Degradation Products During Accelerated and Real 
Time Stability Trials 
At no time during the accelerated or real time stability studies was there any 
appearance of degradation products of progesterone observed in the HPLC 
chromatograms. This is in agreement with the literature, which suggests that 
progesterone is a very stable compound236• This experimental observation led us to 
question why, if progesterone was chemically stable, did we observe a declining 
potency profile in the stability curves (Figures 3.4.1 and 3.4.2.) for these products? 
It was reasoned that the answer to this question lay in the subjective physical 
stability observations which were made on the CIDR ® inserts and in the 
experimentally determined increase in intercept values seen during the invitro drug 
release test which were observed on storage. It was concluded that upon storage, a 
small quantity of progesterone migrated to the surface of the CIDR® inserts. This 
resulted in the slight powdery appearance of the CIDR® inserts and was 
experimentally reflected in a higher intercept value of the invitro drug release curve 
due to the ready availability of this surface progesterone for release. 
Further it was reasoned that the observed loss of potency of CIDR® inserts was a 
result of the dislodgment (onto gloves) of this surface progesterone during the 
extensive manipulations required to prepare CIDR ® inserts for analysis by soxhlet 
extraction. To extract the progesterone from the silicone skin, it had to be removed 
from the spine so that it could be cut into pieces which would fit into the soxhlet 
extraction apparatus. These extensive manipulations were unfortunately unavoidable 
and, on reflection, were an obvious disadvantage of the method. 
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3.4.5 Factors Affecting the Appearance of Progesterone on the Surface of 
CIDR@ Inserts Upon Storage 
3.4.5.1 Post-Manufacture Factors (Storage Conditions) 
3.4.5.1.1 Temperature and Humidity 
A comparison of the results obtained when the inserts were stored under different 
storage conditions revealed that higher storage temperatures and humidities promote 
the appearance of progesterone on the surface of the insert. The pooled real time and 
pooled accelerated time data for the I-up CIDR@I380 Cattle insert (Figure 3.4.3) 
shows this effect. The potency of the I-up CIDR®I380 Cattle inserts stored under 
accelerated time conditions appears to decline more rapidly compared to the I-up 
CIDR®1380 Cattle inserts stored under real time conditions (Figure 3.4.3). 
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Figure 3.4.3 - Pooled potency data for 1-up CIDR@1380 Cattle insert stored under real time (0) 
and accelerated time (A) conditions 
An examination of the pooled invitro drug release test data for I-up CIDR@1380 
Cattle inserts stored under real time conditions (Table 3.4.6) and under accelerated 
time conditions (Table 3.4.7) supports these observations. Although the release rate 
remains relatively constant throughout the observed time frame, the intercept value 
was seen to increase more rapidly when the I-up CIDR®1380 Cattle insert was stored 
under accelerated time conditions than for samples stored under real time conditions. 
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These observations suggest that an increase in temperature and humidity promotes 
progesterone to migrate to the surface of the insert. 
Table 3.4.6 - Pooled in vitro drug release test data for I-up CIDR®1380 Cattle inserts stored 
under real time conditions (2soC/60 % RH) in closed bags 
Time Average Rate SEM Average SEM 
(Months) (Jlg/cm2/hro.5) Intercept 
(j..1g/cm2) 
0 1472 34 417 217 
3 1426 48 789 237 
6 1467 44 1365 212 
12 1289 36 1323 175 
Table 3.4.7 - Pooled invitro drug release test data for I-up CIDR@1380 Cattle inserts stored 
under accelerated time conditions (40°CI75%RH) in closed bags 
Time Average Rate SEM Average SEM 
(Months) (flgl cm 2/hro.5) Intercept 
JJ.lE/cm2) 
0 1472 34 417 217 
3 1365 27 1445 561 
6 1449 9 1063 112 
12 1322 56 1344 156 
3.4.5.1.2 Product Closure (Open versus Closed) 
A comparison of the results obtained when the inserts were stored in closures which 
were open or closed revealed that the appearance of progesterone on the surface of 
the insert remained independent of closure condition (Figures 3.4.4 and 3.4.5). From 
these Figures, one-sided lower confidence interval expiry times were determined and 
are presented in Table 3.4.8. 
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Figure 3.4.4 - Pooled potency data for I-up CIDR®1380 Cattle inserts stored under accelerated 
time conditions (40°C/75% RH) in open bags 
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Figure 3.4.5 - Pooled potency data for 1-up CIDR®1380 Cattle inserts stored under accelerated 
time conditions (40°C/75%RH) in closed bags 
Table 3.4.8 - Calculated expiry times based on one sided lower 950/0 confidence interval data for 
1-up CIDR®I380 Cattle inserts stored under accelerated time conditions (40°CI75% RH) in open 
and in closed bags 
Batch Number Closure Calculated Expiry Time 
(months) 
7307 Open 10.7 
7313 Open 14.2 
7317 Open 12.4 
Pooled Open 12.7 
7307 Closed 14.8 
7313 Closed 15.5 
7317 Closed 14.1 
Pooled Closed 15.4 
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There was no statistical difference in the predicted expiry times of the three batches 
of I-up CIDR®1380 Cattle inserts stored in closed bags compared to the stability of 
those stored in open bags (p = 0.095). The reason for this observation in this study 
probably lies in the fact that polyethylene is moisture permeable and thus, whether 
the closure was closed or open, there would have been free access of moisture to the 
product. 
3.4.5.2 Factors During Manufacture (Manufacturing Conditions) 
Several manufacturing conditions were modified and investigated In this study. 
These included silicone curing temperature, curing cycle time and water content of 
the nylon spine (annealing times). In contrast to the stability study, these 
experiments were designed to quantify the amount of progesterone on the surface of 
the insert as a function of the different manufacturing variables. As InterAg planned 
for the CIDR®1380 Cattle insert to supersede the CIDR®1900 Cattle insert, in 
contrast to the stability study, these investigations were carried out specifically on 
the I-up CIDR®1380 Cattle insert. Results of these determinations are shown in 
Figure 3.4.6. 
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Figure 3.4.6 - Effect of manufacturing conditions on the amount of progesterone determined on 
the surface of a I-up CIDR@I380 Cattle insert as a function of time under accelerated storage 
conditions (40°C/75 % RH) in open bags 
Figure 3 .4.6 shows that in for all manufacturing conditions, the amount of 
progesterone at the surface of the I-up CIDR®1380 Cattle inserts at the time of 
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manufacture was relatively low (left bar of each set of three). The Figure further 
shows that progesterone migration to the surface occurs within the first three months 
of storage (middle bar). After three months storage, progesterone migration appears 
to cease. This is evident from the approximate equivalence of the 12 month and 3 
month values (compare middle and right bars). 
Further examination of Figure 3.4.6 suggests that increasing moulding temperature 
(across temperatures of 130, 160, 190 and 210°C; bar charts 1, 3, 5 and 8) has an 
effect upon the quantity of progesterone migrating to the surface of CIDR@ inserts 
over time. This effect is most clearly observed when the data is expressed as the sum 
of the total amount of progesterone recovered from the surface of CIDR® inserts over 
the study period (i.e., the amount determined at t = 0 plus the amount determined at t 
= 3 plus the amount determined at t = 12 month analysis time). This is shown in 
Figure 3.4.7. 
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Figure 3.4.7 - Effect of moulding temperature on the total amount of progesterone determined 
on the surface of I-up CIDR®1380 Cattle inserts during the study (sum oft = 0, 3 and 12 
months analysis) 
Further examination of Figure 3.4.6 (bar charts 9, 10, 11 and 12) suggests that 
increasing the annealing time, and hence water content of the spine, (across 
annealing times of 0, 2.5, 4.5 and 7.5 hours) affects the quantity of progesterone 
migrating to the surface of I-up CIDR@I380 Cattle inserts upon storage. Again, this 
effect is more apparent when the data is expressed as the sum of the total amount of 
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progesterone recovered from the surface of I-up CIDR@1380 Cattle inserts over the 
study period. This is shown in Figure 3.4.8. 
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Figure 3.4.8 - Effect of spine annealing time on the total amount of progesterone determined on 
the surface of I-up CIDR®1380 Cattle inserts during the study (sum of t = 0, 3 and 12 months 
analysis) 
Figure 3.4.6 (bar charts 4, 5, 6 and 7 from the left) also shows that changing the time 
the I-up CIDR@1380 Cattle insert is in the mould (across the range -15 to +30 
seconds around the optimum cure time) affects the quantity of progesterone 
migrating to the surface of CIDR@ inserts upon storage. Again, this effect is more 
clearly observed when the data is expressed as the sum of the total amount of 
progesterone recovered from the surface of CIDR® inserts over the study period. 
This is shown in Figure 3.4.9. 
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Figure 3.4.9 - Effect of cure time deviations at 190°C curing temperature on the total amount of 
progesterone determined on the surface of I-up CIDR®1380 Cattle inserts during the study 
(sum oft = 0, 3 and 12 months analysis) 
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The amount of progesterone remaining within the skin was also quantified for mass 
balance. The results of these determinations are presented in Figure 3.4.10. 
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Figure 3.4.10 - Total amount of progesterone remaining in the skin of l~up CIDR®1380 Cattle 
inserts after removal of surface progesterone 
The amount of progesterone determined to be remaining in the skin was a reflection 
of the amount determined on the surface. Progesterone content in the skin was 
observed to decline rapidly between zero and three months and then to hold 
relatively steady at that level out to twelve months. Mass balance was achieved 
when summing the quantities observed in the skin with the quantities observed on 
the skin surface. 
3.4.6 Potential Future Manufacturing Strategies 
The conclusions drawn from the manufacturing study which detennined the rate and 
extent of appearance of progesterone on the surface of the insert using a surface 
wash technique, were that both annealing conditions (presence of water in the spine) 
and the temperature of manufacture affect the extent of migration of progesterone to 
the surface of the I-up CIDR®1380 Cattle insert. As a result of these conclusions 
two further studies were initiated to determine the feasibility of utilising this 
knowledge to advantage in the manufacturing process. The first study investigated 
the use of a spine material which did not require annealing, thereby eliminating the 
presence of water in the inert spine. The second study investigated the use of a low 
temperature cure silicone. 
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3.4.6.1 Alternate Spine Material 
Nylon possesses an inherent ambient water content which impels flexibility and 
toughness. These properties, along with excellent heat stability, were the attributes 
for which nylon was originally selected for use as the spine material of CIDR@ 
inserts (personal communication, Vaughan Woodward, Production Manager). 
However, the fabrication of nylon spines by injection moulding requires the 
dehydrated nylon to avoid steam fonnation. To restore the nylon spine's inherent 
properties, its ambient water content is restored by annealing in hot water prior to 
use in the manufacture of CIDR@ inserts. An alternate polymer (polyester) was 
identified for fabrication into spines which still had desirable mechanical properties 
but would not require annealing (personal communication, Vaughan Woodward, 
Production Manager). Therefore polyester was used to replace nylon in the 
manufacture of the I-up CIDR@1380 Cattle inserts for this study. 
Following manufacture of the I-up CIDR@1380 Cattle inserts at 190°C with the 
polyester spines, low initial drug loads were observed when a potency assay was 
undertaken (See Table 3.3.55). Further studies identified that the missing 
progesterone was contained in the polyester spine. It was surmised that during 
manufacture the high temperatures promoted the transfer of progesterone from the 
silicone skin into the polyester spine. A study was therefore initiated which 
investigated the fate of the progesterone in the spine material and, if it left the spine 
with time, whether it re-entered into the silicone skin. The results of that study are 
shown in Figure 3.4.11 together with potency determinations of the silicone skin 
(Figure 3.4.12). 
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Figure 3.4.11 - Amount of progesterone in spines of I-up CIDR@1380 Cattle inserts 
manufactured with polyester spines as a function of time under real time storage conditions 
(2soC/60 % RH) in open bags 
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Figure 3.4.12 - Amount of progesterone in skins of I-up CIDR@1380 Cattle inserts 
manufactured with polyester spines as a function of time under real time storage conditions 
(2soC/60%RH) in open bags 
Figure 3 .4.11 shows that approximately 60 mg of progesterone transfers from the 
silicone into the polyester spine during curing at 190°C, and that upon storage 
approximately 15 mg leaves the spine and either partitions into the silicone skin or 
adheres to the surface of the silicone skin, since it was not visually apparent on the 
surface of the spine. The skin content data (Figure 3.4.12) does not confirm this 
observation since the analytical technique was not precise enough to detect such a 
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small change in drug content. However, the real time potency data obtained to 
approximately twelve months (Figure 3.4.12) suggested that the use of polyester 
spines to replace the annealed nylon spines has reduced the amount of progesterone 
migrating to the surface of the I-up CIDR®1380 Cattle insert. Figure 3.4.12 does not 
appear to exhibit the rapid decline in potency over the early months of storage which 
was observed in the previous real and accelerated time stability study. However, 
despite this apparent improvement in product quality, we conclude from this study 
that polyester is not an acceptable substitute for nylon as a spine material when I-up 
CIDR ® 13 80 Cattle inserts are manufactured using the current high moulding 
temperature due to the quantity of drug which is lost from the skin into the spine 
material. 
3.4.6.2 Low temperature cure silicone 
I-up CIDR®1380 Cattle inserts are currently manufactured using Dow Coming 
Silastic® Q7-4840. To ensure commercial manufacturing efficiencies, CIDR® inserts 
manufactured using this polymer are cured at a high temperature (190°C) which 
results in a cycle time of less than 50 seconds per insert (i.e., it takes 50 seconds to 
injection mould and cure the CIDR® inserts). This high curing temperature and 
associated 50 second cycle time allows InterAg to produce 3-up CIDR®1900 Cattle 
inserts (three CIDR®1900 Cattle inserts are injection moulded in one machine cycle) 
at a rate that allows their manufacture to be a profitable venture. It is possible for 
CIDR ® inserts to be cured at lower temperatures but this would mean longer cure 
times and hence, the process would be less profitable. Recently a new medical grade 
of silicone has become commercially available which has a lower cure enthalpy. 
This silicone is Elastosil® LR3004-40 and is manufactured by Wacker Chemicals 
Ltd. It can be fully cured within 35 seconds at 130°C. In this study this new 
polymer (Elastosil® LR3004-40) was used to manufacture I-up CIDR®1380 Cattle 
inserts to investigate the effect of low temperature curing on the migration of 
progesterone to the surface of I-up CIDR®1380 Cattle inserts under both real time 
(Figure 3.4.14) and accelerated time conditions (Figure 3.4.13). 
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Figure 3.4.13 - Potency data for low temperature cure I-up CIDR@I380 Cattle inserts stored 
under accelerated time conditions (40°CI75% RH) in open bags 
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Figure 3.4.14 - Potency data for low temperature cure I-up CIDR@1380 Cattle inserts under 
real time conditions (25°C/60 % RH) in open bags 
At the time of writing this thesis, only 12 months of data had been collected. 
However, Figures 3.4.13 and 3.4.14 clearly show improvements in the potency 
profile. The one-sided lower 95% confidence interval calculated around the 
regression line of the accelerated time data yielded a tentative expiry time of 32 
months. The real time stability profile also shows no significant reduction in 
potency over the observed time frame. Therefore we conclude that the moulding of 
I-up CIDR®1380 Cattle inserts at a lower temperature has reduced the migration of 
progesterone to the surface of the inserts. Invitro drug release rates for the low 
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temperature cure I-up CIDR®1380 Cattle inserts (see Tables 3.3.60 and 3.3.61) did 
not change significantly over the observed time frame and exhibited low intercept 
values at each time point. We noted, however, that the observed invitro drug release 
rates for the low temperature cure silicone I-up CIDR®1380 Cattle inserts, although 
within specification (See Section 2.4.2) were at the lower end (~1000 J-lg/cm2/hr°.5) of 
the range for the release rate of the conventional high temperature cured I-up 
CIDR®1380 Cattle insert (~900-1840 J-lg/cm2/hr°.5). Given these observations, and 
the potential application of this new low temperature cure silicone in production, we 
thought it would be prudent to question whether the low temperature cure I-up 
CIDR®1380 Cattle insert would be equivalent to the high temperature cure product 
invivo. 
3.4.6.3 Invivo Performance oj Low Temperature Cure Silicone I-up CIDR@1380 
Cattle Inserts 
An invivo comparison of the high temperature cure silicone CIDR@1900 Cattle insert 
and low temperature silicone I-up CIDR®1380 Cattle insert showed (Figure 3.4.15) 
that the inserts were, in fact, bioequivalent. This finding supports the validity of the 
release test specifications as CIDR® inserts displaying invitro drug release rates at 
the lower end of the specifications still exhibit blood plasma profiles which are 
known to possess clinical efficacy. 
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Figure 3.4.15 - Plasma profile for CIDR®1900 Cattle inserts (0) and low temperature cure 
I-up CIDR®1380 Cattle inserts (e) in ovariectomised cows (n = 6, error bars = SEM) over a ten 
day insertion 
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3.5 Conclusions 
In this chapter the chemical and physical stability of the CIDR@1900 Cattle insert 
and I-up CIDR@1380 Cattle insert were determined under real and accelerated time 
conditions. We concluded from the results of the potency analysis and release 
assessment testing of samples stored under controlled conditions that both the 
CIDR@1900 Cattle insert and I-up CIDR@1380 Cattle insert were chemically very 
stable over the storage durations. HPLC chromatograms showed no sign of the 
appearance of any degradation products upon storage, and release rates did not 
change with time. A decline in potency was observed with time for both storage 
conditions but was not sufficient to cause the values to fall below the 90% label 
claim limit which is used to define acceptable stability of a product. We concluded 
that the fall in potency was not due to chemical degradation but was the result of the 
migration of progesterone powder to the surface of the insert over the first three 
months of storage, after which time the level of powder on the surface remained 
constant for the remainder of the study. We concluded that the decline in observed 
potency of the products was a reflection of the dislodgment of progesterone powder 
from the surface of the inserts and that the extensive manipulation of CIDR@ inserts 
during sample preparation is the cause of the progesterone powder dislodgment and 
is a clear limitation of our experimental technique. The higher intercept value in the 
invitro drug release test reflected the immediate availability of the progesterone 
present at the surface of the insert, however, the intercept remained within acceptable 
specifications and release rates remained unchanged over the course of the study, 
indicating that the changes caused by the physical instability of the product were 
only minor, and did not affect the quality, safety and efficacy of the product. 
As a result of these observations, although the stability trial indicated a satisfactory 
product, investigations were initiated to examine if any manufacturing procedures 
could be readily manipulated to reduce the rate and extent of migration of 
progesterone to the surface of the product. We concluded from the results of the 
investigation that water content of the spine material and curing temperature were 
potential factors affecting the rate and extent of migration of progesterone to the 
surface of I-up CIDR@1380 Cattle inserts Cattle inserts. Given this information I-up 
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CIDR@1380 Cattle inserts were manufactured at the same curing temperature 
(190°C) but using a spine made from polyester (in which there is no water content) 
and further I-up CIDR@1380 Cattle inserts were manufactured with the traditional 
annealed nylon spine but using a low temperature cure silicone. 
The I-up CIDR@I380 Cattle inserts manufactured with polyester spines exhibited a 
reduction of progesterone migration to the surface of the I-up CIDR@I380 Cattle 
insert. However, progesterone was observed to penetrate the spine material during 
manufacture, resulting in a low initial load in the silicone skin. We concluded from 
these results that the I-up CIDR®I380 Cattle inserts manufactured with polyester 
spines resulted in less progesterone migrating to the surface, but was not of practical 
use because of the transfer of progesterone into the spine during manufacture at high 
temperatures. 
The I-up CIDR@I380 Cattle inserts manufactured with annealed nylon spines but 
using a low temperature cure silicone exhibited a reduction of progesterone 
migration to the surface of the I-up CIDR@1380 Cattle insert. We concluded from 
these results that the manufacture of I-up CIDR®1380 Cattle inserts with low 
temperature cure silicone resulted in a product which exhibited a reduction in the 
rate and extent to which progesterone appears on the surface of the product. This 
may have practical application in manufacturing, since cycle times for the low 
temperature cure silicone were comparable to those currently employed with the high 
temperature cure silicone. Manufacture of CIDR ® inserts with low temperature cure 
silicone would, therefore, be a commercially viable process. 
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systems for the delivery of progesterone for control of the b()vine 
oestrus cycle. Ill. Invitroand invivo release mechanisms ofCIDR® 
intravaginal drug delivery systems. 
4.1 Introduction 
4.1.1 Mechanism of Release and the Drug Delivery Scientist 
Knowledge of the mechanism of drug release from a veterinary phannaceutical 
provides the fonnulation scientist with the tool to rationally optimise a controlled 
release veterinary drug delivery system237. Many different mechanisms of release 
have been identified in the literature which describe the release of drugs from 
veterinary pharmaceuticals. Complex equations which mathematically describe 
these mechanisms have been derived238-241. In their complete form, such equations 
are cumbersome to use and difficult to understand, requiring the detennination of 
parameters which are often difficult, time consuming or impractical to determine. 
However, simplified versions of these equations have been developed and are widely 
published in the scientific literature240, 242, 243. These simplified versions permit 
elucidation of the mechanism of drug release from a controlled release veterinary 
product by comparing experimentally determined release data to the simplified 
mathematical model. Thus, the modern veterinary formulation scientist does not 
need a detailed knowledge of mathematics to elucidate a mechanism of release from 
a veterinary pharmaceutical. He or she merely needs to be aware of the 
mathematical models which are available, generate appropriate release data and 
curve fit to the models to establish which mechanism of release is the most likely to 
describe release from their delivery system. Confidence in the correct model is 
assured using statistical techniques which provide an indication of the goodness of 
fit. Once armed with knowledge of the mechanism of release the veterinary 
pharmaceutical scientist can examine the appropriate equation and develop or 
optimise their product through rational modification of the parameters which make 
up that equation. 
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Within the phannaceutical literature there are three major mechanisms by which 
drugs are released from controlled release dosage forms. These are referred to as 1 st 
order, zero order and square root of time mechanisms243-246. 
4.1.1.1 The First Order Mechanism 
The first order mechanism occurs where the concentration of drug in the delivery 
system is insufficient to maintain a constant flux over the delivery period. This 
results in a diminishing amount of drug released per unit time from the delivery 
system with time in proportion to the concentration of the drug in the reservoir. This 
type of release mechanism is described by an exponential equation of the type Q = 
Ae-kt where Q = amount released per unit area, A = constant, k = rate constant and t = 
time and provides a characteristic profile shown in Figure 4.1.1. 
Amount 
released 
Time 
Figure 4.1.1- Plot of first order release 
4.1.1.2 The Zero Order Mechanism 
The zero order mechanism typically occurs where the drug is in excess of its 
saturation concentration in a reservoir which is in contact with a rate limiting 
membrane. In this case the amount of drug released per unit time from the delivery 
system is constant. This type of release mechanism is described by a linear equation 
of the type Q = At and provides a characteristic profile shown in Figure 4.1.2. 
Amount 
released 
Time 
Figure 4.1.2- Plot of zero order release 
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4.1.1.3 The Square Root of Time Mechanism (Dispersed Systems) 
The square root of time release mechanism typically occurs where the drug is 
homogeneously distributed throughout a solid matrix in excess of its solubility as 
fine particles. In this case the amount of drug released per unit time from the 
delivery system declines with time (in contrast to the zero order release but in a 
similar fashion as the first-order release mechanism). However, in contrast to the 
first order mechanism it does not decline in an exponential fashion, but as a function 
of the square root of time. This type of release mechanism is described by an 
equation of the type Q = AtYz and provides a characteristic profile shown in Figure 
4.1.3. 
Amount 
released 
(Time) 1/2 
Figure 4.1.3 - Plot of t1l2 release 
In this chapter we investigated the invitro and invivo release mechanism for CrDR ® 
intravaginal drug delivery systems. 
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4.2 Experimental Methods 
4.2.1 Determination of Invitro Drug Release 
The invitro drug release profiles from CIDR®1900 Cattle insert used in this Chapter 
are those determined in Chapter Two using a modified USP dissolution procedure 
described in Chapter Two, Section 2.2.2. 
4.2.2 Determination of Drug Content in Horizontal Plane of CIDR®1900 
Cattle insert 
4.2.2.1 Slicing Method 
A segment of CIDR®1900 Cattle insert of approximately 50 mm2 area was removed 
from the body of the device directly above the capsule socket where the skin thickness 
exists at its greatest (5 mm thickness). The segment was mounted on a sample block 
using cyanoacrylate ester adhesive in preparation for thin slicing along the horizontal 
plane using a vibrating microtome (Vibratome® Series 1000 sectioning system, 
Technical Products International Inc., USA). Consecutive slices of approximately 
100 ~m each were taken, starting from the outer surface of the CIDR® Cattle insert 
matrix and gradually reaching the inner layers to a depth of approximately I mm. 
-..-, .. .. , 
-
Figure 4.2.1 - Slicing ofCIDR'"I900 Cattle insert segments with the Vibratome" Series 1000 
sectioning system 
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4.2.2.2 Extraction of Drug from Horizontal Plane ofCIDR@1900 Cattle insert 
Individual slices of CIDR®1900 Cattle insert matrix were placed in glass sample 
bottles with rubber lined aluminium screw caps. The slices were then extracted with 
approximately 5 mL dichloromethane (HiPerSolv for HPLCTM, BDH, New Zealand) 
for 2 hours after which time the slice was removed from the solvent with stainless 
steel tweezers. The dichloromethane was then allowed to evaporated to dryness 
overnight. The extracts were then reconstituted by addition of approximately 5 mL 
alcohol (SDA-3A, Mobil, New Zealand). With the screw caps on, the samples were 
shaken vigorously and then transferred to a sonic bath (SONOREX SUPER RK 
510H, Bandelin) for 5 to 7 minutes of sonication to ensure complete reconstitution. 
The 5 mL reconstituted samples were then transferred to volumetric flasks. The 
glass sample bottles were rinsed with four consecutive 3 mL aliquots of ethanol 
(SDA-3A, Mobil, New Zealand), each aliquot being transferred to the same 
volumetric flask. After rinsing, the volumetric flasks were made up to volume (25 or 
50 mL) with ethanol (SDA-3A, Mobil, New Zealand) and analysed directly. 
4.2.2.3 Analytical Method 
Analysis of samples for progesterone content was carried out by a validated UV 
spectrophotometric assay (See Section 2.2.1). 
4.2.3 Determination of Invivo Drug Release 
4.2.3.1 Invivo Methodology 
The CIDR®1900 Cattle insert invivo drug release profile was determined using 
intact, normally cycling Friesian cows. The trial involved insertion of a CIDR®1900 
Cattle insert into the vagina of each of 40 cows at a time denoted day O. On each 
subsequent day for 10 days, the cows were herded into yards and four cows were 
selected at random to have their CIDR®1900 Cattle insert removed. The collected 
inserts were rinsed with water, padded dry with paper towels and placed in a plastic 
bag labeled with the insertion duration. The bagged inserts were then stored at -20°C 
until analysis. At a later date, one of the four inserts collected at each insertion 
duration was subjected to the slicing technique and two were subjected to residual 
drug load determination. 
168 
CHAPTER FOUR INVITRO AND INVIVO MECHANISM OF RELEASE 
4.2.3.2 Determination of Residual Drug Load 
Residual progesterone content in devices inserted for time periods encompassing 1 
through 10 days was determined by soxhlet extraction and UV spectrophotometry 
(see Chapter Two, Section 2.2.1). 
4.2.3.3 Determination of the Amount of Drug Released 
Cumulative amount of progesterone released for each day over the treatment period 
was calculated by subtracting the residual progesterone content as determined for 
each day of insertion from the known initial content of the CIDR@1900 Cattle inserts 
(i.e. cumulative progesterone released in 5 days equals the initial load of a 
crDR ®1900 Cattle insert minus the residual progesterone load determined for a 
CID R ® 1900 Cattle after an insertion of 5 days). 
4.2.4 Determination of Drug Content in Horizontal Plane of CIDR@1900 
Cattle insert 
4.2.4.1 Slicing Method 
See Section 4.2.2.1. 
4.2.4.2 Extraction of Drug from Horizontal Plane ofCIDR@1900 Cattle Insert 
See Section 4.2.2.2. 
4.2.4.3 Analytical Method 
See Section 4.2.2.3. 
4.2.5 Determination of Invivo Blood Profile Following Insertion of CIDR@1900 
Cattle Insert 
Plasma progesterone profiles resulting from the insertion of CIDR@1900 Cattle insert 
over 7, 10 and 20 days were determined in Chapter Two, Section 2.2.5. Data from 
the 7, 10 and 20 day studies was collated to form the invivo blood profile of the 
CIDR@1900 Cattle insert reported in this chapter. 
169 
CHAPTER FOUR INVITRO AND INVIVO MECHANISM OF RELEASE 
4.2.6 Statistical Treatment of Data 
Linear regression analysis of both invitro and invivo release data was performed in 
Microsoft Excel, Version 5.0a. Testing for non-linearity by comparing the lack-of-
fit mean square with the pure error (between replicates) mean square, was performed 
utilising statistical calculations derived from (Bolton, 1984; Draper and Smith, 
1966). 
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4.3 Results 
4.3.1 Invitro Drug Release 
Data from the determination of invitro drug release from CIDR@1900 Cattle insert is 
presented in Table 4.3.1 (Data reprinted from Chapter Two, Section 2.3.3.5). 
Table 4.3.1 - Invitro drug release test data for CIDR®1900 Cattle insert (n = 17) 
Cumulative amount of progesterone released per unit area at given time 
~J.tg/cm2'1 
Rep 0.03 2 4 8 12 24 48 72 96 
1 392 1774 2556 3761 4260 6453 9035 10619 11953 
2 368 1805 2438 3442 4389 5934 8171 9607 10837 
3 622 2000 2749 3921 4915 6740 9215 10910 12335 
4 456 1847 2529 3576 4614 6248 8705 10363 11681 
5 557 1854 2665 3868 4724 6864 9381 10999 12494 
6 642 2103 2864 4043 5028 7041 9446 10993 12077 
7 1187 1893 2613 3717 4621 6716 9584 11255 12647 
8 1012 1647 2331 3360 4217 6183 8886 10464 11755 
9 1108 1775 2473 3526 4393 6360 8846 10608 11837 
10 1072 1719 2401 3418 4332 6134 8550 10308 11687 
11 1118 1797 2479 3579 4518 6518 9219 10917 12414 
12 1100 1693 2402 3432 4313 6128 8598 10435 11755 
13 992 1994 2719 3835 4830 6867 9337 11065 12615 
14 964 2570 3471 4709 5660 7636 10256 11932 13045 
15 974 1825 2624 3736 4667 6697 9189 11155 12182 
16 536 2321 3301 4794 5845 7693 10557 12478 13353 
17 814 2530 3414 5186 6465 8779 12015 13583 15218 
Mean 818 1950 2708 3877 4811 6764 9352 11041 12346 
SEM 69 68 87 129 152 174 219 223 229 
4.3.2 Drug Distribution in Horizontal Plane of CIDR@1900 Cattle Insert 
4.3.2.1 Validation of Slice Extraction Method 
Table 4.3.2 contains recovery data for slices of CIDR@1900 Cattle insert extracted 
for five hours. 
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Table 4.3.2 - Drug recovery data for a 5 hour dichloromethane extraction of CIDR®1900 Cattle 
insert slices 
Re~licate Recovery (0/0) 
1 103.74 
2 99.79 
3 96.71 
4 99.19 
5 96.51 
6 98.17 
7 97.24 
8 96.39 
9 98.70 
10 98.32 
11 100.35 
12 98.48 
13 97.35 
14 98.55 
Mean Recovery 98.54 
Standard Error in the Mean 0.51 
Table 4.3.3 contains recovery data for one, two and three hour extractions. 
Table 4.3.3 - Drug recovery data for 1, 2 and 3 hour dichloromethane extractions of CIDR®1900 
Cattle insert slices 
Recovery 0/0) after given extraction time 
Rep_licate 1 hr 2 hr 3 hr 
1 97.06 100.02 96.66 
2 100.73 96.02 98.44 
3 100.74 96.75 114.58 
4 95.51 96.50 91.77 
5 95.14 97.29 99.38 
Mean Recovery 97.83 97.32 100.17 
SEM 1.23 0.71 3.83 
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Table 4.3.4 contains data acquired from the analysis of non-loaded CIDR®1900 
Cattle insert. 
Table 4.3.4 - Results for a 2 hour dichloromethane extraction of non-drug loaded (sample 
blank) CIDR®1900 Cattle insert slices 
Replicate UV Absorbance Implied Progesterone 
@ 240 nrn level (% w/w load) 
1 0.043 0.263 
2 0.030 0.284 
3 0.029 0.299 
4 0.031 0.619 
5 0.021 0.307 
6 0.023 0.325 
Mean 0.029 0.349 
SEM 0.003 0.055 
Table 4.3.5 contains data for extractions carried out in the absence of any sample. 
Table 4.3.5 - Results for a 2 hour dichloromethane extraction in the absence of CIDR@1900 
Cattle insert slices (solvent blank) 
Replicate UV Absorbance @ 240 nrn 
1 0.006 
2 0.005 
3 0.008 
4 0.011 
Mean 0.008 
SEM 0.001 
4.3.2.2 Invitro Release 
Tables 4.3.6 through 4.3.13 contain progesterone loadings determined along the 
horizontal plane of CIDR@1900 Cattle insert at different stages of an invitro drug 
release test. 
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Table 4.3.6 - Progesterone loads along the horizontal plane in a fresh CIDR@1900 Cattle insert 
Median depth into CIDR@1900 Cattle Progesterone load (% w/w) 
insert {!-lm) 
80 10.56 
240 10.80 
420 9.92 
600 10.22 
760 10.68 
920 9.91 
1075 10.54 
1235 10.37 
1395 10.31 
1545 10.04 
Table 4.3.7 - Progesterone loads along the horizontal plane in a CIDR@1900 Cattle insert after 
2 hours invitro release 
Median depth into CIDR@1900 Cattle Progesterone load (% w/w) 
insert (~m) 
60 3.12 
175 7.72 
280 10.59 
380 10.07 
480 10.05 
580 10.28 
680 10033 
780 10.10 
880 10.64 
980 10.79 
Table 4.3.8 - Progesterone loads along the horizontal plane in a CIDR®1900 Cattle insert after 
4 hours invitro release 
Median depth into CIDR@1900 Cattle Progesterone load (% w/w) 
insert (~m) 
75 1.36 
200 6.68 
300 9.24 
400 9.78 
500 9.98 
600 9.58 
700 9.77 
800 10030 
900 10.37 
1000 10.00 
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Table 4.3.9 - Progesterone loads along the horizontal plane in a CIDR@1900 Cattle insert after 
8 hours invitro release 
Median depth into CIDR®1900 Cattle Progesterone load (% w/w) 
insert (!-lm) 
35 0.82 
120 0.51 
225 2.08 
335 6.14 
440 9.07 
540 10.38 
640 10.92 
740 10.34 
840 10.82 
940 11.08 
Table 4.3.10 - Progesterone loads along the horizontal plane in a CIDR@1900 Cattle insert after 
12 hours invitro release 
Median depth into CIDR@1900 Cattle Progesterone load (% w/w) 
insert (J.lm) 
60 0.41 
170 0.61 
285 1.53 
400 6.27 
500 9.54 
600 9.57 
700 9.58 
800 9.93 
900 9.78 
1000 9.98 
Table 4.3.11 - Progesterone loads along the horizontal plane in a CIDR@1900 Cattle insert after 
24 hours invitro release 
Median depth into CIDR@1900 Cattle Progesterone load (% w/w) 
insert (J.1m) 
50 0.65 
155 0.45 
275 0.47 
390 1.10 
500 2.93 
610 7.25 
710 9.11 
810 9.70 
910 9.92 
1010 9.86 
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Table 4.3.12 - Progesterone loads along the horizontal plane in a CIDR®1900 Cattle insert after 
71 hours invitro release 
Median depth into CIDR@1900 Cattle Progesterone load (% w/w) 
insert (J.lm) 
95 0.48 
305 0.33 
520 0.39 
710 0.35 
875 0.85 
1025 5.00 
1175 8.78 
1340 9.60 
1505 9.92 
1655 9.85 
Table 4.3.13 - Progesterone loads along the horizontal plane in a CIDR®1900 Cattle insert after 
137 hours invitro release 
Median depth into CIDR@1900 Cattle Progesterone load (0/0 w/w) 
insert (J..lm) 
100 0.22 
330 0.23 
570 0.27 
790 0.24 
1000 0.27 
1200 4.28 
1410 8.94 
1595 9.76 
1745 9.83 
1895 10.06 
4.3.3 Invivo Drug Release 
Table 4.3.14 contains residual determinations and mean amount of progesterone 
released from CIDR@1900 Cattle insert on each day of a ten day insertion period. 
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Table 4.3.14 - Residual drug loads and average amount of progesterone released from 
CIDR®1900 Cattle insert invivo 
Time Determined residual load (g) Amount Released (g) 
(days) 
Rep 1 Rep 2 Mean Mean SEM 
1 1.80 1.80 1.80 0.12 0.001 
2 1.72 1.71 1.72 0.20 0.005 
3 1.63 1.63 1.63 0.29 0.002 
4 1.60 1.57 1.59 0.33 0.015 
5 1.51 1.53 1.52 0.40 0.008 
6 1.45 1.47 1.46 0.46 0.006 
7 1.42 1.35 1.38 0.54 0.035 
8 1.36 1.32 1.34 0.58 0.021 
9 1.30 1.27 1.29 0.63 0.020 
10 1.29 1.23 1.26 0.66 0.030 
4.3.4 Determination of Drug Content in the Horizontal Plane 
4.3.4.1 Invivo Release 
Tables 4.3.15 through 4.3.25 contain progesterone loadings determined through the 
horizontal plane of CIDR@1900 Cattle insert on days one through ten of an invivo 
insertion. 
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Table 4.3.15 - Progesterone load along the horizontal plane in a fresh CIDR@1900 Cattle insert 
Replicate 1 Replicate 2 
Median depth into CIDR@1900 % Load Median depth into CIDR@1900 % Load 
Cattle insert (J-lm) Cattle insert (!lm) 
80 9.76 80 9.03 
240 10.00 260 8.31 
420 9.12 440 9.10 
600 9.42 600 9.37 
760 9.88 755 10.05 
920 9.11 905 9.87 
1075 9.74 1055 9.98 
Table 4.3.16 - Progesterone load along the horizontal plane in a CIDR®1900 Cattle insert after 
release for 1 day invivo 
Replicate 1 Replicate 2 
Median depth into CIDR@1900 % Load Median depth into CIDR@1900 % Load 
Cattle insert (J-lm) Cattle insert (!lm) 
75 8.09 100 12.77 
225 8.23 275 8.62 
375 8.98 410 8.89 
500 8.51 530 8.99 
625 9.29 650 8.92 
765 9.61 770 9.09 
895 9.31 890 9.87 
1020 9.60 1010 9.30 
1140 9.72 1130 9.95 
1260 9.88 1250 9.95 
Table 4.3.17 - Progesterone load along the horizontal plane in a CIDR®1900 Cattle insert after 
release for 2 days invivo 
Replicate 1 Replicate 2 
Median depth into CIDR@1900 % Load Median depth into CIDR@1900 % Load 
Cattle insert (!lm) Cattle insert (!lml 
95 7.29 95 7.29 
240 8.00 240 8.00 
340 8.77 340 8.77 
440 8.85 440 8.85 
540 8.76 540 8.76 
640 8.93 640 8.93 
740 9.25 740 9.25 
840 9.46 840 9.46 
940 9.71 940 9.71 
1040 9.53 1040 9.53 
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Table 4.3.18 - Progesterone load along the horizontal plane in a CIDR@1900 Cattle insert after 
release for 3 days invivo 
Replicate 1 Replicate 2 
Median depth into CIDR@1900 % Load Median depth into CIDR@1900 % Load 
Cattle insert (~m) Cattle insert (/..lID) 
70 9.12 75 5.52 
190 8.44 205 5.86 
300 8.53 315 7.56 
420 8.80 425 8.85 
490 9.24 525 9.15 
555 9.10 620 9.39 
670 9.12 720 9.61 
785 9.27 820 9.89 
890 9.36 920 10.46 
990 9.39 1020 10.18 
Table 4.3.19 - Progesterone load along the horizontal plane in a CIDR@1900 Cattle insert after 
release for 4 days invivo 
Replicate 1 Replicate 2 
Median depth into CIDR@1900 % Load Median depth into CIDR@1900 % Load 
Cattle insert (IlID) Cattle insert (/..lrn) 
100 6.17 125 5.84 
270 7.09 305 7.26 
400 8.l1 410 7.25 
515 8.61 510 8.23 
620 9.48 610 10.01 
720 9.92 710 10.10 
825 10.07 810 9.61 
935 9.30 910 9.82 
1045 9.70 1005 9.80 
1150 8.87 1100 9.79 
Table 4.3.20 - Progesterone load along the horizontal plane in a CIDR®1900 Cattle insert after 
release for 5 days invivo 
Replicate 1 Replicate 2 
Median depth into CIDR@1900 % Load Median depth into CIDR@1900 % Load 
Cattle insert (/..lm) Cattle insert (~m) 
55 4.34 65 4.10 
165 2.81 195 4.46 
270 3.83 315 4.86 
370 5.71 420 6.32 
475 6.83 520 7.48 
580 8.41 620 8.63 
680 8.87 720 9.29 
790 9.71 820 9.20 
965 9.04 920 9.41 
1205 9.68 1020 9.44 
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Table 4.3.21 - Progesterone load along the horizontal plane in a CIDR®1900 Cattle insert after 
release for 6 days invivo 
Replicate 1 Replicate 2 
Median depth into CIDR@1900 % Load Median depth into CIDR®1900 % Load 
Cattle insert (~In) Cattle insert (~m) 
50 6.60 55 3.05 
155 6.52 160 4.29 
265 6.70 260 4.94 
370 7.33 360 6.17 
470 7.82 455 8.11 
570 8.84 550 8.68 
670 10.01 645 9.19 
770 10.03 740 8.89 
870 9.73 840 9.13 
970 9.48 940 9.69 
Table 4.3.22 - Progesterone load along the horizontal plane in a CIDR@1900 Cattle insert after 
release for 7 days invivo 
Replicate 1 Replicate 2 
Median depth into CIDR®1900 % Load Median depth into % Load 
Cattle insert (~m) CIDR®1900 Cattle insert (~m) 
60 3.87 60 2.97 
170 3.41 185 5.29 
270 4.83 295 5.10 
370 6.59 390 5.42 
470 7.55 490 6.46 
570 8.85 590 7.56 
670 9.58 690 8.52 
770 9.46 790 9.71 
865 9.40 890 9.36 
960 9.73 990 9.79 
Table 4.3.23 - Progesterone load along the horizontal plane in a CIDR@1900 Cattle insert after 
release for 8 days invivo 
Replicate 1 Replicate 2 
Median depth into CIDR@1900 % Load Median depth into % Load 
Cattle insert (~m) CIDR@1900 Cattle insert (~m) 
60 4.07 65 3.13 
170 3.93 170 4.54 
270 5.05 265 5.25 
370 6.06 370 5.61 
480 7.23 470 7.55 
590 8.47 575 8.78 
690 9.59 685 9.16 
790 9.40 790 9.34 
890 9.29 890 9.91 
990 9.46 990 10.16 
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Table 4.3.24 - Progesterone load along the horizontal plane in a CIDR®1900 Cattle insert after 
release for 9 days invivo 
Replicate 1 Replicate 2 
Median depth into CIDR@1900 % Load Median depth into CIDR@1900 % Load 
Cattle insert (J.lm) Cattle insert (Ilm) 
100 2.64 70 3.51 
255 3.19 185 3.57 
360 3.81 280 3.95 
460 4.70 380 4.64 
560 6.22 480 5.18 
660 6.70 585 6.46 
760 8.22 695 7.69 
860 9.31 800 8.56 
960 9.66 900 9.26 
1060 9.29 1000 9.50 
Table 4.3.25 - Progesterone load along the horizontal plane in a CIDR®1900 Cattle insert after 
release for 10 days invivo 
Replicate 1 Replicate 2 
Median depth into CIDR@1900 % Load Median depth into CIDR@1900 % Load 
Cattle insert (J,.Lm) Cattle insert (!-lm) 
65 3.75 70 1.47 
180 3.48 190 2.06 
280 4.45 290 3.34 
380 5.33 390 4.53 
480 7.17 490 6.12 
580 8.17 595 7.l6 
680 8.63 705 8.35 
780 9.02 810 8.44 
880 8.94 910 8.84 
980 9.24 1010 9.56 
4.3.5 Invivo Blood Profile Resulting from Insertion of CIDR@1900 Cattle 
Insert 
Plasma progesterone levels determined over the course of seven, ten and twenty day 
CIDR®1900 Cattle insert insertions are presented in Table 4.3.26 (Data reprinted 
from Chapter Two, Section 2.3 .6). 
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Table 4.3.26 - Plasma progesterone levels in ovariectomised Friesian cows determined during 10 
and 20 day insertions of CIDR@1900 Cattle insert 
Trial and Replicate Plasma progesterone level (ng/mL) on given day (d) 
Od Id 2d 3d 4d 5d 6d 7d 8d 9d lOd 
7 Day Trial # 1 0.04 5.04 3.49 2.82 2.84 3.48 2.77 3.21 - - -
#2 0.10 5.33 4.23 2.71 2.80 2.51 2.53 2.92 - - -
#3 0.18 4.98 3.74 2.66 2.69 3.14 3.35 3.28 
- - -
#4 0.03 6.36 4.20 2.90 2.77 3.13 3.33 3.00 - - -
#5 0.00 6.03 6.10 3.98 4.00 3.52 3.49 2.93 - - -
#6 0.03 5.63 8.56 3.68 3.31 2.92 3.31 2.42 - - -
#7 0.10 3.42 4.34 3.59 3.60 3.03 3.10 2.25 
- - -
#8 0.00 3.44 4.18 3.87 3.09 3.22 3.27 2.67 - - -
10 Day Trial #1 0.04 4.81 4.23 4.69 3.77 3.27 3.53 3.02 2.51 2.76 2.62 
#2 0.06 4.13 2.77 3.92 2.51 3.30 2.80 2.69 2.25 2.34 2.41 
#3 0.05 3.93 3.05 4.84 2.92 3.65 3.45 3.32 2.10 2.10 2.21 
#4 0.04 4.16 2.70 3.20 2.77 3.50 3.85 3.69 1.93 1.81 1.76 
#5 0.00 2.02 2.37 3.56 1.89 2.66 2.88 2.19 1.84 1.55 1.92 
#6 0.00 4.42 3.93 2.89 2.30 2.57 2.87 2.16 1.91 1.97 1.81 
#7 0.00 4.19 2.46 2.47 2.05 2.00 1.98 1.77 l.37 1.42 1.74 
#8 0.00 3.67 3.59 3.32 2.62 2.88 2.95 2.62 2.41 2.57 2.70 
#9 0.92 5.38 4.49 2.80 4.50 5.01 2.53 3.27 4.26 2.73 2.33 
#10 0.00 2.99 3.00 1.91 2.22 4.68 1.47 1.51 l.74 1.65 1.34 
20 Day Trial #1 0.03 4.39 3.17 3.44 2.41 2.74 2.70 2.67 2.08 1.85 1.88 
#2 0.00 3.96 4.67 4.22 2.68 3.65 3.86 3.59 2.55 2.52 3.06 
#3 0.07 3.16 3.37 4.65 2.96 3.47 3.28 2.86 1.90 1.88 2.10 
#4 0.00 4.47 4.25 4.39 3.65 4.08 3.01 3.08 2.70 2.41 3.08 
#5 0.00 3.85 4.32 3.40 3.23 3.22 3.87 2.68 2.47 1.99 2.21 
#6 0.00 4.48 3.94 2.57 2.62 3.22 2.46 2.52 1.73 1.82 2.26 
#7 0.04 3.33 2.69 2.55 2.58 1.94 2.73 2.37 1.61 2.00 2.29 
#8 0.02 2.32 2.07 2.84 2.17 2.14 2.75 2.01 2.16 1.59 2.70 
#9 0.03 3.64 3.52 2.82 2.46 2.53 2.42 2.17 1.65 1.80 1.93 
#10 0.00 4.72 4.03 2.85 3.13 3.50 2.57 2.94 2.45 1.71 3.40 
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4.4 Discussion 
4.4.1 Validation of Slicing Technique 
Extraction of progesterone from the thin horizontal slices produced by the slicing 
technique was shown to be 98% efficient using dichloromethane as the solvent and 
when subjecting the slices to an extraction time of 2 hours. The extraction method 
was shown to be specific with minor interference «4% bias) from unknown 
extractables from the silicone matrix and very low interference from the solvent. 
Overall the slicing technique was accurate and efficient for the purpose for which it 
was being applied. 
4.4.2 Invitro Drug Release Profile for the CIDR@1900 Cattle Insert 
4.4.2.1 Fitting of In vitro Data to Existing Models Describing Drug Release 
Pharmaceutically, the CIDR@1900 Cattle insert can be described as comprising a 
homogenous dispersion of progesterone particles throughout a solid silicone matrix. 
This description is typically used within the phannaceutical literature to describe 
monolithic matrix controlled release drug delivery systems247 • The physical model 
which describes the release of drug from such delivery systems was first described 
by Higuchj248 and is depicted in Figure 4.4.1249,250. The type of release mechanism 
that this physical model describes is often referred to as the square root of time 
release mechanism. 
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Figure 4.4.1 - Theoretical physical model for monolithic controlled release drug delivery 
systems in contact with a perfect sink 
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In Figure 4.4.1, A is the initial amount of drug impregnated in a unit volume of 
matrix; Cp is the solubility of drug in the polymer phase; Cm is the concentration of 
drug at the polymer/solution interface; Cd is the concentration of drug at the 
solution/polymer interface; Cb is the concentration of drug in the bulk of the elution 
solution; hd and ~ are the thickness of the hydrodynamic diffusion layer on the 
immediate surface of the matrix and of the depletion zone, respectively; and d(~) is 
the differential thickness of the depletion zone when more solid drug is released. 
Equations describing release from a monolithic matrix controlled release drug 
delivery system have been derived from the physical model depicted in Figure 4.4.1. 
Such equations state that the cumulative amount of progesterone delivered by the 
monolithic matrix controlled release drug delivery system would be defined by: 
Equation 4.4.1 
Where: 
Q = cumulative amount of drug released from a unit area of matrix (g/cm2) 
A = the initial amount of drug incorporated into a unit volume of matrix (g/cm3) 
Cp = the solubility of the drug in the polymer phase (g/cm3) 
Dp = the diffusion coefficient of the drug in the polymer phase (cm2hr-l) 
t = time (hours) 
Assuming that drug load» Cp then Equation 1 reduces to: 
Equation 4.4.2 
Thus the release profile of progesterone from the matrix is defined by: 
Equation 4.4.3 
and the rate of release becomes time dependent as defined by: 
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dQ = [2ACpDp]fi 
dt 2t 
Equation 4.4.4 
Equation 4.4.2 shows that drug release is dependent upon time, drug content and the 
magnitude of Cp and Dp. 
Thus a plot of Q versus square root of time (fh) should be linear with a slope equal to 
[2ACpDp]Y2. 
Figure 4.4.2 shows the release profile for the CIDR@1900 Cattle insert resulting from 
the pooled data acquired for seventeen individual devices over 94 hours of 
assessment. 
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Figure 4.4.2 - Invitro release profile for CIDR®1900 Cattle insert (N = 17) 
Replotting the data shown in Figure 4.4.2 against the square root of time in accord 
with Equation 4.4.2 we obtain Figure 4.4.3. 
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Figure 4.4.3 - Invitro release profile for CIDR®1900 Cattle insert plotted against the square root 
of time (N=17, error bars = SEM) 
Figure 4.4.3 shows a linear dependence (F=1.867; not significant at a=0.05) of 
cumulative amount released on the square root of time (R2 = 0.997), suggesting that 
the invitro release of progesterone from the CIDR ® 1900 Cattle insert is described by 
a square root of time release mechanism and attests to the appropriateness of this 
model for our experimentally generated data. This analysis and conclusion agrees 
with data reported by Rathbone et al.101. 
4.4.2.2 Experimental Confirmation that Invitro Drug Release from CIDR@1900 
Cattle Insert Occurs via a Square Root of Time Mechanism 
The model fitting exercise suggests that the release of progesterone from the 
CIDR@1900 Cattle insert occurs according to a square root of time mechanism. If 
this is so, then the release of progesterone from the CIDR®1900 Cattle insert can be 
visualized as follows: 
1. The CIDR@1900 Cattle insert delivery system comprises progesterone dispersed 
homogeneously throughout a silicone matrix fonned by cross-linking of 
individual silicone polymer chains. The progesterone exists both in solution in 
the silicone and as discrete solid particles which are evenly distributed throughout 
the silicone polymer network. 
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2. Solid progesterone particles are fixed in position during fabrication of the 
CIDR@1900 Cattle insert and can not delocalize throughout the silicone following 
manufacture. As a result only solubilized drug can be released from the 
CIDR@1900 Cattle insert (i.e., solid particles cannot be released from the 
CIDR@1900 Cattle insert). 
3. Release of progesterone therefore occurs through a series of steps. These are: 
.. dissolution of solid progesterone into the silicone that immediately 
surrounds the drug particle 
.. diffusion of the dissolved progesterone from the area of dissolution 
through the silicone to the surface of the CIDR@1900 Cattle insert 
.. partitioning of solubilized progesterone from the surface of the silicone 
into the surrounding aqueous environment 
.. movement of released progesterone away from the surface of the 
CIDR@1900 Cattle inserta• 
This process results in solid drug near the surface being eluted first. As more and 
more silicone becomes depleted of solid progesterone a zone which is void of solid 
drug becomes apparent. This is referred to as the 'depletion zone'. 
As with any process which involves a series of sequential steps, any of those steps 
can be the rate-limiting step in the process (dependent upon the relative rate of each 
step). The slowest step in the whole process will be the one which ultimately 
controls the rate at which the overall process proceeds. In the case of the release of 
progesterone from the CIDR@1900 Cattle insert it is assumed that the diffusion of 
progesterone through the silicone matrix is the slowest step in the whole process. 
a microscopically a thin layer of stagnant fluid termed the hydrodynamic diffusion boundary layer will 
exist on the immediate surface of the CIDR@1900 Cattle insert. Within this layer, drug molecules 
move, under a concentration gradient, from the surface of the CIDR@1900 Cattle insert in to the bulk 
of the receptor fluid. In our experiments we increased the stirring speed to one which effectively 
eliminates this layer. This layer does not, therefore, play any role in drug release in our invitro 
studies. 
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It should be noted that diffusion through the polymer occurs because the dissolved 
progesterone sets up a concentration gradient between where it has dissolved and the 
surface of the CIDR®1900 Cattle insert. The magnitude of the concentration 
gradient is dependent upon the inherent solubility of the progesterone in the silicone 
polymer (i.e., its saturation solubility) and remains constant for each successive layer 
of progesterone particles. However, as the depletion zone becomes larger, the 
diffusional distance that the next dissolving drug particles must diffuse across to get 
to the interface becomes longer. It is this increase in the distance that dissolved drug 
must diffuse across to reach the interface that causes the non-linear dependence of 
progesterone release with time. 
This description suggests that experimental confirmation of the square root of time 
mechanism could be achieved by taking consecutive horizontal slices to determine 
the change in drug content of each slice as a function of time. If the square root of 
time mechanism was in operation, the technique should show the presence of a drug 
depletion zone. The results from the horizontal slicing technique appeared to 
confirm that the progesterone was being released from the CIDR®1900 Cattle insert 
in accord with the previously described square root of time mechanism (Figure 
4.4.4). Prior to commencement of release, the CIDR@1900 Cattle insert exhibited a 
uniform distribution of progesterone throughout the silicone at the 10% w/w level at 
which progesterone and silicone are combined during manufacturing (0 hours; 
Figure 4.4.4). As release occurred, the outer layers of the CIDR@1900 Cattle insert 
skin became depleted of progesterone and this depletion zone continued to grow 
larger with time (Figure 4.4.4). 
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Figure 4.4.4 - Progesterone loads along the horizontal plane measured by the slicing technique 
in CIDR@1900 Cattle insert subjected to the invitro drug release test for different lengths of 
time 
Further evidence can be provided by comparing the experimentally observed 
depletion zone with the theoretical depletion zone depth calculated from the 
cumulative mass of progesterone released (as predicted by the linear relationship 
between the average cumulative release from the CIDR@1900 Cattle insert and the 
square root of time) at each time point, the mass of CIDR@1900 Cattle insert matrix 
required to deliver this quantity of progesterone, the density of CIDR@1900 Cattle 
insert matrix and the surface area of the CIDR@1900 Cattle insert using equation 
4.4.5. 
s( mt + c) 1 1 1 10000 m.Jt + c h = x-x-x-x =---
m 1000000 A pSI lOp 
Equation 4.4.5 
Where 
~ = thickness of the depletion zone (J.lm) 
S :::: surface area of the CIDR@1900 Cattle insert (120 cm2) 
m = slope of the average cumulative progesterone released per unit area versus root 
time line (1301.6 J.lg.cm-2.hr -0.5) 
c :::: intercept of the average cumulative progesterone released per unit area versus 
root time line (298.6 J.lg.cm-2) 
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t = time (hr) 
A = initial progesterone concentration in CIDR matrix (10 %w/w) 
p = density of 10 %w/w progesterone loaded silicone (1.09 g.cm-3) 
1000000 = Ilg to g conversion factor (/lg.g-l) 
10000 = em to Ilm conversion factor (/lm.cm- I ) 
Calculated values of the depletion depth are tabulated against the observed depletion 
depths in Table 4.4.1 where the observed depletion depth was taken to be the mid-
point of the 'S-shaped' curve in Figure 4.4.4. 
Table 4.4.1 - Theoretical versus observed depletion depths for the invitro slicing experiment 
Time (hours) Square root of Theoretical Observed 
time (hoursO.5) depletion depth depletion depth 
(J..Lm) (f.l,ml 
2 1.41 195 150 
4 2.00 265 220 
8 2.83 364 350 
12 3.46 440 450 
24 4.90 612 600 
71 8.43 1033 1000 
137 11.70 1424 1250 
The calculated and observed values for depletion depth agree well, adding further 
evidence that the invitro release of progesterone from the CIDR@1900 Cattle insert is 
described by the square root of time release mechanism. 
4.4.3 Invivo Drug Release Profile 
4.4.3.1 Fitting of In vivo Data to Existing Models Describing Drug Release 
The invivo release profile determined from the residual load of CIDR@1900 Cattle 
inserts following their intravaginal insertion in Friesian cows for periods of 1-10 
days is shown in Figure 4.4.5. 
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Figure 4.4.5 - Invivo release profile for CIDR®1900 Cattle insert (n = 2, error bars = SEM) 
When the data used to generate Figure 4.4.5 is plotted against the square root of time 
the linear appearance of the curve and high R2 value (R2 = 0.992) appear to suggest 
that progesterone was being released invivo in accord with the square root of time 
mechanism (Figure 4.4.6). Testing for non-linearity confirms this observation 
(F=0.747; not significant at cx,=0.05). 
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Figure 4.4.6 - Invivo release from CIDR@1900 Cattle insert - square root of time plot (N=2, 
error bars = SEM) 
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4.4.3.2 Experimental Evidence that Invivo Drug Release from CIDR@1900 Cattle 
Insert does not Occur via a Square Root of Time Mechanism 
The model fitting exercise on the invivo data suggested that the release of 
progesterone from the CIDR@1900 Cattle insert occurs according to a square root of 
time mechanism. However, the horizontal slicing data obtained on CIDR@1900 
Cattle insert inserted intravaginally for various days, appeared to contradict the 
outcomes of the model fitting exercise (Figure 4.4.7). 
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Figure 4.4.7 - Progesterone loads along the horizontal plane measured by the slicing technique 
in CIDR@1900 Cattle insert inserted in intact Friesian cows for different lengths of time 
Figure 4.4.7 shows that a depletion zone void of any particulate drug does not appear 
to fonn. The question arises therefore, is a depletion zone not observed because it is 
too small to be detected using the horizontal slicing technique? (i.e., if the theoretical 
depletion zones were <100 flm, then the slicing technique would not be capable of 
detecting them). To answer this query, the magnitude of the depletion zones were 
theoretically calculated based on the square root of time regression equation 
generated from the invivo data (Figure 4.4.6) using equation 4.4.5. 
The theoretical depletion zones (Table 4.4.2) suggested that if the square root of time 
mechanism was in operation, they would have been easily detected with the 
horizontal slicing technique. For example, the square root of time model predicted a 
theoretical depletion zone of 438 flm at day 7. A depletion zone of such depth would 
easily have been determined by the slicing technique. Proof of this can be seen in 
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Figure 4.4.4 where the theoretical depletion depth of 440 J..lm which should occur 
after 12 hours of invitro drug release testing, is easily detected using the horizontal 
slicing technique. 
Table 4.4.2 - Theoretical depletion depth according to square root of time mechanism for invivo 
release from CIDR@1900 Cattle insert 
Time (days) Square root of time Theoretical depletion 
(daysO.5) depth (/lm) 
1 1.00 124 
4 2.00 315 
7 2.65 438 
10 3.16 504 
Examination of Figure 4.4.7 shows that progesterone is lost from the CIDR@1900 
Cattle insert during intravaginal insertion. While progesterone is being lost from the 
insert invivo, an unusual phenomenon appears to occur within the silicone matrix 
which contrasts to that which was observed when the insert was examined invitro. 
During invitro release, a drug depletion zone formed as drug was lost from the insert 
and the amount of drug particles per unit volume remained constant beyond the 
depletion zone in accord with the square root of time mechanism (Figure 4.4.4). In 
the invivo case, as drug was being lost, two differences were observed. Firstly, a 
depletion zone did not form. Secondly, progesterone was lost from deeper within the 
silicone matrix than those depths predicted by the square root of time mechanism 
(Table 4.4.2). The result of these differences is a continuously changing gradient in 
which the number of progesterone particles per volume of silicone on any day was 
lowest at the interface and progressively increased with increasing depth into the 
silicone skin. As each day passed, the gradient changed in a characteristic manner, 
with progesterone particle content declining near the surface of the insert (but not 
fanning a depletion zone) and simultaneously extending into the deeper layers of the 
silicone skin. This can be seen more clearly in Figure 4.4.8 when selected days are 
plotted. 
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Figure 4.4.8 - Progesterone loads along the horizontal plane measured by the slicing technique 
in CIDR@1900 Cattle insert inserted in intact Friesian cows - selected insertion times 
The observed change in progesterone profile within the silicone matrix with time 
conflicts with the predictions of the square root of time mechanism and does not 
support the conclusion drawn from simple curve fitting (Figure 4.4.6) that release 
occurs via a square root of time mechanism. The depleted zone and rapid increase to 
full initial particulate progesterone loading observed in the invitro experiment 
(Figure 4.4.4) is clearly not reproduced in the invivo model (Figure 4.4.7). 
It is apparent, therefore, that even though the invivo release data can be fitted to a 
square root of time mechanism plot, the square root of time mechanism does not 
appear to be an appropriate model to describe the invivo release of progesterone 
from the crD R ® 1900 Cattle insert based on the results obtained from the horizontal 
slicing technique. 
Having discounted the square root of time release mechanism as a descriptor of the 
invivo release of progesterone from the CIDR@1900 Cattle insert, the task remains to 
propose a description which more appropriately describes the experimentally 
determined invivo release profile and which concurs with the experimental 
observations. 
An outcome of the phenomenon described above which occurs during invivo release 
of progesterone from the silicone matrix (Figures 4.4.7 and 4.4.8) is that solid 
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particles are always present in the immediate vicinity of the polymer/solution 
interface and the resultant dissolution of such particles into the silicone within this 
vicinity instantly replaces any drug lost from the insert by the process of partitioning. 
This results in the concentration of drug at the polymer/solution interface on the 
polymer side being always equal to the saturation solubility of the drug in the 
silicone matrix. Thus, invivo release of progesterone is controlled via a partitioning 
process rather than a diffusion controlled mechanism. Such a theory would therefore 
predict a constant release of drug from the CIDR ®. Replotting the invivo data as a 
function of time and curve fitting a linear regression to that data (Figure 4.4.9) 
reveals a good fit (F=1.183; not significant at a=0.05) with a reasonable correlation 
coefficient (R2 = 0.9891). Based on the good fit and the results from the slicing 
technique, we suggest that invivo release of progesterone from the CIDR® occurs via 
a zero order release mechanism. 
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Figure 4.4.9 - Invivo release profile for CIDR@1900 Cattle insert with linear regression applied 
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4.4.4 Correlation of Invivo Release Mechanism with Invivo Blood Profile 
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Figure 4.4.10 - Plasma progesterone profIle resulting from insertion of CIDR@1900 Cattle 
insert - combined data (N=28, error bars = SEM) 
Following insertion of a CIDR®1900 Cattle insert an initial spike in plasma 
progesterone level is observed which falls over the next 2-3 days to levels which 
were constant or diminished very slightly over the remaining days of the insertion 
period. The apparent steady-state levels occurring over the latter days of the 
insertion period reflect the constant delivery of progesterone to the cows arising from 
the zero order release of progesterone from the CIDR®1900 Cattle insert. Therefore 
the observed invivo plasma profile appears to support the proposal that the invivo 
release of progesterone from the CIDR®1900 Cattle insert occurs via a zero order 
mechanism. 
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4.5 Conclusions 
In this chapter the invitro and invivo mechanism of release of progesterone from the 
CIDR®1900 Cattle insert was investigated. 
Invitro release of progesterone from the CIDR®1900 Cattle insert was found to occur 
in accordance with the square root of time mechanism as predicted for a matrix type 
drug delivery system and in agreement with the square root of time release 
mechanism model commonly found in the literature249, 250, A horizontal slicing 
technique supported this finding and provided evidence of depletion zone formation 
as the drug release process proceeded. 
Data fitting of the experimentally determined invivo release of progesterone from the 
CIDR®1900 Cattle insert suggested that invivo release of progesterone from the 
CIDR®1900 Cattle insert also followed a square root of time mechanism. However, 
this data fitting exercise was not supported by experimental evidence obtained using 
the slicing technique, which produced evidence that depletion zones did not form as 
drug release occurred. Contrary to the square root of time mechanism, when the 
CIDR®1900 Cattle insert was inserted into the vagina of cattle, progesterone 
appeared to redistribute through the silicone matrix to maintain a level of 
progesterone at the surface of the matrix which sustained a saturation concentration 
of progesterone in the layers of silicone in the immediate vicinity of the 
polymer/solution interface. Since a saturation concentration was maintained in the 
silicone at the interface, drug release was partitioning controlled resulting in a zero 
order release of progesterone from the CIDR®1900 Cattle insert. 
Hopefully, one day, mathematicians will examine the experimental data presented in 
this Thesis and will develop a model to describe the novel release mechanism 
observed. 
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Chapter Five - Optimisation ora Commercially Available 
Silicone/Progesterone Intravaginal· Veterinary Drug Delivery System 
for the Control of the Ovine Oestrous Cycle 
5.1 Introduction 
The CIDR ® Sheep and Goat insert is a commercially available T -shaped intravaginal 
insert used in sheep (Figure 5.1)4, 5. It contains 0.3 g of progesterone which is 
homogeneously dispersed throughout a silicone matrix which is cured over a 
preformed T -shaped nylon spine. In these respects it is similar to the 
CIDR@1380Cattle insert and CIDR@1900Cattle insert which are used in cattle (and 
which have been extensively described in the preceding chapters of this Thesis), 
however, its dimensions are much smaller (Figure 5.1.1) in order to allow it to be 
easily inserted into sheep. 
.. 
5.8 em 
5.4 em 
Tail length = 8.0 em 
Figure 5.1.1 - Diagram of the CIDR® Sheep and Goat insert detailing dimensions 
The CrD R ® Sheep and Goat insert has been successfully used in treatment regimes in 
sheep for seasonal synchronization of oestrus in Australia and New Zealand164, 178. In 
this case, a single CIDR® Sheep and Goat insert is inserted into the vagina of sheep 
and removed 14 days later. It has also been used in embryo transfer fertility 
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applications including superovulating donor synchrony and recipient synchrony 
programmes. In these cases, the use of the CIDR ® Sheep and Goat insert involves 
either simultaneous insertion of two CIDR® Sheep and Goat insert for the entire 14 
day treatment period (simultaneous programme, Figure 5.1.2) or insertion of a single 
CIDR® Sheep and Goat insert into the vagina of sheep for 8 days, at which point it is 
removed and replaced with a fresh one for 6 more days (replacement programme, 
Figure 5.1.2)46-48. These protocols have been designed to provide plasma 
progesterone levels which are elevated above those seen when a single CIDR® Sheep 
and Goat insert is intravaginally inserted. 
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Figure 5.1.2 - Schematics of specialist fertility programmes 
Although the simultaneous insertion of two CIDR® Sheep and Goat insert results in 
successful treatments, the insertion of two crDR ® Sheep and Goat insert 
simultaneously into the vagina of sheep is challenging to the end user, and it would 
be easier if a single silicone/progesterone insert could be developed which produces 
the same plasma levels as those observed when two CIDR® Sheep and Goat insert 
are inserted simultaneously. Likewise the increased time and manpower required to 
removed a CIDR® Sheep and Goat insert at day 8 and replace it with a fresh one 
could be overcome with a single insert which achieved the same clinical effect but 
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which required only a single administration and removal procedure. In this Chapter 
the CIDR® Sheep and Goat insert was optimised to achieve these goals. 
The optimisation criteria were: 
1. The optimised CIDR® Sheep and Goat insert should produce plasma profiles 
which mimicked those seen when the two CIDR® Sheep and Goat insert 
treatment regimes are used (Figure 5.1.2). 
2. The optimised CIDR® Sheep and Goat insert should utilise the same 
manufacturing technology as the CIDR® Sheep and Goat insert. 
3. The optimised CIDR ® Sheep and Goat insert be no more expensive to 
manufacture than a single currently available crDR ® Sheep and Goat insert. 
To optimise the CIDR® Sheep and Goat insert it was pharmaceutically characterised 
with respect to its physical characteristics and invivo performance and thereafter, 
knowledge from literature reports of extensive investigations on the 
CIDR ® 1900 Cattle insert6, 102,222 were used to define the parameters used to produce a 
prototype silicone intravaginal insert. Extensive invivo studies were then performed 
on the prototype silicone intravaginal insert to determine if the optimisation process 
had been successful. 
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5.2 Methods 
5.2.1 Manufacture of CIDR@ Sheep and Goat insert and Prototype Silicone 
Intravaginal Inserts 
CIDR® Sheep and Goat insert were manufactured using InterAg's patented high 
temperature injection moulding technique Progesterone (USP micronised, Phannacia 
& Upjohn, USA) was mixed at 9%w/w in both parts A and B silicone (Silastic® Q7-
4840, Dow Coming, USA) in a dynamic epicentric mixer (InterAg, Hamilton, New 
Zealand) for a minimum of 2 hours. The mixture was then evacuated for a minimum 
of 2 hours at -60 kilopascals. Nylon (Ultramid A3K, BASF, Germany) spines were 
annealed in a water bath at 70°C for 7.5 hours. Spines were then placed in a 4 cavity 
tool mounted into an injection moulding machine (LIM-100-35V, Sanjo Seiki Co., 
Ltd., Japan; Type PS40E5A, Nissei Plastic Industrial Co., Ltd., Japan) and drug 
loaded silicone parts A and B were simultaneously injected through a pre-mixing 
static mixer around the nylon spines and cured for approximately 50 seconds at 
around 190°C. 
Prototype silicone intravaginal inserts were manufactured with the same equipment 
and materials used to manufacture the CIDR® Sheep and Goat insert (See Section 
5.2.1 above) but with the following modifications. Firstly, silicone intravaginal 
inserts were fabricated using a prototype tool which produced inserts with increased 
wing span (7.3 cm) and increased body length (13.4 cm) (Figure 5.2.1). The 
prototype tool allowed the moulding of a silicone skin approximately 1 rom thick 
over the nylon spine. Also silicone intravaginal inserts with different initial drug 
loads were manufactured (10,15,25% w/w progesterone in silicone). 
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Wing span = 7.3 em 
o 
o 
o 
Body = 13.4 em 
o 
o 
Figure 5.2.1 - Diagram detailing dimensions of the silicone intravaginal insert manufactured 
using the prototype tool 
To produce the prototype silicone intravaginal inserts, the bodies of the 
manufactured inserts were cut down to appropriate dimensions (3, 5.5 and 8 cm) to 
give surface areas of 28,40 and 50 cm2• Finally, any exposed nylon spine was sealed 
off with RTV (Room Temperature Vulcanising) silicone and polyester tails were 
fitted to the end of the body opposite the wings to facilitate removal post-treatment. 
5.2.2 Characterisation of Physical Dimensions of the Sheep Vagina 
The depth of the sheep vagina was characterised using an artificial insemination rod 
which was marked in 0.5 cm graduations. Romney ewes were restrained in a bail, 
the graduated rod was dipped into veterinary lubricant and then carefully inserted 
into the vaginal cavity until the head of the rod contacted the cervical entrance. The 
graduation just visible at the vulva was then recorded. This measurement was taken 
as the vaginal depth for each ewe. 
The measured vaginal lengths of the sheep were used to define the maximum length 
of the prototype silicone intravaginal inserts. 
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5.2.3 Characterisation of Physical Dimensions of the CIDR® Sheep and Goat 
insert and Prototype Silicone Intravaginal Inserts 
Wing spans and body lengths of the CIDR® Sheep and Goat insert and prototype 
silicone intravaginal inserts were determined using a calibrated ruler (300 mm, 
TOLEDO Steel International, Japan). 
5.2.4 Determination of Initial and Residual Drug Load in CIDR® Sheep and 
Goat insert and Prototype Silicone Intravaginal Inserts 
The amount of progesterone in the inserts immediately after manufacture, or 
following their removal after insertion into the vagina of test animals was determined 
as follows. The silicone skins of the CIDR® Sheep and Goat insert were removed 
from their nylon spines with a scalpel. The skins were then cut into 2-5 cm lengths, 
weighed on a four figure balance (BP 11 OS, Sartorius, Germany) and placed into 100 
mL capacity soxhlet apparatus, ensuring that the pieces of skin were all below the 
siphon level. 350 mL ethanol (SDA-3A, Mobil, New Zealand) was added to the 
round bottom flask of the Soxhlet apparatus before the flask, Soxhlet and water 
cooled condenser were assembled in a heating mantle (Electromantle ME, 
Electrothermal, Britain). The silicone skins were extracted for approximately 12 
hours and allowed to cool to room temperature. The ethanolic extract was then 
transferred to a 500 mL volumetric flask with rinsing to ensure complete transfer 
before making the volume up to the mark with ethanol (SDA-3A, Mobil, New 
Zealand). The solution was then diluted (1 in 25) in ethanol (SDA-3A, Mobil, New 
Zealand) before analysis by UV spectrophotometry (DU 650i, Beckman, USA) at 
240 nm using a validated assay (See 2.2.1). 
5.2.5 Determination of Surface Area of CIDR® Sheep and Goat insert and 
Prototype Silicone Intravaginal Inserts 
The surface area of the intravaginal inserts was determined using pieces of 
aluminium foil of known weight per unit surface area (0.0034 g/cm2). These were 
adapted over the insert, trimmed and weighed, and surface areas determined from the 
weights on a four figure analytical balance (BPI10S, Sartorius, Germany). Care was 
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taken when the foil was being adapted to the insert to avoid stretching which would 
have caused thinning of the foil. This was overcome by using small individual 
pieces of foil. 
5.2.6 Determination of Skin Weight of CIDR® Sheep and Goat insert and 
Prototype Silicone Intravaginal Inserts 
Silicone skins of CIDR® Sheep and Goat inserts were removed from the spines using 
a scalpel and weighed on a four figure analytical balance (BPII0S, Sartorius, 
Germany). 
5.2.7 Determination of Skin Thickness of CIDR® Sheep and Goat insert and 
Prototype Silicone Intravaginal Inserts 
The thickness of the silicone skin of the intravaginal inserts was measured at a series 
of positions over the insert. Silicone skins were removed from the spine using a 
scalpel and the thickness of the skin was then carefully determined using an outside 
micrometer (Moore and Wright, Sheffield, England) (See Section 2.2.3) taking care 
not to compress the silicone skin during the process. 
5.2.8 Determination of Invivo Plasma Profiles of CIDR® Sheep and Goat insert 
and Prototype Silicone Intravaginal Inserts 
Ethical approval to perform the animal experiments in this part of the Thesis was 
obtained from both the AgResearch, Ruakura Animal Ethics Committee and from 
the University of Waikato Animal Ethics Committee on the Welfare of Experimental 
Animals. 
Details of the insert formulations used in the study and the trial details are given in 
Tables 5.2.1 and 5.2.2. 
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Table 5.2.1 - Trial #1 - determination of the effect of surface area and drug load on plasma 
progesterone levels following intravaginal insertion of various CIDR® Sheep and Goat insert 
treatment regimes and various prototype inserts 
Formulation Insertion Time N umber of Animals 
(days) (N) 
CIDR@ Sheep and Goat insert: 9%w/w, 14 6 
28 cm2 
Two CIDR@ Sheep and Goat insert, 14 6 
replacement programme 
Prototype I: 10%w/w, 29 cm2 14 6 
Prototype II: 10%w/w, 40 cm2 14 6 
Prototype III: 10%w/w, 50 cm2 14 6 
Prototype IV: 15%w/w, 40 cm2 14 6 
Prototype V: 25%w/w, 40 cm2 14 6 
Table 5.2.2 - Trial #2 - supplementary trial protocol to re-examine the effect of surface area on 
plasma progesterone levels following intravaginal insertion into larger ewes 
Formulation Insertion Time Number of Animals 
(days) (N) 
CIDR@ Sheep and Goat insert: 9%w/w 14 6 
28 cm2 
Two Simultaneous CIDR@ Sheep and 14 6 
Goat insert 
Prototype II: 10%w/w, 40 cm2 14 6 
Prototype III: 10%w/w, 50 cm2 14 6 
In each trial, CIDR ® Sheep and Goat insert and prototype silicone intravaginal 
inserts were inserted into the vagina of anoestrus Romney ewes using either a 
standard CIDR® Sheep and Goat insert applicator or modified applicator which had a 
slightly larger barrel bore size. Applicators were dipped in veterinary lubricant prior 
to administration of inserts. Treatments were allocated to the ewes in a random 
manner in Trial # 1, however, larger ewes were selected in Trial #2 for insertion of 
prototype III which had a large surface area. Trials were terminated by removing the 
insert from the vagina by gently, but firmly, pulling on the nylon tail which was 
attached to the inserts and which protruded beyond the vulva of the animals. At the 
termination of trials, sheep underwent vaginal examination to assess for irritation or 
damage caused by the intravaginal inserts during their insertion. In each of the trials, 
plasma samples were collected immediately prior to insertion on day 0, during 
insertion on days 2, 4, 6, 8, 9, 10, 11, 12, 13, 14 and 24 hours following removal of 
205 
CHAPTER FIVE OPTIMISATION OF AN INTRAVAGINAL DRUG DELIVERY SYSTEM FOR USE IN SHEEP 
the inserts. Plasma samples were collected by trained AgResearch personnel from 
the jugular vein of the sheep. Immediately following sampling, the plasma was 
separated by centrifugation and stored at -20°C for subsequent progesterone analysis. 
Concentrations of progesterone in plasma were determined by direct radio immuno 
assay by trained technicians at DRC laboratories using a commercial solid phase 1125 
label (Coat-a-Count, DPC, USA). 
5.2.9 Pharmacokinetic Analysis of Invivo Plasma Profiles of CIDR® Sheep and 
Goat Insert and Prototype Silicone Intravaginal Inserts 
Area Under the Curve (AUe) data were determined from the blood plasma 
progesterone levels determined at given time points over the duration of treatment 
with intravaginal inserts for each individual ewe treated. The AUC were determined 
by simple numeric estimation using the trapezoidal rule229 using the following 
equations: 
Ck +C j AUC.= xT. 
1 2 I Equation 5.2.1 
Equation 5.2.2 
where: 
AUC j is the area under the curve over the itb time interval (ie. Area under curve 
between the jth sample time and the kth sample time). 
Ck is the plasma level (ng/mL) at the kth sample time. 
Cj is the plasma level at the fh sample time. 
Ti is the numerical value of the ith time interval (days) (Le. Time at which the kth 
sample was taken minus time at which the fb sample was taken). 
The AVC for the different treatments were then compared by Oneway Un stacked 
ANOVA (MINI TAB 8.2 Statistical Software). 
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5.3 Results 
5.3.1 Manufacture of CIDRi!> Sheep and Goat insert and Optimised CIDR 
Inserts 
H-
-
.... 
) , 
Figure 5.3.1 - Pbotograpb oftbe CIDR~ Sbeep and Goat insert and tbe prototype I, II and ill 
silicone intravaginal inserts used in tbe trials (left to rigbt, respectively) 
5.3.2 Physical Dimensions ofthe Sheep Vagina 
The average vaginal depth ofthe sheep was 13.4 ± 0.3 cm. 
5.3.3 CIDRi!> Sheep and Goat insert and Prototype Silicone Intravaginal Insert 
Dimensions 
Dimensions of the CIDRi!> Sheep and Goat insert and prototype silicone intravaginal 
insert are shown in Table 5.3.1. 
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Table 5.3.1 - Dimensions of the CIDR® Sheep and Goat insert and prototype silicone 
intravaginal inserts (N=3) 
Insert type WingSpan Length 
(± 0.1 cm) (± 0.1 cm) 
CIDR® Sheep and Goat insert (28 5.8 5.4 
cm2) containing 9%w/w 
progesterone 
Prototype I (29 cm2) containing 7.3 3.0* 
10%w/w progesterone 
Prototype II (40 cm2) containing 7.3 5.5 
10%w/w progesterone 
Prototype III (50 cm2) containing 7.3 8.0 
10%w/w progesterone 
*ThlS figure represents the length ofCIDR with drug loaded skm - to prevent msert rotation m the vagma, the actual length of 
the insert was 5.5 em, with the additional 2.5 em being blank silicone (see Figure 5.3.1). 
5.3.4 Initial Drug Load and Skin Weight 
The initial drug load and skin weight results for the CIDR® Sheep and Goat insert 
and the prototype silicone intravaginal inserts are presented in Table 5.3.2. 
Table 5.3.2 - Skin weight and drug load of CIDR® Sheep and Goat insert and prototype silicone 
intravaginal inserts (N=3) 
Formulation Skin Weight Drug Load Drug Load 
(g) (g) (%w/w) 
Average ± SEM Average ± SEM Average ± SEM 
CIDR® Sheep and Goat insert (28 4.17 ± 0.01 0.37 ± 0.003 8.77 ± 0.05 
cm2) containing 9%w/w 
progesterone 
Prototype I (29 cm2) containing 3.68 ± 0.02 0.35 ± 0.002 9.54 ± 0.09 
lO%w/w progesterone 
Prototype II (40 cm2) containing 4.80 ± 0.01 0.46 ± 0.003 9.53 ± 0.05 
IO%w/w progesterone 
Prototype III (50 cm2) containing 6.11 ± 0.02 0.59 ± 0.01 9.67 ± 0.09 
10%w/w progesterone 
Prototype IV (40 cm2) containing 4.95 ± 0.002 0.76 ± 0.003 15.39 ± 0.06 
15%w/w progesterone 
Prototype V (40 cm2) containing 4.87 ± 0.03 1.21 ± 0.02 24.79 ± 0.35 
25%w/w progesterone 
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5.3.5 Surface Area 
The surface area of the CIDR® Sheep and Goat insert and prototype silicone 
intravaginal inserts is shown in Table 5.3.3. 
Table 5.3.3 - Surface areas of CIDR® Sheep and Goat insert and prototype silicone intravaginal 
inserts (N=3) 
Formulation Surface area (cm2) 
Average ± SEM 
CIDR ® Sheep and Goat insert (28 cm2) containing 28.2 ± 0.6 
9%w/w progesterone 
Prototype I (29 cm2) containing 1 O%w/w progesterone 29.1 ± 0.3 
Prototype II (40 cm2) containing 10%w/w progesterone 39.7 ± 1.5 
Prototype III (50 cm2) containing 10%w/w progesterone 50.1 ± 0.6 
Prototype IV (40 cm2) containing 15%w/w progesterone 39.7 ± 1.5 
Prototype V (40 cm2) containing 25%w/w progesterone 39.7 ± 1.5 
5.3.6 Skin Thickness 
Skin thickness of the CIDR® Sheep and Goat insert was measured and was found to 
be 3 mm over the insert body, 2 mm on the underside of the wings and 1 mm on the 
top of the wings. 
Skin thickness of the prototype silicone intravaginal inserts was measured and was 
found to vary between 1 and 1.3 mm dependent upon the position the measurement 
was made on the insert. 
5.3.7 Invivo Plasma Profiles 
5.3. 7.1 Trial #1 Plasma Progesterone Data 
Table 5.3.4 contains blood plasma progesterone levels detennined in sheep during a 
14 day insertion of a single CIDR® Sheep and Goat insert. Table 5.3.5 contains 
blood plasma progesterone levels determined in sheep during the insertion of two 
CIDR ® Sheep and Goat insert over 14 days in a replacement programme (Figure 
5.1.2). Tables 5.3.6 to 5.3.8 contain blood plasma progesterone levels determined in 
sheep during the insertion of prototype silicone intravaginal inserts with surface 
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areas of 29, 40 and 50 cm2, respectively. Tables 5.3.9 and 5.3.10 contain blood 
plasma progesterone levels detennined in sheep during the insertion of prototype 
silicone intravaginal inserts with a surface area of 40 cm2 containing 15%w/w and 
25%w/w initial progesterone loadings, respectively. 
Table 5.3.4 - Blood levels resulting from insertion of a single CIDR® Sheep and Goat insert in 
Trial #1 
Replicate Plasma progesterone concentration (ng/mL) at each time following insertion (days) 
0 2 4 6 8 9 10 11 12 13 14 15 
1 0.22 2.97 2.81 1.90 2.20 1.36 1.28 1.04 1.00 0.85 1.22 0.08 
2 0.06 l.99 1.73 2.10 1.56 1.64 1.09 1.22 l.14 1.15 0.95 0.08 
3 0.09 2.25 1.88 2.01 1.56 1.53 1.39 1.46 1.42 1.78 1.56 0.19 
4 0.07 l.93 1.53 1.34 1.17 1.04 1.00 0.93 1.07 1.02 1.17 0.30 
5 0.07 2.29 2.49 2.53 1.89 1.33 l.58 1.29 1.53 0.93 1.34 0.14 
6 0.03 l.87 1.45 1.70 1.34 0.89 0.80 0.96 1.34 1.01 0.95 0.21 
mean 0.09 2.22 1.98 1.93 1.62 1.30 1.19 1.15 1.25 1.12 1.20 0.17 
SEM 0.03 0.17 0.22 0.16 0.15 0.12 0.12 0.08 0.09 0.14 0.10 0.03 
Table 5.3.5 - Blood levels resulting from insertion of two CIDR® Sheep and Goat insert in a 
replacement programme (Figure 5.1.2) in Trial #1 
Replicate Plasma progesterone concentration (ng/mL) at each time followinf;?; insertion (daysl 
0 2 4 6 8 9 10 11 12 13 14 15 
1 0.31 2.49 2.50 2.64 2.78 2.01 2.25 l.92 1.96 1.97 1.40 0.09 
2 0.19 2.05 1.94 1.88 1.52 2.52 1.68 1.39 1.18 1.26 1.29 0.20 
3 0.07 2.77 2.63 2.92 1.90 2.41 2.54 1.59 1.59 2.85 1.64 0.16 
4 0.20 2.68 2.14 2.78 1.49 2.99 2.76 2.03 1.67 1.86 1.65 0.13 
5 0.06 2.34 1.83 2.52 1.35 1.71 1.92 1.43 1.25 1.52 1.29 0.09 
6 0.17 2.64 2.98 2.54 1.85 3.84 2.59 2.15 1.34 1.37 1.37 0.30 
mean 0.17 2.49 2.34 2.54 1.81 2.58 2.29 1.75 1.50 1.81 1.44 0.16 
SEM 0.04 0.11 0.18 0.15 0.21 0.31 0.17 0.13 0.12 0.24 0.07 0.03 
Table 5.3.6 - Blood levels resulting from insertion of prototype silicone intravaginal inserts with 
a surface area of 29 cm2 in Trial #1 
Replicate Plasma progesterone concentration (ng/mL) at each time following insertion ( days) 
0 2 4 6 8 9 10 11 12 13 14 15 
1 0.04 1.71 1.53 2.38 1.32 1.12 1.22 6.84 1.17 1.02 1.06 0.13 
2 0.20 3.00 2.47 3.15 2.26 1.70 1.35 1.15 0.85 1.18 1.39 0.19 
3 0.08 1.29 1.44 1.86 1.32 1.16 1.06 1.06 0.99 1.25 1.18 0.16 
4 0.09 1.58 1.87 1.69 1.42 1.12 0.91 0.74 0.66 0.72 0.74 0.06 
5 0.04 2.11 2.16 2.03 2.32 1.76 1.46 1.15 1.30 1.37 1.44 0.09 
6 0.06 2.90 2.23 1.66 1.44 0.86 0.98 1.02 1.14 1.24 1.36 0.13 
mean 0.09 2.10 1.95 2.13 1.68 1.29 1.16 1.02 1.02 1.13 1.19 0.13 
SEM 0.02 0.29 0.17 0.23 0.19 0.15 0.09 0.97 0.10 0.09 0.11 0.02 
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Table 5.3.7 - Blood levels resulting from insertion of prototype silicone intravaginal inserts with 
a surface area of 40 cmz in Trial #1 
Replicate Plasma ~rogesterone concentration (ng/mL) at each time following insertion (days) 
0 2 4 6 8 9 10 11 12 13 14 15 
1 0.09 3.30 3.37 3.64 2.67 2.31 2.44 2.04 2.12 2.34 2.05 0.17 
2 0.17 4.41 3.49 3.54 3.12 2.31 2.42 1.97 2.25 1.98 1.53 0.12 
3 0.04 3.74 2.69 3.76 2.20 2.70 2.33 1.99 1.97 1.90 1.69 0.23 
4 0.07 4.17 4.18 3.75 3.24 3.65 2.59 2.62 2.17 2.52 2.02 0.85 
5 0.06 3.18 2.38 2.40 1.91 1.80 1.82 1.99 2.09 1.89 1.91 0.12 
6 0.04 4.52 4.92 3.45 2.93 2.31 2.19 2.38 1.93 1.95 1.70 0.09 
mean 0.08 3.89 3.50 3.42 2.68 2.51 2.30 2.17 2.09 2.10 1.82 0.26 
SEM 0.02 0.23 0.38 0.21 0.22 0.26 0.11 0.11 0.05 0.l1 0.08 0.12 
Table 5.3.8 - Blood levels resulting from insertion of prototype silicone intravaginal inserts with 
a surface area of 50 cm2 and 10%,w/w initial load in Trial #1 
Replicate Plasma progesterone concentration (ng/mL) at each time following insertion (days) 
0 2 4 6 8 9 10 11 12 13 14 15 
1 0.04 4.20 3.86 4.17 3.20 2.37 2.57 1.72 1.92 2.06 1.91 0.19 
2 0.19 3.86 3.45 4.10 2.69 2.38 2.41 1.43 1.66 1.98 2.04 0.19 
3 0.10 3.03 2.17 3.94 2.82 2.65 2.45 2.43 2.01 1.90 2.07 0.14 
4 0.05 2.76 3.38 2.86 2.56 2.28 2.10 1.56 1.29 1.31 1.22 0.04 
5 0.04 3.72 3.44 3.48 2.98 2.46 2.38 2.21 2.05 1.87 1.88 0.07 
6 0.01 4.30 3.77 3.82 2.76 2.02 1.69 2.28 2.07 2.02 2.08 0.48 
mean 0.07 3.64 3.34 3.73 2.83 2.36 2.27 1.94 1.83 1.86 1.87 0.18 
SEM 0.03 0.25 0.25 0.20 0.09 0.08 0.13 0.17 0.13 0.11 0.13 0.06 
Table 5.3.9 - Blood levels resulting from insertion of prototype silicone intravaginal inserts with 
a surface area of 40 cm2 and 15%w/w initial load in Trial #1 
Replicate Plasma progesterone concentration (ng/mL) at each time following insertion I days) 
0 2 4 6 8 9 10 11 12 13 14 15 
1 0.06 3.70 4.00 3.77 2.42 2.88 2.80 2.01 2.22 1.96 1.93 0.17 
2 0.10 2.93 2.95 2.42 1.56 1.57 1.79 1.31 1.61 1.70 1.70 0.11 
3 0.04 3.60 1.66 1.45 1.85 1.28 1.14 1.20 1.25 1.64 0.98 0.05 
4 0.30 3.60 3.24 3.51 3.18 2.36 2.47 1.84 1.81 2.35 1.99 0.l0 
5 0.10 4.10 1.88 2.10 1.86 1.38 1.20 1.40 1.83 1.86 1.53 0.22 
6 0.10 2.98 2.66 2.78 2.73 1.76 1.85 2.13 1.93 1.48 1.59 0.12 
mean 0.12 3.49 2.73 2.67 2.27 1.87 1.87 1.65 1.77 1.83 1.62 0.13 
SEM 0.04 0.18 0.36 0.36 0.25 0.25 0.27 0.16 0.13 0.12 0.15 0.02 
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Table 5.3.10 - Blood levels resulting from insertion of prototype silicone intravaginal inserts 
with a surface area of 40 cm2 and 25% w/w initial load in Trial #1 
Replicate Plasma progesterone concentration (ng/mL) at each time following insertion (days) 
0 2 4 6 8 9 10 11 12 13 14 15 
1 1.27 4.45 4.45 6.08 4.90 4.26 4.84 3.51 3.33 3.39 3.81 0.61 
2 0.03 2.82 2.58 2.11 2.44 l.38 1.36 1.29 l.33 1.40 1.50 0.07 
3 0.05 2.52 2.03 2.79 3.08 2.13 2.16 1.76 2.14 1.83 2.06 0.06 
4 0.06 2.21 2.64 2.59 2.42 1.49 1.60 1.49 1.60 1.51 1.66 0.21 
5 0.18 2.72 3.15 3.53 3.06 3.72 2.50 2.13 2.08 2.29 1.78 0.12 
6 0.02 3.27 3.42 2.16 1.79 1.51 1.21 1.41 1.55 1.37 1.25 0.l5 
mean 0.27 3.00 3.05 3.21 2.95 2.41 2.28 1.93 2.00 1.97 2.01 0.20 
SEM 0.20 0.32 0.34 0.61 0.44 0.51 0.55 0.34 0.29 0.32 0.38 0.08 
5.3. 7.2 Trial #2 Plasma Progesterone Data 
Table 5.3.11 contains blood plasma progesterone levels determined in sheep during a 
14 day insertion of a single CIDR® Sheep and Goat insert insert. Table 5.3.12 
contains blood plasma progesterone levels determined in sheep during the insertion 
of two CIDR® Sheep and Goat insert inserts in a simultaneous manner (Figure 5.1.2). 
Tables 5.3.13 and 5.3.14 contain blood plasma progesterone levels determined in 
sheep during the insertion of 40 cm2 and 50 cm2 prototype silicone intravaginal 
inserts both with 10%w/w initial drug loads, respectively. 
Table 5.3.11 - Blood levels resulting from insertion of a single CIDR® Sheep and Goat insert in 
Trial #2 
Replicate Plasma progesterone concentration (ng/mL) at each time following insertion (days) 
0 2 4 6 8 9 10 11 12 13 14 15 
1 1.30 5.99 7.75 7.60 7.39 9.34 3.66 1.98 1.21 1.04 1.54 0.15 
2 0.14 l.44 1.44 1.46 1.42 1.08 1.36 1.12 1.31 1.30 1.40 0.22 
3 0.14 2.29 2.32 2.07 2.41 1.91 1.92 2.20 1.35 1.56 1.35 0.17 
4 0.83 4.50 5.60 7.50 6.29 5.09 2.51 2.48 1.86 1.64 1.83 0.16 
5 0.15 1.39 1.36 1.38 1.31 1.47 1.27 1.79 1.30 1.25 1.05 0.09 
6 0.06 2.40 2.70 2.75 3.22 3.18 3.00 2.62 1.81 2.01 2.47 0.14 
mean 0.12 1.88 1.96 1.91 2.09 1.91 1.89 1.93 1.44 1.53 1.57 0.16 
SEM 0.13 0.51 0.70 1.04 0.83 0.66 0.30 0.25 0.12 0.12 0.23 0.02 
212 
CHAPTER FIVE OPTIMISATION OF AN INTRA VAGINAL DRUG DELIVERY SYSTEM FOR USE IN SHEEP 
Table 5.3.12 - Blood levels resulting from insertion of two simultaneous CIDR® Sheep and Goat 
insert in a simultaneous manner (Figure 5.1.2) in Trial #2 
Replicate Plasma progesterone concentration (ng/mL) at each time following insertion (days) 
0 2 4 6 8 9 10 11 12 13 14 15 
1 0.18 4.14 4.72 4.17 3.66 3.95 3.87 4.60 2.79 2.82 3.24 0.34 
2 0.15 6.00 4.76 4.83 5.26 4.38 4.00 4.50 3.90 3.45 3.81 0.33 
3 0.41 3.41 2.39 1.54 1.63 1.31 1.80 2.03 1.97 2.67 1.96 0.47 
4 0.11 4.79 4.66 3.70 4.34 4.00 4.16 3.34 3.14 2.48 2.96 0.17 
5 0.09 3.56 3.26 2.42 2.39 2.48 2.52 2.86 2.68 2.41 3.15 0.46 
6 0.05 3.21 4.63 2.98 3.63 2.77 2.84 2.48 2.16 2.32 2.84 0.22 
mean 0.16 4.18 4.07 3.27 3.49 3.15 3.20 3.30 2.77 2.69 2.99 0.33 
SEM 0.05 0.43 0.41 0.49 0.53 0.48 0.39 0.43 0.28 0.17 0.25 0.05 
Table 5.3.13 - Blood levels resulting from insertion of prototype silicone intravaginal inserts 
with a surface area of 40 cm2 and 10%w/w initial load in Trial #2 
Replicate Plasma progesterone concentration (ng/mL) at each time following insertion Idays) 
0 2 4 6 8 9 10 11 12 13 14 15 
1 0.06 3.55 3.14 3.15 3.07 2.50 1.76 2.25 1.57 1.56 2.11 0.16 
2 0.25 2.40 3.16 2.88 2.78 2.40 3.00 3.07 2.59 2.52 2.04 0.26 
3 0.15 4.57 3.66 3.60 3.34 3.41 1.95 2.18 2.06 1.40 2.21 0.17 
4 0.07 4.35 3.99 3.48 3.44 2.89 2.77 3.10 3.45 2.54 2.80 0.14 
5 0.12 4.16 3.49 3.14 2.44 2.29 1.98 2.27 2.37 2.03 2.28 0.17 
6 0.19 2.74 3.18 3.03 3.02 2.46 2.31 2.09 2.11 1.93 2.83 0.37 
mean 0.14 3.63 3.44 3.21 3.01 2.66 2.29 2.49 2.36 2.00 2.38 0.21 
SEM 0.03 0.37 0.14 0.11 0.15 0.17 0.20 0.19 0.26 0.19 0.14 0.04 
Table 5.3.14 - Blood levels resulting from insertion of prototype silicone intravaginal inserts 
with a surface area of 50 cm2 and 10%w/w initial load in Trial #2 
Replicate Plasma pro2esterone concentration (ng/mL) at each time following insertion tdays} 
0 2 4 6 8 9 10 11 12 13 14 15 
1 0.17 6.03 3.86 4.04 3.72 2.22 3.24 3.31 2.90 2.63 2.95 0.29 
2 0.33 6.44 4.54 3.90 3.90 4.12 3.56 3.43 2.89 2.55 2.69 0.33 
3 0.12 5.31 3.68 3.31 3.74 3.81 3.03 4.06 2.84 2.81 3.13 0.20 
4 0.00 4.60 3.91 3.44 3.18 2.64 2.87 3.41 2.38 2.32 2.52 0.12 
5 0.97 6.19 7.86 8.01 9.38 4.90 3.16 2.95 2.67 2.48 3.01 0.15 
6 0.06 3.39 3.53 2.49 2.87 2.98 2.40 2.96 2.07 2.39 2.21 0.12 
mean 0.14 5.15 3.90 3.43 3.48 3.15 3.02 3.43 2.61 2.54 2.70 0.21 
SEM 0.05 0.50 0.16 0.25 0.18 0.32 0.18 0.16 0.15 0.08 0.15 0.04 
5.3.8 Pharmacokinetic analysis of Invivo Plasma Profiles of CIDR® Sheep and 
Goat insert and Prototype Silicone Intravaginal Inserts 
Areas under the Curve calculated for the invivo plasma profiles ofCIDR® Sheep and 
Goat insert and prototype silicone intravaginal inserts in Trial #1 and Trial #2 are 
shown in Table 5.3.15. 
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Table 5.3.15 - Area under the curve data for invivo plasma profIles of CIDR® Sheep and Goat 
insert and prototype silicone intravaginal inserts in Trial #1 and Trial #2 
Trial Formulation Area Under Curve (AUe) 
Day 0-8 Day 8-15 Day 0-15 
Average ± SEM Avera2e ± SEM Average ± SEM 
1 CIDR® Sheep and Goat - - 22.06 ± 1,45 
insert 
1 2 CIDR® Sheep and 16.73 ± 0.88 12.35 ± 0.75 29.08 ± 1.59 
Goat insert replacement 
1 Prototype I 14.12 ± 1.33 8.69 ± 1.06 22.81 + 1.80 
1 Prototype II 24.38 ± 1.62 14.45 ± 0.70 38.83 + 2.11 
1 Prototype III 24.33 ± 1.18 13.63 ± 0.56 37.96 ± 1,48 
2 Prototype IV - - 31.96 + 2.64 
2 Prototype V - - 35.90 ± 5,47 
2 CIDR ® Sheep and Goat - - 25.11±4.13 
insert 
2 2 CIDR® Sheep and - - 46.71 ± 4.97 
Goat insert 
simultaneous 
2 Prototype II - - 39.51 ± 1.66 
2 Prototype III - - 52.99 ± 5.62 
5.3.9 Vaginal Inspection After Removal 
Examination of all ewes immediately following removal of each insert used in the 
study showed that no damage and minimal vaginal discharge was present. 
5.3.10 Residual Drug Load After Removal 
5.3.10.1 Trial #1 
Residual drug loads In CrDR ® Sheep and Goat insert and prototype silicone 
intravaginal inserts detennined following 14 day insertion are shown in Table 5.3.16 
along with initial loads and the calculated amount of progesterone released during 
the 14 day insertion. 
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Table 5.3.16 - Residual drug loads in CIDR® Sheep and Goat insert and prototype silicone 
intravaginal inserts determined following 14 day insertion (N=6) in Trial #1 
Formulation Initial Residual Amount Released 
Load Load 
(g) (g) (g) SEM 
CIDR® Sheep and Goat insert 0.38 0.21 0.17 0.01 
Prototype I 0.35 0.16 0.19 0.01 
Prototype II 0.46 0.19 0.27 0.01 
Prototype III 0.59 0.26 0.33 0.01 
Prototype IV 0.76 0.47 0.29 0.01 
Prototype V 1.21 0.90 0.31 0.01 
5.3.10.2 Trial #2 
Residual drug loads in CIDR® Sheep and Goat insert and prototype silicone 
intravaginal inserts determined following 14 day insertion are shown in Table 5.3.17 
along with initial loads and the calculated amount of progesterone released during 
the 14 day insertion. 
Table 5.3.17 - Residual drug loads in CIDR® Sheep and Goat insert and prototype silicone 
intravaginal inserts determined following 14 day insertion (N=3) in Trial #2 
Formulation Initial Residual Amount Released 
Load (g) Load (g) 
(g) SEM 
CIDR ® Sheep and Goat insert 0.37 0.16 0.22 0.01 
Two Simultaneous CIDR ® 0.74 0.34 DAD 0.02 
Sheep and Goat insert 
Prototype II 0.46 0.16 0.30 0.02 
Prototype III 0.59 0.25 0.34 0.01 
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5.4 Discussion 
Research in this Chapter set out to optimise the commercially available CIDR® 
Sheep and Goat insert so that a single intravaginal insert could be used in 
donor/recipient synchrony programmes for embryo transfer. Such treatment regimes 
currently require the use of two CIDR® Sheep and Goat insert inserted in either a 
simultaneous or replacement programme (Figure 5.4.1 )46-48 to provide plasma 
progesterone levels which are elevated above those seen when a single CIDR® Sheep 
and Goat insert is inserted. 
Plasma progesterone levels in sheep following insertion of a single CIDR® Sheep 
and Goat insert has been reported by several investigators46, 47,179,182,183, However, a 
review of the published research in this area revealed that plasma profiles resulting 
from the administration of two CIDR® Sheep and Goat insert either in a 
simultaneous or replacement programme was sparse46-48, and where it had been 
reported, it was performed in intact ewes and the resultant profiles were the sum of 
both exogenous and endogenous progesterone. Since the success of the optimisation 
process was to be based on plasma profiles, the first step in the optimisation process 
involved the determination and documentation of plasma profiles resulting from the 
administration of two CIDR ® Sheep and Goat insert in both a simultaneous and 
replacement programme (Figure 5.l.2). Figure 5.4.1 shows the resultant plasma 
progesterone levels in anoestrus sheep for a single CIDR ® Sheep and Goat insert, 
two CIDR® Sheep and Goat insert inserted simultaneously and a single CIDR® Sheep 
and Goat insert inserted for 8 days, removed and immediately replaced by insertion 
of a second, fresh, CIDR® Sheep and Goat insert. The use of anoestrus sheep in this 
trial provided the opportunity to determine plasma progesterone levels resulting from 
the intravaginal insertion of progesterone-containing inserts while endogenous 
progesterone was absent. 
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Figure 5.4.1- Plasma progesterone levels in sheep resulting from insertion of a single CIDR® 
Sheep and Goat insert (0), simultaneous insertion of two CIDR@ Sheep and Goat insert (A.; 
simultaneous programme, Figure 5.1.2) and consecutive insertion of two CIDR® Sheep and 
Goat insert (.; replacement programme, Figure 5.1.2) 
The profile for the single CIDR® Sheep and Goat insert is typical of those already 
reported in the literature46, 47, 179, 182, 183 (Figure 5.4.1). The profile is characterised by 
an initial increase in plasma progesterone (which occurs as a result of the absorption 
of exogenous progesterone from the intravaginal insert) followed by slowly 
declining plasma levels over the insertion period. Once the CIDR ® Sheep and Goat 
insert is removed, progesterone levels fall rapidly to basal values (Figure 5.4.1). 
When a single CIDR® Sheep and Goat insert is replaced by a second fresh CIDR® 
Sheep and Goat insert at day 8 of treatment, an increase in plasma progesterone is 
observed over days 8 through 14. The elevation is probably due to an initial burst 
release of progesterone from the CIDR ® Sheep and Goat insert which is a 
characteristic of matrix-type drug delivery systems. The plasma progesterone level 
is then observed to slowly decline to those levels observed when a single CIDR® 
Sheep and Goat insert is inserted (Figure 5.4.1). When two CIDR® Sheep and Goat 
inserts are inserted simultaneously for a 14 day insertion period, the same 
progesterone profile trend is observed as that observed for a single CIDR® Sheep and 
Goat insert, except that the progesterone levels are higher than those observed for a 
single CIDR® Sheep and Goat insert over the entire treatment period (Figure 5.4.1). 
These profiles formed the basis for the optimisation process which was based upon 
217 
CHAPTER FIVE OPTIMISATION OF AN INTRA VAGINAL DRUG DELIVERY SYSTEM FOR USE IN SHEEP 
developing a prototype insert which produced plasma progesterone levels which 
mimicked those seen in these programmes (Figure 5.4.1). 
In the scientific literature, Rathbone et al has recently reported on the optimisation of 
a silicone/progesterone intravaginal drug delivery system for the control of the 
oestrous cycle in cattle, namely, the CIDR@1900 Cattle insert6• The CIDR@1900 
Cattle insert is manufactured using the same technology as the CIDR@ Sheep and 
Goat insert, however, the CIDR@1900 Cattle insert is larger to facilitate its use in 
cattle. Rathbone et aI's results suggested that the only way to increase blood 
progesterone levels in cows was to increase the surface area of the CrDR@1900 
Cattle insert6 and that release of progesterone occurred only from the first 1 nun of 
skin. Variables such as drug load, or the inclusion of various formulation additives 
to the silicone, had no effect on plasma progesterone levels in cattle6, 102, 222. These 
authors also found that the mechanism of invivo release of progesterone from 
silicone was different to the invitro mechanism of release [Rathbone, Personal 
communication]. Chapter Four of this Thesis investigated the release of 
progesterone from the CrDR ® 1900 Cattle insert and confirmed that mechanistic 
differences exist between the invitro and invivo cases. Therefore, invitro 
formulation development work performed on silicone/progesterone intravaginal 
inserts does not correlate well with the invivo perfonnance of such drug delivery 
systems. As a result of this knowledge, in this Chapter, we opted not to perform any 
invitro experimentation, but rather, to focus on conducting invivo experiments to 
assess the effectiveness of any prototype intravaginal inserts. 
Based on the work of Rathbone et a16, we modified both the surface area and skin 
thickness of the CIDR ® Sheep and Goat insert and assessed if these parameters could 
be manipulated to produce an optimised version of the CIDR® Sheep and Goat insert. 
In addition, even though the results of Rathbone et al6 indicated that drug load had 
no effect on plasma progesterone levels from silicone based intravaginal drug 
delivery systems, we also investigated the effect of drug load (l0%, 15% and 
25%w/w) upon the magnitude of the plasma progesterone profiles in sheep, in case 
of any interspecies differences in the intravaginal release of progesterone from 
silicone. 
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Our results suggested that initial drug load had no effect on plasma progesterone 
levels following insertion of silicone/progesterone intravaginal inserts (Figure 5.4.2). 
For each of the inserts, the AUC values were not significantly different from each 
other (p=0.442). Therefore when silicone/progesterone intravaginal inserts with the 
same surface area but different initial loads were inserted into the vagina of sheep, 
the same plasma progesterone levels resulted (Figure 5.4.2). These observations 
supported those previously reported by Rathbone et al in cattle6• 
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Figure 5.4.2 - Plasma progesterone levels in sheep resulting from the insertion of prototype 
silicone intravaginal inserts of the same surface area but with initial drug loads of lO%w/w Ce), 
15% w/w (At.) and 25%w/w (X) progesterone in silicone 
In contrast, if prototype silicone intravaginal inserts with the same initial drug load 
but different surface areas were inserted into the vagina of sheep, significantly 
different plasma profiles were observed (p<O.OOI) (Figure 5.4.3). 
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Figure 5.4.3 - Plasma progesterone levels in sheep resulting from insertion of prototype silicone 
intravaginal inserts with surface areas of 29 cm2 (X), 40 cm2 (A) and 50 cm2 (e) and initial drug 
loads of lO%w/w 
Statistical analysis of the area under the curves of each plasma progesterone curve 
revealed a significant difference (p<O.OOl) between the 29 cm2 insert and the 40 cm2 
and 50 cm2 intravaginal inserts. However, statistical analysis of the AVe of the 
plasma progesterone curves for the 40 cm2 and 50 cm2 intravaginal inserts showed 
that these were not significantly different (p=O.744). This latter result was not 
expected; Rathbone et al had previously shown that the elevation in plasma 
progesterone levels was not limited by insert size6• Upon further investigation, the 
lack of an increase in plasma levels produced by the 50 cm2 insert may be explained 
by subjective reports from the field hands that, as the trial progressed, they observed 
that most of the 50 cm2 inserts were protruding from the vaginas of the ewes. It 
would appear that some backward migration of the inserts was occurring, resulting in 
the inserts protruding from the vagina. Although the plasma progesterone profiles 
for the 40 cm2 and 50 cm2 overlapped (Figure 5.4.3), the amount of progesterone 
released from the 50 cm2 insert over the 14 day treatment (0.33 g) was higher than 
the amount released from the 40 cm2 insert (0.27 g). This observation may be 
explained by postulating that the inserts spent several days completely within the 
vagina before they began to protrude and, whilst protruding, they would have been 
regularly flushed with urine, which may have promoted drug release. 
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Comparison of the profiles obtained following insertion of the prototype inserts to 
those obtained when the CIDR ® Sheep and Goat insert is used in its various 
programmes is shown in Figure 5.4.4. 
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Figure 5.4.4 - Plasma progesterone levels in sheep resulting from insertion of a single CIDR® 
Sheep and Goat insert (0), insertion of two CIDR® Sheep and Goat insert in a replacement 
programme (ii), insertion of 10%w/w initial drug loaded prototype silicone intravaginal inserts 
with surface areas of 29 CX), 40 (.6.) and 50 cml Ce) and insertion of two CIDR® Sheep and Goat 
insert in a simultaneous programme (D) 
The prototype silicone intravaginal inserts which had the same surface area as the 
commercially available CIDR ® Sheep and Goat insert produced plasma progesterone 
profiles which mimicked those of the CIDR® Sheep and Goat insert (Figure 5.4.3) 
and provided AUC values which were not statistically different (p=0.754). The 40 
cm2 and 50 cm2 prototype silicone intravaginal inserts exhibited an increase in 
plasma levels and amount released (0.27 g and 0.33 g released respectively) over the 
single CIDR® Sheep and Goat insert (0.17 g released) (Figure 5.4.3) and provided 
AUe values which were statistically different (p<0.001). However, the prototype 
silicone intravaginal inserts did not give the same plasma levels as two CIDR® Sheep 
and Goat insert in either the simultaneous or replacement treatment programmes 
(p=0.004). These inserts provided AUC values which were larger than the two 
CIDR® Sheep and Goat insert replacement programme treatment regime and smaller 
than those observed during the two CIDR® Sheep and Goat insert simultaneous 
programme. However, examination of the profiles (Figure 5.4.4) suggests that the 
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difference between the profiles of Prototype II and Prototype III and the two CIDR® 
Sheep and Goat insert replacement programme occurs at the beginning of the 
treatment period but each of these profiles are very similar towards the end of the 
treatment period. Their AUC values for the first 8 days were significantly different 
(p=O.OOI), however, they were not significantly different from days 8 to 15 of 
insertion (p=0.119). Since the second CIDR® Sheep and Goat insert was inserted to 
elevate plasma levels over the last 6 days of insertion in the programme, it is 
proposed that the 40 cm2 insert could be considered an optimised product for the 
replacement programme, but does not provide sufficiently high enough plasma levels 
to be considered a product which would mimic, and therefore could be considered 
optimised for the simultaneous insertion treatment programme. 
From Figure 5.4.4 it would appear that optimisation of the CIDR® Sheep and Goat 
insert to mimic the two CIDR® Sheep and Goat insert simultaneous programme is 
not possible. However, as indicated above, the lack of difference between plasma 
profiles produced by the 40 cm2 and 50 cm2 inserts was unexpected and possibly due 
to the observation by field hands that most of the 50 cm2 inserts were protruding 
from the vaginas of the ewe. Consequently, a second trial was initiated with the 50 
cm2 inserts, however, on this occasion they were deliberately inserted into ewes with 
longer vaginas to ensure that they were fully contained within the vaginal cavity over 
the time course of the insertion period. The resulting plasma progesterone profiles 
are presented in Figure 5.4.4. In this trial the 50 cm2 intravaginal inserts produced 
elevated plasma progesterone levels and statistical analysis of the AVC showed a 
significant difference between the 40 cm2 and 50 cm2 prototype intravaginal inserts 
(p=0.044). Indeed, Figure 5.4.4 shows that when the 50 cm2 inserts were contained 
within the vagina of sheep for the entire administration period, they produced plasma 
levels which were equivalent to the plasma levels produced following insertion of 
two CIDR® Sheep and Goat insert in a simultaneous programme and this was 
confirmed by the AVe values (p=0.423). In the same trial the 40 cm2 prototype 
silicone intravaginal insert and single CIDR ® Sheep and Goat insert treatments gave 
the same plasma profiles as in Trial #1 and similar AVC values (Table 5.3.14). 
Interestingly, the quantities of progesterone released by the two CIDR® Sheep and 
Goat insert in a simultaneous programme and the 50 cm2 prototype silicone 
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intravaginal insert were 0.40 g and 0.34 g, respectively. The amounts released were 
significantly different (p=0.050) suggesting that insertion of a single large delivery 
system resulted in a superior bioavailability of progesterone to that arising from the 
delivery of progesterone from two simultaneously inserted inserts. 
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Figure 5.4.5 - Plasma progesterone levels in sheep resulting from insertion of a single CIDR® 
Sheep and Goat insert (0), insertion of two CIDR® Sheep and Goat insert in a simultaneous 
programme (e) and insertion of prototype silicone intravaginal inserts with surface areas of 40 
cm2 (A) and 50 cm2 (X) with initial drug loads of lO%w/w 
These latter results suggested that a 50 cm2 insert could be considered an optimised 
product for the simultaneous programme. Indeed, since both the simultaneous and 
replacement programmes are designed to elevate plasma progesterone levels above 
those observed for the single CIDR® Sheep and Goat insert, the final design 
parameters of an optimised CIDR ® Sheep and Goat insert were based on the 50 cm2 
since this insert could not only elevate plasma progesterone levels which mimicked 
those observed with the two CIDR ® Sheep and Goat insert simultaneous programme, 
but provided plasma levels which were elevated above those seen in the two CIDR@ 
Sheep and Goat insert replacement programme. These parameters are summarised in 
Table 5.4.1. 
Table 5.4.1 - Design parameters of an optimised CIDR® Sheep and Goat insert 
Wing Span Length Surface Area Skin Drug load 
(cm) (cm) (cm2) Thickness 
(mm) 
7.3 5.5< length <8.0 50 1 10%w/w 
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Clearly, however, from the results presented in the first trial (Trial #1) some design 
work would have to be performed in order to produce an optimised intravaginal 
insert with a surface area of 50 cm2 but with a body length that is more appropriate 
with the available length of the vagina of the majority of the flock e.g., the body of 
the optimised insert may be shorter but have a larger diameter. 
The question to be answered before such an optimised insert would be considered for 
commercialisation is whether or not the insert would be cost effective. This question 
can be answered by comparing the physical characteristics of the optimised insert to 
the characteristics of the CIDR ® Sheep and Goat insert. 
Table 5.4.2 - Comparative surface areas, skin thicknesses and progesterone loaded silicone skin 
volumes for CIDR® Sheep and Goat insert and optimised insert 
Parameter Characteristics of Proposed 
CIDR@ Sheep and Goat Characteristics of 
insert Optimised Insert 
Surface area 28 cm2 50 cm2 
Skin thickness Variable: 0.1-0.3 cm 0.1 cm 
Volume of drug loaded skin 4.2 cm3* 5.0 cm3** 
"Experimentally determined from known skin weight (Table 5.3.2) and the density of progesterone 
loaded silicone = 1.09 (personal communication, Vaughan Woodward, Production Manager) 
""Calculated from [(required surface area) x (required skin thickness)] 
Table 5.4.2 shows that there is the potential for an optimised insert to be fabricated 
from a similar amount of drug loaded skin as the current commercially available 
CIDR® Sheep and Goat insert. Since progesterone and silicone are the most 
expensive components of the CIDR ® Sheep and Goat insert, an optimised insert 
which has a larger surface area, but a reduced skin thickness would be comparable in 
price to a single CIDR® Sheep and Goat insert. Having such an optimised insert 
would subsequently improve the end user cost-effectiveness of the intravaginal insert 
since they would only need to purchase one optimised insert per animal to be treated, 
rather than two of the currently available CIDR ® Sheep and Goat insert. 
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5.5 Conclusions 
It can be concluded that the commercially available CIDR ® Sheep and Goat insert 
could be optimised to meet the criteria discussed in the introduction to this Chapter. 
In this Chapter, prototype silicone intravaginal inserts were manufactured whose 
insertion into anoestrus Romney ewes resulted in plasma progesterone profiles which 
mimicked those seen for the two CIDR® Sheep and Goat insert treatment regimes 
(Figure 5.1.2). An optimised insert could therefore be fabricated using existing 
manufacturing technology and as such, would require no maj or capital expenditure 
by the Company. Further to this, the optimised insert would be of a similar 
manufacturing cost to the currently available CIDR® Sheep and Goat insert to 
manufacture. In addition, the ability to use a single insert in embryo transfer fertility 
programmes at a similar cost to that of a single CIDR® Sheep and Goat insert would 
improve the marketability of the product and represent savings for the end user. 
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Chapter Six - Development and Optimisation of a New Intravaginal 
Veterinary Drug Delivery System Containing Progesterone for the 
Control of the Ovine Oestrous Cycle 
6.1 Introduction 
Chapter Five discussed the optimisation of the commercially available CIDR@ Sheep 
and Goat insert, a silicone based intravaginal insert for control of oestrus in sheep. 
The optimisation criteria stipulated that the optimised product must utilise the same 
manufacturing technology as the CIDR® Sheep and Goat insert. This was to ensure 
that, if successful optimisation was achieved and the parameters of the optimised 
insert could be defined, then by using an existing in-house manufacturing 
technology, such a product could be rapidly developed to full scale production 
without significant expense to the Company. This would provide a short tenn 
solution to the product optimisation challenges outlined in Chapter Five. However, 
the silicone injection moulding technology used to manufacture CIDR® Sheep and 
Goat insert has certain limitations. Therefore a more long term strategy should also 
be considered which involves the introduction of a new, improved technology with 
the potential to overcome the current limitations of the silicone technology whilst 
remaining cost effective. From a Company perspective, such technologies should 
involve exploitation of the Manufacturing Team's core competencies i.e., injection 
moulding, but should not be limited to thennosetting polymers (even though the 
Company has invested much time and expense in thermosetting equipment). Such a 
strategy may involve up front investment costs for new machinery, but this would be 
weighed against the potential benefits and new products which could arise from the 
introduction of the new technology. 
The main limitation of the silicone injection moulding technology mentioned above 
is the temperature of 190°C which is required to cure the polymer in an efficient time 
226 
CHAPTER SIX DEVELOPMENT OFA NEW INTRA VAGINAL DRUG DELIVERY SYSTEM FOR USE IN SHEEP 
frame. This high temperature limits the application of this technology as only the 
most heat stable drugs can withstand the high cure temperatures. As a result the 
silicone based technology supports a limited number of drug candidates and 
therefore has limited clinical applications. A further disadvantage of silicone is that 
it is a non-biodegradable polymer. If spent silicone inserts are disposed of by burial 
they will not decompose. Therefore, the purpose of this Chapter was to identify an 
injection mouldable, biodegradable polymer which can be fabricated into 
intravaginal inserts using low moulding temperatures. Once identified, a further 
purpose of the Chapter was to investigate the effect of formulation variables on 
plasma profiles of intravaginal inserts fabricated using the biodegradable polymer. 
In this Chapter progesterone was used as a model drug to investigate the potential of 
the biodegradable polymer as an intravaginal drug delivery platform in sheep. In this 
respect, intravaginal inserts containing progesterone were formulated to determine if 
an insert fabricated with the biodegradable polymer could mimic the plasma profiles 
observed when a single CIDR® Sheep and Goat insert was inserted. 
The biodegradable polymer chosen for the study was poly-( 8-caprolactone). It was 
chosen because it exhibited certain desirable properties which include: 
• Biocompatibility: This is well documented in the literature216 and allows poly-( 8-
caprolactone) to be used in products which contact animal tissues. 
• Biodegradability: This is also well documented in the literature216, 251 and 
contributes to increased environmental acceptability of any poly-( 8-caprolactone) 
product in comparison to non-biodegradable polymers. 
• Low glass transition temperature216 : This allows the polymer to be flexible under 
conditions of use, even in winter months, thereby offering the potential that the 
final insert will not need an internal spine to provide form for the insert and will 
not become brittle and break when flexed during use. 
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• Melting point of 60°C216 : This allows poly-(e-caprolactone) to be injection 
moulded at relatively low temperatures, making it possible to incorporate drug 
candidates with low tolerance for heat. 
• Permeability to lipophilic drugs: Poly-( e-caprolactone) is hydrophobic and 
therefore lipid soluble drugs can permeate though it by diffusion216 • 
• Permeability to hydrophilic drugs: Unlike silicone, if channel forming agents are 
incorporated into and leached out of a poly-( s-caprolactone) insert, the insert can 
maintain its structural integrity. This mechanical strength allows the 
incorporation of hydrophilic drugs into poly .. ( s-caprolactone) for release by 
diffusion through the formed pores and channels. 
• There is evidence in the literature that poly-( 8-caprolactone) can be fabricated into 
intravaginal inserts which have the potential for use as a platform for drug 
delivery in cattle193• 
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6.2 Methods 
6.2.1 Manufacture of CIDRi!> Sheep and Goat insert 
CIDRi!> Sheep and Goat insert were manufactured as described in Chapter Five, 
Section 5.2.1. 
6.2.2 Manufacture of Poly-(s -caprolactone) Intravaginal Inserts 
Poly-( s-caprolactone) intravaginal inserts were manufactured by hand. This was 
achieved by mixing progesterone (USP micronised, Phannacia & Upjohn, USA) and 
granular poly-(s-caprolactone) (Tonei!> P-767, Union Carbide, USA) in the required 
ratio (8% and 9%w/w progesterone) in a glass beaker at a temperature of 
approximately BO°C (Sunbeam Bake 'n' Grill Oven). Following thorough mixing the 
resultant melt was compressed into flat sheets (140 x 90 x 2 mm) in a specially cut 
aluminium tool (Figure 6.2.1) which had previously been pre-warmed to 6O°C 
(Contherm SERIES FIvE INCUBATOR, Contherm Scientific Ltd., New Zealand). 
Figure 6.2.1 - Photo of aluminium tool used to cast flat sheets of progesterone loaded poly-(&-
caprolactone) 
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After cooling to ambient temperature, the resultant flat sheets were removed from 
the aluminium tool and then cut into pieces of suitable dimensions for plastic 
welding into the desired shape of the poly-(s-caprolactone) intravaginal inserts. This 
involved the following: 
• From the 2 mm thick drug loaded poly-( s-caprolactone) sheet, 15 nun by 63 rom 
strips were cut to form the wings and 15 mm by 50 mm segments were cut to 
form the bodies of the intravaginal inserts. The insert was then fabricated by 
thermo-welding one end of the body to the centre of the wing, creating aT-shaped 
insert (Insert I). The comers were then rounded offusing a scalpel and sandpaper. 
• A further insert was then constructed by thermo-welding 0.65 mm by 50 mm 
segments of 2 mm sheet to each side of the body providing a second insert with a 
larger surface area (Insert II). 
• A third insert was also fabricated (Insert III). In this case a strip of 45 mm by 48 
mm was cut from the flat sheet and was formed into a cylinder before thermo-
welding one of its ends onto the middle of a wing (17 mm by 63 nun). The 
comers were then rounded off using a scalpel and sandpaper and the open end of 
the cylinder was sealed with drug loaded poly-(s-caprolactone). 
6.2.3 Determination of Initial and Residual Drug Load in CIDR@ Sheep and 
Goat insert and PoIY-(B-caprolactone) Intravaginal Inserts 
The amount of progesterone in the intravaginal inserts immediately after 
manufacture, and after their removal following insertion into the vagina of test 
animals was determined as follows. 
The initial and residual drug load of CrDR ® Sheep and Goat inserts was determined 
as described in Chapter Five, Section 5.2.4. 
The initial and residual drug load of poly-( s-caprolactone) intravaginal inserts was 
determined as follows. The intravaginal inserts were cut using engineer's side 
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cutters into small pieces (::::::2 x 5 x 5 mm) and placed in 150 mL glass medicine 
bottles. The progesterone was then extracted from the poly-( e-caprolactone) with 
three consecutive 100 mL aliquots of ethanol (SDA-3A, Mobil, New Zealand), each 
aliquot being maintained in a waterbath at approximately 37°C (waterbath) for 16-24 
hours before being replaced with the next aliquot. Successive extracts were collected 
and combined in a 500 mL volumetric flask. The medicine bottle was rinsed with 50 
mL ethanol (SDA-3A, Mobil, New Zealand) following each extraction before the 
fresh aliquot was added. These rinses were also collected and combined into the 
volumetric flask. When the third extract and rinse was collected, the 500 mL flask 
was made up to the mark with ethanol (SDA-3A, Mobil, New Zealand). This 
solution was then diluted (1 in 25) in ethanol (SDA-3A, Mobil, New Zealand) before 
analysis by UV spectrophotometry (DU 640, Beckman, USA) at 240 nm using a 
validated assay (see Chapter Two, Section 2.2.1). 
6.2.4 Determination of Weight of Poly-(s-caprolactone) Intravaginal Inserts 
The weight of each poly-(s-caprolactone) intravaginal insert was determined on a 
four decimal place analytical balance (BPII0S, Sartorius, Germany). 
6.2.5 Determination of Surface Area of CIDR@ Sheep and Goat insert and 
Poly-( s-caprolactone) Intravaginal Inserts 
The surface area of CIDR ® Sheep and Goat inserts and poly-( e-caprolactone) 
intravaginal inserts was determined as described in Chapter Five, Section 5.2.5). 
6.2.6 Determination of Invivo Plasma Profiles of CIDR@ Sheep and Goat insert 
and Poly-(e-caprolactone) Intravaginal Inserts 
Ethical approval to perform the animal experiments in this part of the Thesis was 
obtained from both the AgResearch, Ruakura Animal Ethics Committee and from 
the University of Waikato Animal Ethics Committee on the Welfare of Experimental 
Animals. 
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Details of the inserts used in the study and the trial details are given in Tables 6.2.1 
and 6.2.2. 
Table 6.2.1 - Surface Area Trial protocol 
Insert Insertion Time Number of Animals 
(days) (N) 
CIDR® Sheep and Goat insert 14 8 
(28 cm2) containing 9%w/w 
progesterone 
Two Simultaneous CIDR@ 14 8 
Sheep and Goat insert 
Insert I (40 cm2) containing 14 8 
8% w/w progesterone 
Insert I (40 cm2) containing 14 8 
9% w/w progesterone 
Insert II (51 cm2) containing 14 8 
8% w/w progesterone 
Insert II (51 cm2) containing 14 8 
9%w/w progesterone 
Table 6.2.2 - Shape Trial protocol 
Insert Insertion Time Number of Animals 
(days) (N) 
Two Simultaneous CIDR® 14 8 
Sheep and Goat insert 
Insert II (51 cm2) containing 14 8 
9%w/w progesterone 
Insert III (50 cm2) containing 14 8 
9%w/w progesterone 
In each trial, CIDR® Sheep and Goat insert and poly-(e-caprolactone) intravaginal 
inserts were inserted into the vagina of anoestrus Romney ewes using either a 
standard CIDR ® Sheep and Goat insert applicator or modified applicator which had a 
slightly larger barrel bore size. Treatments were allocated to the ewes in a random 
manner. Sufficient animals were treated in each trial to detect significant treatment 
effects. Treatment was terminated by removal of the insert from the vagina by 
gently, but finnly, pulling on the nylon tail which was attached to the intravaginal 
inserts and which protruded beyond the vulva of the animals. At the termination of 
trials, sheep underwent vaginal examination to inspect for any irritation or damage 
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caused by the intravaginal inserts during their insertion. In the Surface Area Trial 
(Table 6.2.1), plasma samples were collected immediately prior to insertion on day 
0, during insertion on days 2, 4, 6, 8, 9, 10, 11, 12, 13, 14 and 24 hours following 
removal of the intravaginal inserts. In the Shape Trial (Table 6.2.2), plasma samples 
were collected immediately prior to insertion on day 0, during insertion on days 2, 4, 
7, 9, 12, 14 and 24 hours following removal of the intravaginal inserts. Plasma 
samples were collected by trained AgResearch personnel from the jugular vein of the 
sheep. Immediately following sampling, the plasma was separated by centrifugation 
and stored at -20°C for subsequent progesterone analysis. Concentrations of 
progesterone in plasma were determined by direct radio immuno assay by trained 
technicians at DRC laboratories using a commercial solid phase 1125 label (Coat-a-
Count, DPC, USA). 
6.2.7 Pharmacokinetic Analysis of Invivo Plasma Profiles of CIDR® Sheep and 
Goat insert and Poly-( E-caprolactone) Intravaginal Inserts 
Area Under the Curve (AUe) data were determined from the blood plasma 
progesterone levels determined at given time points over the duration of treatment 
with intravaginal inserts for each individual ewe treated. The AUe were determined 
by simple numeric estimation using the trapezoidal rule229 using equations 5.2.1 and 
5.2.2 as described in Chapter Five, Section 5.2.9. The AVe for the different 
treatments were then compared by Oneway Unstacked ANOVA (MINITAB 8.2 
Statistical Software). 
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6.3 Results 
6.3.1 Manufacture of Poly-(e-caprolactone) Intravaginal Inserts 
The poly-( e-caprolactone) intravaginal inserts resulting from the fabrication process 
are shown in Figure 6.3.1. 
so 100 .00 
I 
I ) 
Figure 6.3.1- Photograph of the CIDRit Sheep and Goat insert and poly-(e -caprolaclone) 
intravaginal inserts (CIDRit Sheep and Goat insert; left, Insert I; centre left, Insert II; centre 
right, Insert ill; right) 
6.3.2 Insert Dimensions, Surface Area, Initial Skin Weight and Drug Load 
Insert dimensions, surface area, initial skin weight and drug load of the poly-( e-
caprolactone) intravaginal inserts are shown in Tables 6.3.1 , 6.3.2 and 6.3 .3, 
respectively. 
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Table 6.3.1 - Physical dimensions of CIDR® Sheep and Goat insert and poly-(e -caprolactone) 
intravaginal inserts 
Poly-( 8~caprolactone) intravaginal Wing* length Body* length 
inserts (cm) (cm) 
CIDR ® Sheep and Goat insert (28 cm2) 58 54 
containing 9%w/w.progesterone 
Insert I (40 cm2) containing 63 50 
8% w Iw progesterone 
Insert I (40 cm2) containing 63 50 
9% w /w progesterone 
Insert II (51 cm2) containing 63 50 
8% w/w progesterone 
Insert II (51 cm2) containing 63 50 
9% w Iw progesterone 
Insert III (50 cm2) containing 63 50** 
9%w/w progesterone 
*poly-( c-caprolactone) intravaginal inserts fabricated from 2 nun thick sheet with wing and body 
being 15 mm wide 
**Insert III body was hollow (2 mm wall thickness) and had a diameter of approximately 17 mm 
Table 6.3.2 - Surface area determinations of poly-(e -caprolactone) intravaginalinserts 
Replicate Insert I Insert II Insert III 
1 38.36 50.57 49.92 
2 40.79 51.25 49.15 
3 42.69 51.13 49.94 
4 40.40 50.76 51.16 
5 41.25 51.50 Not detennined 
Mean 40.70 51.04 50.04 
Table 6.3.3 - Weights and initial drug loads ofpoly-(e -caprolactone) intravaginal inserts (n=2) 
Insert Insert Weight Drug Load Drug Load 
(g) 19l (%w/w) 
Insert I (40 cm2) containing 4.68 0.37 7.82 
8%w/w progesterone 
Insert II (51 cm2) containing 5.92 0.47 7.98 
8%w/w progesterone 
Insert I (40 cm2) containing 4.36 0.38 8.58 
9%w/w progesterone 
Insert II (51 cm2) containing 5.69 0.53 9.25 
9%w/w progesterone 
Insert III (50 cm2) containing 8.90 0.80 9.03 
9%w/w progesterone 
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6.3.3 Invivo Plasma Profiles of CIDR® Sheep and Goat insert and Poly-(a-
caprolactone) Intravaginal Inserts 
6.3.3.1 Surface Area Trial 
Blood plasma progesterone levels determined during insertion of a CIDR@ Sheep and 
Goat insert for 14 days are shown in Table 6.3.4. Blood plasma progesterone levels 
determined during insertion of 8% w/w progesterone loaded Insert I and Insert II 
poly-(e-caprolactone) intravaginal inserts for 14 days are shown in Tables 6.3.5 and 
6.3.6, respectively. Blood plasma progesterone levels determined during insertion of 
9% w/w progesterone loaded Insert I and Insert II poly-( a-caprolactone) intravaginal 
inserts for 14 days are shown in Tables 6.3.7 and 6.3.8, respectively. 
Table 6.3.4 - Blood plasma progesterone levels resulting from a 14 day insertion of a CIDR® 
Sheep and Goat insert in Surface Area Trial 
Replicate Plasma progesterone concentration (ng/mL) at each time foIlowing insertion days) 
0 2 4 6 8 9 10 11 12 13 14 15 
1 0.07 3.18 2.42 2.00 1.72 1.96 1.48 1.81 2.56 1.58 1.69 0.19 
2 0.19 2.46 1.84 1.62 1.69 1.79 1.75 1.69 1.72 1.60 1.29 0.14 
3 0.24 2.58 2.55 1.63 1.01 1.33 1.06 1.82 1.13 0.95 1.37 0.06 
4 0.03 2.21 2.00 2.22 1.96 1.89 1.48 1.45 1.86 1.22 1.50 0.10 
5 0.03 2.40 1.93 1.93 2.46 2.35 1.56 1.50 1.28 1.42 1.33 0.20 
6 0.05 2.86 2.41 1.66 1.36 1.46 1.35 1.93 1.94 1.69 1.24 0.08 
7 0.11 2.32 2.10 1.90 1.42 1.75 1.69 1.14 0.95 1.03 0.97 0.15 
8 0.10 2.58 2.83 2.24 2.18 2.75 1.72 1.47 1.51 1.41 1.49 0.14 
mean 0.10 2.57 2.26 1.90 1.72 1.91 1.51 1.60 1.62 1.36 1.36 0.13 
SEM 0.03 0.11 0.12 0.09 0.17 0.16 0.08 0.09 0.18 0.10 0.08 0.02 
Table 6.3.5 - Blood plasma progesterone levels resulting from a 14 day insertion of a Insert I 
(poly-(e -caprolactone) intravaginal insert containing 8% w/w progesterone) in Surface Area 
Trial 
Replicate Plasma progesterone concentration (ng/mL) at each time following insertion (days) 
0 2 4 6 8 9 10 11 12 13 14 15 
1 0.03 2.84 2.02 l.86 l.71 1.52 1.42 0.83 0.97 1.09 l.01 0.10 
2 0.19 2.82 1.76 1.38 l.10 1.01 l.02 0.83 0.91 0.79 0.78 0.07 
3 0.14 3.40 2.40 l.94 1.12 1.39 l.33 1.37 1.10 0.84 1.37 0.13 
4 0.11 2.72 2.00 l.57 l.62 1.36 1.02 1.19 1.06 0.98 0.98 0.08 
5 0.02 1.75 1.97 0.80 l.13 0.88 0.91 0.56 0.67 0.59 0.77 0.01 
6 0.05 2.40 1.49 l.01 0.98 1.27 0.88 1.11 0.71 0.73 0.91 0.06 
7 0.09 3.28 2.72 1.58 1.79 1.38 1.25 1.17 1.07 0.88 1.02 0.12 
8 0.06 1l' 1.32 1.26 1.10 1.39 1.17 1.25 1.19 0.87 0.90 0.07 
mean 0.09 2.74 1.96 1.42 1.32 1.27 1.13 1.04 0.96 0.85 0.97 0.08 
SEM 0.02 0.20 0.16 0.14 0.12 0.08 0.07 0.10 0.07 0.05 0.07 0.01 
'U'Lost sample 
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Table 6.3.6 - Blood plasma progesterone levels resulting from a 14 day insertion of a Insert II 
(poly-(c: -caproiactone) intravaginal insert containing 8% w/w progesterone) in Surface Area 
Trial 
R~l!licate Plasma progesterone concentration (ng/mL) at each time following insertion (days) 
0 2 4 6 8 9 10 11 12 13 14 15 
1 0.11 4.12 3.47 2.83 2.11 2.50 1.65 1.62 'it 1.67 1.57 0.24 
2 0.04 3.06 2.14 1.60 1.64 1.65 1.24 0.94 1.27 1.32 l.32 0.12 
3 0.04 3.94 2.63 2.07 1.60 1.83 1.19 1.28 1.29 l.91 1.30 0.08 
4 0.19 4.03 3.42 1.79 1.73 1.80 1.39 1.46 1.45 1.29 1.37 0.12 
5 0.05 3.05 2.58 2.05 1.51 2.00 1.37 1.14 1.26 1.07 1.19 0.13 
6 0.06 2.52 2.19 1.47 1.60 0.90 1.01 1.38 1.44 0.91 0.84 0.12 
7 0.00 3.07 2.10 1.53 1.47 2.39 1.91 0.97 1.18 1.14 1.20 0.08 
8 0.18 2.72 2.71 2.15 2.35 1.80 1.52 1.54 1.25 0.97 1.42 0.12 
mean 0.08 3.32 2.65 1.93 1.75 1.86 1.41 1.29 1.30 1.29 1.28 0.13 
SEM 0.02 0.22 0.19 0.16 0.11 0.17 0.10 0.09 0.04 0.12 0.08 0.02 
'1ILost sample 
Table 6.3.7 - Blood plasma progesterone levels resulting from a 14 day insertion of a Insert I 
(poly-(c: -caprolactone) intravaginal insert containing 9% w/w progesterone) in Surface Area 
Trial 
Replicate Plasma progesterone concentration (ng/mL) at each time following insertion (days) 
0 2 4 6 8 9 10 11 12 13 14 15 
1 0.44 3.80 3.25 1.88 1.78 2.16 1.92 1.68 1.72 1.18 1.40 0.23 
2 0.08 2.37 1.75 1.51 1.11 1.45 1.59 1.15 0.83 0.91 0.65 0.06 
3 0.03 3.00 3.57 2.06 1.67 1.76 1.34 1.11 1.16 1.05 1.26 0.14 
4 0.02 2.52 3.08 1.87 1.70 1.37 1.16 1.23 1.15 1.02 1.05 0.10 
5 0.08 3.36 2.22 1.92 1.63 1.91 1.46 1.15 1.25 1.30 0.85 0.05 
6 0.15 3.95 2.48 2.40 2.41 2.11 1.95 1.57 1.32 1.20 1.23 0.29 
7 0.16 2.47 3.48 2.46 1.79 2.68 1.64 1.67 1.53 1.34 1.43 0.10 
8 0.00 2.47 1.99 1.80 1.45 1.58 0.92 0.98 1.17 0.77 1.09 0.16 
mean 0.12 2.99 2.73 1.99 1.69 1.88 1.50 1.32 1.27 1.10 1.12 0.14 
SEM 0.05 0.23 0.25 0.11 0.13 0.15 0.13 0.10 0.09 0.07 0.10 0.03 
Table 6.3.8 - Blood plasma progesterone levels resulting from a 14 day insertion of a Insert II 
(pOIY-(E -caprolactone) intravaginal insert containing 9% w/w progesterone) in Surface Area 
Trial 
Replicate Plasma progesterone concentration (ng/mL) at each time following insertion (days) 
0 2 4 6 8 9 10 11 12 13 14 15 
1 0.08 4.16 2.83 1.89 2.04 2.08 1.27 1.34 1.70 1.46 1.32 0.10 
2 0.08 2.86 2.78 1.58 1.18 1.27 1.31 1.10 1.51 1.20 1.18 0.09 
3 0.16 3.86 3.42 2.67 2.57 2.91 1.97 2.05 1.60 1.14 1.64 0.06 
4 0.04 4.05 3.14 2,49 2.10 2.15 1.54 1.76 1.88 2.04 1.56 0.10 
5 0.07 3.78 3.05 2,49 2.00 2.07 1.36 1.26 1.28 1.27 1.22 0.11 
6 0.14 3.37 1.86 1.82 1.61 2.03 1.22 1.08 1.29 1.24 1.19 0.12 
7 0.20 4.59 3.78 2.76 3.10 4.21 2.31 1.96 2.09 1.71 2.05 0.18 
8 0.42 4.84 3.60 2.58 2.34 3.47 2.08 1.64 1.79 1.40 1.44 0.15 
mean 0.15 3.94 3.06 2.28 2.12 2.52 1.63 1.52 1.64 1.43 1.45 0.11 
SEM 0.04 0.22 0.21 0.16 0.21 0.33 0.15 0.13 0.10 0.11 0.11 0.01 
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6.3.3.2 Shape Trial 
Blood plasma progesterone levels detennined during insertion of two CIDR@ Sheep 
and Goat insert in a simultaneous programme (Figure 5.1.2) for 14 days are shown in 
Table 6.3.9. Blood plasma progesterone levels determined during insertion of 9% 
w/w progesterone loaded Insert II and Insert III poly-( s-caprolactone) intravaginal 
inserts for 14 days are shown in Tables 6.3.10 and 6.3.11, respectively. 
Table 6.3.9 - Blood plasma progesterone levels resulting from a 14 day insertion of two CIDR® 
Sheep and Goat insert simultaneously in Shape Trial 
Replicate Plasma progesterone concentration (ng/mL) at each time following insertion 
(days) 
0 2 4 7 9 12 14 15 
1 0.64 7.93 8.01 6.65 5.07 5.48 2.90 0.20 
2 0.15 4.01 4.20 3.13 2.60 2.77 2.12 0.25 
3 0.10 2.50 4.38 3.07 2.14 2.98 2.00 0.24 
4 0.09 5.96 5.30 3.64 2.79 2.51 1.81 0.19 
5 0.11 3.62 2.88 2.33 2.44 2.41 1.94 0.25 
6 0.33 3.40 5.21 3.75 2.43 2.73 2.36 0.09 
7 0.03 2.62 5.64 3.85 3.57 3.68 3.20 0.30 
8 0.41 2.69 4.17 2.90 3.00 2.30 2.31 0.16 
mean 0.23 4.09 4.98 3.67 3.01 3.11 2.33 0.21 
SEM 0.09 0.78 0.61 0.53 0.38 0.43 0.20 0.03 
Table 6.3.10 - Blood plasma progesterone levels resulting from a 14 day insertion of a Insert II 
(poly-(e -caprolactone) intravaginal insert containing 9% w/w progesterone) in Shape Trial 
Replicate Plasma progesterone concentration (ng/mL) at each time following insertion 
(days) 
0 2 4 7 9 12 14 15 
1 0.79 1.80 3.82 2.07 2.37 1.57 1.18 0.12 
2 0.11 2.28 3.76 2.12 2.03 1.12 1.36 0.21 
3 0.09 2.68 3.64 2.76 2.31 1.47 1.48 0.28 
4 0.56 3.67 3.17 2.39 2.27 1.58 1.10 0.09 
5 0.15 3.08 4.31 2.90 2.21 1.85 1.80 0.37 
6 1.11 3.80 4.11 2.59 2.54 1.36 1.09 0.22 
mean 0.47 2.88 3.80 2.47 2.29 1.49 1.33 0.22 
SEM 0.17 0.32 0.16 0.14 0.07 0.10 0.11 0.04 
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Table 6.3.11 - Blood plasma progesterone levels resulting from a 14 day insertion of a Insert III 
(poIY-(E -caprolactone) intravaginal insert containing 9% w/w progesterone) in Shape Trial 
Replicate Plasma progesterone concentration (ng/mL) at each time following insertion 
(days) 
0 2 4 7 9 12 14 15 
1 0.10 2.52 4.36 2.47 2.36 2.42 1.50 0.16 
2 0.10 2.87 3.22 2.72 2.23 2.17 2.17 0.27 
3 0.08 5.51 6.16 4.87 3.18 1.94 1.79 0.37 
4 0.02 3.86 3.19 2.46 2.l9 2.80 1.58 0.14 
5 0.80 4.26 5.23 5.45 3.38 2.03 1.86 0.21 
6 0.15 2.27 4.28 4.85 4.77 2.62 1.91 0.30 
mean 0.23 3.55 4.41 3.80 3.02 2.33 1.86 0.26 
SEM 0.12 0.50 0.47 0.57 0.41 0.14 0.10 0.04 
6.3.4 Pharmacokinetic Analysis of Invivo Plasma Profiles of CIDR® Sheep and 
Goat insert and Poly-(e-caprolactone) Intravaginal Inserts 
Areas under the Curve calculated for the invivo plasma profiles of CIDR® Sheep and 
Goat insert and prototype silicone intravaginal inserts in the Surface Area Trial and 
the Shape Trial are shown in Table 6.3.12. 
Table 6.3.12 - Area under the curve data for invivo plasma profiles of CIDR® Sheep and Goat 
insert and prototype silicone intravaginal inserts in Surface Area Trial and Shape Trial 
Trial Insert Area Under Curve (AUC) 
Day 0-10 Day 10-15 Day 0-15 
Averaee + SEM Avera2e ± SEM Average ± SEM 
Surface Area CIDR® Sheep and 18.82 ± 0.64 6.76 ± 0.37 25.58 ± 0.87 
Goat insert 21.98 ± 0.70* 3.60 ± 0.23* 
Surface Area 2 CIDR ® Sheep - - 47.83 ± 5.92 
and Goat insert 
simultaneous 
Surface Area Insert I, 8%w/w - - 20.77 ± 1.43 
Surface Area Insert II, 8%w/w - - 25.93 ± 1.13 
Surface Area Insert I, 9%w/w - - 26.31 ± 1.55 
Surface Area Insert II, 9% w/w 25.22 ± 1.77 6.92 ± 0.45 32.14 ± 2.17 
Shape 2 CIDR® Sheep - - 48.89 ± 5.38 
and Goat insert 
simultaneous 
Shape Insert II, 9%w/w 29.87 ± 1.21 * 3.60 ± 0.25* 33.47 ± 1.31 
Shape Insert III, 9%w/w - - 44.02 ± 3.61 
*No day 10 sample was taken in Shape Trial so these calculations performed were AUCO_12 and 
AUC 12_15 
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6.3.5 Vaginal Inspection After Removal 
Examination of all ewes immediately following removal of each insert used in the 
study showed that no damage and minimal vaginal discharge was present. 
6.3.6 Residual Drug Load after Vaginal Insertion 
6.3.6.1 Surface Area Trial Residual Drug Loads 
Residual drug loads in CIDR® Sheep and Goat insert and poly-(e-caprolactone) 
intravaginal inserts determined following 14 day insertion are shown in Table 6.3 .13 
along with initial loads and the calculated amount of progesterone released during 
the 14 day insertion. 
Table 6.3.13 - Residual drug loads in CIDR® Sheep and Goat insert and poIY-(E-caprolactone) 
intravaginal inserts determined following 14 day insertion in sheep (n=3) in Surface Area Trial 
Insert Initial Residual Amount Released 
Load Load 
(g) (g) 
(2) SEM 
CID R ® Sheep and Goat insert 0.38 0.17 0.21 0.01 
Insert I (40 cm2) containing 0.37 0.18 0.19 0.01 
8%w/w progesterone 
Insert II (51 cm2) containing 0.47 0.27 0.20 0.01 
8%w/w progesterone 
Insert I (40 cm2) containing 0.38 0.20 0.18 0.02 
9%w/w progesterone 
Insert II (51 cm2) containing 0.53 0.30 0.23 0.01 
9%w/w progesterone 
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~. 6.2 Shape Trial Residual Drug Loads 
sidual drug loads in CIDR@ Sheep and Goat insert and poly-(s-caprolactone) 
ravaginal inserts determined following 14 day insertion are shown in Table 6.3 .14 
)ng with initial loads and the calculated amount of progesterone released during 
~ 14 day insertion. 
'able 6.3.14 - Residual drug loads in CIDR® Sheep and Goat insert and POIY-(E-caprolactone) 
intravaginal inserts determined following 14 day insertion in sheep (n=5) in Shape Trial 
,sert Initial Residual Amount Released 
Load Load 
(g) (g) 
(g) SEM 
wo simultaneous CIDR ® 0.74 0.37 0.37 0.01 
leep and Goat insert 
LSert II (51 cm2) containing 0.53 0.32 0.21 0.02 
Yow/w progesterone 
lsert III (50 cm2) containing 0.80 0.40 0.40 0.04 
%w/w progesterone 
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6.4 Discussion 
The design of the poly-( B-caprolactone) intravaginal inserts used in this study was 
based upon two criteria; (i) the constraints imposed upon the length of intravaginal 
inserts due to the depth of the ovine vaginal anatomy reported in Chapter Five, 
Section 5.3.2 and (ii) the need to retain the insert over the duration of the insertion 
period. Since the currently available CIDR® Sheep and Goat insert fits comfortably 
within the vagina of even small or maiden ewes, and it exhibits very high retention 
rates4 the design of the poly-( e-caprolactone) intravaginal inserts were based on the 
shape and dimensions of the currently available CIDR® Sheep and Goat insert 
(Figure 6.3.1). The design of the poly-(e-caprolactone) intravaginal inserts (Figure 
6.3.1) proved to be very appropriate since during our trials all of the poly-( s-
caprolactone) intravaginal inserts were retained within the vagina of the ewes used in 
the trials (100% retention rate) for the duration of the 14 day insertion period, and 
post-removal vaginal inspection revealed only minor membrane irritation and 
minimal mucopurrelant reaction. 
In the Surface Area Trial, plasma progesterone levels following insertion of poly-( s-
caprolactone) intravaginal inserts with two different initial drug loads (8% and 9% 
w/w) and two different surface areas (40 cm2 and 50 cm2) were determined and 
compared to those observed following insertion of a single CIDR® Sheep and Goat 
insert (90/0 w/w; 28 cm2) and the insertion of two CIDR@ Sheep and Goat insert 
simultaneously. The resultant plasma progesterone profiles obtained are shown in 
Figure 6.4.1. 
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Figure 6.3.1 - Plasma progesterone profiles resulting from the insertion of a single CIDR® Sheep 
and Goat insert (0), two CIDR® Sheep and Goat insert simultaneously (D), Insert I containing 
8% w/w progesterone (X), Insert I containing 9%)w/w progesterone (A), Insert II containing 
8%w/w progesterone (.) and Insert II containing 9%w/w progesterone (+) 
In Figure 6.4.1 the typical plasma progesterone profile for the CIDR® Sheep and 
Goat insert as described in the literature and seen in Chapter 5 (Figure 5.4.1) was 
observedl79• In the typical CIDR® Sheep and Goat insert profile, plasma 
progesterone levels rise following its intravaginal insertion and then slowly decline 
over the treatment period and then drops to basal values rapidly once the CIDR® 
Sheep and Goat insert is removed (Figure 6.4.1). The plasma profiles obtained 
following insertion of the poly-( €-caprolactone) intravaginal inserts appeared to 
mimic the same trend seen for the CIDR ® Sheep and Goat insert. Insert I containing 
8%w/w progesterone produced a profile which was slightly lower than that of the 
CIDR® Sheep and Goat insert and gave an AVC value which was significantly 
different to that of the CIDR® Sheep and Goat insert (p=O.013), Insert II containing 
8%w/w progesterone and Insert I containing 9%w/w progesterone both produced 
plasma profiles which overlapped with that of the CIDR® Sheep and Goat insert and 
had AVC values which were significantly different to that of the CIDR® Sheep and 
Goat insert (p=O.912). Insert II containing 9%w/w progesterone gave elevated 
plasma levels above those of the CIDR® Sheep and Goat insert during the early 
stages of treatment (AUCo_1o significantly different; p=0.004) but not over the final 
four days of insertion (AUCll_14 not significantly different; p=0.794). These 
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observations were supported by the residual detennination data which indicated that 
the Insert I containing 8%w/w progesterone released less progesterone that a CIDR@ 
Sheep and Goat insert, Insert II containing 8%w/w progesterone and Insert I 
containing 9%w/w progesterone both released approximately the same amount of 
progesterone as the CIDR® Sheep and Goat insert (p=0.337) and Insert II containing 
9%w/w progesterone released slightly more progesterone than a CIDR® Sheep and 
Goat insert over the 14 day insertion period (p=O.043). 
Figure 6.4.1 shows that none of the poly-( c;-caprolactone) intravaginal inserts 
achieved plasma levels which mimicked those produced following the simultaneous 
insertion of two CIDR@ Sheep and Goat insert. This observation was supported by 
residual determinations which indicated that each of the inserts studied released 
much less progesterone than that which was released by two CIDR® Sheep and Goat 
inserted simultaneously and by differences in AVe (p<O.001). As indicated in 
Chapter 5, it would be desirable to develop the new technology to produce plasma 
progesterone levels which mimicked those seen when two CIDR® Sheep and Goat 
insert are inserted simultaneously, to enable its use in specialised fertility 
programmes. 
Factors such as initial drug load and surface area are well documented in the 
literature as parameters which influence the release of drugs from poly-( s-
caprolactoneY 93,218. Figure 6.4.1 shows the effect of initial drug load on plasma 
profiles. At a fixed surface area, initial drug load influenced the magnitude of the 
plasma profiles. At fixed surface areas of both 40 and 50 cm2 an increase in initial 
load resulted in a significant increase in Aue (Table 6.3.12) (p=0.027). However, 
this increase was not sufficient to elevate plasma progesterone levels to mimic those 
seen following insertion of two CIDR® Sheep and Goat insert simultaneously. 
Figure 6.4.1 also shows the effect of surface area on plasma profiles. At a fixed 
initial drug load, surface area influenced the magnitude of the plasma profiles. At a 
fixed initial drug load both the 40 and 50 cm2 intravaginal inserts resulted in a 
significant increase in AUC (Table 6.3.12) (at 8%w/w p=O.018, at 9%w/w p=O.046). 
However, this increase was not sufficient to elevate plasma progesterone levels to 
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mImIC those seen following insertion of two CIDR® Sheep and Goat insert 
simultaneously. This was a surprising result based on observations made in Chapter 
Five with silicone based intravaginal drug delivery systems where a similar increase 
in surface area produced very different (elevated) plasma profiles. We had expected 
to see a significant difference between plasma levels for different surface area poly-
(s-caprolactone) intravaginal inserts. Indeed the 9% loaded Insert II poly-( 8-
caprolactone) intravaginal insert was theoretically designed to mimic the plasma 
profile produced following the simultaneous insertion of two CIDR® Sheep and Goat 
insert. 
Recently Bunt observed that when intravaginal inserts with the same surface area but 
with different shapes were placed into cattle vaginas they produced different plasma 
progesterone levels depending upon the shape of the insert (Bunt; Unpublished 
observation). He reasoned that higher plasma progesterone levels would be achieved 
using inserts whose shape allowed more surface area to contact with the vaginal 
mucosa. Applying this theory to our case, one can imagine the vagina as a collapsed 
tube which, following the insertion of an intravaginal insert, would contact more 
surface area of an insert with a cylindrical-shaped body. In contrast less contact 
might be envisaged with an insert manufactured with a flat-shaped body. In this case 
the vaginal mucosa would contact with the edges of the insert, but would be hindered 
from completely contacting the flat surface of the insert. Therefore we postulated 
that if we manufactured a further insert which had a cylindrically-shaped body and a 
surface area of 50 cm2, then it should produce higher plasma progesterone levels than 
its flat bodied counterpart, even though the surface area of both inserts are identical. 
A Shape Trial was therefore initiated to test this theory. The resulting plasma 
profiles for the Shape Trial are shown in Figure 6.4.2. 
245 
CHAPTER SIX 
r--- 5 
t ~ 4 
'--" 
Q) § 3 
2 
cr.J 
~ 2 
8 
0.. S 1 
~ 
DEVELOPMENT OFA NEW INTRA VAGINAL DRUG DELIVERY SYSTEM FOR USE IN SHEEP 
E::O-+-------+--------+------.-:r 
o 5 10 15 
Time (days) 
Figure 6.3.2 - Plasma progesterone profiles resulting from the insertion of a single CIDR® Sheep 
and Goat insert (+), two CIDR® Sheep and Goat insert simultaneously (e), Insert II poly-(a-
caprolactone) 90/0 w/w initial load intravaginal inserts (A) and Insert III polY-(B-caprolactone) 
90/0 w /w initial load intravaginal inserts (X) 
In the Shape Trial we again observed a profile for Insert II containing 9%w/w 
progesterone which was elevated initially above that of the CIDR® Sheep and Goat 
insert (AUCo_12 significantly different; p<O.OOl) but which was not significantly 
different to that of the CIDR® Sheep and Goat insert towards the end of treatment 
(AUC12_15 not significantly different; p=O.994). In contrast, Insert III containing 
9%w/w progesterone and having an equivalent surface area to Insert II but of 
cylindrical design produced elevated plasma progesterone levels. AVC values for 
Insert III were significantly different to those obtained following insertion of Insert 
II. Indeed, the AUC produced by Insert III were not significantly different to the 
levels produced when two CIDR® Sheep and Goat insert are inserted simultaneously 
(p=0.500). Given this observation we conclude that it may be possible to produce a 
poly-( s-caprolactone) intravaginal insert which produces plasma progesterone 
profiles which mimic those seen when two CIDR ® Sheep and Goat inserts are 
inserted simultaneously through the modification of the surface area of an insert 
which is appropriately shaped. 
The new poly-( s-caprolactone) technology offers many advantages over the currently 
used silicone technology as an intravaginal drug delivery platfonn. Poly-( s-
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caprolactone) is a thermoplastic and can be processed at lower temperatures than 
silicone. Being a thermoplastic, poly-{ s-caprolactone) can be reprocessed if 
required. The main advantage of low temperature processing is that it allows the 
opportunity to incorporate drugs other than progesterone which are less heat~stable. 
A further advantage of low temperature processing is the energy saving it provides. 
The innate rigidity of poly-( s-caprolactone) eliminates the need for an internal inert 
spine to provide form to the insert (which is currently required with the silicone 
technology). The poly-(s-caprolactone) also provides the opportunity to incorporate 
channel forming agents within the formulation which would enable hydrophilic 
drugs to be incorporated and delivered even though they cannot permeate through 
the polymer itself in the same manner as lipophilic drugs can. This latter property of 
poly-( 8-caprolactone) greatly increases the potential list of drug candidates which 
could be incorporated within a poly~( s-caprolactone) intravaginal drug delivery 
system. Although poly-( s-caprolactone) has sufficient rigidity to be self supporting, 
it is also flexible enough to be fabricated into a 'T -shaped' insert which can be 
retained intravaginally by exerting gentle pressure on the vaginal membrane. The 
low glass transition temperature of -60°C means that this flexibility is retained by 
inserts fabricated from poly-(s-caprolactone), even in the winter months of the colder 
geographic locations. Finally, poly-(s-caprolactone) offers the advantage of 
biodegradability. Although an intravaginal insert fabricated from poly-(s-
caprolactone) does not degrade invivo over the duration of a fertility treatment, when 
spent devices are buried they degrade substantially within 6 months 193. This 
biodegradability offers advantages for the disposal of intravaginal inserts made of 
poly-( c;-caprolactone) after use. 
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6.5 Conclusions 
It can be concluded from the work presented in this Chapter that the application of 
poly-(s-caprolactone) as an intravaginal controlled drug delivery insert technology is 
feasible. The poly-( s-caprolactone) intravaginal inserts used in this study were 
proven to be capable of elevating and sustaining plasma progesterone in sheep at 
levels similar to those achieved with the CIDR® Sheep and Goat insert. Formulation 
factors such as drug load, surface area and even the shape of poly-(e-caprolactone) 
intravaginal inserts containing progesterone were shown to have an effect on the 
magnitude of blood plasma progesterone levels following their insertion into sheep. 
These parameters could be rationally modified (optimised) to fabricate a poly-( 8-
c apro lactone ) intravaginal insert which produces plasma progesterone profiles which 
mimic those seen when two CrDR ® Sheep and Goat insert are inserted 
simultaneously. 
The cited advantages of poly-( 8-caprolactone) as both an intravaginal drug delivery 
system and as a technology to replace the current silicone technologies, coupled with 
the promising results of the feasibility studies described in this chapter open up the 
opportunity for further development and implementation of this technology in the 
future. 
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